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Dystroglycan is a ubiquitously expressed adhesion receptor and signalling scaffold found at the 
plasma membrane. DG function at the PM is disrupted in multiple human diseases including 
muscular dystrophy and epithelial carcinomas. More recently DG has also been identified in 
the nucleus of many cell types, however its nuclear functions and the mechanisms of its 
nuclear localisation are relatively poorly understood. In support of a growing number of 
reports, in this thesis βDG was found to localise at the nuclear envelope, nucleoplasm and 
distinct nuclear foci in multiple prostate cell lines, normal and cancerous. Furthermore, in 
fibroblasts lacking DG, nuclear morphology was severely disrupted, supporting a role for DG in 
nuclear structure. The nuclear levels of βDG are variable suggesting a dynamic regulation. DG 
protein levels and localisation have previously been reported to be regulated in a cell cycle 
dependent manner. Upon investigation via immunoblots, the nuclear levels of βDG also appear 
to slightly fluctuate in a cell cycle dependent manner, with an increase in the nuclear levels of 
a phosphorylated form (pY892) of βDG weakly correlating with cells in S phase following 
quantification, however this observation was not supported via immunofluorescence analysis 
and requires additional investigation. To further understand the precise mechanisms of 
nuclear translocation of βDG we investigated a role for regulatory post-translational 
modification, specifically phosphorylation at residue T788 within the c-terminal of βDG. Whilst 
mutations at residue T788 did not clearly affect the nuclear localisation of βDG, preliminary 
evidence suggests that this residue may be important in protein stability. Finally, it was 
observed that βDG antibodies colocalised to the centrosome in immunofluorescence studies 
however this localisation was demonstrated to be an antibody artefact. Studying the functions 
and regulation of βDG at intracellular locations is important to better understand the 
numerous roles of this multifunctional protein in maintaining cellular homeostasis and may 
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The human body consists of vast numbers of highly specialised cells, that together form 
complex tissues with specific tasks. It is critical for a cell to interact with its surrounding 
environment and neighbouring cells and respond accordingly to regulate its growth, division, 
movement and activity. The complex behaviour of a cell is a result of a network of incredibly 
diverse molecular components. These molecules are highly regulated by the cell to ensure 
their correct spatial and temporal expression and activity. Disruptions to the levels, processing, 
and functions of these molecules can cause an imbalance in the cell homeostasis, resulting in 
perturbed tissue integrity and ultimately a vast array of human diseases. Studying the 
regulation, interactions and functions of these molecules is fundamental in the understanding 
of the human body and disease processes.  
1.1 THE BIOSYNTHESIS AND STRUCTURE OF DYSTROGLYCAN 
 
Initially isolated as cranin, a laminin binding glycoprotein in neural cells (Smalheiser et al. 
1987), the same protein was later isolated and characterised in skeletal muscle (Ibraghimov-
Beskronaya et al. 1992) and the brain (Gee et al. 1993) and subsequently named dystroglycan 
(DG). Dystroglycan is encoded for by the DAG1 gene which is comprised of two exons 
separated by a single intron (Ibraghimov-Beskronaya et al. 1993). Following the transcriptional 
and translational processing of the DAG1 gene the product is a single 895 amino acid 
polypeptide (in humans) that is post-translationally cleaved in the endoplasmic reticulum (ER) 
between Gly653/ Ser654 to form two subunits, α- and β-dystroglycan (Ibraghimov-Beskronaya 
et al. 1993, Holt et al. 2000) (Fig 1.1).  
αDG is a peripheral membrane protein with globular immunoglobulin like N- and C- terminal 
domains that are linked by a mucin-like linker domain (Brancaccio et al, 1995, Brancaccio et al. 
1997, Bozic et al 2004) (Fig 1.1). The linker domain is highly glycosylated O- linked glycans, 
which are important for its interaction with its ligands in the ECM (Talts et al. 1999, Tisi et al, 
2000). The molecular weight of αDG is predicted to be 72 KDa, however the mature protein 
runs on SDS PAGE gels between 120-180 KDa, depending on the tissue, as a result of its highly 
glycosylated state (Durbeej et al, 1998, Ervasti et al. 1991, Yamada et al, 1994). βDG has a 
globular, N-glycosylated, extracellular N-terminal domain, a short transmembrane domain and 
a cytoplasmic, largely disordered and proline rich, C-terminal domain (Fig 1.1). The βDG core 
peptide is predicted to have a molecular weight of 26 KDa, however the mature protein runs at 
43 KDa on SDS-PAGE as a consequence of its proline rich composition and post-translational 
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modifications (Ibraghimov-Beskrovnaya et al 1992, Holt et al 2000).  In its mature form DG is a 
type 1 transmembrane domain protein in which the α and β subunits interact non-covalently. 
 
Figure 1.1: The domain structure of human dystroglycan. (Top) Schematic diagram of the domains of α 
and β dystroglycan. SP: Signal peptide, Ecto: N terminal- Ectodomain, TM: transmembrane, NLS: Nuclear 
localisation signal, Cyto: Cytoplasmic domain. Amino acid positions are denoted beneath the structure. 
Arrowhead indicates site of cleavage between α and β dystroglycan. Domains are not to scale. (Bottom) 
Cartoon diagram of the extracellular α and transmembrane β dystroglycan subunits with glycosylation 
modifications in pink. 
Dystroglycan orthologues can be found widely across Metazoa although not in the 
choanoflagellates, the unicellular relatives of the metazoan (Adams et al. 2015). There is a high 
degree of homology between human DG and vertebrate orthologues, with a 94% identity 
between mice and humans whilst other animal models have varying degrees of homology; 
Xenopus (69%), Zebrafish (59%), Drosophila (33%) and C. elegans (24%) (Adams et al. 2015).  
Dystroglycan is expressed ubiquitously in mammalian tissues, with high expression in skeletal 




1.2 DYSTROGLYCAN IN THE DYSTROPHIN ASSOCIATED GLYCOPROTEIN COMPLEX (DAPC) 
 
In its characterisation in skeletal muscle dystroglycan was identified as a binding partner of 
dystrophin in the dystrophin associated glycoprotein complex (DAPC) (Ervasti et al. 1991, 
Ibraghimov-Beskrovnaya et al. 1992) and it is within this context that DG is best understood 
(Fig 1.2).  αDG interacts with components of the extracellular matrix including laminin α1 and 
α2 (Ervasti et al. 1993), biglycan (Bowe et al. 2000), agrin (Deyst et al. 1995) and perlecan 
(Peng et al. 1998). βDG is a transmembrane component of the DAPC, interacting with the c-
terminal of αDG via its extracellular N-terminal domain (Sciandra et al. 2001, Bozzi et al. 2003) 
and various binding partners, including dystrophin via its cytoplasmic C-terminal domain (Jung 
et al. 1995, Yoshida et al. 1990) (Fig 1.2). Dystrophin is a member of the spectrin family of 
proteins and binds to the actin cytoskeleton through its N-terminal actin binding domain and 
βDG through its cysteine rich and C-terminal domains (Suzuki et al. 1992, Rentschler et al. 
1999, Corrado et al. 1994).  As such, the DAPC provides a physical tether between the 
extracellular environment and the actin cytoskeleton (Ervasti et al. 1993).  
In muscle tissue a number of other proteins were co-purified with dystrophin and dystroglycan 
and have been characterised as the other major components of the DAPC and are briefly 
described below (Ervasti et al. 1991, Ibraghimov-Beskrovnaya et al. 1992) (Fig 1.2). The 
transmembrane sarcoglycans (α,β,γ,δ) form the sarcoglycan subcomplex (SGC) (Holt et al. 
1998). The SGC interacts with DG and is proposed to strengthen the interaction between the 
DG subunits, as well as DG’s interaction with dystrophin (Iwata et al. 1993, Roberds et al. 
1993). The stabilising role of the SGC was proposed following observations of destabilised 
interactions between these components in animal models lacking the SGC (Iwata et al. 1993, 
Roberds et al. 1993), however how the interactions are stabilised by the SGC remains unclear. 
The SGC also provides a scaffold for other DAPC components, such as dystrobrevin (Yoshida et 
al. 2000). Sarcospan binds to the SGC (Crosbie et al. 1999) and is proposed to have a role in 
clustering DAPCs to form membrane micro-domains (Miller et al. 2007). α-Dystrobrevin, a 
muscle specific dystrobrevin isoform, is proposed to interact with the SGC and dystrophin and 
acts to recruit syntrophins (Nawrotzki et al. 1998, Newey et al. 2000). Syntrophins can interact 
with both dystrophin and dystrobrevins (Newey et al. 2000, Suzuki et al. 1995) and are able to 
recruit and bind a number of adaptor proteins, such as Grb2, and signal transduction 
molecules, such as microtubule associated serine/threonine kinase (MAST), to their PDZ 
domains (Bhat et al. 2013, Oak et al. 2002, Lumeng et al. 1999). Neural nitric oxide synthase 
(nNOS) is another signalling molecule that has been identified to interact with syntrophins and 
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dystrophin and contributes towards a functional DAPC and can modulate calcium homeostasis 
(Lai et al. 2009, Ito et al. 2013). 
Figure 1.2: The dystrophin associated glycoprotein complex.  A schematic representation of the DAPC 
linking the ECM to the actin cytoskeleton. Extracellular αDG binds to components of the ECM and to the 
transmembrane βDG which binds to dystrophin which in turn binds to F-actin. Additional 
transmembrane components of the complex includes α,β,γ and δ Sarcoglycans making up the SGC and 
sarcospan. Syntrophins, α-dystrobrevin and nNOS are intracellular members of the DAPC. The DAPC also 
acts as a scaffold for various adaptor and signalling proteins. The scale and relative positions are for 
simplicity and not to scale. 
The DAPC is a critical adhesion complex and confers protection to muscle cells during their 
contraction and relaxation (Ervasti et al. 1993, Campbell. 1995, Petrof 1998). Indeed, the loss 
or mutation of members of the DAPC leads to muscular dystrophies of varying severity 
(Mercuri et al. 2013, Campbell 1995, Holt et al. 1998). However, the DAPC is not simply a 
physical connection between a cell and its environment and multiple components of the DAPC 
have networks of interacting partners with roles in signal transduction, a number of which 
shall be discussed in the following sections. Importantly, the composition of complexes within 
which DG is found varies both within and between tissues. Thus DG containing complexes have 
both important structural adhesion and signal transduction scaffold roles in multiple tissues. 
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1.3 DYSTROGLYCAN POST-TRANSLATIONAL MODIFICATIONS AND PROTEIN INTERACTIONS 
 
Dystroglycan is a complex protein and undergoes a plethora of post-translational modifications 
(PTM) that are important for its localisation, stability and interaction with a number of binding 
partners.  
1.3.1 Alpha-dystroglycan is highly glycosylated and interacts with the ECM 
The α-dystroglycan subunit is highly glycosylated, the N and C-terminal domains contain 
multiple N-glycosylation sites whilst the mucin-like domain is heavily O-glycosylated 
harbouring at least 21 potential sites of glycosylation (Stalnaker et al. 2010, Yoshida-Moriguchi 
et al. 2015).  There is evidence of multiple, heterogeneous glycosyl structures including O-
manosyl and O-linked –N-acetylglucosamine (Chiba et al. 1997, Tran et al. 2012). The 
glycosylation of α-DG requires the initial presence of the N-terminal domain which is later 
cleaved by furin at residue 312 (Kanagawa et al. 2004, Singh et al. 2004) (Fig 1.3). The extent to 
which αDG is glycosylated depends upon both the developmental stage and the tissue in which 
it is expressed, this is reflected in the range of molecular weights (from 100-200KDa) that αDG 
presents as in western blots of lysates from different tissues (Barresi et al. 2006, Durbeej et al, 
1998, Ervasti et al. 1991, Yamada et al, 1994). A number of ECM components that contain a 
laminin G (LG) binding module (Hohenester et al. 1999) including laminins (Ervasti et al. 1993, 
Chiba et al. 1997), agrins (Bowe et al.1994) and perlecan (Talts et al. 1999, Peng et al. 1998) 
interact with α-DG through the O-glycans decorating the mucin-like domain whilst biglycan 
binds to the N-terminal domain of αDG (Bowe et al. 2000). Preventing the correct O-
mannosylation (Chiba et al. 1997), including its phosphorylation (Yoshida-Moriguchi et al. 
2010) and other glycosylation events (Combs et al. 2005) of the mucin-like domain of αDG 
inhibits its ability to act as an ECM receptor (Ervasti et al. 1993), indeed hypoglycosylation of 
αDG is implicated in multiple diseases (See section 1.5) (Barresi et al. 2006). Disrupting the N-
glycosylation, however does not disrupt α-DG’s ECM receptor function (Ervasti et al. 1993) and 
the interaction between the α- and βDG subunits occurs in a glycosylation-independent 
manner (Di Stasio et al. 1999, Sciandra et al. 2001). It is thought that the heterogeneity in 
glycosylation of αDG across tissues enables the fine tuning of binding to relevant ECM 
components (Yoshida-Moriguchi et al. 2015). αDG also acts as a receptor for various pathogens 
including Mycobacterium leprae (Rambukkana et al. 1998), Lassa Virus and lymphocytic 
choromeningitis viruses (Cao et al. 1998), again in a glycosylation dependent manner (Kunz et 
al. 2005) and a DG-like protein in ticks, I. scapulatris dystroglycan-like protein (ISDLP) is 
important for the migration from the gut of Borrelia burgdorferi, the causative agent of Lymes 




Figure 1.3 Posttranslational modifications of dystroglycan. (Top) Cartoon depicting known and 
predicted PTM of DG including proteolytic cleavage by and the resulting fragments, glycosylation, 
ubiquitination, sumoylation and phosphorylation. (Bottom) PTM annotated sequence of β-dystroglycan. 
yellow residues: Transmembrane domain, Green residues: NLS, orange residue: reported site of 
palmitoylation, Purple residues: Potential/ reported sites of ubiquitination, red residues: Reported sites 
of phosphorylation by mass spectrometry studies, validated Y892 phosphorylation site is enlarged. Grey 





1.3.2 Beta-Dystroglycan: a highly modified structural scaffold and signal transducer 
βDG is a complex subunit that is dynamically regulated by multiple PTM (Fig 1.3) and interacts 
with a growing number of protein partners (Fig 1.4), overthrowing the notion that dystroglycan 
is a simple adhesion receptor. 
1.3.2.1 Post-translational modifications of βDG 
Like the α subunit, βDG is also glycosylated with a small number of N-glycosylation sites 
identified in its ectodomain, although the functional relevance of these modifications is as yet 
unknown (Holt et al. 1998, Mitchell et al. 2013, Zielinska et al. 2010) (Fig 1.3). A little studied 
PTM of βDG is palmitoylation. During a global study of palmitoylated proteins in neural cells 
Cys774, situated at the transmembrane domain boundary of βDG, was identified as a site of 
palmitoylation (Kang et al. 2008) and was also identified in mass spectrometry analysis of βDG 
in LNCaP cells (Leocadio, 2014) (Fig 1.3). Whilst there have been no further studies into this 
modification, palmitoylation has been demonstrated to play a role in the retention of proteins 
at the plasma membrane (Linder et al. 2007). Furthermore, it is a reversible modification and 
as such may be an important regulator of βDG localisation (Linder et al. 2007). 
One of the best studied PTM of βDG is phosphorylation. Phosphorylation at a tyrosine residue 
(Y892 in human, Y890 in mice) within the extreme C-terminus of the cytoplasmic domain of 
βDG is an important regulator of βDG (Fig 1.3). Phosphorylation at Y892 is catalysed by c-Src 
(Sotgia et al 2001). Phosphorylation of βDG is proposed to occur in an adhesion dependent 
manner following an observed electrophoretic shift of βDG as detected by anti-DG and 
phospho-tyrosine antibodies in adhered compared to suspended HeLa cells (James et al 2000). 
The site of phosphorylation was identified at Y892 through a combination of site specific 
monoclonal antibodies and peptide spot arrays of the cytoplasmic domain of βDG (James et al 
2000). Interestingly, phosphorylation at Y892 within the PPxY motif has been shown to 
modulate the interaction of βDG with its WW and SH2 domain containing binding partners.  
(James et al. 2000, Ilsley et al. 2001, Sotgia et al. 2001)(see below). Furthermore, it has been 
shown that phosphorylation at residue Y892 results in the internalisation of βDG from the 
plasma membrane and targeting to the late endosomes (Sotgia et al. 2003, Miller et al. 2012) 
as well as potentially its ubiquitination and subsequent degradation (Miller et al. 2012). 
Phosphorylation at Y892 is also induced by lassa virus binding and helps to facilitate virus 
internalisation (Moraz et al. 2013). Y892 is the only site to have been confirmed to be 
phosphorylated by site specific methods (James et al. 2000). However, in cells treated with src 
inhibitors, whilst phosphorylation at Y892 was inhibited, βDG was still detected by an anti-
phospho tyrosine antibody, indicative of additional tyrosine residues that could be 
phosphorylated by non-src kinases (Moraz et al. 2013). Furthermore, there is evidence in the 
form of 2D gel electrophoresis combined with phospho- specific antibodies (James et al. 2000), 
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high-throughput mass spectrometry analysis (Hornbeck et al. 2014) and in silico analysis of 
consensus sites (Gould et al. 2010), for the phosphorylation of additional tyrosine, threonine 
and serine residues within the cytoplasmic tail of βDG (Fig 1.3). As yet the functional roles of 
these putative phospho-sites are unknown but hint at additional levels of regulation for βDG.  
As mentioned above there are reports of the ubiquitination of DG (Miller et al. 2012). 
Dystrophic mdx mice in which DAPC components are lost from the PM saw a restoration of 
βDG at the PM upon treatment with the proteasomal inhibitor MG-132 (Bonuccelli et al. 
2003). Additionally, in lysates obtained from in vitro models, MG-132 treatment resulted in 
increased levels of βDG and its fragments (see below) (Leocadio et al. 2016). Whilst not direct 
evidence of DG ubiquitination, these studies hint at a role for the ubiquitin proteasome system 
in DG fate. Importantly, ubiquitination at sites within βDG has been identified by mass 
spectrometry studies (Kim et al. 2011, Lee et al. 2011) and βDG is detected upon pull-down 
with Multi-Dsk (Miller et al. 2012), a high affinity resin specifically detecting ubiquitinated 
proteins (Wilson et al. 2012). Interestingly, the species of βDG isolated with MultiDsk was 
detected with a pY892 specific antibody, suggesting interplay between these forms of 
modifications (Miller et al. 2012). The importance of ubiquitination on βDG interaction, 
modifications and turnover requires further investigation but is crucial given the vital 
functional roles of DG. It should also be noted that there is preliminary evidence of the 
sumoylation of βDG (S. Winder, personal communication). Small Ubiquitin-like Modifiers 
(SUMO) proteins are structurally similar to ubiquitin and have roles in localisation, protein 
stability and transcriptional activity of modified target proteins (Flotho et al. 2013).  
Finally, βDG can be proteolytically cleaved into a 31 KDa and a 26 KDa fragment by MMP-2 and 
-9 and γ-secretase or furin respectively (Yamada et al. 2001., Leocadio et al. 2016) The 
cleavage of βDG by MMPs is proposed to occur within the ectodomain as the fragment retains 
the transmembrane domain and is detected by antibodies recognising the cytoplasmic C-
terminal tail (Yamada et al. 2001, Bozzi et al. 2009, Zhong et al. 2006). The 26 KDa fragment is 
a result of regulated intramembrane proteolysis (RIP) within the transmembrane domain, 
again this fragment is detected by C-terminal targeted antibodies (Hemming et al. 2008, 
Leocadio et al. 2016). Cleavage of proteins by γ-secretase is often preceded by the N-terminal 
proteolysis of their targets by an additional protease (Wolfe, 2010, Hemming et al. 2008), for 
example MMPs, thus suggesting a sequential processing of the fragments of βDG. There is also 
some evidence for the cleavage of βDG by furin at a juxtamembrane site, as seen in the 
increase in the levels of the 26 KDa fragment upon treatment with a furin 1 inhibitor 
(Decanoyl-RVKR-CMK) (Leocadio et al. 2016). The fate of these C-terminal fragments of βDG is 
unclear, however they can be detected to varying extents within the nuclear and cytoplasmic 
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fractions of biochemically fractionated cells (Mathew et al. 2013, Mitchell et al. 2013, Leocadio 
et al. 2016). Furthermore, nothing is known about the fate of the N-terminal portions of the 
cleaved DG as there are no antibodies targeted to these regions. The 26KDa fragment retains 
the putative palmitoylated Cys residue and therefore there is still the possibility that it may be 
retained at the PM. It is unclear if the fragments are simply targeted for degradation, indeed 
the fragments increased upon MG-132 treatment (Leocadio et al. 2016). However, the 
fragments may also have functional roles. The fragments both contain multiple sites of 
interactions with binding partners (Gould et al. 2010, Sotgia et al. 2001, James et al. 2000) and 
their nuclear targeting results in altered gene expression (See section 1.6.4 ) (Mathew et al. 
2013). The principle of PM protein fragments being cleaved to perform signalling roles in not 
unfamiliar, with well characterised examples being the EGF receptor and Notch (Wang and 
Hung, 2012). Thus understanding the fate of the cytoplasmic fragments of βDG may provide 
further levels of regulation and functions to an already complex protein. Furthermore, the 
cleavage and loss of βDG from the plasma membrane has been implicated in multiple diseases 
including muscular dystrophies (Matsumura et al. 2015) and cancer (Singh et al. 2004, Cross et 
al. 2008, Mitchell et al. 2013, Leocadio et al. 2016) and thus gaining an understanding into βDG 
proteolytic cleavage may provide important insights into disease mechanisms (see section 1.5). 
1.3.2.2 βDG as a scaffold for multiple binding partners 
βDG also forms multiple interactions with a plethora of binding partners which enables it to 
fulfil its mechanical role as well as establishing βDG as a signal transduction hub (Moore et al. 
2010) (Fig 1.4). The complexes DG forms vary across the tissues and depend upon its post-
translational modifications, its adhesion state and other binding interactions, indeed these 
events are often inextricably linked (Moore et al. 2010, Ilsley et al. 2001, Sotgia et al. 2003). 
Within its cytoplasmic tail βDG contains consensus binding sites for WW (Ilsley et al. 2001, 
James et al. 2000, Sotgia et al. 2000), SH2 (Sotgia et al. 2001) and SH3 domain containing 
proteins (Russo et al. 1995, Yang et al. 1995) (Fig 1.4). In its role as an adhesion receptor βDG 
interacts with the C-terminal WW domain of dystrophin or utrophin, an approximately 30 aa 
region containing two conserved tryptophans, via the proline rich PPxY motif at its extreme C-
terminus (Huang et al 2000, Pereboev et al 2001, Ilsley et al. 2001, Ilsley et al. 2002, Jung et al. 
1995, James et al. 2000). In the case of dystrophin and utrophin the WW domain is necessary 
but not sufficient for interaction with βDG and also requires interaction with the EF-hand-like 
region for stabilisation and orientation of the interaction (Rentschler et al. 1999, Jung et al. 
1995). The DG-Dystrophin/utrophin interaction is a good example of the tissue specificity and 




Figure 1.4 Dystroglycan and putative sites of protein interaction. (Top) Cartoon of dystroglycan with 
identified sites of protein interactions with SH2, SH3 and WW domain proteins interacting at the C-
terminus of βDG and the proteins interacting at the ‘hotspot’ overlapping with the NLS. Proteins are 
indicated as having roles in signal transduction (*) or cytoskeleton binding and stabilisation(ǂ) (Adapted 
from Leocadio 2014). Interaction sequence within βDG is indicated. (Bottom) Annotated sequence of β-
dystroglycan with putative sites of interaction as determined by ELM underlined. Yellow residues: 
Transmembrane domain, Green residues: NLS, grey underline: SH2 motifs. Blue underline: SH3 motifs. 
Pink underline: WW motifs, Red underline: site of multiple interactions ‘hotspot’ including ERK, Ezrin 
and Rapsyn.  
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The dystrophin gene has multiple promoters and can produce multiple isoforms of varying 
lengths and tissue specificity which can form DAPC like complexes (Muntoni et al. 2003). Full 
length dystrophin can be expressed from three tissue specific promoters and is expressed in 
the muscle and cardiac tissue with small amounts in the brain (Torelli et al. 1999), the 
hippocampus (Gorecki et al. 1992) and the purkinje fibres (Bies et al. 1992). Alternative 
promoters result in shorter isoforms such as Dp140 which is expressed in the brain, retina and 
kidneys (Lidov et al. 1995) whilst a short Dp71 isoform is expressed largely in non-muscle 
tissues (Bar et al. 1990). Alternatively, utrophin is a ubiquitously expressed homologue of 
dystrophin with high level of homology (Pearce et al. 1993) that fulfils the cytoskeletal linker 
role in non-muscle tissues as well as muscle tissues (Durbeej et al. 1999, James et al. 1996, Thi 
Man et al. 1995, Winder et al. 1995) binding DG in the same manner as dystrophin (Ilsley et al. 
2001). Moreover residue Y892, a key site of phosphorylation within βDG, lies within the PPxY 
binding motif of DG. Immunoprecipitation experiments with phosphorylated and 
unphosphorylated βDG as well as binding studies using peptide arrays of the cytoplasmic 
domain of βDG indicate that phosphorylation at Y892 of βDG disrupts its interaction with 
dystrophin and utrophin (Ilsley et al. 2001, James et al. 2000, Pereboev et al 2001). As 
discussed above this phosphorylation occurs in an adhesion dependent manner (Ilsley et al. 
2001, Sotgia et al. 2003), thus demonstrating the role of βDG in facilitating internal response to 
external stimuli. It is likely that additional, unknown factors contribute to the phosphorylation 
status of pY892 and within a cell βDG may be phosphorylated and dephosphorylated in a 
stochastic manner.  Importantly, phosphorylation and disruption of dystrophin/utrophin 
interactions at this site enables a variety of outcomes for βDG including its internalisation 
(Sotgia et al. 2003, Miller et al. 2012), degradation (Miller et al. 2012, Lipscomb et al. 2016) or 
interaction with different binding partners (Sotgia et al. 2001) all of which can affect the 
adhesion and signalling properties of a cell.  
In addition to dystrophin and utrophin, Caveolin-3, a protein with roles in membrane domain 
organisation, was identified as interacting with the PPxY site through its WW domain although 
is insensitive to phosphorylation at Y892 (Sotgia et al. 2000, Ilsley et al. 2001). The 
phosphorylation of Y892 not only promotes the release of WW domain partners but also 
creates an SH2 binding site pYxPP. A number of SH2 domain containing proteins including 
tyrosine kinases c-Src, Fyn, Csk and the adaptor proteins NCK and SHC have been shown to 
interact with βDG at this site (Sotgia et al. 2001).  Moreover, an interaction site, RxxxPxxP, for 
SH3 domain proteins has also been found to overlap with the C-terminal WW and SH2 binding 
sites (Moore et al. 2010). Grb2, an adaptor protein with roles in the Ras-MAP kinase signalling 
cascade, has been shown to bind at this site through its SH3 domain (Russo et al. 2000, Yang et 
al. 1995). Vinexin, a binding partner of vinculin found at focal adhesions (Thompson et al. 
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2010), and Tsk5 a scaffolding protein with roles in podosome formation (Thompson et al. 
2008) can also bind to the C-terminal of βDG via their SH3 domains.  
In addition to the C-terminal region a cytoplasmic site, close to the trans-membrane domain, 
has been identified as a ‘hot-spot’ for the interaction of binding partners with βDG (Moore et 
al. 2010) (Fig 1.4). An NLS which binds importins has been identified at this site (Lara-Chacon et 
al. 2010, Oppizzi et al. 2008) (Discussed further in section 1.6). βDG has been shown to interact 
with ERM (Ezrin, Radixin, Moesin) family member, Ezrin and its binding site was identified as 
RKKRK, overlapping with the NLS (Spence et al. 2004a). ERM family proteins can link actin and 
microtubule networks to plasma membrane proteins and as such have key roles in cell 
adhesion, polarity and shape but also in signal transduction (Louvet-Vallee, 2000). It has been 
shown in REF52 cells that following ezrin binding to DG, a Rho GEF; Dbl was recruited to the 
plasma membrane where it locally activated the Rho GTPase Cdc42 and subsequently drove 
filopodia formation (Batchelor et al. 2007). Additionally, DG has been shown to act as a 
scaffold for Ras-MAP kinase pathway components MEK and ERK. DG is not a substrate nor 
does it affect the activity of these kinases, however it appears to sequester these components 
at different locations at the membrane (Spence et al. 2004b). Again the binding site for ERK 
(RKKRKxxLxL) overlaps with the NLS and ezrin interaction site on βDG (Moore et al. 2010). 
Rapsyn, which interacts with and clusters nicotinic acetylcholine receptors at the 
neuromuscular junctions also interacts with βDG at the juxta-NLS site (Kahl et al. 2003) (Fig 
1.4).  
The above selection of βDG interactions demonstrates how βDG can act as a scaffold for 
proteins involved in a variety of important processes including membrane organisation and 
remodelling (Thompson et al. 2010, Thompson et al. 2008, Batchelor et al. 2007, Spence et al. 
2004a, Kahl et al. 2003), mechanical strength (James et al. 2000, Ilsley et al. 2001) and multiple 
signalling pathways (Spence et al. 2004b, Sotgia et al. 2001, Yang et al. 1995). The overlapping 
sites of interaction likely provide a means of regulating the binding partners and functions of 
βDG through competitive interactions and can be fine-tuned by PTM in response to the 
external environment (Moore et al. 2010, Sotgia et al. 2001, Ilsley et al. 2001). Moreover, it is 
important to note that other components of the DGC act as signalling scaffolds, such as 
syntrophin and dystrophin (Bhat et al. 2013, Oak et al. 2002, Lumeng et al. 1999) and that the 
DGC itself associates with other signalling hubs such as the integrin-talin-vinculin signalling hub 
in cardiac muscle (Anastasi et al. 2009). Furthermore, there is crosstalk between the signalling 
hubs as is seen in the case of the inhibitory modulation of βDG on the ERK activation of α6β1 
integrin (Ferletta et al. 2003). The presence of additional putative interaction sites with the 
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cytoplasmic region of βDG and its localisation at multiple cellular locations (See section 1.6) 
hints at further unknown interactions and roles for this complex protein. 
1.4 DYSTROGLYCAN: IMPORTANT ROLES IN DEVELOPMENT AND TISSUE HOMEOSTASIS 
 
DG has been implicated in a broad range of processes including cell adhesion (Ervasti et al. 
1993, Thompson et al, 2010, Galvagni et al. 2016), polarity (Deng et al, 2003, Weir et al. 2006, 
Schroder et al. 2007),  migration and invasion (Thompson et al. 2008, Batchelor et al. 2007, 
Mitchell et al. 2012, Galvagni et al. 2016), neuromuscular junction composition (Deyst et al. 
1995, Cohen et al. 1995, Peng et al. 1998, Kahl et al. 2003), proliferation (Hosokawa et al. 
2001, Sgambato et al. 2006, Higginson et al. 2008, Mitchell et al. 2012), differentiation 
(Schroder et al. Sgambato et al. 2006) and cell death (Langenbach et al. 2002) Furthermore, 
the functions of DG are by no means completely understood and new roles are constantly 
emerging. 
DG has important roles in development and tissue homeostasis. The vital role of DG during 
development is seen in the embryonic lethality at embryonic day 6.5 of DAG1 deletion in mice 
in which there is disruption of the formation of Reichart’s membrane and subsequent 
implantation defects (Williamson et al. 1997).  DG has also been proposed to have roles in 
basement membrane formation (Henry and Campbell, 1998) maybe through the organisation 
of laminins in the ECM (Cohen et al. 1997. Henry et al. 2001). Chimeric mice demonstrated 
progressive muscular dystrophy (Côté et al. 1999).  Drosophila have multiple DG isoforms but 
just one containing a mucin-like region (Schneider et al. 2006) however RNAi silencing of DG 
results in muscle degeneration, neuronal and eye abnormalities (Shcherbata et al. 2007) and 
disrupting the binding capabilities of DG can result in oocyte arrest (Yatsenko et al. 2009).  
Dystroglycan null zebrafish are viable, however they display a number of defects including 
dystrophic muscles and abnormal brain and eye structure (Gupta et al. 2011). The loss or 
disruption of DG in animal models has clear implications in maintaining healthy muscles but its 
ubiquitous nature also underlies important functions in other tissues (Sciandra et al. 2015). 
Blocking the binding of dystroglycan to laminins resulted in defects in branching of epithelial 
organs including the lungs, kidney and salivary glands (Durbeej et al. 1995, Durbeej et al. 
2001). Conditional knockouts in mice have shown that DG is also important for the 
development and organisation of multiple neuronal structures such as branching of 
oligodendria (Eyermann et al. 2012) and formation of the myelin sheath and NMJ, (Côté  et al. 
1999, Saito et al. 2003, Kahl et al. 2003, Jacobson et al. 1998) and clustering of sodium 




1.5 DYSTROGLYCAN IN DISEASE 
 
Given the wide range of cellular roles of DG and the severe defects seen in animal models in 
which DG function is abrogated, it is of no surprise that DG has been implicated in multiple 
human diseases. 
1.5.1 Dystroglycan in Muscular Dystrophies 
Muscular dystrophies are a group of heterogeneous diseases characterised by the progressive 
degeneration of muscle tissue. Many muscular dystrophies are a consequence of mutated 
DAPC components or nuclear membrane proteins (Mercuri et al. 2013). Given its important 
roles in muscle it is unsurprising that a large body of the studies on DG are with regards to its 
context in the DAPC and muscular dystrophies. Indeed, the initial characterisation was a 
consequence of a study of binding partners for dystrophin (Ibraghimov-Beskronaya et al. 
1993), which is lost from the sarcolemma in the X-linked, inherited Duchenne Muscular 
Dystrophy (DMD) (Koenig et al. 1987, Campbell, 1995). In DMD the absence of dystrophin 
results in the loss of multiple components of the DAPC, including DG, from the sarcolemmal 
membrane (Campbell, 1995, Ervasti et al. 1990). Subsequently there is a weakening of muscle 
fibres and increased fibrosis of the muscle tissue resulting in eventual loss of ambulation 
(Mercuri et al. 2013). DMD patients also have respiratory and cardiac weakness (Mercuri et al. 
2013). Interestingly it has been observed that there is an increase in the 31 kDa fragment of 
βDG as a consequence of MMP-2/9 cleavage of its ectodomain in DMD and 
sarcoglycanopathies but not other muscular dystrophies (Matsumura et al. 2005). Thus the 
proteolytic cleavage of βDG is another mechanism through which the ECM- cell interaction is 
disrupted and can contribute to muscle degeneration in DMD patients. 
More than 200 mutations, including point mutations, deletions and duplications within the 
DMD gene have been reported, resulting in DMD or the related Becker Muscular Dystrophy 
(BMD) which retains a short form of dystrophin and displays a milder phenotype than DMD 
(Koenig et al. 1989). A large proportion of current research into therapeutic approaches for the 
treatment of DMD aims at restoring shorter, yet functional versions, of dystrophin in muscle 
cells, which in turn should recruit other DAPC components to the sarcolemma. For example, 
exon skipping is being developed for use in patients in which a deletion has caused a frame 
shift mutation and subsequently prevents the expression of functional dystrophin (Kole et al. 
2015). Targeting of antisense oligonucleotides to splice sites within the pre-mRNA results in 
the ‘skipping’ of the mutated exons, restoring the reading frame and enabling the production 
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of a shorter but functional dystrophin protein (Kole et al. 2015). Other approaches aim to 
upregulate expression of utrophin, a dystrophin homologue, which can also form functional 
complexes at the sarcolemma (Miura et al. 2006). Other components of the DAPC are also 
potential therapeutic targets for the treatment of DMD and BMD. Overexpressing DG in a 
DMD model, the Mdx mouse, did not improve the DMD phenotype or restore DAPC 
components to the membrane (Hoyte et al. 2004) however another approach is aiming to 
retain DG at the plasma membrane rather than altering the overall levels of the protein. The 
hypothesis is that by targeting PTM of DG, such as phosphorylation or ubiquitination, which 
control its degradation and internalisation there will be an increased level of DG at the PM, 
which may recruit other components of the DAPC and therefore partially restore some of its 
function and reduce the dystrophic phenotype (Miller et al. 2012, Lipscomb et al. 2016). 
Dystroglycan is also implicated more directly in a number of muscular dystrophies termed 
dystroglycanopathies (See below). 
1.5.1.1 Primary Dystroglycanopathies 
Mutations in DAG1 itself in humans are rare with only four reported cases to date, a telling 
indicator of the crucial roles that DG fulfils. The first patient identified was a 16 year old girl 
with a heterozygous deletion of ~2MB in chromosome 3 (Frost et al. 2010). The patient 
presented white matter abnormalities, learning difficulties and facial hypotonia and mild 
myopathy (Frost et al. 2010). Upon further investigation it was shown that that patient had a 
60% reduction in DAG1 mRNA levels compared to wild-type tissue, however the deletion also 
includes the sequence for 62 protein coding genes and 3 miRNAs, thus the symptoms may not 
be attributed solely to the DG deficiency (Frost et al. 2010). A second patient had a 
homozygous missense mutation converting Thr192 to a methionine (Hara et al. 2011). This 
mutation disrupted the receptor capabilities of DG by inhibiting its O-glycosylation by LARGE 
by disrupting its binding site within the N-terminus of αDG (Hara et al. 2011, Kanagawa et al. 
2004). The patient had Limb-girdle Muscular Dystrophy and mental retardation. The same 
mutation in mice caused consistent skeletal muscle abnormalities and neurological impairment 
(Hara et al. 2011).  Two siblings were found to have a homozygous missense mutation in the 
DAG1 resulting in a cysteine to phenylalanine substitution at residue 669 within the 
ectodomain of βDG (Geis et al. 2013). As a result the patients had severe muscle-eye-brain 
(MEB) disease as well as macrocephaly and multicystic white matter disease (Geis et al. 2013). 
The above cases demonstrate the effects of reduced levels of DG or preventing PTM, such as 
glycosylation, of DG on health and development. In the most recently reported patients (5 
patients from a consanguineous family) however, there was an absence of both α and β DG 
core proteins (Riemersma et al. 2015).  A homozygous single base pair deletion at nucleotide 
743 resulted in a frameshift and a premature stop codon at residue 248 (p.Ala248Glufs*19) 
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with subsequent biochemical analysis detecting a small PCR product but no alternative spice 
products, no core protein as detected by immunoblot and no laminin binding in a laminin 
overlay assay of cultured patient myotubes (Riemersma et al. 2015). The patients had Walker-
Warburg syndrome (WWS) displaying congenital muscular dystrophy, hydrocephaly and ocular 
malformations with infantile death at ages from a couple of hours to 3.5 months as a result of 
respiratory failure or aspiration pneumonia, tragically reinforcing the crucial and wide-reaching 
functions of DG (Riemersma et al. 2015).  
1.5.1.2 Secondary Dystroglycanopathies 
As previously described, the PTM of DG are crucial to its function. Interestingly, a number of 
diseases have been linked to genes which affect the PTM of DG as opposed to DAG1 itself and 
have been termed secondary dystroglycanopathies (Godfrey et al. 2011). Secondary 
dystroglycanopathies are more common than primary, with 18 genes identified as the 
causative factors behind secondary dystroglycanopathies to date (Table 1.1) (Taniguchi-Ikeda 
et al. 2016). The majority of these genes have roles in the modification of αDG with the 
glycosyl moieties that are so important in its receptor function. Diseases that are represented 
within the secondary dystroglycanopathies include a number of LGMD, MEB, Fukuyama 
congenital muscular dystrophy (FCMD), and WWS. These heterogenous groups of muscular 
dystrophies occasionally occur in conjunction with ocular and brain abnormalities (Godfrey et 
al. 2011, Yoshida-Moriguchi et al. 2015). Different mutations within the same gene can cause 
different diseases as is the case with FKTN, mutation in which can cause FCMD, WWS and 
LGMD (Kobayashi et al. 1998, De Bernabe et al. 2003, Puckett et al. 2009).  In the case of some 
genes such as POMT1 and POMT2 the severity of the disease correlated positively with 
hypoglycosylation of αDG, however this does not hold true for all genes (Jimenez-Mallebrera 
et al. 2009). Furthermore, the enzymes encoded by the dystroglycanopathy genes often have 
multiple substrates and therefore the resulting disease phenotypes and their varying severity 












Table 1.1 Proteins identified as mutated in secondary dystroglycanopathies (Adapted from 






1.5.2.1 ECM-Cell interactions in cancer 
Alterations in ECM components, ECM receptors and components of the acto-myosin 
cytoskeleton results in the loss of normal tissue architecture, increased proliferation and 
invasion and metastasis of surrounding tissue, all features of cancer progression (Hu et al. 
2008, Olson et al. 2009, Zutter et al. 1995). Indeed, mutations in these groups of proteins are 
highly represented in exome studies of cancer patients (Shah et al. 2012).  Additionally, the 
composition and properties of the ECM are altered in cancer patients, with increased cross-
linking, deposition and proteolysis of ECM components (Levental et al. 2009, Provenzano et al. 
2006, Xu et al. 2001), with ECM modifiers frequently reported as upregulated in cancer 
patients and models. 
 There is a complex, reciprocal relationship between the ECM and the cell, the tight regulation 
of which is lost upon oncogenic transformation (Van Dijk et al. 2013).  Cell proliferation, 
survival, differentiation, adhesion and migration can all be regulated by the composition and 
mechanical properties of the ECM (Beattie et al. 2010, Bae et al. 2014, Baker et al. 2013, 
Levental et al. 2009, Calvacanti- Adam et al. 2006). Furthermore invasion of cells requires 
degradation of the surrounding ECM and, in the case of mesenchymal migration, there is often 
the formation of specialised invadosome structures which are enriched in and regulated by 
adhesion molecules (Ridley et al. 2003, Beaty et al. 2014, Kelly et al. 1994, Brooks et al. 1996). 
The interaction between the cell and the ECM is also regulated by the subsets, levels and 
activities of adhesion receptors expressed at the PM (Hua et al. 1993, Zutter et al. 1995, 
Desgrosellier et al. 2010). 
Integrins are extremely well characterised adhesion receptors, binding to ECM components 
such as collagen and fibronectin, and can contribute to the malignant transformation of cells 
through a number of processes. Integrin levels vary in cancers, with αvβ3 levels upregulated in 
some cancers whilst α2β1 is downregulated in a number of cancers, with both instances 
correlating with poor prognosis (Desgrosellier et al. 2010, Takayama et al. 2005). Moreover, 
the vesicular recycling of integrin at the PM is reported as altered in cancers through a number 
of mechanisms, including altered levels of proteins involved in its vesicular transport (Cheng et 
al. 2004, Caswell et al. 2007), and its PTM regulation such as phosphorylation by c-src, which 
modulates the interaction with important intracellular binding partners and signalling 
molecules (Oxley et al. 2008).  Consequently the adhesion mediated integrin signalling 
pathways are disrupted, including the ERK MAPK regulation of cell cycle progression (Moro et 
al. 1998, Walker et al. 2005). Furthermore, invadopodia are integrin- rich structures and 
integrins are implicated in the early stages of their formation, stabilising the structure and 
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promoting its maturation (Beaty et al. 2014, Beaty et al. 2013, Destaing et al. 2010). Normal 
growth requires a balance of signals from different adhesion receptors, including integrins but 
also, syndecans, and other glycoprotein receptors such as CD44, CD36 and DG (Desgrosellier et 
al. 2010, Hua et al. 1993, Durbeej et al. 1998, Chung et al. 2016). Investigating the distinct 
contributions of the different adhesion receptors is important in the understanding of 
mechanisms of cancer progression. 
1.5.2.2 Dystroglycan in cancer 
 As a ubiquitously expressed adhesion receptor the interaction of DG with the ECM provides an 
important physical tether between the cell and its environment (Ervasti et al. 1993) but also 
regulates ECM organisation (Williamson et al. 1997, Henry et al. 2001b), cytoskeletal 
organisation (Spence et al. 2004a, Thompson et al. 2008) and signal transduction events 
(Spence et al 2004b, Ferletta et al 2003, Yang et al. 1885, Sotgia et al.2001) and ultimately cell 
proliferation, differentiation, polarity, survival and migration (Fig 1.5). All of the above 
processes are crucial in normal tissue homeostasis and when aberrant are drivers of cancer 
development and progression.  
Dystroglycan has been shown to be important for normal branching epithelial morphogenesis 
in tissues such as the kidney and salivary gland (Durbeej et al. 19997), moreover the loss of DG 
has been reported in numerous adenocarcinomas (Cross et al. 2008). Epithelial carcinomas 
including oesophageal (Parberry-Clark et al. 2011, Cross et al. 2008), colon (Losasso et al. 2000, 
Sgambato et al. 2003), skin and squamous cell (Jing et al. 2004, Herzog et al. 2004, Shang et al. 
2008), cervical (Sgambato et al. 2006), renal cell (Sgambato et al. 2010), breast (Henry et al. 
2001, Muschler et al. 2002, Sgambato et al. 2003, Cross et al. 2008) and prostate (Henry et al. 
2001, Sgambato et al. 2007b, Mathew et al. 2013) cancer have reported a reduction in DG 
protein expression from the PM in comparison to benign tissue. Moreover, this progressive loss 
of DG correlated to higher grade, more aggressive tumours and the ability to metastasise 
(Mathew et al. 2013, Mitchell et al. 2013, Sgambato et al. 2010, Esser et al. 2013). A number of 
groups have examined the impact of βDG expression on the growth and behaviour of cancer 
cells. Sgambato et al. observed that overexpression of DG had an inhibitory effect on cell growth 
and reduced tumourigenicity in mice, an effect also observed in breast cancer cell lines 
(Sgambato et al, 2007, Sgambato et al., 2006). This work was expanded upon in a study by 
Mitchell et al in which shRNA depletion of DG in prostate cancer cell lines saw an increase in 
growth on soft agar and a reduction in invasive capability whilst overexpression of DG abolished 
growth on soft agar and increased invasion (Mitchell et al., 2013). Consequently, a model was 
proposed in which initial loss of functional DG in the primary tumour promotes tumour growth 
and disruption of ECM organisation but at later stages an increase in DG may be required for 
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MET and anchorage of invading cells at secondary sites (Mitchell et al. 2013). This is supported 
by the re-expression of DG in some metastatic samples in an immunohistochemical study 
(Mitchell et al, 2013, Mathew et al.2013). One group has also reported a potential role for DG in 
angiogenesis based upon the observation of dynamic expression levels of DG in vascular 
endothelial cells regulating proliferation, migration and formation of tubes in matrigel assays 
(Hosokawa et al. 2002).  Combined the above information suggests a potential role for DG in 
epithelial carcinoma progression although the precise mechanisms through which it achieves 
this requires further validation. It is therefore important to understand not only the functions of 
DG which could contribute to this process but also the mechanisms behind its regulation.  
The loss of functional DG in carcinomas does not appear to be a consequence of reduced 
transcription or mutations of DAG1¸rather it is a consequence of altered PTM (Singh et al. 2004, 
Bao et al. 2009) (Fig 1.5). A number of groups are therefore addressing the question of the 
underlying mechanisms of reduced DG and the contributions of these to cancer progression. 
Once again the glycosylation status of αDG is highly implicated in its disease contribution, with 
hypoglycosylation of the α subunit reported in prostate (Bao et al. 2009, Shimojo et al. 2011, 
Esser et al. 2013), breast (Muschler et al, 2002, Singh et al. 2004), colon (Singh et al. 2004, 
Losasso et al. 20000) and clear cell renal cell carcinoma (Miller et al. 2015). Furthermore, 
glycosylation inversely correlates with the Gleason scores of prostate cancers (Esser et al 2012). 
Reduced glycosylation of αDG perturbs its binding to laminin and other ECM components and 
disrupts downstream signalling cascades (Chiba et al. 1997, Yoshida-Moriguchi et al. 2015). The 
loss of anchoring to laminin has been reported to be widespread in cancers and was 
characteristic of aggressive cancer subtypes (Akhavan et al. 2012). The importance of this 
interaction in cancer was further demonstrated by Bao et al. in prostate cancer cells in which 
reduced levels of laminin binding glycans, including of DG, resulted in increased cell migration 
and tumour formation compared to their glycosylated counterparts (Bao et al. 2009). The 
reduced glycosylation and increased invasion correlated with reduced expression of 
glycosyltransferases β3GnT1 and LARGE, key enzymes in the glycosylation of αDG which, along 
with ISPD, have been reported as downregulated in a number of human cancers, correlating 
with reduced DG glycosylation and poor prognosis (Bao et al. 2009, Esser et al. 2013, Miller et 
al. 2015). In prostate cancer the loss of LARGE was a consequence of the important EMT 
transcription factors snail and zeb1 (Huang et al. 2015). Increased invasion of cells as a 
consequence of hypoglycosylation is reduced upon overexpression of β3GnT1 or LARGE and a 
more specific role of αDG demonstrated by increasing migration by blocking the αDG-laminin 





Figure 1.5: Aberrant modifications and potential contributions of DG in cancer. Cartoon of 
dystroglycan with known aberrant modifications and processing of DG highlighted in red. Increased 
levels of Src and subsequent phosphorylation and abnormal androgen receptor (AR) signalling have all 
been hypothesised as potential causes of disrupted DG regulation including potential changes to its 
interactions, recycling, degradation and nuclear translocation. These changes may ultimately alter the 
regulation of genes, ECM adhesion and signalling pathways and consequently alter the ability of the cell 
to survive, migrate, proliferate and differentiate, all of which can contribute to cancer progression,  
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Whilst hypoglycosylation of DG is a clear feature of many cancers, if and how this contributes to 
the disease progression is more difficult to unravel. The signalling cascades modulated by DG 
binding to the ECM are likely to be perturbed upon hypoglycosylation of the α subunit, indeed 
levels of phospho-ERK and phospho-AKT were increased in cells in which αDG, β3GnT1 or LARGE 
were depleted by RNAi (Bao et al. 2009). DG can sequester ERK and MEK of the MAPK cascade 
and has been shown to modulate integrin signalling pathways (Spence et al. 2004, Ferletta et al. 
2003), thus loss of DG function may contribute to cancer progression by disrupting the fine 
balance of signalling from ECM receptors. Furthermore, laminin can be internalised by 
endocytosis and this process is disrupted in cancers in which DG function is perturbed and 
restored by DG re-expression. (Leonoudakis et al. 2014) The majority of the internalised laminin 
was transported through the late endosome for degradation, however, other than ECM 
remodelling, the functional significance of this is unclear both in normal cells as well as cancer 
(Leonoudakis et al. 2014). 
As mentioned previously, hypoglycosylation of αDG makes the ectodomain more vulnerable to 
cleavage by MMPs, resulting in a ~31kDa fragment, which can be further cleaved to a 26 kDa 
cytoplasmic fragment by gamma secretase and furin (Cross et al. 2008, Singh et al. 2004, 
Leocadio et al. 2016). The 31 KDa fragment has been detected at increased levels in multiple 
cancers including breast, colon, prostate, skin and squamous cell carcinomas, with smaller 26 
kDa and 17kDa fragments also variably detected (Singh et al. 2004, Mathew et al. 2013, Cross et 
al. 2008, Shang et al. 2008, Herzog et al. 2004). Moreover, the production of the 31 and 26 kDa 
fragments were regulated in a cell density dependent manner (Mitchell et al. 2013). 
Interestingly, treating cells with resveratrol, a potent activator of the notch signalling pathway, 
resulted in an increase in the formation of the 26kDa fragment, indicating a potential role for 
the notch signalling pathway, which is known to detect cell-density changes, in the proteolysis 
of βDG (Leocadio et al. 2016). MMPs are upregulated in a number of cancers (Morgia et al. 
2005), tumours are inherently dense populations of cells and abrogated notch signalling is 
widely reported in the neoplastic transformation of cells (Yuan et al. 2015), all of which, 
alongside hypoglycosylation may account for increased proteolytic cleavage of DG in cancer 
cells. There is also increased shedding of the N-terminal of αDG in a furin dependent manner, 
but independent of βDG cleavage (Singh et al. 2004) Proteolytic cleavage of DG again leads to 
reduced adhesion and disrupted signalling cascades the implications of which in cancer have 
been discussed above, however the fate and potential functions of the cytoplasmic fragments 
of βDG are not clearly understood.  
 Recent studies have shown the targeting of a population of these fragments to the nucleus in 
prostate cancer cells (Mathew et al. 2013, Leocadio et al. 2016), if these fragments are then 
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targeted for degradation or have a signalling function is unknown. A recent microarray 
comparing nuclear targeted to nuclear excluded c-terminal βDG in metastatic prostate cancer 
LNCaP cells saw the differential expression of 34 genes (Mathew et al. 2013). ETV1, a 
transcription factor involved in a number of cellular processes including promoting proliferation 
and differentiation, was up-regulated by 4.44 fold in cells with increased nuclear localisation of 
the C-terminal fragment of βDG. This is of particular interest because overexpression of ETV1 is 
reported in approximately 40% of CaP and correlates with increased invasiveness (Hsu et al, 
2004, Cai et al, 2007). Thus DG appears to be able to modulate gene expression, though it has 
no identified DNA binding sites itself. 
Many of the aforementioned studies on glycosylation, proteolytic cleavage, localisation and 
nuclear translocation of fragments of DG in cancer have been carried out in prostate cancer cell 
lines and tissues. Both subunits of DG are lost from the basement membrane and intracellular 
junctions in mid to high grade prostate cancer and are re-expressed at sites of secondary 
metastasis (Cross et al. 2008, Henry et al.2001, Mathew et al. 2013, Mitchell et al. 2013). In 
addition to the nuclear targeting of the cytoplasmic fragments it was reported that there was a 
potential increase of Y892 phosphorylated βDG in the nucleus of cancer cells compared to wild 
type tissue (Mathew et al. 2013). Interestingly, DG is dynamically regulated in prostate cells with 
regards to the androgen receptor (AR) (Sgambato et al. 2007b). The AR is a critical regulator of 
proliferation, differentiation and cell survival and mutations or increased levels of the AR can 
lead to androgen independent signalling and the development and progression of prostate 
cancer (Feldman et al. 2001, Knudsen et al, 2006).  Anti-androgen treatment of androgen 
responsive cells resulted in the decreased expression of DG whilst androgen treatment resulted 
in a dose dependent increase as well as translocation of βDG to the nucleus (Sgambato et al. 
2007b, Mathew et al. 2013). The promoter sequence of DG also contains a putative androgen 
responsive element (ARE), suggesting DG may be regulated by AR at both the DNA and protein 
level, though this requires further validation (Sgambato et al. 2007b). 
Combined, the above information suggests a potential role for DG not only in muscular 
dystrophies but also epithelial cancer progression, often through abrogation of its complex PTM 
(Barresi et al. 2006) It is therefore important to understand not only the functions of DG which 
could contribute to the disease processes but also the mechanisms behind its regulation. 
Furthermore, the majority of studies focus on DG at the cell membrane, with much emphasis on 
the disrupted interaction with the ECM. DG is observed in the nucleus of a variety of tissues 
including muscle and epithelial cells, both normal and in disease states. It is therefore important 
to gain a greater understanding of the regulation of DG at both the membrane and nucleus and 
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to consider that aberrant processing may impact nuclear levels and functions of DG and may 
contribute towards the disease state. 
1.6 NUCLEAR DYSTROGLYCAN 
 
Whilst initially surprising, the localisation of βDG in the nucleus of many cell lines and tissues 
of many origins, both cancerous and normal, has now been reported by multiple groups 
(Oppizzi et al. 2008, Martinez-Vieyra et al. 2013, Mitchell et al. 2013, Mathew et al. 2013). The 
nuclear localisation of βDG hints at yet more roles for this enigmatic, multifunctional protein 
and there is a growing field of research aimed at understanding its nuclear functions and 
regulation. 
1.6.1 The Nucleus  
The nucleus contains the DNA and coordinates cellular activities such as growth, division and 
protein synthesis. The nucleus is a membrane bound organelle, separating the highly regulated 
nuclear contents and processes from the surrounding cytoplasm (Prunuske et al. 2006). The 
nucleus also contains organelles such as the nucleolus, dense structures that are sites of 
ribosome and rRNA synthesis and assembly. In interphase the nucleoli can be described as 
three main structures; the fibrillar centers (FCs), the dense fibrillar component (DFC) and the 
granular component (GC) (Hernandez-Verdun 2011).The nuclear envelope consists of the 
nuclear membranes, the nuclear lamina and the nuclear pore complexes (Hertzer et al. 2010) 
(Fig 1.6). The nuclear membrane is made of two phospholipid bilayers; the outer nuclear 
membrane (ONM) which is contiguous with ER and the inner nuclear membrane (INM) 
(Purunske et al. 2006). Both the INM and ONM contain differing populations of integral and 
associated membrane proteins (Foisner et al. 2003, Manilal et al. 2008, Worman et al. 1988, 
Hertzer et al. 2010).  Embedded within the NE are the nuclear pore complexes, large 
complexes of nucleoporin proteins, which act as channels for communication between the 
nucleoplasm and cytoplasm (Alber et al. 2007). Beneath the INM is a protein meshwork 
referred to as the nuclear lamina (Gruenbaum et al. 2005). The nuclear lamina consists 
predominantly of intermediate filaments formed by A and B type lamins, the lamins form 
coiled-coil dimers which associated to form higher order network structures (Gruenbaum et al. 
2005, Stuurman et al. 1998, Shimi et al. 2015). The lamins are connected to the INM through 
their interactions with proteins embedded within the INM such as emerin, lamin binding 
receptor (LBR) and lamin-associated peptides 1 and 2 (LAP1 and -2) (Gruenbaum et al. 2005, 
Foisner et al. 2003, Worman et al.1988, Sakaki et al. 2001) (Fig 1.6).  The nuclear lamina serves 
as a scaffold at the nuclear periphery, where it plays a structural role in maintaining the shape 
of the nucleus and the spacing of the NPCs but also has active roles in organising chromatin, 
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DNA replication and regulating transcription factors (Gruenbaum et al. 2005, Dorner et al. 
2007, Prokocimer et al.2009). 
A mechanical link between the external cytoskeleton and the nucleus is formed by the Linker 
of the nucleoskeleton to the cytoskeleton (LINC) complex (Mejat et al. 2010). A prototypical 
LINC complex consists of transmembrane SUN proteins in the INM which can interact with the 
nuclear lamina and associated proteins within the INM such as emerin, and with the ONM 
KASH proteins in the perinuclear space (Razafsky et al. 2009, Haque et al. 2010, Haque et al. 
2006) (Fig 1.6). The KASH proteins, such as nesprins of which there are many isoforms, project 
into the cytoplasm where they interact with cytoskeletal and signalling proteins, directly or 
through linkers or motor proteins such as plectin or dynein (Zhang et al. 2002, Wilhelmsen et 
al. 2005, Razafsky et al. 2009). Thus the LINC complex forms a bridge between the nucleus and 
the cytoskeleton and has important roles in transducing extracellular mechanical forces to the 
nucleus and regulating cellular functions such as cell division, cytoskeleton organisation and 
organelle position (Mejat et al. 2010, Razafsky et al. 2009, Chang et al. 2015). 
Mutations in the genes of a number of nuclear envelope proteins have been identified as the 
cause of a heterogenous array of human diseases, for example emerin is mutated in X-linked 
EDMD (Bione et al. 1994), and over 200 mutations in LMNA, the gene encoding A-type lamins 
have been identified (Mejat et al. 2009) resulting in several laminopathies including autosomal 
dominant-EDMD (Bonne et al. 1999), Limb Girdle Muscular dystrophy (LGMD) (Muchir et al. 
2000) and Hutchinson-Gilford progeria syndrome (HGPS) (Eriksson et al. 2003). Interestingly a 
common phenotype within NE diseases is muscle defects and the ongoing work into 
understanding of the structural and signalling roles is providing valuable insight into these 
diseases (Mejat et al. 2010).  
Correct nuclear functions are vital for maintaining a healthy, viable cell, therefore the spatial 
and temporal regulation of proteins with nuclear roles is tightly regulated (Handwerger et al. 
2006). The complexities of selectively transporting sufficient levels of the necessary proteins to 
the desired locations within the nucleus are amplified as a result of the rapid shuttling of 
proteins between the cytoplasm and the nucleus, the need of the nucleus to respond to 
external signals transmitted by the cell and the vast changes in nuclear morphology and 
processes, such as DNA replication, required for a cell to divide (Foisner et al. 2003).  
1.6.2 Nuclear Translocation Pathways 
The compartmentalisation of different processes is a key principle of the eukaryotic cell, and in 
the case of the nucleus, separates the transcription and synthesis of DNA from the 
translational processes in the cytoplasm. The nuclear envelope (NE) forms the barrier whilst 
the tightly controlled nuclear pore complexes (NPC) form selective routes for transport and 
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communication between the two compartments (Cautain et al. 2015). Proteins smaller than 40 
kDa can traverse through the NPC via diffusion however larger proteins require the assistance 
of adaptor proteins (carriers). Importins and exportins (Karyopherins) are the carriers that 
facilitate the transport into and out of the nucleus respectively (Cautain et al. 2015). The 
importins and exportins recognise specific transport sequences within the cargo protein 
known as nuclear localisation signal (NLS) or nuclear export signals (NES), enabling the 
transport across the pore (Lange et al. 2007, Wen et al 1995). The characterised NLS are either 
classical or non-classical, with the classical members being either a short, highly basic signal of 
~4-5 residues (monopartite) or two stretches of basic residues separated by a linker region 
generally between 10-12 residues long (Kalderon et al. 1984, Lange et al. 2007, Lange et al. 
2010). Non-classical NLS include PY-NLS in which a central arginine residue is flanked N-
terminally by a hydrophobic motif and C-terminally by a PY sequence and these proteins often 
do not require an adaptor but bind directly to the transporter (Cautain et al. 2015, Suel et al. 
2008). NES are often leucine rich with the consensus sequence ɸ1-X(2-3)- ɸ2- X(2-3)- ɸ3-X- ɸ4, 
(where ɸ is a hydrophobic residue, L, V, I, F, or M and X is any residue but preferentially small, 
charged or polar) but can be more complex, requiring 3D structural features of the protein to 
be recognised (La Cour et al. 2004, Cautain et al. 2015) . The recognition signals for many of 
the karyopherin family remain to be characterised. The majority of the nuclear transport 
receptors are members of the karyopherin β family, such as the import receptors Importinβ, 
which can either bind directly to the NLS or via an adaptor which are members of the Impα 
family (Lange et al. 2007, Cautain et al. 2015). In the case of export receptors, chromosome 
region maintenance 1 (CRM1) is one of the best characterised and is also a karyopherin β 
family protein (Fornerod et al. 1997). 
 In the case of nuclear import of a classical NLS cargo protein, Imp-α and -β form a heterodimer 
in the cytoplasm, following which Imp-α binds to the cargo protein and the complex then 
translocates through the nuclear pore, where Imp-β interacts with components of the NPC, 
into the nucleoplasm, whereby the complex dissociates (Isgro et al. 2005, Cautain et al. 2015, 
Lange et al. 2007) (Fig 1.7). Using CRM1 as a classical example in the case of nuclear export, 
CRM1 binds to cargo within the nucleoplasm, occasionally through adaptors, transporting the 
complex through the NPC to be dissociated in the cytosol (Fornerod et al. 1997, Cautain et al. 
2015) (Fig 1.7). The loading and unloading of cargo proteins from the transport complexes 
requires metabolic energy and is regulated by RAN GTPases (Moore, 1998). RanGEFs are 
predominantly nuclear whilst Ran GAPs are predominantly cytoplasmic in localisation, thus 


































































































































































































































































































































































































































































































































































































The RanGTP in the nucleus promotes the dissociation of the import complex, whilst it 
promotes the formation of the export complexes (Gorlich et al. 1996, Lindsay et al. 2001). 
Importins α- and β- are recycled back out of the nucleus in complex with RanGTP, and in the 
case of importin- α, with export transporters such as exportin-2 or CAS, and are released 
through the action of RanGAPs in the cytoplasm to start a new import cycle (Moore, 1998, 
Kutay et al. 1997) (Fig 1.7). 
 
 
Figure 1.7: The nucleo-cytoplasmic transport of proteins. A schematic diagram depicting the nuclear 
import of a protein cargo with a classical NLS through the nuclear pore in complex importins α and β. 
Once in the nucleus high levels of RanGTP, catalysed by RanGEFs, cause the dissociation of the complex 
and release of the cargo. Importin β and importin α are transported back into the cytoplasm in a RanGTP 
dependent manner, and in the case of importin α in complex with a nuclear export transporter (Exp). In 
the cytoplasm the importins are released through the activity of RanGAPs for further cycles of transport. 
Nuclear proteins can be bound by nuclear export proteins such as Crm1 at their NES, in an interaction 





A number of membrane receptors are trafficked to the nucleus, either as full length receptors 
or as proteolytically cleaved fragments, where they also have nuclear functions, however, the 
mechanisms of transport are poorly defined (Chen et al. 2015). Receptor tyrosine kinases 
(RTKs) such as EGFR, MET and FGFR have been shown to be transported to the nucleus and a 
large proportion of the understanding of the nuclear translocation of cell surface receptors 
comes from the study of these proteins (Bryant et al. 2005, Chen et al. 2015, Lo et al. 2006). 
Membrane receptors can be internalised from the membrane into vesicles by clathrin-
dependent or independent mechanisms from which they can be recycled, degraded or 
undergo retrograde transport back through the golgi and the ER (Wang et al. 2010a. Chen et 
al. 2015). At least two methods of traffic of endocytic membrane receptors from the ER to the 
nucleus have been identified: integral trafficking from the ER to the nuclear envelope transport 
(INTERNET) or integrative nuclear FGFR1 signalling (INFS) (Chen et al. 2015, Myers et al. 2003, 
Wang et al. 2012). Receptors trafficked via INTERNET remain membrane bound, for example 
EGFR has been shown to traffic from the ER to the ONM where it binds to a NPC and through 
to the INM from which it can be transported into the nucleoplasm in a Sec61 dependent 
manner (Wang et al. 2010a, Wang et al. 2010b, Wang et al. 2012). This process requires the 
binding of importin-β to the NLS of EGFR (Lo et al. 2006). In INFS the receptors become soluble 
following release from the ER and are translocated to the nucleus through the NPC in an 
importin α/β dependent manner (Chen et al. 2015, Myers et al. 2003). Additionally, a number 
of membrane proteins are cleaved by caspases or through RIP after which the intracellular 
domain can perform signalling functions, often within the nucleus to which it is transported in 
an importin α/β dependent manner (Chen et al. 2015). Some receptors are also proposed to 
enter the nucleus by ‘piggy-backing’ with another protein, such as the case with some 
cytokines through the NLS in their cognate interleukin ligands (Jans et al. 1998). A recent study 
by Chaumet et al. has identified an alternative route of nuclear transport for surface proteins 
in a process mediated by nuclear envelope-associated endosomes (NAE) (Chaumet et al. 
2015). Through this route the LRP1 receptor was internalised into endosomes which then 
associated with, and fused to the outer membrane of the NE, where it released its contents 
into the NE lumen (Chaumet et al.2015). The receptor was then released into the nucleoplasm 
through a process that was shown to require the NE proteins SUN1 and SUN2 as well as the 
Sec61 translocon (Chaumet et al. 2015). The authors could find no interaction with importin-β 





1.6.3 Nuclear translocation of βDG 
Oppizzi and colleagues were first to report a functional bipartite NLS located directly C-
terminal to the transmembrane domain in βDG (Oppizzi et al. 2008). The study in breast cancer 
cells demonstrated variable levels of full length glycosylated βDG within the nucleus, as 
determined by immunoblots following cellular fractionation, in a manner that was 
independent of the glycosylation status or ligand binding capability of αDG (Oppizzi et al. 
2008).  The NLS was further characterised by Lara-Chacon et al. in myoblasts who determined 
that residues 776RKKRKGK782 were necessary and sufficient for the nuclear localisation of βDG 
through a combination of site directed mutagenesis studies as well as the fusion of this 
sequence to a tetra-GFP molecule (Lara-Chacon et al. 2010). Furthermore, this group 
demonstrated that DG was undergoing rapid nucleocytoplasmic shuttling and the nuclear 
localisation was prevented upon blocking the nuclear pore complex with Agaricus bisporus 
lectin (ABL), which binds to the N-acetyl glucosamine of nucleoporins with high affinity (Lara-
Chacon et al. 2010). An α/β importin heterodimer bound the cytoplasmic NLS of βDG with a Kd 
of 0.8 nM and mediated the nuclear translocation of βDG in a Ran dependent manner, 
suggesting the nuclear import of βDG occurs through a classical importin mediated pathway 
through the NPC (Lara-Chacon et al. 2010).  
Multiple groups have also shown that C-terminal fragments of βDG target strongly to the 
nucleus within the nucleoplasm (Oppizzi et al. 2008, Lara-Chacon et al. 2010, Mitchell et al. 
2013, Mathew et al. 2013, Leocadio et al. 2016), as has also been seen with the nuclear 
targeting of numerous ICD of RTK receptors and cleavage products of other proteins such as 
Notch (Guruharsha et al. 2012, Chen et al. 2015). The production of the 31kDa and 26kDa 
cytoplasmic fragment of βDG increases in a cell density dependent manner. Additionally, the 
nuclear 31kDa DG fragment may undergo a sequential proteolysis event by γ-secretase to form 
the 26kDa fragment (Mitchell et al. 2013, Leocadio et al. 2016). The nuclear translocation of a 
cytoplasmic fragment of βDG can be prevented by mutating the NLS within it (Mitchell et al. 
2013, Mathew et al. 2013). It is possible that the fragments of βDG in the nucleus may be 
targeted to the nuclear proteasome or exported to the cytoplasmic proteasomes for 
degradation or they may have a functional role (See section 1.6.4). 
An important question when addressing the nuclear localisation of a protein that also has roles 
at the plasma membrane is if it is internalised from the PM to the nucleus or if it is a separate 
population. Whilst still not clear in the case of βDG, biotinylation experiments followed by 
fractionation suggest a pool of nuclear βDG, at least some of which has been at the PM 
(Vasquez-Limeta et al. 2014).  
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Another important observation is that the nuclear levels of βDG are variable within a 
population, independent of αDG, suggesting that it is dynamically regulated (Oppizzi et al 
2008, Mitchell et al. 2013, Mathew et al. 2013, Martinez-Vieyra et al. 2013). A number of 
groups have therefore addressed different aspects of the regulation of nuclear translocation of 
βDG. Phosphorylation is known to be an important regulator of nuclear translocation of 
proteins (Nardozzi et al. 2010).  Given the importance of phosphorylation at Y892 for the 
interactions (Ilsley et al. 2001, James et al. 2000, Sotgia et al. 2001) and internalisation of βDG 
from the PM (Sotgia et al. 2003, Miller et al. 2012) it was hypothesised that it may also be 
important for the nuclear localisation of βDG. Initial studies suggest that the effect of 
phosphorylation on nuclear translocation is complex. A non-phosphorylatable Y892F form of a 
GFP-tagged c-terminal fragment of βDG accumulated in the nucleus, although no change in 
nuclear levels were seen when the same mutation was introduced into full length flag-tagged 
mouse DG (Lara-Chacon et al. 2010, Leocadio, 2014). In immunohistochemical studies of 
prostate samples from normal and cancerous tissues from patients a pY892 form of βDG was 
identified at the BM and cell junctions but also in the nucleus (Mathew et al. 2013). 
Peroxyvanadate (PV) treatment and consequent increased tyrosine phosphorylation also 
caused an increase in nuclear accumulation of βDG, although it must be considered that PV 
treatment will have broad targets within the cell. (Lara-Chacon et al., 2010). Therefore, 
phosphorylation at different sites may have both promoting and inhibitory roles in nuclear 
translocation. In addition to sites of tyrosine phosphorylation within the sequence of βDG 
there are also phosphorylated serine and threonine residues identified by mass spectrometry, 
potential regulatory roles of which are as yet unknown (Hornbeck et al. 2014) Alternatively, 
βDG is subject to other PTM such as ubiquitination or sumoylation with as yet unclear 
functions on the fate of βDG. PTM can contribute to the nuclear localisation of proteins by 
facilitating or destabilising interactions with binding partners, for example import or export 
machinery or protein partners which may sequester the protein in the cytoplasm (Nardozzi et 
al, 2010, Gill, 2004).  It will therefore be important to identify PTM that play a role in the 
nuclear translocation of βDG. 
The nuclear or cytoplasmic retention or translocation of proteins can be affected by their 
binding partners. As previously described the binding site of ezrin overlaps with the site of 
importin binding at the NLS of βDG (Spence et al. 2004a, Lara-Chacon et al. 2010). However, 
rather than competing with importins to prevent nuclear accumulation of βDG, overexpression 
or increased activation of ezrin resulted in an increase in the nuclear levels of βDG and 
occurred in a manner that required the actin binding function of ezrin (Vasquez-Limeta et al. 
2014). Furthermore, disruption of the actin cytoskeleton resulted in lower levels of nuclear 
accumulation of βDG, suggesting that the cytoskeleton, which can be reorganised depending 
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upon the cellular requirements, could contribute to the nuclear translocation of a pool of βDG 
(Vasquez-Limeta et al. 2014). 
Additionally, it has been shown that androgen stimulation of the androgen sensitive prostate 
cancer cell line, LNCaP, resulted in the nuclear accumulation of βDG (Mathew et al. 2013). 
DAG1 contains an ARE and DG levels are regulated by androgens (Sgambato et al. 2007b). It is 
possible that βDG is targeted to the nucleus in complex with the AR, which translocates to the 
nucleus to act upon target genes, however the inability to detect an interaction between the 
androgen receptor and βDG, the delayed response of nuclear translocation after treatment 
and the fact that the same result was achieved through serum addition to starved cells suggest 
that nuclear translocation of βDG could be a consequence of the mitogenic effects of androgen 
in LNCaP as opposed to a direct response to the androgen pathway itself (Mathew. 2011). 
Interestingly, Sgambato and colleagues have reported that DG mRNA and protein expression are 
cell cycle regulated (Sgambato et al, 2006). Furthermore, delays in cell cycle progression at S 
phase, G2/M and G0/G1 transitions following reduction of βDG levels have been reported 
(Sgambato et al, 2006, Higginson et al, 2008, Villarreal-Silva et al., 2011). It has also been 
proposed that DG may play a mechanical role in the contractile ring and tethering the membrane 
to the cytoskeleton during cell division following the observation that in REF52 cells DG 
colocalised with ezrin to the cleavage furrow and midbody during cytokinesis (Higginson et al., 
2008). This observation also indicates that DG localisation as well as expression can be regulated 
in a cell cycle dependent manner. If the nuclear levels of DG fluctuate in a cell cycle dependent 
manner requires further investigation, furthermore a reason as to why DG would be required in 
the nucleus at specific stages of the cell cycle is unknown. The nucleus undergoes dynamic 
structural and signalling changes as the cell cycle progresses which DG may contribute to. 
However, a great deal of investigation is required to establish if this is indeed the case. 
Thus, whilst our understanding of the mechanisms of the nuclear translocation of βDG is 
improving, there still remain many questions regarding the triggers, such as the proliferation 
status or in response to external stimuli, and mechanisms, such as binding partners or PTM, 
that regulate the nuclear translocation of βDG. 
1.6.4 Nuclear functions of βDG 
Within the nucleus βDG has been identified at the INM of the NE, dispersed throughout the 
nucleoplasm and at distinct nuclear structures including the nucleoli, splicing speckles and cajal 
bodies through immunofluorescence and EM studies in multiple cell lines including HeLa cells, 
C2C12 myoblasts, LNCaP, PNT1A and PC3 prostate cancer cells as well as in epithelial and 
carcinoma prostate tissue from patients  (Lara-Chacon et al. 2010, Martinez-Vieyra et al. 2013, 
Mitchell et al. 2013, Mathew et al. 2013). As the studies of nuclear DG grows, so too does the 
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evidence towards nuclear functions for DG and, in accordance with the diverse localisation of 
βDG within the nucleus, seem to hint at both static and dynamic functions of βDG. 
βDG is not the only member of the DAPC to have been found in the nucleus. Indeed, the first 
reports of βDG in the nucleus came from studies with the aim of investigating DAPC 
components in the nucleus following the observation of a short isoform of dystrophin, Dp71 in 
the nucleus of HeLa (cervical), C2C12 (muscle) and N1E-115 (neuroblast) cells (Gonzalez et al. 
2000). Further studies in HeLa, C2C12 and PC12 cells identified not only Dp71 but also βDG, α 
and β-dystrobrevin, α,β,ε-sarcoglycan and α and β-syntrophin in the nucleus, including at the 
nuclear envelope (Villarreal-Silva et al. 2010, Gonzalez-Ramirez et al. 2008, Fuentes-Mera et al. 
2006, Martinez-Vieyra et al. 2013). α-dystrobrevin and Dp71 also translocate to the nucleus in 
an importin α/β dependent manner, although only βDG contains a classical NLS and it is 
possible that other components of the DAPC can enter the nucleus in complex with these 
components (Aguilar et al. 2015, Suarez-Sanchez et al. 2014). Furthermore, multiple 
interactions between the DAPC components were identified via immunoprecipitations of the 
nuclear fractions, prompting the hypothesis of the existence of a nuclear DAPC (Villarreal-Silva 
et al. 2010, Gonzalez-Ramirez et al. 2008, Fuentes-Mera et al. 2006, Martinez-Vieyra et al. 
2013). Depleting the levels of Dp71 resulted in reduction of other nuclear DAPs, similar to loss 
of dystrophin at the PM in DMD patients and demonstrating its importance for stability of the 
complex (Villarreal-Silva et al. 2010). 
Given the structural role of the DAPC at the PM, the possibility for similar roles within the 
nucleus was exciting. Multiple components of the nuclear DAPC can interact with the nuclear 
matrix which underlies the nuclear envelope (Fuentes-Mera et al. 2006, Martinez-Vieyra et al. 
2013, Aguilar et al. 2015). Through immunoprecipitations βDG was shown to interact with 
nuclear lamina proteins, lamin B1 and lamin A/C, and lamin binding protein, emerin, in C2C12 
myoblasts (Martinez-Vieyra et al. 2013). Support for a structural role for βDG within the 
nucleus was seen upon RNAi depletion of βDG whereby lamin B1 and emerin levels were 
reduced and mislocalised (Martinez-Vieyra et al. 2013). Moreover, the βDG depleted cells 
displayed aberrant nuclear morphology including disrupted morphology of the NE, nucleoli, 
cajal bodies and splicing speckles (Martinez-Vieyra et al. 2013). It is interesting to consider if 
the role of βDG at the nucleoli, cajal bodies and splicing speckles is solely structural or if it can 
also contribute to their functions in ribosomal assembly, pre-mRNA splicing and rRNA 
processing. Similar disrupted morphology phenotypes were displayed upon depletion of α-
dystrobrevin or Dp71 (Aguilar et al. 2015, Hernandez-Ibarra et al. 2015, Villarreal-Silva et al. 
2010). Interestingly preliminary studies suggest an interaction between βDG and SUN1 a 
component of the LINC complex located within the inner nuclear membrane (M. Laredo and S. 
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Winder personal communication), the functional significance of this interaction is currently 
under investigation but could be another route through which DG contributes to the 
mechanical properties of the cell.  Additionally, in βDG depleted cells there was an increased 
distance between the nuclear envelope and the centrosomes (Martinez-Vieyra et al. 2013). 
The association between the centrosome and NE is mediated in part by NE proteins. 
Interestingly, βDG antibodies detect punctate structures within a variety of cells, which may be 
the centrosome or primary cilia (Personal communication S. Winder) and the potential of an 
uncharacterised role for βDG at another subcellular structure with links to the nucleus would 
be interesting to investigate. The above information indicates that, βDG, along with other 
DAPC components, has a role in maintaining nuclear structure and may contribute to nuclear 
envelope mediated functions.  
Just as DG has multifunctional roles at the plasma membrane, there is emerging evidence that 
the same is true within the nucleus. As previously discussed, the differential regulation of 34 
genes was detected in a microarray comparing the expression of genes in LNCaP cells 
expressing either a cytoplasmic fragment of βDG which targets to the nucleus or is excluded 
from the nucleus via mutation of its NLS (Mathew et al. 2013). No DNA binding sites have been 
identified in DG, however the microarray results highlight the exciting possibility that nuclear 
βDG may regulate the transcription of genes, maybe through sequestering a transcription 
factor. The idea of the proteolytically cleaved fragments of surface proteins interacting with 
transcription factors within the nucleus is by no means new and has been reported for 
numerous receptors including RTKs. For example, the ICD of Erb4 interacts with STAT5 within 
the nucleus and modulates the transcription of β-casein (Williams et al. 2004). Alternatively, 
βDG may regulate nuclear functions through the signalling pathways that it modulates. Given 
that both DG and ERK translocate to the nucleus it is possible that they may interact there in a 
manner which modulates signalling activity (Chen et al., 1992.). Erk may even play a role in the 
translocation of DG as its binding site overlaps that of DG’s NLS as is seen with ezrin as 
described above (Moore et al. 2010, Vasquez-Limeta et al. 2014). Therefore, although there is 
no direct evidence, it is tempting to speculate that nuclear DG may have a signalling role.  
Given DG’s crucial roles within development and tissue homeostasis and its ability to 
contribute to multiple disease states it is important to better understand the functions and 





1.7 PROJECT OUTLINE 
 
Originally identified as an adhesion receptor at the plasma membrane, DG is now acknowledged 
as a multifunctional molecule also acting as a scaffold for numerous signal transduction 
pathways (Ervasti et al. 1993, Sotgia et al. 2001, Spence et al. 2004). Importantly, the level of 
functional DG at the cell membrane is reduced in many human diseases including muscular 
dystrophies and epithelial cancers (Barresi et al. 2006).  More recently βDG has been identified 
in the nucleus of numerous cell types (Oppizzi et al. 2008, Lara-Chacon et al. 2010, Mathew et 
al. 2013), hinting at yet more roles for this versatile protein. Yet the mechanisms of translocation 
and function of βDG in the nucleus are relatively unknown. Interestingly the reported levels of 
nuclear βDG are variable within a population of cells, suggesting that it is dynamically regulated 
(Mitchell et al. 2013, Martinez-Vieyra et al. 2013). DG is highly regulated by its PTM, with 
phosphorylation of βDG implicated in its subcellular localisation (Sotgia et al. 2003, Miller et al. 
2012). There are multiple sites of phosphorylation identified within βDG with as yet 
uncharacterised functions (Hornbeck et al. 2014), therefore one aim of this project is to 
investigate the role of phosphorylation on the regulation and nuclear localisation of βDG. There 
is also emerging evidence that the nuclear level of βDG fluctuates as the cell cycle progresses 
(Mathew. 2011). DG expression and the cell cycle have been shown to be intrinsically linked 
(Higginson et al. 2008, Sgambato et al, 2007b, Villarreal-Silva et al, 2011). Therefore, a second 
aim of this project is to investigate the potential cell cycle dependent nuclear translocation of 
βDG. Finally, DG antibodies have been reported to detect structures within the cell which may 
be the centrosomes. Furthermore, centrosome number and position has been shown to be 
disrupted upon DG depletion (Martinez-Vieyra et al. 2013), which may be a consequence of the 
role of βDG at the nuclear envelope. Consequently, a further aim of this project is to investigate 
a novel localisation of βDG at the centrosome. 
1.7.1 Project aims 
1. To characterise the different βDG antibodies used in the study of dystroglycan  
2. To investigate the role of specific phosphorylation events of the regulation and nuclear 
localisation of βDG in prostate cell lines. 
3. To investigate the localisation of βDG and its nuclear translocation throughout cell 
cycle progression in prostate cell lines. 
4. To study the localisation of βDG at the centrosomes. 
5. To use dystroglycan null fibroblasts to investigate potential nuclear functions of DG 




2. Materials and Methods  
2.1 BACTERIAL TECHNIQUES 
2.1.1 BACTERIAL GROWTH CONDITIONS 
Escherichia Coli (E. coli) strains DH5α (Lucigen) and XL-10 Gold (Stratagene) were grown at 
37°C in 5 ml 2x YT liquid media (Appendix A) with the appropriate antibiotic; ampicillin 
(100µg/ml) or kanamycin (30µg/ml) as required for selection. 
2.1.2 PREPARATION OF COMPETENT BACTERIA 
A single colony of DH5α was used to inoculate 10 ml of 2x YT. The starter culture was grown 
overnight at 37°C in a shaking incubator. The following morning 1ml of the starter culture was 
used to inoculate 100ml of 2xYT which was then incubated at 37°C in a shaking incubator until 
OD600 was 0.4-0.6 AU as determined on the spectrophotometer (Jenway). The bacteria was 
pelleted by centrifuging the culture at 700g for 10 minutes at 4°C (Sigma 12169-H rotor). The 
supernatant was discarded and the pellets resuspended in 10ml ice cold 100mM CaCl2 and 
incubated on ice for 2 hours. The bacterial cells were centrifuged again at 700xg, 10 minutes at 
4°C. The supernatant was discarded and the pellet resuspended in 2ml ice cold CaCl2 
supplemented with glycerol to a final concentration of 15%. The bacterial glycerol solution was 
divided into 100µl aliquots and snap frozen in liquid nitrogen prior to storage at -80°C for up to 
6 months  
2.1.3 TRANSFORMATION OF COMPETENT BACTERIA 
Aliquots of E.coli (50 µl) were thawed on ice. DH5α and XL-10 Gold were used for plasmid 
purification. In the case of the commercial super competent XL-10 Gold cells 2 µl Β-
mercaptoethanol was added to each aliquot and swirled gently. Cells were incubated on ice for 
10 minutes. 100-150ng of plasmid DNA was added to the cells. Cells were incubated on ice for 
30 minutes, heat shocked at 42°C for 30 seconds and then incubated on ice for 2 minutes. 500 
µl of pre-warmed non-selective media, NZY+ broth, was added to the cells and placed at 37°C 
for 1 hour in a shaking incubator to recover. Cells were then harvested in a benchtop 
centrifuge (3000g, 2 minutes) and the non-selective media removed. Cells were resuspended 
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in 200 µl non-selective media and plated on agar plates containing the required selection 
antibiotic (Table B.1) and incubated overnight at 37°C. 
2.1.4 GLYCEROL STOCKS OF BACTERIAL CULTURES 
Bacteria was transformed with the required plasmid and grown on an agar plate with 
antibiotic selection overnight. A single colony was picked and grown overnight at 37°C in 5ml 
2x YT with antibiotic selection. 750µl of the overnight culture was added to an equal volume of 
50% glycerol and stored at -80°C 
2.2 MOLECULAR BIOLOGY TECHNIQUES 
2.2.1 PLASMID PURIFICATION BY MINI- OR MAXIPREP 
Plasmids were purified from transformed E.coli  for small and large scale preparations by mini- 
and maxiprep kits (Qiagen) respectively, according to the manufacturer’s instructions. Briefly, 
the cells are lysed with an alkaline lysis solution following which the DNA is bound to an anion 
exchange membrane or resin.  A medium salt wash is used to remove impurities The purified 
plasmid DNA was eluted and then subject to isopropanol precipitation in order to desalt and 
concentrate the DNA, the eluted DNA is dissolved in sterile dH2O or 10mM Tris-HCl pH 8.5 and 
the concentration determined using A260 via a nanodrop (NanoDropLite, Thermo Scientific) and 









Figure 2.1. Plasmid map of pcDNA3.1 (+) vector including the αβDGflag insert. The αβDGflag insert is 
flanked by EcoR1 and Xho1 restriction sites in the multiple cloning region as designed by D. Leocadio 
(Leocadio, D. 2014). The multiple cloning site is under the T7 promoter. The plasmid contains neomycin 
and ampicillin resistance. BGHpA: Bovine Growth Hormone polyadenylation sequence.  
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2.2.2 SITE-DIRECTED MUTAGENESIS (SDM) 
Site-directed mutagenesis was carried out using the QuikChange Lightning Site-Directed 
Mutagenesis Kit (Agilent Technologies). T788A and T788D mutations were introduced into the 
full length sequence of mouse αβDG. The αβDG with a flag tag was in a pcDNA3.1+ plasmid as 
generated by D. Leocadio Victoria (Figure 2.1). The two complimentary mutagenic 
oligonucleotide primers were designed according to the kit guidelines (Table B.2).  The 
reaction mixture was set up as follows: 
Component Amount 
10x Reaction Buffer 5 µl 
αβDGflag pcDNA 3.1 (+) 20 ng 
Forward Primer 125 ng 
Reverse Primer 125 ng 
dNTP Mix 1 µl 
QuikSolution Reagent 1.5 µl 
QuikChange Lightning Enzyme 1 µl 
dH2O Make up to 50 µl 
 
The reaction was then cycled under the following parameters: 
Segment Cycles Temperature Time 
1 1 95°C 2 minutes 
2 18 95°C 20 seconds 
60°C 10 seconds 
68°C 4.5 minutes (30 
seconds/kb plasmid 
length) 
3 1 68°C 5 minutes 
4 1 4°C 10 minutes/ Hold 
 
2µl (20 Units) of restriction enzyme Dpn1  (New England Biosciences) was added to the 
resulting amplification reaction and incubated for 15 minutes at 37°C in order to digest any 
remaining parental plasmid. 2µl of Dpn1 treated amplification reaction was then transformed 
into XL-10 gold competent cells as per the manufacturer’s instructions and grown on agar 
plates with antibiotic selection (Table B.1). Colonies were then selected for overnight cultures 
and subsequent minipreps for restriction digests and sequencing. 
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2.2.3 RESTRICTION ENZYME DIGEST OF PLASMID DNA 
Prior to sending plasmids for sequencing there were analysed by restriction enzyme digests to 
assess for positive clones. Digestion with the restriction enzymes EcoR1 and Xho1 (New 
England Biosciences) would be expected to produce a 2.09 Kb insert containing fragment as 
well as the remaining plasmid fragment at 5.4Kb. The restriction digest per reaction was set up 




10x Buffer 4 2 µl (1x) 
100x BSA 0.2 µl (1x) 
Plasmid DNA  0.1-0.5µg 
dH2O Make up to 20 µl 
 
The mixture was then incubated for 2 hours at 37°C. 
2.2.4 DNA SEQUENCING  
Isolated plasmid DNA at a concentration of 100ng/µl in a total volume of 5 µl was sent for 
sequencing at Source Bioscience for verification. Bovine growth hormone (BGH) and T7 stock 
primers were used. 
2.2.5 DNA ELECTROPHORESIS 
DNA samples were mixed with 10x loading buffer and run on a 0.8% agarose gel containing 
ethidium bromide (0.5µg/ml) alongside 2.5 µl 1Kb Hyper ladder (New England Biosciences, 
NO4685). The gel was run at 100V in 1x TAE buffer (40mM Tris-Acetate, 1mM EDTA) until the 
loading dye front has migrated the desired distance. The DNA gel was then imaged on a UV 
trans-illuminator (UVitec with Mitsubishi P91 printer). 
2.3 TISSUE CULTURE TECHNIQUES 
2.3.1 GROWTH AND MAINTENANCE OF CELL LINES 
LNCaP (Horoszewicz et al., 1983) and PNT1a (Lang et al., 2000) cells were maintained in RPMI 
1640, [+] L-Glutamine (Gibco, Life technologies), supplemented with 10% (v/v) fetal bovine 
serum (FBS) (Gibco, Life technologies). PC3 (Kaighn et al., 1979), Normal Adult Primary Human 
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Dermal Fibroblasts (HDF ATCC-PCS-201-012 a kind gift from Irene Canton) and Human DAG1 
null fibroblasts (Riemersma et al., 2015) were maintained in Dulbecco’s Modified Eagle 
Medium (DMEM), + D-Glucose, +L-Glutamine, + pyruvate (Gibco, Life technologies), 
supplemented with 10% (v/v) FBS. HDF were also supplemented with 1% (v/v) penicillin/ 
streptomycin (Gibco, Life technologies). All cells were grown in an incubator (Galaxy S Biohit) 
at 37°C, 5% CO2. Cells were passaged between 60-80% confluency as assessed on an inverted 
microscope (CETI) at 10 x magnification. Cells were passaged with 0.25 % (v/v) trypsin-EDTA 
(Sigma) and neutralised with media. Dissociated cells were centrifuged 100x g (11030 rotor, 
Sigma) for 3 minutes and resuspended in culture media before prior to plating at the required 
density for future experiments or further growth in plastic culture flasks (Greiner Bio-one). 
2.3.2 POLY-L-LYSINE COATING OF DISHES AND COVERSLIPS 
The tissue culture surface was covered aseptically with 0.1mg/ml poly-L- lysine (Sigma) in PBS. 
Surfaces were incubated in solution for 2 hours before washing twice with PBS followed by 
drying in the incubator. 
2.3.3 CELL COUNTING USING A HAEMOCYTOMETER 
10 µl of a single cell suspension in growth media was diluted 1:10 in 90 µl Trypan Blue solution 
0.4% (Sigma, T8154). Cells were counted using a haemocytometer. The glass slide of the 
haemocytometer is laser etched with counting grids. The indentation creates a capillary space 
over the counting grids of 0.1mm. 10 µl of the cell suspension diluted in trypan blue was 
loaded to fill the capillary space of the haemocytometer and the cells counted according to the 
manufacturer’s instructions. Briefly, the number of cells inside 8 x 1mm2 squares of the 
chamber grid were counted using a 10x magnification on an inverted microscope (CETI). Non- 
viable cells that had taken up trypan blue were discounted. Each mm2 contains 100 nl of liquid 
therefore to calculate the number of cells per ml average number of cells per mm2 must be 
multiplied by 104. Viable cell number was calculated using the following formula: 
𝑉𝑖𝑎𝑏𝑙𝑒 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 8  𝑚𝑚2 𝑠𝑞𝑢𝑎𝑟𝑒𝑠
8
 × 𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝐹𝑎𝑐𝑡𝑜𝑟(×104  ) = 𝑇𝑜𝑡𝑎𝑙 𝑣𝑖𝑎𝑏𝑙𝑒 𝑐𝑒𝑙𝑙𝑠/𝑚𝑙  
2.3.4 GROWTH CURVE OF LNCAP CELLS IN STANDARD CONDITIONS 
Cells were trypsinised from a flask at 60-80% confluency and counted using a 
haemocytometer. Cells were then centrifuged and resuspended in growth medium to make a 1 
x 106 cells/ml cell suspension which was then counted again to verify accurate cell numbers. 
The suspension was diluted in growth medium to produce a 1 x 104 cells/ml suspension. 1 ml 
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of the suspension was then added to each well of a 12 well plate that had been pre-coated 
with poly-l-lysine.  Cells were counted every other day for 12 days using the CASY Model TT 
Cell counter and analyser (Innovatis). Media was changed in the remaining wells on days 2, 6 
and 10.  
To count the cells the media was removed from the 4 replicate wells into a 15ml falcon tube. 
The wells were washed with 0.5 ml PBS, which was also added to the tube. 0.5 ml trypsin-EDTA 
was added per well and incubated at 37°C until all the cells had detached. 0.5 ml of growth 
media was added to neutralise and the cell suspension added to the tube. The well was 
washed a final time with 0.5 ml sterile CASYton solution (Roche) and added to the collected 
cells. 1 ml of the 3ml cell suspension was made up to 10ml with CASYton solution in a CASYCup 
(Roche) and inverted gently several times to mix. Cells were counted using the 150 µM 
capillary, scale 0-40 µM, range 10- 34 µM with 3 cycles of 400 µl for each count and a dilution 
of 1: 10 as 1 ml of cell suspension was diluted in 9 ml CASYton. A background count of CASYton 
alone was calculated and subtracted from the cell count of each well. The cells/ ml value was 
multiplied by 3 to get a total cell number per well. Four independent growth curves were 
conducted. 
2.3.5 NEON TRANSFECTION SYSTEM ELECTROPORATION OF LNCAP CELLS 
Cells were electroporated using the Invitrogen Neon transfection System with the MPK 5000 
electroporator. Cell numbers and transfection conditions, for both 100 µl and 10 µl kits, were 
optimised based upon the Neon transfection cell protocol and cell line data and are 
























3.6 x 106 3.6 120 1200 20 2 
 
LNCaP cells were grown to the required density and then trypsinised as described above. Cells 
were washed once in PBS and then resuspended in PBS and counted using a haemocytometer. 
The necessary number of cells was centrifuged 500 x g for 3 minutes (11030 rotor, Sigma) and 
resuspended in the recommended amount of Solution R. The resuspended cells were 
combined with the amount of DNA shown in the table. The DNA and cell suspension was 
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loaded into the appropriate volume Neon pipette tip which was then docked in the pipette 
station containing 3ml E2 Solution. The cells were then microporated under the conditions 
detailed in the table.  Electroporated cells were seeded onto culture dishes or coverslips that 
had been pre-coated with poly-l-lysine and contained pre-warmed growth medium. Cells were 
grown for a minimum of 24 hours prior to subsequent experiments. 
2.3.6 CYCLOHEXIMIDE PULSE CHASE ASSAY OF ΑΒDGFLAG, ΑΒDGFLAGT788A AND 
ΑΒDGFLAGT788D IN LNCAP 
LNCaP cells were transfected with αβDGflag, αβDGflagT788A or αβDGflagT788D (Appendix B, 
Table B.1) and seeded into 100mm dishes as described above. Cells were grown for 24 hours. 
Cells were washed once with PBS and then incubated with growth medium containing either 
DMSO (control) or 100µg/ml cycloheximide (Sigma, C7698). The cells were incubated at 37°C, 
5% CO2 and harvested at 0, 6, 12 and 24 hours post cycloheximide treatment. 
2.3.7 THYMIDINE BLOCK SYNCHRONISATION OF LNCAP FOR CELL CYCLE ANALYSIS 
2.3.7.1 Thymidine block treatment of LNCaP cells optimisation 
LNCaP cells were seeded at a density of 5 x 105 per 100mm dish, pre-coated with poly-l-lysine 
and allowed to adhere and grow for 48 hours. Cells were washed gently 2 times with PBS and 
incubated with RPMI 1640, 10% FBS supplemented with 2mM thymidine (Sigma, Cat no. 
T1895) or PBS control. Cells were returned to the incubator and over a time course of every 2 
hours 18-32 hours post thymidine treatment one 100mm dish was fixed for flow cytometry 
and cell cycle profiling. 
2.3.7.2 Double thymidine block synchronisation for cell cycle analysis of LNCaP cells 
LNCaP cells were seeded at a density of 5 x 105 per 100mm dish, pre-coated with poly-l-lysine 
and grown for 48 hours. Cells were washed twice with PBS and incubated with RPMI 1640, 
10% (v/v) FBS containing either 2mM thymidine or PBS control. Cells were incubated with 
2mM thymidine for 32 hours and then washed carefully twice with PBS. Fresh growth medium 
was added to release cells from the block for 9 hours. The cells were then subject to a second 
2mM thymidine block for a further 22 hours.  Cells were washed twice with PBS and released 
into the cell cycle by the addition of fresh growth medium.  The cells were harvested every 2 
hours over a 14 hour time course post release (Adapted from Bootsma et al. 1964 and Bostock 
et al. 1971). One 100mm dish was fixed for flow cytometry analysis, One 100mm dish was 




2.3.8 NOCODAZOLE TREATMENT OF LNCAP CELLS 
2.3.8.1 Nocodazole treatment of LNCaP cells optimisation 
LNCaP cells were seeded at a density of 5 x 105 per 100mm dish and grown for 48 hours on 
poly-l-lysine pre-coated dishes. Following two PBS washes the cells were incubated with either 
50 ng/ml, 100 ng/ml or 500 ng/ml Nocodazole (Sigma, Cat. No. M1404) or DMSO diluted in 
growth medium at 37°C, 5% CO2. One dish per condition was then fixed for cell cycle analysis 
through flow cytometry at 12, 18, 24 and 30 hours after Nocodazole treatment. 
2.3.8.2  Nocodazole induced mitotic arrest of LNCaP cells 
LNCaP cells were seeded at a density of 5 x 105 per 100mm dish and grown for 48 hours on 
poly-l-lysine pre-coated dishes. Cells were washed twice with PBS and incubated with growth 
medium containing 100 ng/ml Nocodazole or DMSO for 30 hours at 37°C, 5% CO2. Cells were 
then fixed or harvested for downstream applications. Adapted from Zieve et al. 1980. 
2.3.9 FLOW CYTOMETRY ANALYSIS OF PROPIDIUM IODIDE STAINED MAMMALIAN CELLS  
2.3.9.1 EtOH fixation of cells for flow cytometry 
Media from the cells to be analysed were added to a falcon tube. The remaining cells were 
detached from the dish with tryspin-EDTA and added to the tube. Cells were centrifuged 500 x 
g for 3 minutes at room temperature and washed in 10 ml PBS. The cell number was calculated 
via a haematocytometer and 1.5 x 106 cells centrifuged as above. The PBS was aspirated 
leaving approximately 200 µl in which the cells were gently resuspended. Ice cold 70% (v/v) 
EtOH was added dropwise with gentle resuspension up to 1 ml. Following a 30 minute 
incubation on ice the cell suspension was centrifuged 500 x g for 7 minutes at 4°C (Sigma 1-
15K, rotor 12132-H) and the supernatant aspirated, leaving 200 µl. The cells were subject to a 
second dropwise resuspension in ice cold 70% EtOH and incubated for a further 30 minutes on 
ice prior to freezing at -20°C for up to two weeks prior to staining and flow cytometric analysis. 
 
2.3.9.2 Propidium Iodide (P.I.) staining of LNCaP cells 
EtOH fixed cells stored at -20°C were incubated on ice for 5 minutes. Following centrifugation 
(Sigma 1-15K, rotor 12132-H) at 500 x g for 7 minutes at 4°C the cell pellets were washed twice 
by the dropwise addition of ice cold PBS to 1.5 ml. The cells were then resuspended in 1 ml of 
propidium iodide stain (20 µg/ml propidium iodide (Sigma, Cat. No, P4170), 200 µg/ml RNAse 
A (Sigma, Cat no. R6513) in PBS) for 30 minutes in the dark at room temperature. Cells were 
then centrifuged and the supernatant aspirated, leaving 600 µl remaining. The cells were 
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resuspended in the remaining stain, transferred to a FACStube for analysis on the flow 
cytometer (Adapted from Pozarowski et al. 2004). 
2.3.9.3 Flow cytometry analysis of the cell cycle population of P.I stained LNCaP cells 
Each sample was analysed on the CyAn ADP (Beckman Coulter) using Summit software with 
the assistance of Dr. Mark Jones, Andrews Lab. Cells were first gated for side scatter (size) and 
forward scatter (granularity) to exclude debris and the majority of apoptotic cells from the 
analysis. The subsequent population was gated for doublet discrimination.  Cells were gated 
for pulse width against pulse area or length to discriminate between single cells in G2 or two 
G1 cells which are stuck together. These would have similar fluorescence but doublet cells are 
slightly larger, therefore taking longer to pass through the laser and can be excluded from the 
analysis. Finally, histograms of the single cell population were created, plotting cell count 
against FL3 area (P.I.) as a measure of fluorescence intensity. Cells in G1 have a 2N DNA 
content whilst cells which have replicated their DNA but not yet divided, ie those in G2 or M 
phases, have a 4N DNA content. Cells in S phase will have DNA content ranging between 2N 
and 4N. Data was analysed as above and final figures produced with FlowJo software. 
2.3.10  FACS ANALYSIS OF AN ASYNCHRONOUS POPULATION OF MAMMALIAN CELLS FOR CELL 
CYCLE ANALYSIS 
2.3.10.1 Cell Dissociation 
Cells were grown in T175 flasks for at least 48 hours to 60% confluency. The growth medium 
was removed to a falcon tube and following two PBS washes, cells were incubated with PBS 
based enzyme-free cell dissociation buffer (Gibco, LifeTechnologies, 13151-014) until cells 
detached from the flask. Cells were collected in growth medium, combined with the washes 
and retained media and centrifuged at 500 x g for 3 minutes (11030 rotor, Sigma) ready for 
subsequent fixation or staining. 
2.3.10.2 EtOH fixation and propidium iodide staining of an asynchronous population for FACS 
analysis. 
Cell pellets were resuspended in 20 ml PBS and the cell density calculated using a 
hemocytometer. Cells were centrifuged at 500 x g for 3 minutes at room temperature and a 
minimum of 4 x 107 cells were resuspended dropwise in ice cold 70 % EtOH (v/v) to a final 
concentration of 1.5 x 106 cells/ml. Fixation and P.I. staining protocols were continued as 
described in sections 2.3.9.1. and 2.3.9.2 prior to FACS analysis by Dr. Mark Jones. 
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2.3.10.3 Hoechst 33342 (H33342) staining of an asynchronous population of live mammalian 
cells for FACS analysis 
2.3.10.3.1 Dissociated Cells 
Cell pellets from section 2.3.10.1 were resuspended in growth medium and counted using a 
hemocytometer. 2-5 x 107 cells were resuspended in pre-warmed growth medium containing 5 
µg/ml H33342 (Sigma, Cat no. B2261) at a concentration of 5 x106 cells/ml. A control 
population of cells was incubated with dH2O diluted in growth medium. Cells were mixed 
gently and incubated in the dark at 37°C for 30 minutes. Cells were transferred to FACS tubes. 
FACS implementation was conducted by Dr. Mark Jones on the Jazz (BD Life Science) FACS 
machine see section 2.3.10.4. 
2.3.10.3.2 Adhered Cells 
5 µg/ml H33342 in pre-warmed growth medium was added to cells whilst still adhered to the 
flask at approximately 60% confluency (5 ml/ T175) for 30 minutes at 37°C. Cells were 
detached from the flask as described in section 2.3.10.1, with the addition of 5 µg/ml H33342 
to the dissociation buffer, and resuspended in growth medium supplemented with 5 µg/ml 
H33342 at a concentration of 5 x 106 cells/ ml prior to FACS analysis by Dr. Mark Jones see 
section 2.3.10.4. 
2.3.10.4 FACS of asynchronous populations of mammalian cells for cell cycle analysis. 
Cells were sorted on the Jazz (BD Life Science) MoFlo (Beckman Coulter) FACS machines by Dr. 
Mark Jones using BD FACS or Summit software respectively. Cells were gated to exclude 
debris, select single cells and display cell cycle phases based upon DNA content as described 
previously in section 2.3.9.3. When sorted on the MoFlo all three cell cycle phases were 
collected into PBS or growth medium simultaneously whilst on the Jazz, S and G1 were 
collected first until 1- 2 x 106 viable cells had been collected for each phase and then S and G2M 
cells collected for the remainder of the sample. Collected samples were centrifuged at 500 x g 
for 3 minutes at 4°C (Sigma 4-16KS, rotor 12269) and processed according to downstream 
applications. 
2.4 ZEBRAFISH HUSBANDRY 
2.4.1 HOME OFFICE REGULATION 
All studies were carried out in accordance with Home Office requirements for the use of 
animals in scientific research. Embryos under 5 days post-fertilisation (d.p.f) were used under 
UK Home Office project license of Prof. Steve Winder, license number 40/3693. 
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2.4.2 MAINTENANCE OF ADULT ZEBRAFISH 
Adult zebrafish were maintained in the UK Home Office approved Bateson centre aquaria at 
the University of Sheffield. The aquaria follow a 14:10 hour light: dark cycle and are 
maintained according to standard protocols (Nϋsslein- Volhard and Dahm, 2002). 
2.4.3 ZEBRAFISH STRAINS 
Heterozygous Dystroglycan mutant ( dag1hu3072) zebrafish (Lin et al 2011, Gupta et al 2011) are 
kept as breeding stocks in the aquaria on a London Wildtype (LWT) background. 
2.4.4 EMBRYO COLLECTION 
A tray containing marbles with a filter grid bottom was inserted into a collection tray and 
placed securely into the tank containing adult heterozygous DAG zebrafish, ensuring that the 
fish can move into and around the tray. The trays were left in the tank overnight. The eggs 
were removed from the collection tray and washed with clean system water to remove debris. 
The eggs were transferred to 10cm petri dishes containing E3 media (5mM NaCl, 0.17mM 
KCl, 0.33mM CaCl2, 0.33mM MgSO4, 0.0001% methylene blue) with 40 eggs per dish and 
incubated at 28°C. 
2.4.5 DETECTION OF MUSCLE PHENOTYPE VIA BIREFRINGENCE ASSAY 
At 4 days post-fertilisation (d.p.f.) embryos in E3 media in petri dishes were incubated on ice to 
slow movement and then transferred to a glass dish. Embryos were viewed between two 
polarising filters on a dissecting microscope (Leica MZ FLIII). The polarising filters are rotated 
so that only the light refracting through the striated muscle was visible. The sibling embryos 
were then sorted into wt or mutant groups based upon the degree of disrupted muscle 
phenotype. Images were acquired using a Jenoptik ProgRes C4 camera attached to a Leica MS5 
microscope with Prog Res Capture Pro software. 
2.5 MICROSCOPY TECHNIQUES 
2.5.1 IMMUNOFLUORESCENCE STAINING OF MAMMALIAN CELLS 
Cells were seeded onto 13mm glass coverslips (VWR) pre-coated with poly-l-lysine at the 
required density and grown for a minimum of 24 hours. Prior to fixation the cells were washed 
three times with PBS. Cells were fixed with paraformaldehyde (PFA) except for when 
visualising microtubules or, when indicated, centrosomes in which case a methanol/ acetone 
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fixation was used.  For PFA fixation cells were fixed for 10 minutes with 3.7% (v/v) PFA (Sigma) 
in PBS and permeabilised for 5 minutes with 0.1% triton X-100 in PBS. In the case of 
methanol/acetone fixation, cells were fixed for 10 minutes with methanol at -20°C followed by 
1 minute of acetone at -20°C. Coverslips were then washed 3 times with PBS and inverted cell 
side down onto 20 µl blocking buffer (5% (v/v) FBS, 3% BSA (w/v) in PBS) on parafilm for 1 hour 
at room temperature in a humidified chamber. Coverslips were then transferred to 15 µl 
primary antibody diluted in blocking buffer and incubated for 1 hour as described above. The 
cells were then washed in PBS 3 times to remove any unbound or low affinity binding of the 
primary antibody. Coverslips were again inverted cell side down onto blocking buffer 
containing diluted, fluorescent conjugated secondary antibodies and incubated in the 
humidified chamber in the dark for 1 hour at room temperature. The coverslips were then 
washed gently three times in PBS to remove excess secondary antibody and allowed to dry. 
Coverslips were then mounted onto 5µl hydromount (National Diagnostics) containing 10 
ng/ml DAPI (Sigma) as a nuclear counterstain and 2.5% of the antifade preservative 1,4- 
Diazabicyclo [2.2.2]octane (DABCO) (Sigma) on glass slides (Fisher, 0.8-1.0mm). Slides were 
stored in the dark at 4°C before viewing on a microscope. 
2.5.2 BRDU INCORPORATION AND STAINING OF MAMMALIAN CELLS FOR MICROSCOPY 
ANALYSIS 
Cells were grown on 13mm glass coverslips pre-coated with poly-l-lysine for at least 48 hours. 
The growth media was then removed and replaced with 10µM BrdU (Sigma, Cat. No. 
M099488)) or H2O control diluted in pre-warmed growth medium for 1 hour at 37°C, 5 % CO2.  
For double immunofluorescence staining of BrdU alongside another antibody, the cells were 
fixed, blocked and stained first for the other antibody according to the immunofluorescence 
protocol in section 2.5.1. The following procedure was carried out in a humidified chamber, 
protected from the light. After the incubation with the secondary antibody the coverslips were 
washed three times in PBS and fixed for a second time in 3.7 % PFA (v/v) for 10 minutes at 
room temperature. The cells were then permeabilised and the DNA denatured by incubation in 
4 N HCl, 0.1% triton x-100 in PBS for 10 minutes at room temperature. Following three PBS 
washes the cells were incubated with a primary antibody against BrdU diluted in blocking 
buffer for 1 hour at room temperature. Cells were then washed three times prior to incubation 
with an appropriate fluorescent conjugated secondary antibody against the Brdu primary 
antibody in blocking buffer. The coverslips were washed a further three times with PBS, 
allowed to dry and then mounted on glass slides in hydromount, 10 ng/ml DAPI, 2.5 % (w/v) 
DABCO and stored at 4°C in the dark until viewed on a microscope. 
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2.5.3 WHOLE MOUNT IMMUNOFLUORESCENCE STAINING OF ZEBRAFISH EMBRYOS 
Four d.p.f. sibling embryos, sorted by birefringence were euthanised by hypothermal shock. 
The embryos were then placed into 1.5ml Eppendorf tubes with five embryos per tube. The 
embryos were gently washed once with 1 ml PBS and then fixed in 1.5 ml 4% PFA in PBST (PBS, 
0.2% (v/v) tween-20) on a slow rotator at 4°C overnight. All subsequent washes are 1ml 
unless stated otherwise. Following fixation the embryos were washed in PBST followed by 
dH2O for 5 minutes each at room temperature with gentle rocking. The embryos were then 
incubated with acetone at -20°C for 15 minutes, followed by one 5 minute dH2O wash and two 
5 minute washes with PBST at room temperature. The embryos were then blocked in PBD 
(PBS, 0.2% (v/v) tween-20, 1% BSA (w/v) 0.01% DMSO (v/v)) supplemented with 2% FBS (v/v) 
for 30 minutes at room temperature with gentle rocking. The embryos were then submerged 
in 500 µl primary antibody diluted in PBD/FBS blocking buffer and incubated on a roller at 4°C 
overnight. The following day the embryos were washed for 30 minutes in PBD four times and 
then incubated in 1ml of secondary antibody diluted in PBD, 2% FBS overnight at 4°C. The 
embryos were then washed four times for 30 minutes in PBD at room temperature, followed 
by a further two 5 minute washes in PBST. The embryos were then positioned in the desired 
lateral orientation with thin forceps onto 1% (w/v) agarose combs in 35 mm dishes. The 
embryos were then sealed in position by the addition of a thin layer of 1.5% (w/v) low melting 
agarose. Once set the agarose was immersed in PBS and the dishes stored at 4°C in the dark 
prior to viewing on the confocal microscope. 
2.5.4 EPIFLUORESCENCE MICROSCOPY 
Slides were viewed using a Leica DMIRE2 inverted fluorescent microscope powered by a Leica 
CTRMIC controller. Leica narrow pass filters were used; A4; DAPI (excitation at 360 nm, 
emission at 400nm), L5; FITC/GFP/Alexa Fluor 488 (excitation at 480 nm, emission at 505 nm) 
and N2.1; Rhodamine/ Texas Red/ Alexa-Fluor 594 (excitation 515-560 nm, emission at 580 
nm) Images were obtained with a Leica HCX PL 63x oil immersion objective lens and a Leica 
DC350F CCD camera. Images were acquired using the Leica Q-Fluoro software and analysed 






2.5.5 CONFOCAL MICROSCOPY 
Confocal microscopy was carried out in the Wolfson Light Microscopy Facility, University of 
Sheffield. 
2.5.5.1 Nikon A1 Confocal 
Confocal images of mammalian cells were obtained using an inverted Nikon A1 confocal with a 
CFI Plan ApoChromat VC 60x oil (NA 1.4) objective. The immersion oil had a refractive index of 
1.518 (Immersion oil Type-F, Olympus) Excitation sources: 405 nm, 457-514 argon laser, 561 
nm sapphire laser, 642 nm diode laser. The detector collected emission bandwidths for each 
filter as follows; blue, DAPI; 425-475 nm, Green; AlexaFluor488/ FITC; 500-550nm, red; 
AlexaFluor594/ Texas Red; 570- 620nm. During image acquisition the pinhole was set at 1.0 
Airy Units (A.U.) and the pixel size set at 512 x 512 or 1024 x 1024. Z stacks were collected 
bottom to top. Images were acquired using Nikon NIS Elements software V4.30 and were 
processed and analysed using Fiji (is just ImageJ) software. 
2.5.5.2 Olympus FV1000 Confocal BX61 Upright 
Confocal images of zebrafish embryos were acquired on and Olympus FV1000 Confocal BX61 
Upright using a LUMPlan F1 60x (NA 0.9) water dipping lens. Excitation source 405 nm diode, 
488 argon laser, 543 diode and 640nm diode. The emission filters had bandwidths of blue; 
DAPI; 425-475 nm, green; AlexaFluor488; 500-530nm, red; AlexaFluor594/ Texas Red; >560 
nm. During image acquisition the pinhole was set to 1.0 A.U. and pixels 512 x512. Images were 
acquired using Olympus Fluoview FV-ASW software and processed using Image J. 
2.5.6 FIJI PROCESSING OF MICROSCOPY IMAGES 
Images were analysed using FIJI (Is Just Image J). Images from each channel were opened in 
greyscale as 16 bit images. Intensity and gamma levels were manually adjusted taking care not 
to add or subtract from visual data. Images were then scaled and cropped and saved as TIFF 
images. In the case of z stacks individual slices were also saved as Jpegs. False colour images 
were generated and converted to RGB colour. Images were saved in TIFF and Jpeg formats.  
2.5.7 FIJI QUANTIFICATION OF CENTROSOME TO NUCLEUS DISTANCE 
Images were opened in FIJI and the scale set. The straight line tool used to manually draw a 
line between the centrosome and the nucleus and the distance recorded and exported to 
Graphpad Prism 6.0 
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2.6 BIOCHEMISTRY TECHNIQUES 
2.6.7 LYSATE PREPARATION FROM MAMMALIAN CELLS 
Cells in petri dishes were washed twice with cold PBS on ice and then lysed with radio 
immunoprecipitation assay buffer (50mM Tris- HCl pH 7.5, 150 mM NaCl, 1 mM EGTA, 1 mM 
EDTA, 1% Triton X-100 (v/v), 0.5% Sodium Deoxycholate (w/v), 0.1% SDS (w/v)) or mild lysis 
buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100 (v/v) supplemented 
with the appropriate protease and phosphatase inhibitors (Table B.3) on ice for 15 minutes. 
Cell lysates were then harvested using a cell scraper and transferred to a 1.5ml Eppendorf 
tube. To shear the DNA, lysates were sonicated (Sanyo Soniprep 150) briefly three times for 10 
seconds followed by 10 seconds of rest and then centrifuged at 18000 x g (Sigma 1-15K, rotor 
12132-H) for 15 minutes at 4°C to pellet the cell debris. The resulting supernatant was 
transferred to a micro centrifuge tube and either used immediately or stored at -20°C (James 
et al. 2000) 
2.6.8 LYSATE PREPARATION FROM ZEBRAFISH EMBRYOS 
One euthanised 4 d.p.f. embryo was added to 20 µl RIPA buffer supplemented with protease 
and phosphatase inhibitors (Table B.3) in a 1.5 ml Eppendorf tube on ice. The embryo and RIPA 
buffer was then pipetted up and down 25 times to disrupt the tissue and then sonicated briefly 
3 times for 10 seconds with a 10 second break in between each sonication (Sanyo Soniprep 
150). The tubes were then centrifuged at 18000 x g (Sigma 1-15K, rotor 12132-H) for 15 
minutes at 4°C. The resulting supernatant was removed to a fresh micro centrifuge tube and 
mixed with an equal volume of 2x laemelli sample buffer before boiling for 10 minutes at 
100°C in a dry heat block. The lysates were then stored at -20°C for future use. 
2.6.9 CELL FRACTIONATION AND NUCLEAR FRACTION PREPARATION FROM MAMMALIAN 
CELLS 
Cells were washed twice with cold PBS on ice and incubated with the minimum volume of cold 
hypotonic Buffer I (0.32M Sucrose, 10mM Tris-HCl pH 8.0, 3mM calcium chloride, 2mM 
magnesium acetate, 0.1mM EDTA, 0.5% NP-40 (v/v), 1mM DTT) supplemented with protease 
and phosphatase inhibitors (Table B.3.) on ice for 15 minutes. The cells were collected using a 
cell scraper and disrupted further with 35 strokes in a cold glass Dounce homogeniser. The 
lysate was then centrifuged at 600 x g for 10 minutes at 4°C (Sigma 4-16KS, rotor 12269). The 
resulting pellet containing the nuclear fraction and the non- nuclear supernatant were 
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retained for further purification. The supernatant was centrifuged twice at 9300 x g for 10 
minutes at 4°C (Sigma 4-16KS, rotor 12269) to remove nuclear contaminants and the final 
supernatant retained as the purified non-nuclear fraction. The pellet containing the nuclear 
fraction following the 600 x g centrifugation was resuspended in 400 µl Buffer I and an equal 
volume of buffer II (2M Sucrose, 10mM Tris-HCl ph 8.0, 5mM Magnesium Acetate, 0.1mM 
EDTA, 1mM DTT). This mixture was carefully overlaid onto an equal volume of a 1.8 M sucrose 
cushion in an ultracentrifuge tube and centrifuged at 21000 x g for 55 minutes at 4°C 
(Beckmann Coulter Optima™ MAX Ultracentrifuge, rotor MLA-80). The resulting pellet was 
resuspended in RIPA buffer or mild lysis buffer supplemented with protease and phosphatase 
inhibitors, sonicated (Sanyo Soniprep 150) three times for 10 seconds to shear the DNA and 
centrifuged at 18000 x g for 15 minutes at 4° (Sigma 1-15K, rotor 12132-H) and the 
supernatant retained as the nuclear fraction. The fractions were either used immediately or 
stored at -20°C for future use (Mathew et al. 2013). 
2.6.10 PROTEIN CONCENTRATION DETERMINATION VIA THE MICROBCA™ASSAY 
The protein concentration of lysates and fractionation samples was calculated using the 
MicroBCA™ protein assay kit (Thermo Scientific), according to the manufacturer’s instructions. 
Briefly the protein sample was diluted 1:125 in RIPA buffer to a total volume of 500 µl and 
mixed with 500 µl working reagent (Reagents MA:MB:MC at a ratio of 25:24:1) along with a 
blank consisting of working reagent and RIPA buffer. Each sample was made in triplicate. The 
diluted protein samples were then incubated at 60°C for 1 hour, protected from light and then 
allowed to cool to room temperature. The absorbance of each sample at 562 nm was 
measured via a spectrophotometer (7315 model Jenway) in 1cm path length polystyrene 
cuvettes. The average reading per lysate was then used to calculate the protein concentration 
from a standard curve of BSA concentrations of 0- 200 µg/ ml.  
2.6.11 IMMUNOPRECIPITATION OF FLAG- TAGGED PROTEINS USING ANTI-FLAG M2-
AGAROSE AFFINITY GEL 
Immunoprecipitation (IP) of flag-tagged proteins was carried out using Flag M2 resin (Sigma, 
Cat no. A2220) according to the manufacturers protocol. Briefly, the Flag M2 resin was 
thoroughly resuspended and 40 µl/IP was transferred to a clean tube. The resin was washed 
five times with 20 resin bed volumes of 1x TBS at 7000 x g for 30 seconds (Sigma 1-15K, rotor 
12132-H). 200-400 µg of lysate was incubated with the resin and adjusted to a total volume of 
1 ml with lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100 
(v/v)). The samples were then left at 4°C on a roller overnight. Following incubation the 
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samples were centrifuged at 7000 x g for 30 seconds at 4°C (Sigma 1-15K, rotor 12132-H) and 
the supernatant carefully removed using a narrow-end pipette tip. The resulting resin was 
washed three times with 500 µl cold 1x TBS. Samples were either boiled in 2x Laemelli sample 
buffer at this stage and stored at -20°C until use or the flag tagged protein was eluted. To elute 
the flag tagged protein the resin was incubated with 150 ng/ml of competing 3x flag peptide 
(Sigma, Cat. No. F4799) on a roller for 30 minutes at 4°C. The mixture was then centrifuged for 
30 seconds at 7000 x g at 4°C (Sigma 1-15K, rotor 12132-H) and the supernatant containing the 
eluted protein was transferred to a new tube for immediate use or stored at -20°C. 
2.6.12 SDS- POLYACRYLAMIDE GEL ELECTROPHORESIS (SDS-PAGE) 
SDS-PAGE mini-gels (10 cm x 10 cm x 1 mm) were prepared individually using the Bio-rad 
casting system. The mini-gels consisted of a 10 or 12 % resolving gel with a 5% stacking gel 
(Table B.4.). The samples, having previously been boiled with Laemelli sample buffer, were run 
on the mini-gels in Bio-rad tanks filled with 1x SDS running buffer(200 mM Glycine, 25mM Tris, 
0.01% SDS). Samples were run alongside a broad range molecular weight protein ladder 
(PageRuler Plus Prestained Protein ladder, Thermo Scientific, Cat no. 26619). Samples were 
separated at 100 V through the stacking gel and at 120- 150 V at fixed voltage through the 
resolving gel.  
2.6.13 COOMASSIE BLUE SAFE STAIN OF SDS-PAGE GELS 
Following SDS electrophoresis, gels were rinsed briefly in dH2O. Gels were then immersed in 
Coomassie Blue Safe Stain (60-80mg Coomassie brilliant blue G250, 3ml Concentrated 
HCl )and microwaved for 10 seconds before incubation at room temperature and gentle 
rocking for 1 hour. The coomassie stain was then discarded, the gel washed in dH2O twice and 
then destained in dH2O overnight. Gels were imaged using the Biorad Chemidoc XRS system 
with Image Lab software (Biorad). 
2.6.14 SEPARATION OF PROTEIN LYSATES ON PHOS-TAG GELS (KINOSHITA ET AL. 2009) 
Phos-Tag (Phos-Tag™ Acrylamide AAL-107, NARD) gels were prepared in the same way as the 
mini gels described above with the changes recommended in the manufacturer’s protocol. 
Prior to the addition of the polymerising reagents APS and TEMED to the 10% resolving gel, the 
Phos-tag reagent and MnCl2 were added at a molar ratio of 2:1 MnCl2: Phostag. Gels with 
Phostag concentrations of 20 µM, 50 µM and 100 µM were used. The 5% stacking gel was 
prepared as above (Table B.4.). Phos-tag mini gels were run at 100 V through the stacking gel 
and 30mA through the resolving gel until the dye front had migrated the desired distance. 
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Prior to downstream electrotransfer and western blotting, the gels were removed from the 
glass cassettes and washed twice with 2 mM EDTA in transfer buffer for 10 minutes to chelate 
Mn2 ions, which may interfere with the transfer, followed by two washes of 5 minutes in 
transfer buffer alone. 
2.6.15 ELECTROTRANSFER 
Proteins were electroblotted from SDS-PAGE mini gels to PVDF (Polyvinylidene fluoride) 
membranes (Immobilon- PSQ, 0.2 µM, Merck Millipore) using a mini Trans-Blot electrophoretic 
transfer cell (Biorad). The SDS-PAGE gel containing the electrophoresed proteins was 
immersed in Towbin transfer buffer (25 mM Tris, 192 mM Glycine, 20 % Methanol (v/v), 0.02% 
SDS (w/v)) along with the methanol activated PVDF, chromatography paper (Whatman) and 
fibre pads. Once all the components had been equilibrated in transfer buffer for 10 minutes 
they were assembled into the transblot cassettes and the chamber filled with Towbin transfer 
buffer as per the manufacturer’s instructions. The membranes were blotted at a fixed voltage 
of 100 V for 75 minutes. Membranes were then removed from the transfer apparatus and 
immersed in TBST (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.5% Tween 20 (v/v)). 
2.6.16  WESTERN BLOTTING 
Electroblotted membranes were blocked in 5% (w/v) skimmed milk powder or 5% BSA in TBST 
for 1 hour at room temperature with gentle rocking. The membrane was then incubated with 
the primary antibody (Table B.5.) diluted to the required concentration in blocking buffer at 
4°C overnight with gentle rocking. The membranes were then washed three times with TBST 
for 10 minutes followed by incubation with the appropriate secondary antibody (Table B.6.) in 
blocking buffer for 1 hour at room temperature. Excess unbound antibody was removed from 
the membranes with three further TBST washes of 10 minutes each. A chemiluminescent 
signal was generated by incubating the membranes with freshly mixed ECL solution (equal 
volumes of ECL I (100 mM Tris-HCl pH8.5, 25mM Luminol, 396µM p-Coumaric Acid) and ECL II 
(100 mM Tris-HCl pH8.5, 0.02% (v/v) H2O2) for 30 seconds. The membrane was then 
transferred to the Bio-rad Chemidoc XRS system and the chemiluminescent signal recorded 
over a time course of up to 45 minutes. 
2.6.17  MEMBRANE STRIPPING 
In instances when the membrane was to be re-probed the antibody were removed from 
membranes using a low pH mild stripping buffer (15g Glycine, 1g SDS, 1 ml Tween 20, pH 
2.2). The membrane was incubated twice for 10 minutes each with mild stripping buffer at 
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room temperature, followed by two 10 minute PBS washes and two 5 minute TBST washes. 
The membrane was then ready to continue with the blocking and antibody incubation steps as 
described in section 2.6.10.  
2.6.18 PEPTIDE ARRAYS 
Peptide arrays consisting of 15 residue oligomers, with a single step residue, covering the 
cytoplasmic domain of βDG were obtained from Intavis AG. The arrays were washed three 
times for 10 minutes with TBST and then blocked with 5% (w/v) skimmed milk powder in TBST 
for 1 hour at room temperature. The array was then incubated with primary antibody diluted 
in blocking buffer overnight at 4°C. The following day the array was washed three times in 
TBST for 10 minutes each to remove excess antibody and then incubated with the appropriate 
secondary antibody in blocking buffer for 1 hour at room temperature. The array was subject 
to three final 10 minute TBST washes before incubation with ECL solution for 30 seconds to 
generate a chemiluminescent signal which was the recorded on the Biorad Chemidoc XRS 
system. 
2.6.19 DENSITOMETRY QUANTIFICATION OF WESTERN BLOT BANDS 
Densitometry analysis of western blot bands was carried out using the Image Lab software 
(Biorad). Images with saturated pixels were excluded from analysis. Lanes were manually 
defined and the bands detected automatically. Using plots of intensity versus relative front the 
integrated area under the peak for each band was recorded (Volume intensity) and exported 
to GraphPad 6.0 for analysis.  
The nuclear: non-nuclear ratio was calculated by dividing the intensity of the western blot 
bands, as detected by densitometric analysis, by the volume loaded for 20µg of each sample to 
determine the intensity/µl. The approximate total volume of the non-nuclear and nuclear 
fractions for each sample was 440µl and 110µl respectively. The nuclear fraction is therefore 4 
times more concentrated than the non-nuclear fraction. The intensity/µl of the cytoplasmic 
fraction was multiplied by 4 to adjust for the fact that an absolute amount (20µg) rather than 
proportional amounts were loaded for the fractionation experiments. The nuclear: non-





2.6.20  STATISTICAL ANALYSIS 
Data was compiled and analysed in Microsoft excel and graphpad prism 6.0. The mean and 
standard error of the mean (S.E.M) are reported. Normality distribution was analysed via 
histogram and the D’Agostino and Pearson and Shapiro-Wilk normality tests. For correlation 
analysis the Spearman non-parametric test was used.  Mann-Whitney U test was used in the 


























Characterisation and validation of β-
Dystroglycan antibodies 
3.1 INTRODUCTION 
3.1.1 DYSTROGLYCAN LOCALISATION AND EXPRESSION 
 
DG expression is ubiquitous, and its expression and localisation has been well characterised in 
multiple tissues including skeletal muscle, heart, small intestine, kidney, skin, mammary gland, 
prostate and the central nervous system (Ibraghimov-Beskrovnaya et al 1993, Durbeej et al. 
1995, Durbeej et al. 1998, Henry et al. 2001, Sgambato et al. 2006, Herzog et al. 2004, Mathew 
et al. 2013). 
DG expression and localisation is also well studied in multiple research models used by the 
scientific community. For example, in zebrafish, DG and other components of the DGC localise 
to the vertical myosepta, the boundaries between somites to which the muscle fibres attach 
(Gupta et al. 2011, Lin et al. 2011) and in mice DG is located at the PM of cells with strong 
localisation at sites in contact with the basement membrane (Durbeej et al.1995, Williamson 
et al. 1997, Anderson et al. 2007). Multiple cell lines including myoblasts, fibroblasts and 
numerous cancer cell lines have also been used to study DG localisation, regulation and 
function (Gonzalez-Ramirez et al. 2008, Mathew et al. 2013, Mitchell et al. 2013, Sgambato et 
al. 2006, Sotgia et al. 2003, Thompson et al. 2010). DG expression levels are variable across 
different cell lines as is the extent of post-translational events such as glycosylation and 
proteolytic cleavage.  (Mathew et al. 2013, Thompson et al. 2010, Mitchell et al. 2013, Losasso 
et al. 2000). In most cell lines, DG localises to the plasma membrane and is strong at the basal 
surface and cell-cell junctions, as well as at focal adhesions and filopodial and invadapodial 
protrusions, consistent with its role as an adhesion molecule. (Spence et al. 2004, Thompson et 
al. 2010). Importantly, in both tissue samples and cell lines, DG is also detected within the 
nucleus and intracellular vesicles (Lara-Chacon et al 2010, Mathew et al 2013, Leocadio et al 
2016, Sotgia et al 2003). Characterising the localisation and expression of βDG provides 
important clues as to its regulation as well as the emerging functions of DG, distinct from its 
role at the PM. 
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3.1.3 DYSTROGLYCAN ANTIBODIES AS RESEARCH TOOLS 
Key to many techniques investigating the modification, localisation and function of DG are 
antibodies. Western blots (WB), Immunoprecipitation, ELISAs, flow cytometry, 
immunohistochemistry (IHC) and many other techniques all require the use of antibodies. 
Antibodies can detect a specific protein, or even specific modified forms of a protein, and can 
provide a wealth of information on the target protein of interest. 
3.1.5 DYSTROGLYCAN ANTIBODIES 
3.1.5.1 α-Dystroglycan antibodies 
The study of αDG is notoriously difficult due to the relative lack of antibodies that reliably 
detect αDG. This unreliability is largely due to the highly variable glycosylation of αDG. The 
most widely used αDG antibodies are the monoclonal antibodies IIH6 and VIA4-1, both of 
which recognise close, but distinct, epitopes on the fully glycosylated form of αDg (Ervasti et al, 
1993, Durbeej et al 1993, Hara et al 2011, Humphrey et al 2015). Because of its ability to block 
laminin binding, the IIH6 epitope is proposed to be the glycosylated laminin binding site added 
by the glycosyltransferase LARGE, however this is not the case for VIA4-1 (Durbeej et al 1995, 
Hara et al 2011). IIH6 and VIA4-1 recognise smears of signal between 120-180 KDa depending 
on the tissue analysed via western blot (Holt et al 2000, Ervasti et al, 1993, Durbeej et al 1993). 
Both antibodies stain the sarcolemma in normal skeletal muscle when detected by IHC (Ervasti 
et al, 1993, Durbeej et al 1993, Humphrey et al 2015). IIH6 and VIA4-1 are widely used clinically 
because the hypoglycosylation typical in many dystroglycanopathies is detected by a loss of 
immunoreactivity by both antibodies (Brown et al 2004.). This loss of staining may also in part 
be due to loss of core αDG from the membrane (Brown et al 2004).  
Antibodies that recognise the peptide backbone in the less highly glycosylated C-terminal 
domain of αDG are also being produced. For example, a polyclonal antibody produced by 
Kroger et al raised against amino acids 565-584 of the C-terminal of αDG stains the 
sarcolemma in skeletal muscle sections in IHC but works poorly on western blots (Herrmann et 
al 2000). This is also the case for DAG-6F4, a monoclonal antibody that recognises a seven 
amino acid epitope (493PNQRPEL499) in the C-terminal domain of αDG (Humphrey et al. 2015). 
This epitope is at the start of a predicted IgG-like domain near to the βDG binding site and is 
proposed to be in an extended conformation with little glycosylation (Humphrey et al. 2015). 
Why these antibodies are efficient in IHC but not in western blots, where the proteins have 
been extracted and denatured, remains unclear but is likely due to the difference in 3D 
conformation of the glycan side chains in each technique (Humphrey et al. 2015), again 
highlighting the difficulties in antibody technology imposed by high levels of glycosylation. 
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3.1.5.2 β-Dystroglycan antibodies 
A larger number of reliable antibodies are available for the study of βDG, those used in this 
study are detailed in Table 3.1. Currently βDG antibodies are limited to detecting the very C-
terminus of the cytoplasmic domain of βDG and as of yet no antibodies are available to the 
extra cellular or even juxtamembrane cytoplasmic domains. One of the best characterised anti- 
βDG antibodies is the mouse monoclonal MANDAG2 (MDG2) (Helliwell et al 1994). MDG2 was 
raised against an immunogen peptide of the last 15 amino acid residues in the C-terminus of 
βDG (Helliwell et al 1994). The epitope of MDG2 was further elucidated by functional epitope 
mapping studies by James et al and Pereboev et al using spot arrays and point mutations or 
random phage display libraries respectively (James et al 2000, Pereboev et al 2001). James et 
al.  identified the crucial residues of the epitope to be PxYVP, which is within the seven 
residues SPPPYVP that Pereboev et al. concluded contained the epitope (James et al 2000, 
Pereboev et al 2001). James et al went on to show that MDG2 binding to the epitope was 
abolished by introduction of phosphorylation at Y892 (James et al 2000). In support of this 
specificity to the non-phosphorylated form of Y892, both groups showed that a substitution of 
Y892 to a phenylalanine, which is essentially used as a non-phosphorylatable control for the 
phospho-tyrosine residue, was tolerated by MDG2 but no other substitutions were (James et al 
2000, Pereboev et al 2001). As previously mentioned, phosphorylation at Y892 has important 
functional implications for βDG interactions and localisation, therefore an antibody sensitive to 
phosphorylation at this site is a valuable tool. 
 
1709 is a rabbit polyclonal antibody that was raised against phospho-peptide 
KNMTPYRSPPPpYVPP (Ilsley et al 2001) found at the C-terminal of βDG. The epitope is very 
similar to that of MDG2 but crucially is specific for phosphorylation at Y892. Indeed, on peptide 
SPOT arrays 1709 does not detect the same peptide without phosphorylation at Y892 (Miller et 
Table 3.1. βDG antibodies used in this study. The antibodies are reported alongside their 
reported epitopes, species, class and source. 
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al. 2012).  JAF1 is also a rabbit polyclonal antibody raised against a peptide containing 7 C-
terminal amino acid residues of βDG (Rivier et al. 1999).  C20 is a commercially available goat 
polyclonal antibody raised against the C-terminal 20 residues of βDG. Other commercially 
available antibodies include the mouse monoclonal 43DAG, which was raised against a peptide 
containing 15 C-terminal residues, much like MDG2, and also the rabbit polyclonal anti- βDG H-
242 which targets residues 831-895 of βDG. All of the above have been shown to detect a 
43KDa band corresponding to full length βDG via western blot and localise to the sarcolemma 
in skeletal muscle sections via IHC (James et al 2000, Ilsley et al 2001, Pereboev et al 2001, 
Rivier et al 1999, Lara-Chacon, 2010, Mathews et al 2013, Miller et al 2012). Given the number 
of βDG antibodies now available it was decided to compare the epitopes, localisation and the 
expression profiles detected by the antibodies MDG2, 1709, JAF1 and C20 , particularly in the 
prostate cancer cell lines to be used as the model systems in this body of research.  
Given that the βDG antibodies have been raised against different antigens, they are likely to 
detect different epitopes (Pereboev et al. 2001, Ilsley et al. 2001, Rivier et al. 1999). The 
antibodies may therefore detect distinct populations of βDG, for example as a consequence of 
regulatory PTM contained within the epitopes, as is the case with 1709 and its detection of 
βDG phosphorylated at Y892 (Ilsley et al. 2001). The use of 1709 as a tool in the 
characterisation of βDG localisation is of particular interest for this body of research, as 
phosphorylation at Y892 has been implicated in the regulation of the nuclear localisation of 
βDG (Lara-Chacon et al. 2010). Whilst the antibodies MDG2, 1709, JAF1 and C20 have all been 
used, to varying extents, in the investigation of βDG localisation and expression in a number of 
model systems, there has been little direct comparison of the populations of βDG that these 
antibodies detect. A thorough comparison of βDG with the different antibodies in the prostate 
cell lines to be used as a model system in this project may provide further insight into the 
subcellular localisation of βDG in these cells as well as clues as to the regulation of βDG. It is of 
equal importance to validate each of the anti- βDG antibodies as specific tools in the detection 
of βDG. 
3.1.6. THE IMPORTANCE OF ANTIBODY VALIDATION 
Antibodies are routinely used in research for a number of techniques as well as clinically. In 
order to obtain reliable results, it is therefore important to validate antibodies to determine 
their specificity and reproducibility in the varying techniques in which they are used. An 
antibody that works efficiently at recognising the epitope in western blots, when the protein is 
denatured, may not recognise the epitope when the protein is in its native conformation in 
IHC. In addition, in techniques such as IHC a fixative may further complicate the issue by 
altering the presentation of the epitope (Bordeaux et al 2010). Moreover, antibodies must be 
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assessed for cross reactivity whereby an antibody may recognise an epitope in a protein other 
than the intended target. In the case of polyclonal serum antibodies additional IgG that 
recognise different antigens may also be present and therefore produce background signal 
which may confound interpretation of the results (Bordeaux et al 2010, Lipman et al 2005).  
3.1.7 CHAPTER AIMS 
The aims of the research conducted in this chapter are: 
- to validate the specificity of four βDG antibodies used in this study in different applications, 
namely immunoblotting and immunofluorescence microscopy. 
 - to characterise the expression and localisation of βDG, as detected by the different 
antibodies, in the model systems used in this body of work. 
3.2 RESULTS 
3.2.1 CHARACTERISATION OF CARBOXYL TERMINAL EPITOPES OF Β-DYSTROGLYCAN 
ANTIBODIES BY PEPTIDE ARRAYS 
The different antibodies used in this study to detect βDG (Table 3.1) have been raised against 
different epitopes in the carboxyl terminus of βDG (Helliwell et al 1994, Ilsley et al 2001, Rivier 
et al 1999). In order to characterise and compare the differences in epitope at the most basic 
residue sequence level, the antibodies were used to immunoblot βDG peptide arrays obtained 
from Invatis AG (Fig 3.1A,B). Each array consists of the 110 amino acids of the cytoplasmic 
domain of βDG synthesised as 15 residue peptides, overlapping in 1 residue steps (Fig 3.1B), 
each repeated three times. 
The monoclonal antibody, MDG2, was raised against a peptide covering the 15 carboxyl 
residues of βDG and therefore, unsurprisingly, detects the carboxyl terminal two spots with a 
consensus sequence of KNMTPYRSPPPYVP (Helliwell et al 1994) (Fig 3.1A). MDG2 does not, 
however, detect a peptide of the same sequence that has been modified to contain a 
phosphorylated tyrosine residue (Y892), KNMTPYRSPPPpYVPP (Spot E15). 1709, on the other 
hand, specifically detects only this phosphorylated peptide (Fig 3.1A). MDG2 and 1709 can 
therefore, in principle, be used to specifically detect non-phosphorylated and phosphorylated 
Y892 βDG respectively. MDG2 has been extensively analysed in the literature and the epitope 




The JAF1 polyclonal antibody, a kind gift from D. Mornet, was raised against the 7 C-terminal 
amino acid residues of βDG (Rivier et al 1999). The JAF1 peptide array detects strong binding 
on 2 spots with a consensus sequence KNMTPYRSPPPYVP, confirming a short carboxyl 
terminus epitope which potentially overlaps with that of MDG2. JAF1 also detects a peptide 
modified to replace Y892 with a phenylalanine (Fig 3.1A). The peptide array results indicate 
that the JAF1 epitope includes Y892 and is sensitive to its phosphorylation status, detecting the 
non-phosphorylated form. 
The commercial goat polyclonal antibody C20 detects far more spots on the peptide array, 
corresponding to the 16 peptides covering the final 30 residues at the carboxyl terminus of 
βDG. There is not a single consensus sequence contained within all of these spots, however, 
C20 is a polyclonal antibody and therefore likely to bind to multiple epitopes within the 
antigen. From the staining of the peptide array with C20 one could argue that there at least 2 
epitopes within this stretch of residues. Residues PMEGKGSRP (Green residues, Fig 3.1A) are 
contained within the strongly stained spots D23-E5 whilst spots E13 and E14 are also strongly 
detected and may contain another epitope. C20 does not detect the phospho-Y892 peptide 
nor the Y to F peptide of spot E18. Given the larger stretch of peptides detected, there is the 
possibility that C20 recognises an epitope that is independent of the phosphorylation status of 
Y892. It is important to consider that the epitope(s) recognised by C20 may not be sequential, 
and may depend on 3D structural elements that are not represented in the 15 amino acid 
peptides. 
The peptide arrays confirm that the four βDG antibodies have epitopes in the carboxyl 
terminus of βDG, however they are all subtly different with respect to the length and position 





3.2.2 CHARACTERISATION OF ΒDG ANTIBODIES VIA IMMUNOBLOTTING 
Immunoblotting enables the detection of the levels and potential modification of specific 
proteins within a sample. Antibodies have varying degrees of robustness and specificity for 
every technique. Moreover, different epitope recognition, as is the case with the βDG 
antibodies used in this study, may result in the detection of different species or fragments of a 
protein by different antibodies. Total cell lysates from five different cells lines were 
immunoblotted with MDG2, 1709, JAF1 and C20 antibodies to assess the performance of the 
antibodies as well as the protein expression profiles of the lysates of the model systems to be 
used in this study (Figure 3.2). 
Figure 3.1. Peptide arrays of βDG immunoblotted with βDG antibodies. A. Peptide arrays covering 
the sequence of βDG in 15 residue length peptides were probed with MDG2, 1709, JAF1 and C20. 
The corresponding peptide position and sequence are detailed with validated epitopes highlighted in 
red. Two separate potential epitopes of C20 are highlighted in green. B. The layout of the peptide 
array.Each array contains 3 repeat units therefore each antibody is assessed in triplicate. MDG2 and 






The ‘normal’ immortalised prostate cell line, PNT1A, and the prostate cancer cell lines, LNCaP 
and PC3, all show strong detection of the 43 KDa band representing mature, full length βDG 
(Fig 3.2). The levels of full length βDG detected by 1709 and MDG in these three lysates 
appears to be similar whilst the levels detected by JAF1 and C20 appear to be more variable, 
with slightly lower levels detected in the LNCaP lysates (Fig 3.2). A strong 43 KDa band can also 
be detected in control primary human dermal fibroblast (HDF) cells by all four antibodies. 
Importantly, in the case of MDG2, 1709 and C20 the 43KDa band is not detected in a lysate 
obtained from primary human DAG null fibroblast cells (Fig 3.2). These cells have been isolated 
from a patient with Walker-Warburg Syndrome with a homozygous loss-of-function frameshift 
mutation, resulting in a premature stop codon in the N-terminal sequence encoding αDG and 
subsequently are absent for both full length α and βDG (Riemersma et al. 2015). As such this 
lysate can be used as a control for antibody specificity. JAF1, however, occasionally does 
detect a faint band at approximately 43 KDa (not shown) but the inconsistent appearance of 
this band suggests it may be an artefact of the experiment, whilst 1709 and C20 also detect 
some high molecular weight bands between 70-130 KDa in the DAG null lysates (Fig 3.2). There 
is therefore some non-specific binding by these antibodies.  
Figure 3.2. βDG antibodies immunoblot comparison and specificity on a range of total cell lysates. 
20µg of lysates from ‘normal’ prostate cell line PNT1A, prostate cancer lines; LNCaP and PC3 and 
primary fibroblasts; control HDF and DAG null fibroblasts were immunoblotted with MDG2, 1709, 





In addition to the full length 43 KDa protein, a 31 KDa protein fragment comprising the 
transmembrane and cytoplasmic domain and a 26 KDa cytoplasmic domain have been 
reported in the literature as a result of proteolytic cleavage (Figure 3.3 B) (Yamada et al, 2001, 
Zhong et al. 2006, Losasso et al 2000, Singh et al 2004, Cross et al 2008, Leocadio et al 2016). 
Both MDG2 and 1709 detect bands at 31 and 26 KDa when lysates collected from LNCaP grown 
at high density were immunoblotted (Figure 3.3 A). JAF1 detects the 26 KDa band strongly but 
does not consistently detect the 31 KDa band, whilst C20 does not robustly detect either 
fragment. Very occasionally a 17KDa fragment can be detected by 1709 and MDG2 (See 
Matthew et al 2013).   
For the majority of this study MDG2 and 1709 are the main antibodies used for the reason that 
they robustly and specifically detect 43 KDa βDG, are sensitive to the cleavage fragments of 
βDG and give important information regarding the phosphorylation status of βDG at Y892. 
3.2.3 CHARACTERISATION OF BETA-DYSTROGLYCAN ANTIBODIES AND BETA-DYSTROGLYCAN 
LOCALISATION VIA IMMUNOFLUORESCENCE MICROSCOPY IN PROSTATE CELL LINES. 
Immunofluorescence microscopy is a widely used technique in investigating the localisation of 
a specific protein. The different βDG antibodies available in this study were used to stain the 
Figure 3.3. The detection of βDG fragments in LNCaP lysates via immunoblotting. A. Immunoblots 
with MDG2, 1709, JAF1 and C20 on total cell lysates of LNCaP grown at high density detect the full 
length 43 KDa band of βDG. In addition, MDG2, 1709 and JAF1 detect a 26KDa fragment of βDG, 
furthermore a 31 KDa band is also detected by MDG2 and 1709. B. A schematic diagram of full length 
43 KDa βDG and the subsequent 31 KDa and 26 KDa βDG cytoplasmic fragments produced by 
proteases MMP2/9 and γ- secretase respectively (orange arrows). The nuclear localisation signal 
(NLS) is marked in green. 
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three different prostate cell lines that are the model systems used in this work, with the aim of 
characterising the localisation of βDG in these cell lines and determining if the different 
antibodies detect different localisation patterns of βDG as a consequence of their different 
epitopes. 
3.2.3.1 βDG localisation and antibody characterisation via immunofluorescence microscopy in 
LNCaP cells 
 
The lymph node derived, metastatic prostate cancer LNCaP cells were grown in 2D culture, 
immunostained and imaged via confocal microscopy. MDG2 staining shows a strong 
localisation of the non-phosphorylated Y892 form of βDG at the cell periphery and cell-cell-
junctions (Figure 3.4A, arrows) and faintly in the cytoplasm. There is also staining at the 
nuclear envelope (Figure 3.4A, arrowheads). The Y892 phosphorylated form of βDG, as stained 
by 1709, also localises to the cell periphery and cell-cell junctions, albeit fainter than MDG2. 
1709 displays a stronger cytoplasmic and nucleoplasmic localisation. JAF1 staining is 
reminiscent of MDG2, which is unsurprising given their similar epitopes, and stains the cell 
periphery, cell-cell junctions and cell protrusions. JAF1 also stains the nuclear envelope and 
faintly punctately in the nucleoplasm. C20 gives a distinctly different localisation pattern to the 
other βDG antibodies described above. C20 stains extremely faintly at the cell periphery and 
clearly detects βDG in nuclear structures that may be the nucleoli. βDG localisation in the 
nucleoli has previously been reported in C2C12 cells via colocalisation studies with nucleolar 
protein Nopp140 (Martinez-Vieyra et al. 2013). Control staining was carried out with the 
relevant secondary antibodies alone (Figure 3.4.B). Extremely faint, uniform background 
staining was detected with all the secondary antibodies, indicating that the staining patterns 







Figure 3.4.A βDG localisation as detected by different βDG antibodies via immunofluorescence in 
LNCaP cells. LNCaP cells were stained with MDG2, 1709, JAF1 and C20 (green) and the nuclei 
counterstained with DAPI (blue).  All βDG antibodies detect βDG localisation at the plasma 
membrane and cell-cell interactions (arrows) and also in the nucleoplasm, nuclear membrane or, in 
the case of C20, nucleoli to varying degrees (arrow heads). Images are confocal slices of 0.28µm 














Figure 3.4. B. Secondary antibody control validation. LNCaP cells were processed and analysed as in 
Fig 3.4.A but lacking the primary antibody. Alexa rabbit 488, Alexa mouse 488 or Alexa goat 488 
secondary antibodies (green).  Nuclei were counterstained with DAPI. Images are confocal slices of 











Figure 3.5 βDG localisation as detected by different βDG antibodies via immunofluorescence in PC3 
cells. PC3 cells were stained with MDG2, 1709, JAF1 and C20 (green) and the nuclei counterstained 
with DAPI (blue). βDG can be seen at the plasma membrane (arrows), cytoplasm and in the nucleus 




3.2.3.2 βDG localisation and antibody characterisation via immunofluorescence microscopy in PC3 
cells 
The prostate cancer cell line, PC3, displayed strong peripheral and cell-cell junction staining of 
βDG when immunostained with MDG2 (Figure 3.5, arrows), similar to the LNCaP cells, and 
faint localisation at the nuclear envelope (Figure 3.5, arrowheads). PC3 cells, however, had far 
fainter cytoplasmic staining of βDG when detected by MDG2 than LNCaP. 1709 detected faint 
peripheral localisation of pY892 βDG and a strong punctate cytoplasmic stain. 1709 also 
detects a diffuse nucleoplasmic localisation, which appears to be excluded from the nucleoli. 
JAF1 faintly stains the cell periphery as well as a very faint cytoplasmic and perinuclear 
localisation. There is also some very faint staining within the nucleus. C20 very faintly stains 
the cell periphery and detects localisation in the nucleoli. 
Figure 3.6. βDG localisation as detected by different βDG antibodies via immunofluorescence in 
PNT1A cells. PNT1A cells were stained with MDG2, 1709, JAF1 and C20 (green) and the nuclei 
counterstained with DAPI (blue).  βDG can be seen at the plasma membrane (arrows), cytoplasm and 
in the nucleus (arrow heads). Images are confocal slices. Images were taken at 60x magnification. Scale 




3.2.3.3 βDG localisation and antibody characterisation via immunofluorescence microscopy in 
PNT1A cells 
In the immortalised ‘normal’ prostate epithelium line, PNT1A, MDG2, again showed strong 
localisation of βDG at the cell periphery and cell-cell junctions as well as cell protrusions 
(Figure 3.6). MDG2 also detected faint staining at the nuclear envelope. However, MDG2 also 
displayed punctate cytoplasmic and perinuclear localisation along with some faint localisation 
within the nucleus. 1709 does not appear to uniformly stain the cell periphery but could be 
detected in cell protrusions and regions of the cell periphery. Once again, 1709 displayed 
punctate cytoplasmic and perinuclear staining as well as clear nucleoplasmic localisation. JAF1 
staining at the cell periphery was weak and irregular however JAF1 detected a strong, punctate 
cytoplasmic and perinuclear stain. JAF1 also stained at the nuclear envelope and nucleoplasm 
as well as some punctate nuclear structures. C20 faintly detected βDG at cell protrusions and 
faintly in the cytoplasm, but its localisation was again strongest in the nucleoli structures.  
When immunostained for βDG the prostate cell lines all had similar but subtly different 
localisation patterns, this may be a consequence of the different origins of derivation, disease 
status and subsequent processing of βDG of the cell lines. In all three cell lines βDG was to 
some extent localised to the cell periphery and cell junctions in accordance with its role as a 
cell adhesion molecule, and was also detected in the nucleus at the nuclear envelope, 
nucleoplasm and nucleoli. Furthermore, it is clear that the different antibodies raised to detect 
βDG in some instances have strikingly different localisation profiles within a cell type. This is 
due to the different epitopes recognising different subsets of βDG, be it a result of different 
PTM, for example phosphorylation at Y892 or additional unknown PTM, different fragments or 
epitope availability all of which may have a different fate or function and therefore different 
localisation within a cell.  
3.2.4 ΒDG ANTIBODY LOCALISATION AND CHARACTERISATION IN HUMAN DERMAL 
FIBROBLASTS (HDF) AND DAG NULL FIBROBLASTS 
To obtain a more comprehensive understanding of βDG localisation as detected by the 
different antibodies in a wider range of cell types, immunostaining was carried out on human 
primary fibroblast cells. Furthermore, DAG null fibroblasts, as previously described, have a 
mutation in the DAG1 gene, resulting in the absence of both α and βDG (Figure 3.1) and are 
therefore a good negative control to test the βDG antibodies on (Riemersma et al 2015). 
HDF and DAG null fibroblasts were immunostained with βDG antibodies and imaged via 
confocal microscopy (Figure 3.7). Figure 3.7 shows that when the control HDF cells are stained 




Figure 3.7. βDG antibody localisation and specificity comparison in HDF and DAG null fibroblasts via 
confocal immunofluorescence microscopy. HDF and DAG null fibroblasts were immunostained with 
MDG2, 1709, JAF1 and C20 (green) and the nuclei counterstained with DAPI (blue). βDG was detected at 
the plasma membrane by all 4 antibodies and to varying degrees in the nucleus at the nuclear envelope, 
the nucleoplasm and the nucleoli in the control HDF cells. MDG2 shows an almost complete lack of 
staining in DAG null fibroblasts whereas 1709, JAF1 and C20 show different extents of staining non-
specific to βDG. Images are confocal slices. Magnification 60x. Scale bar is 15 µm. 
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localisation is detected. 1709 does not localise strongly to the periphery or cell-cell junctions, 
nor does JAF1, however both antibodies detect diffuse cytoplasmic staining and strong 
nucleoplasmic and nuclear envelope localisation (Figure 3.7). C20 staining is relatively weak in 
HDF cells, though there is faint, diffuse cytoplasmic staining and accumulation in the nucleoli. 
When stained and imaged in the same conditions, the DAG null fibroblasts give an indication of 
βDG antibody specificity. The majority of MDG2 staining is absent, with no staining at the 
periphery and a very faint signal detected in the nucleus (Fig 3.7). 1709 and JAF1, however, 
display a relatively strong signal, although it is reduced compared to the HDF cells (Fig 3.7). 
Cytoplasmic and nuclear staining can be detected by both antibodies in the DAG null cells. Very 
little non-specific fluorescence signal is detected by C20 in these conditions. These results 
show that MDG2 and C20 are largely reliable antibodies for use in immunofluorescence 
studies, whilst care must be taken if using 1709 and JAF1 antibodies when interpreting images, 
particularly the nuclear signal. 
3.2.5 ΒDG ANTIBODY LOCALISATION AND CHARACTERISATION IN DAG1 AND SIBLING 
ZEBRAFISH 
Zebrafish have been used to study the regulation and function of DG. Importantly, for studies 
of DG, there is a mutant line, which has a point mutation in the DAG1 gene and subsequently 
reduced transcripts and a complete absence of DG protein (Lin et al 2011, Gupta et al 2011). 
For the purpose of this chapter the DAG1 model also provides a second system in which to 
characterise βDG localisation and to test the specificity of the βDG antibodies. 
4 d.p.f DAG1 zebrafish embryos were sorted into DAGsib (DAG+/+ and DAG+/-) or DAG-/- 
populations according to their muscle phenotype as assessed by birefringence assay. DAGsib 
displayed smooth, bright muscle segments when viewed with polarised light whilst DAG-/- 
embryos had patchy, disrupted muscles (Figure 3.8.A). In order to confirm the accuracy of the 
phenotype characterisation by the birefringence assay and assess βDG antibody specificity, 
total lysates were obtained from the zebrafish embryos, run on SDS PAGE and immunoblotted 






All three antibodies detected bands corresponding to full length, 43 KDa βDG in the DAGsib 
lysates, though the bands detected by MDG2 were very faint. The 43 KDa bands were absent 
in the DAG-/- lysates, indicating, firstly, that the birefringence assay was a robust technique to 
identify DAG-/-  embryos, although to be certain genotype analysis would be required. Secondly 
it shows that all three antibodies are specifically detecting βDG at 43 KDa. 1709 detects bands 
at a range of molecular weights in both DAGsib and DAG-/- lysates, indicating that 1709 can 
detect bands that are not specific to βDG and should thus be interpreted cautiously. None of 
the antibodies detected the smaller fragments of βDG, this could be because of the processing 
of βDG in these embryos or because the protein concentration obtained from the embryos 
was low and the assay is not sensitive enough to detect low concentrations of these 
fragments. 
 
Figure 3.8. βDG immunoblotting antibody comparison and specificity in DAG-/- and DAGsib zebrafish 
embryos. A. Representative images of DAGsib and DAG-/- phenotypes as detected by birefringence 
assay clearly showing the disrupted muscle phenotype in the DAG-/- embryos. B. Total lysates obtained 
from single 4 d.p.f DAGsib and DAG-/-  zebrafish embryos were immunoblotted with MDG2, 1709 and 
JAF1. Full length βDG was detected in DAGsib lysates but was absent from DAG-/- indicating antibody 





DAGsib and DAG-/-  4 d.p.f embryos were also subject to immunostaining and imaging via 
confocal microscopy (Figure 3.9). In the DAGsib embryos MDG2 staining was predominantly in 
the myosepta with some faint, punctate staining within the somites, which may be the 
neuromuscular junctions (NMJ). 1709 and JAF1, however, detect punctate staining in the 
somites as well as a more diffuse stain in these segments. Both 1709 and JAF1 also localise 
strongly to the myosepta in the DAGsib embryos. In DAG-/- embryos MDG2 does not stain the 
aforementioned structures and looks to be specific for βDG. In embryos immunostained with 
1709 and JAF1, the staining is lost from the myosepta, indicating that this is true βDG 
localisation, however, the somites display clear punctate and diffuse staining that is therefore 
non-specific to βDG. A secondary antibody control confirms that the staining observed is a 
consequence of the primary antibodies (Figure 3.9). These results concur with the specificity 
conclusions drawn from the immunofluorescence analysis with the HDF and DAG null 
fibroblast cells. 
Figure 3.9.:  βDG antibody immunofluorescence comparison and specificity in DAG-/- and DAGsib 
zebrafish embryos. 4 d.p.f DAG-/- and DAGsib zebrafish embryos were stained with MDG2, 1709 and 
JAF1 antibodies (green) and imaged via confocal microscopy. Secondary antibody controls for mouse 
and rabbit Alexa488 antibodies alone on DAGsib embryos was included. All three βDG antibodies 
clearly stain the myosepta in the sibling embryos however 1709 and JAF1 also display staining non-




3.3.1 CHARACTERISING AND COMPARING THE EPITOPES OF ΒDG ANTIBODIES 
 
To date the antibodies available for the detection of βDG have epitopes in the C-terminal 
cytoplasmic domain of the protein, a region which is largely unstructured and contains close to 
25% proline residues. The four antibodies recognising βDG used in this study; MDG2, 1709, 
JAF1 and C20 were all raised against peptide immunogens in the C-terminus of βDG (Helliwell 
et al 1994, Ilsley et al 2001, Rivier et al 1999). Although the peptide immunogens give some 
indication as to the epitope of the protein, epitope mapping can be used to refine and gain 
further specificity insight into the antibody epitope(s).  
The peptide spot array for MDG2 identifies a consensus sequence of KNMTPYRSPPPYVP in 
which the epitope lies and concurs with the previously published functional epitope mapping 
studies by James et al and Pereboev et al (James et al 2000, Pereboev et al 2001). Pereboev et 
al.  also proposed that P891 played an important role in epitope recognition by MDG2. The 
authors proposed that the high number of epitope residue matches in the chemically 
synthesised peptides used by James et al.  could mask the contribution of residues that 
become slightly less important as more residues match, such as P891, whilst the random 
peptide library may be more sensitive to these residues (James et al 2000, Pereboev et al 
2001). Regardless of P891 contribution, both reports and the array presented in this study 
agree on an overlapping consensus epitope of MDG2 containing PxYVP. The observation that 
MDG2 is sensitive only to the non-phosphorylated Y892 peptide and not the phospho-peptide 
included on the array again agrees with the previously published epitope mapping studies 
(James et al 2000, Pereboev et al 2001). Phosphorylation at Y892 is a key regulator of βDG and 
has been shown by multiple groups to be involved in DG localisation, degradation and 
interaction with binding partners (James et al 2000, Ilsley et al 2001, Sotgia et al 2001, Sotgia 
et al 2003, Yang et al 1995, Miller et al 2012, Lara-Chacon et al 2010, Mathew et al 2013) 
The peptide spot arrays indicate that 1709 has an epitope that is very similar to that of MDG2 
with the vital difference that it specifically recognises phosphorylated Y892. Point mutation 
studies have not been conducted to refine the epitope, however, support for 1709 specificity 
to the pY892 species is seen in its inability to recognise the Y892F peptide on the array and its 
loss of immunoreactivity for lysates run on western blots and in IHC sections from 
Y890F/Y890F mice, whilst MDG2 still detects βDG in these samples (Miller et al 2012).  Thus 
MDG2 and 1709 are specific sensors for the phosphorylation status of Y892 in the C-terminal 
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tail of βDG and as such are valuable tools in the study of βDG and its fate given the key 
regulatory role of pY892. 
The JAF1 epitope also appears to overlap with MDG2 and be sensitive to the phosphorylation 
status of Y892, recognising the non-phosphorylated form of βDG only. The C20 antibody likely 
detects multiple epitopes, as is expected for a polyclonal antibody and it is possible that at 
least one site does not include Y892 and is therefore independent of Y892 phosphorylation 
status, unlike the other antibodies presented above. Further refinement of JAF1 and C20 
epitope to the specific vital residues would require further analysis such as systematic point 
mutations. There may also be other PTM within the epitopes that affect antibody binding 
which are not represented in these peptide arrays. For example, βDG is thought to contain at 
least one other phosphorylated tyrosine, of which there are multiple potential candidate 
residues within the C-terminal tail of βDG (James et al 2000, Moraz et al 2012).  
The epitope of MDG2, 1709, JAF1 and potentially C20 overlap with the PPxY sequence which is 
a known recognition motif for WW domain protein binding as well as the binding motifs for 
SH2 and SH3 domain proteins (Pereboev et al 2001, James et al 2000, Yang et al 1995, Sotgia et 
al 2001) and is the site at which multiple interaction partners have been shown to bind to DG 
(Reviewed in Moore et al. 2010). The plethora of interactions at this site raises the question of 
‘epitope masking’ whereby the antibody cannot access the epitope as it is blocked by another 
protein or structural element. 3D X-ray crystallography analysis of a βDG 15mer peptide, 
containing the PPxY motif, show the βDG peptide binding a surface made by one of the EF 
hands and the WW domain of dystrophin (Huang et al 2000, Pereboev et al 2001). In theory 
the PPxY and WW domains are interacting in this way at the sarcolemma, therefore there is 
some question as to how MDG2 and JAF1 still recognise this epitope in tissue sections. 
Explanations may be that the antibody still weakly recognises the epitope in complex, that the 
antibody displaces dystrophin in the IHC staining procedure or that not all the βDG at the 
sarcolemma is in complex via the epitope and is therefore available for antibody recognition 
(Pereboev et al 2001).Furthermore, the visualisation of βDG at certain adhesion structures 
such as focal adhesions has historically been difficult to detect because of molecular crowding 
and subsequent epitope masking at this site and can be improved using SDS antigen retrieval 
techniques (Moore et al 2010, Thompson et al. 2010). The competition between antibodies 
and interacting partners can be advantageous as demonstrated in the use of utrophin 
monoclonal antibodies that disrupted utrophin binding to βDG to determine the site of 
interaction between the two proteins (Morris et al 1999).   
Peptide libraries and other forms of epitope mapping are useful in providing a basis of the core 
peptides involved in epitope recognition, however they are limited as they give no information 
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regarding how an antibody may interact with an epitope in the protein’s 3D native 
conformation. An antibody’s interaction with its antigen involves the shape, charge, 
hydrophilicity and hydrogen bonds of the available epitope side chains. Side chains that are 
available in the relatively linear peptide arrays may be buried in 3D structures or the antibody 
may recognise residues that are distant in the linear peptide sequence but spatially close in the 
3D structure. Peptide arrays also do not account for the contributions of PTM unless 
specifically designed to do so. However, given the immunogen used, the peptide array data 
and the fact that the cytoplasmic domain of βDG is largely disordered, it can be proposed that 
at least MDG2, 1709 and JAF1 recognise linear epitopes in the βDG protein.  
3.3.2 BETA-DYSTROGLYCAN ANTIBODY CHARACTERISATION AND VALIDATION IN 
IMMUNOBLOTTING 
 
In western blots proteins have been denatured from their native 3D conformation and 
separated by size via SDS PAGE. It may therefore seem logical that antibodies that recognise 
linear epitopes should work well for western blots, however this is not always the case, an 
example being the aforementioned α-DG antibody DAG-6F4 (Humphrey et al 2015). In the case 
of MDG2, 1709, JAF1 and C20, all of the antibodies detected a band at 43KDa in all of the 
lysates tested from cell lines LNCaP, PC3, PNT1A and HDF as well as those from the DAGsib 
zebrafish embryos. The 43 KDa band represents the mature form of βDG and its mass reflects 
the high number of prolines within its cytoplasmic tail as well as PTM including N-glycosylation 
(Holt et al. 2000).The βDG antibodies used in this study have been widely reported in the 
literature as detecting the 43KDa band of βDG in blots across a range of species including 
human, mouse, zebrafish and different tissue and cell types including skeletal muscle, brain 
and prostate (Pereboev et al 2001, Rivier et al 1999, Lara- Chacon et al 2010, Miller et al 2012, 
Lipscomb et al 2016, Mathew et al 2013). More specifically MDG2 and 1709 have been shown 
in previous studies by the Winder group to detect full length βDG in the ‘normal’ immortalised 
prostate cell line PNT1A and the metastatic prostate cancer lines LNCaP and PC3 (Mitchell et al 
2013, Mathew et al 2013, Leocadio et al 2016). The levels of DG expression in prostate cell 
lines are heterogeneous (Mathew et al 2013). The level of βDG was reported to be highest in 
LNCaP out of the prostate lines tested by Mathew et al (Mathew et al 2013) however the same 
cannot be concluded from figure 3.1, where the levels of βDG detected by JAF1 and C20 in the 
LNCaP lysate are low when compared to the other cell lines, though relatively strong when 
detected by MDG2 and 1709. βDG levels look largely similar across the cell lines when 
detected by MDG2 and 1709 and slightly more variable with JAF1 and C20. It is hard to dissect 
what this means for total βDG levels. These cell lines may truly have different ratios of species 
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detected by the different epitopes or may be detecting overlapping pools. Regardless, all four 
antibodies clearly detect full length βDG.  
The βDG antibodies also detect the 31 and 26 KDa βDG fragments in LNCaP lysates to varying 
degrees. The 31 and 26 KDa fragments are produced by cleavage of the cytoplasmic domain by 
MMP2/9 and γ-secretase respectively and have been reported in previous studies by the 
Winder group and others in multiple cell lines including LNCaP (Yamada et al, 2001, Zhong et 
al. 2006, Losasso et al 2000, Mitchell et al 2013, Mathew et al 2013, Leocadio et al 2016).  All 
of the epitopes are in the extreme C-terminal domain and are present in theory in both 
fragments, it is therefore unclear why C20 does not detect the fragments in this instance. It is 
possible that PTM within these fragments may disrupt C20 binding to the epitope or that C20 
has a weak affinity for the antigen and the signal is reduced even further in the case of the low 
levels of the fragments. JAF1 and C20 were not extensively screened on lysates of different cell 
densities in other cell types and it cannot be ruled out that they would detect fragments there. 
1709 has also been reported to detect a 17KDa fragment and can detect more and higher 
levels of fragments than MDG2 in the same sample, suggesting a potential role for Y892 
phosphorylation in the fate or regulation of these fragments (Mathew et al 2013, Leocadio et 
al 2016). The functions of these fragments are as of yet unknown however their presence is 
increased upon increasing cell density and stimulation of the notch pathway (Mitchell et al 
2013, Leocadio et al 2016). This could account for the variability of the presence of fragments 
in different experiments. Moreover, different cell lines appear to produce different levels of 
fragments, perhaps indicating different DG processing in these cell lines. Increased proteolytic 
cleavage of DG has been reported in carcinoma cells (Cross et al. 2008, Singh et al. 2001), 
therefore the different detection of c-terminal fragments in different cell lines might be a 
consequence of altered DG processing activity in the cancer cells.  It is also interesting to 
consider that no antibodies are available to detect the remaining portions of βDG once the C-
terminal has been cleaved so the fate of these N-terminal fragments remains unclear. 
Importantly the validity of the antibodies in immunoblotting was tested in two different 
systems lacking the DG protein; the DAG null fibroblasts and the DAG-/- zebrafish embryos.  It 
should be noted that the HDF line is not the best control for the DAG null fibroblasts as they 
are of different origins. Ideally the null fibroblasts re-expressing βDG or fibroblasts from the 
same origin in a healthy patient would be used as a control. HDF cells are, however, sufficient 
for the purpose of this analysis as a wildtype DG expressing fibroblast line. C20 and 1709 
detected some high molecular weight bands in the null systems, thus indicating cross-reactivity 
with additional proteins. The cross-reactivity could be a consequence of recognition of the 
epitope in other proteins, indeed, proline stretches followed by a tyrosine are not uncommon. 
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A search of the epitope PPYVP in BLAST returns 30 proteins in humans that also contain this 
sequence in addition to DG (Altschul et al. 1990). It is important to note that PPYVP is the 
epitope for MDG2, as BLAST searches do not account for PTM, however it is possible that 
these proteins may also be phosphorylated at the tyrosine residue and thus represent the 
1709 epitope. In addition, that MDG2 appears to specifically detect βDG (Fig 3.7, Fig 3.8) 
despite the potential presence of other proteins containing the relevant epitope, suggests that 
either a structural element is important in the recognition of the epitope, or that the 
alternative epitopes contain a modification or interaction that precludes detection by MDG2. 
In the case of polyclonal antibodies such as 1709, JAF1 and C20, additional IgG antibodies 
produced by the host may be present and therefore detect other proteins. This latter scenario 
could be resolved by affinity purification of the antibodies. 
3.3.3 BETA- DYSTROGLYCAN LOCALISATION AND ANTIBODY VALIDATION VIA 
IMMUNOFLUORESCENCE TECHNIQUES  
 
Whilst valuable information regarding expression levels and modifications can be learnt from 
immunoblotting, a further and complementary technique to investigate βDG localisation is 
immunofluorescence microscopy. Multiple groups have shown βDG to be localised to a range 
of cellular compartments including the cell periphery, NMJ, filopodia, nucleus and intracellular 
vesicles (Pereboev et al 2001, Spence et al. 2004, Thompson et al. 2010, Lara-Chacon et al 
2010, Mathew et al 2013, Leocadio et al 2016, Sotgia et al 2003, Miller et al 2012) across a 
variety of tissues and species, consistent with a range of functions and fates of βDG, some 
known and others yet to be elucidated. 
The four βDG antibodies were used to stain a selection of human cell lines and zebrafish tissue. 
Interestingly, not only did the cell lines display slightly different localisation of βDG when 
analysed with the same antibody but the antibodies detected different localisations of βDG 
within a cell line. The strong localisation of the non-phosphorylated Y892 species, as detected 
by MDG2, at the cell periphery fits with a current hypothesis in the literature that non-
phospho Y892 βDG is able to interact with binding partners e.g. utrophin at the plasma 
membrane whilst disruption of these interactions leaves the cytoplasmic tail free for 
phosphorylation by src and subsequent internalisation and potential degradation (Sotgia et al 
2003, Miller et al 2012, Lipscomb et al 2016) or translocation to the nucleus (Lara-Chacon et al 
2010, Mathew et al 2013, Leocadio et al 2016). In line with this hypothesis, pY892 βDG as 
detected by 1709, is reduced at the cell periphery in all cells and is virtually non-existent in 
PNT1A cells and instead displays a more diffuse cytoplasmic and nuclear localisation.  
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JAF1 staining varies considerably between the cell types, resembling that of MDG2 at the 
periphery in LNCaP, is greatly reduced at the PM and cytoplasmic in PC3 cells and shows a 
stronger cytoplasmic and nuclear staining in PNT1A. The peptide epitope is similar to MDG2 
and it may therefore be logical to expect more PM staining however it is difficult to tell how 
JAF1 is detecting the native conformation of the epitope. These results also raises questions 
about the differential processing of βDG at different stages of prostate cancer progression 
(Cross et al 2008, Henry et al 2001, Mitchell et al 2013, Mathew et al 2013, Leocadio et al 
2013), as modelled to some extent by the included cell lines (Horoszewicz et al 1983, Mathew 
et al 2013). 
C20 gives a strikingly different localisation pattern with very little at the plasma membrane and 
strong staining of structures within the nucleus that are likely nucleoli. βDG localisation at the 
nucleoli has previously been reported in C2C12 myoblasts by Martinez-Vieyra et al via confocal 
microscopy and was supported by the presence of Nopp140, a nucleoli marker in the fraction 
containing proteins immunoprecipitated by βDG (Martinez- Vieyra et al, 2013). Why C20 stains 
the nucleoli so strongly where the other antibodies do not is curious but could be due to a 
different population that is detected by a more N-terminal epitope or the localisation may be 
regulated by PTM within the C20 epitope. Furthermore, it is not possible to tell from 
immunofluorescence analysis which size species of βDG is present. Some species of βDG 
appear to have preferential locations, for example it has been shown that a tagged 26KDa 
fragment of βDG targets strongly to the nucleus (Mathew et al 2013). Alternative techniques 
such as biochemical fractionation and subsequent western blotting could help to resolve this. 
All four antibodies show nuclear localisation of βDG, though to varying extents and at different 
nuclear structures. The detection of βDG in the nucleus raises questions as to its role and 
regulation there and shall be examined further throughout this thesis. 
As with immunoblotting, it is important to verify antibody specificity for immunofluorescence 
microscopy. MDG2 and C20 look to be specific for βDG as they gave little to no staining in the 
DAG null systems that they were tested in, with a very faint nuclear presence detected by 
MDG2. 1709 and JAF1 perform poorly in the DAG null systems. In both systems the signal 
detected with 1709 and JAF1 is notably reduced or absent in areas of known βDG localisation 
such as the cell periphery and vertical myosepta however cytoplasmic and nuclear staining is 
still present in both DAG null fibroblasts and the DAG-/- zebrafish. Controls with secondary 
antibody alone indicate that the staining is a consequence of the primary antibody. These 
results suggest that although 1709 and JAF1 detect βDG, that is not the only protein that they 
detect. This background staining may be because of the antibodies binding to especially ‘sticky’ 
structures such as skin in the zebrafish embryos but may also be due to similar epitopes being 
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detected in proteins other than DG or the presence of other antibodies in the sera. Any 
immunofluorescence studies undertaken with 1709 and JAF1 should be interpreted with 
caution and validated with other techniques such as comparing staining patterns in DAG null 
systems or using a tagged protein. To improve and ensure the specificity of the antibodies they 
should be subject to affinity purification. 
3.3.4 SUMMARY 
1. The peptide epitopes of the βDG antibodies used in this study are located at the 
extreme C-terminal of βDG and are subtly distinct in location or PTM recognition. 
2. The antibodies all detect full length 43 KDa βDG and variably detect the 31 and 26 KDa 
cytoplasmic fragments of βDG in a range of cell lines and tissues. 
3. All four antibodies display different localisation patterns of the different populations of 
βDG within a cell line and variably detect βDG at the cell periphery, nucleus, cell 
protrusions, myosepta and intracellular vesicles.  
4. According to the DG null systems used MDG2, 1709 and C20 can be used to specifically 
detect the 43 KDa band of βDG via immunoblotting although 1709, JAF1 and C20 can 
detect non-specific bands of higher molecular weight. 
5. MDG2 and C20 appear to be specific for βDG in immunofluorescence studies whilst 


















Chapter 4: Nuclear β Dystroglycan 
and the role of phosphorylation at 
T788  
4.1 INTRODUCTION 
4.1.1 THE FUNCTION AND MECHANISMS OF TRANSLOCATION OF NUCLEAR BDG 
The concept of βDG being solely an adhesion receptor at the plasma membrane with 
structural roles in the DGC no longer holds true, with the expanding knowledge of 
interacting partners and its localisation to subcellular compartments, such as the nucleus, 
all hinting at a multitude of complex functions (Oppizzi et al. 2008, Lara-Chacon et al 2010, 
Sotgia et al, 2001, Spence et al 2004, Moore and Winder 2010). The information regarding 
βDG in the nucleus is growing, however a great deal remains to be understood about the 
nuclear functions and mechanisms of regulation of βDG.  
DG appears to be important for maintaining nuclear morphology and interacts with a number 
of structural nuclear proteins (Martinez-Vieyra et al, 2013). Regarding the mechanisms of 
nuclear translocation, it has been established that βDG is capable of undergoing rapid 
nucleocytoplasmic shuttling and contains a NLS located at the juxtamembrane region of its 
cytoplasmic domain (Lara-Chacon et al., 2010, Oppizzi et al., 2008). Furthermore, βDG was 
identified as interacting with importin a/b and Ran-GTP suggesting the classical nuclear 
import cycle across a nuclear pore as a likely method of nuclear translocation (Lara Chacon et 
al., 2010). However, little is known about the series of events and potential PTM that regulate 
βDG nuclear translocation and its retention and functions in the nucleus.  
4.1.2. PHOSPHORYLATION OF ΒDG  
Phosphorylation is a particularly well studied and important modification of βDG. As has 
previously been mentioned, phosphorylation at Y892 (human) /Y890 (mouse) by src kinases 
is a key modulator of βDG regulating its interactions with binding partners and signalling 
molecules (Ilsley et al 2001, James et al. 2000, Yang et al. 1995). Phosphorylation at Y892 also 
promotes internalisation from the plasma membrane (Sotgia et al. 2001) and potentially 





Figure 4.1. Schematic of α and β Dystroglycan with selected putative sites of phosphorylation in the 
cytoplasmic domain of βDG. The locations of the transmembrane (TM, yellow) domain and the nuclear 
localisation signal (NLS, green) of mouse βDG are indicated. Putative sites of tyrosine (Y), Threonine 
(T) and Serine (S) phosphorylation as reported on phosphosite plus are indicated in black. Only residues 
that have been reported in more than five independent reports have been included. Adjacent numbers 
in red indicate the number of reports in which phosphorylation at these residues have been detected 
through high throughput proteomic mass spectrometry. Adjacent numbers in blue are reports in which 
phosphorylation of a residue has been identified using site-specific methods (Hornbeck et al. 2014).  
 
Phosphorylation at Y892 is the only site to have been confirmed to be phosphorylated by site 
specific methods, however there is evidence for the phosphorylation of βDG at other residues 
within its cytoplasmic tail, as previously described. Analysis of the sequence of βDG identifies 
multiple putative sites of phosphorylation not only at tyrosine, but also serine and threonine 
residues. Furthermore, according to PhosphoSite plus, a resource for the studies of protein 
modifications (Hornbeck et al. 2014), the phosphorylation of βDG has been identified in 
multiple reports in high through put mass spectrometry studies at Y, S and T residues (Fig 
4.1). These putative sites of phosphorylation must be interpreted with caution as they have 
only been identified through non-targeted mass spectrometry and may therefore be false 
positives or not biologically significant however there is certainly enough evidence to warrant 
further investigation into the role of phosphorylation at these putative sites on the regulation 
of βDG.  
   4.1.3 THE ROLE OF PHOSPHORYLATION ON THE NUCLEAR LOCALISATION OF PROTEINS.  
Phosphorylation is known to regulate the nuclear transport of a number of proteins, though 
the method through which this is achieved can be complex. Phosphorylation is able to both 
enhance and inhibit nuclear import of different target proteins (Nardozzi et al. 2010).  
Phosphorylation can enhance nuclear localisation by a number of mechanisms for example 
phosphorylation may enhance the binding affinity (eg Epstein-Barr virus Nuclear antigen 
(EBNA)) (Kitamura et al. 2006) or recognition by importins (e.g. Hepatitis B virus (HBV)) (Rabe 
et al. 2003). Alternatively, phosphorylation can promote a conformational change that alters 
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the position of the NLS enhancing its docking to the nuclear pore complex (e.g. SV40) (Fontes 
et al. 2003) or exposing the NLS to the relevant importins (e.g. Signal transducers and 
activators of transcription (STATs)) (Meyer et al. 2002). Phosphorylation of some components 
of the nuclear translocation machinery inhibits nuclear import whilst phosphorylation within 
the NLS can also promote cytoplasmic retention of a protein, potentially by reducing its 
affinity for importins (eg parathyroid hormone related protein (PTHrP)) (Lam et al. 1999).   
4.1.4 PHOSPHORYLATION AND NUCLEAR ΒDG 
The phosphorylated Y892 form of βDG has been identified in the nucleus of multiple cell types 
(Mitchell et al. 2013, Mathew et al. 2013, Leocadio et al. 2016). It was initially proposed that 
tyrosine phosphorylation may play a role in nuclear translocation of βDG. However, as 
discussed in section 1.6.3, the role of phosphorylation on the regulation of nuclear βDG is 
complex. Peroxyvanadate treatment of C2C12 cells saw an increase in the nuclear level of 
βDG, however point mutation studies using a non-phosphorylatable form, Y892F (human), in 
C2C12 cells and the equivalent residue, Y890F, in a construct containing mouse DG in LNCaP 
cells do not suggest a role for this modification in nuclear localisation of full length βDG (Lara-
Chacon et al. 2010, Leocadio 2014).  pY892 βDG might regulate functions of βDG in the 
nucleus and interestingly it has been proposed that the level of pY892 βDG is slightly 
increased in the nucleus of prostate cancer tissues relative to normal tissue in 
immnunohistochemical stains (Mathew et al. 2013). The increase in nuclear level seen with 
peroxyvanadate may be accounted for by the phosphorylation of another residue within βDG 
or by influencing any number of proteins involved in nuclear transport or βDG interaction that 
may also be phosphorylated.   
Given the potential role for additional phosphorylated residues in the nuclear translocation 
of βDG it was of great interest when, in a recent mass spectrometry study conducted in the 
Winder lab, the presence of a phosphorylated threonine peptide, at residue T790 in human 
which is equivalent to residue T788 in mouse DG, was identified in a nuclear fraction but not 
the non-nuclear fraction of LNCaP cells (Leocadio et al. 2014). Residue T790 (human) and T788 
(mouse) have been identified as phosphorylated in 28 independent mass-spectrometry 
studies from a variety of tissues and cell types, reported on the curated modifications 
database Phosphositeplus, though it has not yet been confirmed by site-specific techniques 
(Fig 4.1) (Hornbeck et al. 2014). Originally Oppizzi et al. reported the NLS to be a bipartite 
sequence with a pair of lysines 793KK794 10 amino acids downstream of the NLS at 
776RKKRKGK782 and is conserved in multiple organisms. It has since been shown that residues 
776-782 are necessary and sufficient for βDG nuclear targeting (Oppizzi et al. 2008, Lara-
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Chacon et al. 2010). Interestingly T790 sits between these two sequences. We therefore 
hypothesised that βDG is phosphorylated at T790 and is important for its nuclear localisation 
or function. A construct containing mouse DG is used to study the effects of phosphorylation 
at this threonine residue of interest, which shall therefore henceforth be referred to as T788 
in this thesis. 
4.1.5 CHAPTER AIMS 
The aims of the research conducted in this chapter are:  
- To investigate the effect of the loss of DG on nuclear morphology in Human primary 
DAG null fibroblasts.  
- To characterise the subcellular localisation of endogenous βDG in prostate cell lines.  
- To investigate the phosphorylation of βDG and a potential role for phosphorylation 
at T788 on the nuclear localisation of βDG and βDG regulation.  
4.2 RESULTS 
   4.2.1 NUCLEAR MORPHOLOGY IS DISRUPTED IN DAG NULL PRIMARY FIBROBLASTS 
The availability of a fibroblast cell line isolated from a patient with Walker Warburg 
syndrome with a mutation resulting in the absence of α- and βDG protein (Riemersma et al. 
2015) provides a useful tool in the study of DG function and was used to address the 
question of whether DG plays a role in nuclear morphology. Immunoblots of whole cell 
lysates (WCL) harvested from the DAG null fibroblasts and probed with antibodies against 
βDG (MDG2) and pY892 βDG (1709) confirmed the absence of βDG at the protein level in 
the DAG null fibroblasts whilst full length 43 KDa βDG is strongly expressed in the control 
HDF cells (Fig 4.2 Ai). In order to determine if complete loss of βDG from the cell affects the 
overall nuclear morphology HDF and DAG null fibroblasts were immunostained for lamin 
A/C and the nucleus counterstained with DAPI and viewed via immunofluorescence 
microscopy (Fig 4.2 A-I). Nuclei were classified as having a ‘normal’ morphology if the 
nucleus was a regular oval shape with a smooth and even lamin A/C distribution (Fig 4.2 A-
C). 92.7% of the HDF control cells displayed a ‘normal’ nuclear morphology compared to 
only 36.8% of the DAG null fibroblasts. 63.2% of the DAG null fibroblasts were classified as 
having an abnormal nuclear morphology compared to just 7.3% abnormal nuclei in the HDF 
cells (Fig 4.2 J). The DAG null fibroblasts displayed a broad array of disrupted morphology 
including blebbing, displayed in 41.71% of cells (Fig 4.2 D, E, K), irregular shape, including 







Figure 4.2 Nuclear morphology is disrupted in DAG null fibroblasts. Ai) Immunoblot of HDF and 
DAG null fibroblast total cell lysates. Immunoblot with anti- βDG (MDG) (left) and pY892 βDG 
(1709) (right). GAPDH was used as a loading control. A-I) Immunofluorescent microscopy of HDF 
and DAG null fibroblast nuclei. Cells were stained for lamin A/C (red) and the nuclei 
counterstained with DAPI (blue). A-C) ‘Normal’ nuclei from HDF cells. D-I) ‘Abnormal’ nuclei from 
DAG null fibroblasts, representative images of blebbing (D, E), irregular shape (E, F, G), multiple 
nuclei (H) and micronuclei (I). Images were taken via widefield epifluorescent microscopy, 
magnification 60x, Scale bars 10µm. J) Quantification of mean percentage of ‘normal’ and 
‘abnormal’ nuclear morphology of HDF and DAG null fibroblasts. Error bars ±SD. N=2, at least 100 
cells per cell type/replicate.  K) Classification of the types of aberrant nuclear morphology as a 
percentage of the total population of DAG null fibroblasts. Nuclei were classified as blebbed, 
irregular shape/ twisted/ micronuclei or multiple nuclei. N=2, at least 100 cells per cell 
type/replicate.   
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8.71% (Fig 4.2 H, K) and micronuclei 4.35% (Fig 4.2 I, K) Percentage quantifications of the 
classifications of aberrant nuclei of the DAG null fibroblasts is summarised in the Fig 4.2 K   
The dramatic disruption of nuclear morphology upon the absence of α and β DG clearly 
suggests a role for βDG in maintaining correct nuclear morphology. However further 
investigation is required to determine the contribution of loss of the nuclear DG and 
subsequent effects on its nuclear interactions versus the loss of DG from the PM and 
elsewhere in the cell which will potentially result in signalling or cytoskeletal defects both of 
which are important to nuclear positioning and morphology.  
4.2.2 LAMIN LOCALISATION IN DAG NULL FIBROBLASTS 
The lamins are components of the nuclear lamina and play an important role in nuclear 
structure and transcriptional regulation (Prokocimer et al. 2009). It has previously been shown 
that cells with reduced levels of DG as a result of RNAi have mislocalised lamin B1 (Lara-
Chacon et al. 2010). HDF and DAG null fibroblasts were immunostained with antibodies 
detecting lamin A/C or lamin B1 to investigate if these nuclear lamina components were also 
mislocalised in primary human fibroblasts absent for DG. Lamin B1 staining in the DAG null 
fibroblasts was slightly fainter and less uniform compared to the HDF control cells (Fig 4.3 A). 
Lamin B1 staining of HDF cells was not as uniform as expected within the nucleus and may be 
a consequence of the antibody. Lamin A/C staining does not appear to be different between 
the DAG null and control fibroblasts (Fig 4.3 B). Although further analysis such as western blot 
to detect the levels and more detailed confocal analysis is required, these results suggest that 
lamin B1 but not lamin A/C localisation is affected by the absence of DG.  
4.2.3 CHARACTERISATION OF NUCLEAR ΒDG IN PROSTATE CELL LINES  
DG has been shown to be localised to the PM and in the nucleus of prostate cells and is 
implicated in prostate cancer progression (Losasso 2000, Sgambato et al 2007, Mitchell et al. 
2013, Mathew et al. 2013, Leocadio et al. 2016). Whilst DG has been studied in primary 
prostate tissue samples from patients, the expression, nuclear translocation and a number of 
PTM of βDG have been investigated in a number of prostate cell lines, particularly LNCaP, a 
widely used model of prostate cancer (Horoszewicz et al. 1983, Thalmann et al. 1994). LNCaP 
and other CaP lines and have provided valuable information as to how DG affects epithelial-
mesenchymal transition, migration and metastasis and consequently how DG may play a role 
in the disease state but also contribute to the broader knowledge of how DG is modified and 
regulated (Losasso 2000, Sgambato et al 2007, Mitchell et al. 2013, Mathew et al. 2013, 







Figure 4.3: Lamin B1 and lamin A/C localisation in DAG null fibroblasts. HDF and DAG null fibroblasts 
were fixed and immunostained with lamin B1 (A) (above) or lamin A/C (B) (below) (red). Nuclei were 
counterstained with DAPI (blue). Inset are enlarged images of a representative nuclei (box, merge). Cells 





The nuclear localisation of βDG was characterised in the immortalised normal prostate 
epithelial cell line PNT1A and the metastatic prostate cancer cell lines PC3 and LNCaP. 
Whilst the focus of the research in this chapter is on nuclear βDG, further characterisation 
of βDG in these cell lines can be found in Chapter 3, sections 3.2.2 and 3.2.3. Biochemical 
fractionation and subsequent immunoblotting of PNT1A, LNCaP and PC3 cells detected full 
length 43 KDa βDG strongly in the non-nuclear fractions and more weakly in the nuclear 
fractions of all the cell lines (Fig 4.4).  βDG was detected by antibodies against the non-
phosphorylated and phosphorylated Y892 form of βDG. The level of nuclear βDG is variable 
and is strongest in the LNCaP cells.  Whilst it is preferable to quantify the nuclear to non-
nuclear ratio from the immunoblots this was not possible due to the detection of βDG 
bands in the non-nuclear fractions reaching saturation before the βDG in the nucleus is 
sufficiently detected. High molecular weight species of βDG at ~ 60 KDa and between 130-
250 KDa can also be detected in the nuclear fraction with the pY892 βDG antibody (Fig 4.4). 
The high molecular weight species detected may be a modified form of βDG, for example, 
ubiquitination of βDG has been proposed (Miller et al. 2012, Leocadio 2014). Alternatively, 
the band between 130-250 KDa may represent an oligomerised form of βDG (Holt et al. 
2000). As discussed in Chapter 3, mass spectrometry would be required to confirm these 
bands as βDG as 1709 can sometimes detect non-specific bands. The 31 and 26KDa 
fragments of βDG could occasionally be detected in both fractions but less in the nuclear 
fraction (Data not shown.) Although the markers of the non-nuclear and nuclear fractions 
are clean, to fully confirm the purity of the fraction and the nuclear localisation of βDG a 
marker of the ER, such as calnexin, should be included. 
βDG localisation was also investigated via confocal immunofluorescence microscopy. Anti-
βDG antibodies MDG2 and C20 were used as they give minimal background staining in  
immunofluorescence studies (Chapter 3). Confocal slices from the middle of the nucleus and 
MAX projections across the whole cell were used. MDG2 detects βDG faintly at the nuclear 
envelope in LNCaP, PC3 and PNT1A cells (Fig 4.5 White arrowhead). A diffuse nucleoplasmic 
as well as some brighter foci are detected within the nucleus. The nucleoplasmic stain is 
slightly stronger in the PNT1A cells compared to the LNCaP and PC3 cells (Fig 4.5 White 
arrowhead). βDG is also detected strongly at the PM, cell-cell junctions, cell protrusions and 
in the case of PC3 and some LNCaP cells in a perinuclear structure that is potentially the 
endoplasmic reticulum or golgi. C20 detects a distinctly different localisation of βDG in the 
nucleus. Whilst a faint nuclear envelope stain could sometimes be detected, C20 
















































































































































































































































































































To further characterise the localisation of βDG at the nuclear envelope, LNCaP cells were 
coimmunostained for βDG (MDG2) and lamin B1. Confocal microscopy analysis shows that 
βDG and lamin B1 colocalise at the nuclear envelope (Fig 4.7 A). Moreover, in the 
orthogonal view of a cross-section of the nucleus, βDG colocalises with lamin B1 at the 
nuclear envelope at the top and along the depth of the nucleus (Fig 4.7 B). Interestingly βDG 
was often detected strongly on top of the nucleus in patches.  
Combined these results agree with the growing number of reports showing that DG is found 
in the nucleus of prostate cell lines, both non-cancer and cancer derived. Moreover, βDG is 
found at multiple nuclear structures. The fact that the two antibodies detect different 
localisation and therefore potentially separate populations of βDG is interesting and could 
mean that PTM, differentially detected by the antibodies, could affect the nuclear 
localisation of βDG. Finally, these results indicate that LNCaP, PC3 and PNT1A can be used as 












Figure 4.5: Confocal immunofluorescence microscopy localisation of βDG in prostate cell lines using 
anti-βDG antibody MDG2. LNCaP, PC3 and PNT1A cells were fixed and stained for βDG (MDG2) 
(Green) and the nuclei counterstained with DAPI (Blue). Representative images of a maximum 
projection of βDG staining and Z slices from the middle of the nucleus are presented. Enlarged images 
of the nucleus indicated in the merged image with a box. In the nucleus βDG is detected at the nuclear 
envelope (filled white arrowhead), nucleoplasm (*) and as strong foci (empty white arrow heads). 





Figure 4.6: Confocal immunofluorescence microscopy localisation of βDG in prostate cell lines 
using antiβDG antibody C20. LNCaP, PC3 and PNT1A cells were fixed and stained for βDG (C20) 
(Green) and the nuclei counterstained with DAPI (Blue). Representative images of a maximum 
projection of βDG staining and Z slices from the middle of the nucleus are presented. Enlarged 
images of the nucleus indicated in the merged image with a box. In the nucleus βDG is detected 
faintly at the nuclear envelope and nucleoplasm and strongly in subnuclear compartments, likely 

























Figure 4.7. βDG and lamin B1 colocalise at the nuclear envelope in LNCaP cells. LNCaP cells 
were fixed and stained for βDG (MDG2) (green) and Lamin B1 (red). Nuclei were 
counterstained with DAPI (blue). Colocalisation of βDG and lamin B1 can be seen in Z-slices 
from the middle of the nucleus (A) and in orthogonal views of the stacked images (B). 






4.2.4 FLAG TAGGED ALPHA-BETA DYSTROGLYCAN CAN BE DETECTED IN THE NUCLEUS OF 
LNCAP CELLS 
In the study of a protein it is often useful to incorporate a tag. Among other uses, tags 
enable the purification and detection of a protein of interest. Previously in the Winder lab 
an internal flag tag has been incorporated into mouse full length αβDG (Leocadio 2014, 
Leocadio et al. 2016) because of concern that a C-terminal tag affects phosphorylation at 
Y892. A flag tag is a hydrophilic peptide consisting of eight residues, DYKDDDDK. The flag tag 
was inserted at residue 803 (Fig 4.8 A) (Leocadio et al. 2016), a site within the cytoplasmic 
domain of βDG, with few sites of interaction as predicted by ELM and C-terminal to the NLS 
(green box, Fig 4.8 A) (Gould et al. 2010). Sequence alignment also shows that the sequence 
of βDG at this site already contains a number of residues required for a flag tag and 






Figure 4.8. αβDGflag is detected in the nucleus of 
LNCaP cells. A) Sequence alignment of the original 
sequence of βDG and the sequence of αβDGflag. 
The flag tag (red residues) was inserted C-terminal 
to the NLS (green box and residues) of βDG in the 
cytoplasmic domain.  Residues that were retained 
from the original sequence are denoted with an *.  
B) LNCaP cells transiently transfected with the 
control empty plasmid, PcDNA3.1+ or αβDGflag 
and grown for 24 hours. Cells were subject to 
biochemical fractionation and immunoblotted for 
anti-flag M2. GAPDH and Fibrillarin were used as 
purity/loading controls for the non-nuclear and 





αβDG flag expression in LNCaP cells has been characterised in detail elsewhere (Leocadio, 
2014) and in section 4.2.9 below. LNCaP cells were transiently transfected with a plasmid 
containing αβDGflag, grown for 24 hours and then subject to biochemical fractionation. 
Importantly, whilst the majority of βDG is in the non-nuclear fraction, a full length band of 
βDG can be seen in the nuclear fraction when detected with M2 anti-flag antibody (Fig 4.8 
B). Faint higher molecular weight bands can also be detected at 60-70 KDa and ~160 KDa in 
the nuclear fractions as was also detected by 1709 (Fig 4.4). As previously mentioned these 
high molecular weight species may be as a consequence of other post-translational 
modifications. It is also important to consider that the M2 antibody has previously been 
reported to detect native proteins in mammalian cells in addition to the exogenous FLAG 
tag (Schafer et al. 1995). The detection of native proteins may account for the bands 
detected in the lysates from the pcDNA3.1+ transfected cells, including a band at ~90 KDa, 
which can also be seen in the αβDGflag transfected lysate. 
4.2.5 INVESTIGATING THE PHOSPHORYLATION OF BETA-DYSTROGLYCAN 
Phosphorylation at residues additional to Y892 may also regulate the localisation and 
function of βDG. To investigate the phosphorylated species of βDG, WCL from αβDGflag 
transfected LNCaP cells was run on a phostag gel and immunoblotted for M2 flag, βDG 
(MDG2) and pY892 βDG (1709). Phostag gels contain an acrylamide accessory which 
specifically binds to divalent phosphate groups via its two metal ions (Mn2+) and thus 
retards the movement of the protein through the gel in SDS-PAGE (Kinoshita et al. 2005).  
The presence of two bands detected by each of the antibodies suggests the presence of 
phosphorylated species of βDG (Fig 4.9) 1709 and MDG2 are reporters of the 
phosphorylated and non-phosphorylated Y892 forms of βDG respectively (See Chapter 3) 
(Pereboev et al. 2001, Ilsley et al 2001, James et al. 2000), therefore the fact that both of 
Figure 4.9. Full length αβDGflag resolves into 
two bands on a phostag gel. Total cell lysate 
was harvested from LNCaP cells transiently 
transfected with αβDGflag and grown for 24 
hours. Lysate was run on a 20 µM phostag, 10% 
acrylamide gel and immunoblotted for flag (M2 
antibody), βDG (MDG2 antibody) or pY892 βDG 
(1709 antibody). Two distinctly resolved bands 




these antibodies detects two distinct bands suggests that βDG is also being phosphorylated 
at a site distinct from Y892.  However, Fig 4.9 should be interpreted with caution as it does 
not include the necessary controls to confirm that the two bands are a result of 
phosphorylation. In order to confirm that the shift in band migration is due to 
phosphorylation the lysates should be treated with phosphatases to remove the 
phosphorylation and thus only one band should be detected on the phostag blot. 
Additionally, to determine that the two bands are not an artefact of the flag tagged protein, 
a control of non-transfected cells should have been included. 
 
Figure 4.10. Calyculin A treatment of αβDGflag LNCaP cells. LNCaP cells transiently transfected with 
αβDGflag were grown for 24 hours and then incubated with either DMSO or Calyculin A at a final 
concentration of 50, 100 or 200nM Calyculin A for 20 minutes. Total cell lysates were then collected and 
immunoblotted for anti-flag M2. Empty vector PcDNA3.1 treated with DMSO was included as an 
antibody specificity control. Enlarged version with a straight line drawn for migration comparison. 
GAPDH was included as a loading control.  
An alternative method to determine if a protein is phosphorylated is by treating with 
phosphatases or phosphatase inhibitors. When treated with increasing concentrations of 
Calyculin A, an inhibitor of serine/threonine phosphatases very little, if any, change was 
seen in the migration of full length βDG flag, as detected by M2 anti-flag, relative to the 
DMSO treated control (Fig 4.10). Whilst Fig 4.10 does not support the presence of 
phosphorylation of βDG at serine and threonine residues, it does not rule it out. It is 
possible that the small migration shift (~80 Da) caused by an altered phosphorylation state 
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of one or two residues would be too small to detect on a 12.5% acrylamide gel. If this 
experiment were to be repeated a detection method with increased sensitivity such as 
Phostag gels, should be used.  It is also important to note that it not possible to determine 
from this experiment whether any detected mobility shift in a protein is direct 
phosphorylation at a serine or threonine residue or if the broad Calyculin A treatment is 
affecting an upstream signalling pathway that in turn modulates the phosphorylation at a Y, 
S or T residue.  
4.2.6 GENERATION OF ALPHA-BETA DG FLAG T788A AND T788D LNCAP TRANSGENIC 
LINES 
Multiple studies have shown that Y892 is not crucial for the nuclear localisation of βDG 
(Lara-Chacon et al. 2010, Leocadio 2014). Other sites of phosphorylation within βDG may 
regulate the nuclear localisation of βDG. In order to investigate the effect of 
phosphorylation at T788 on the localisation of βDG, site directed mutagenesis was used to 
substitute the threonine to an alanine or an aspartate to represent a non-phosphorylatable 
and phospho-mimetic form of T788 respectively (Fig 4.11). Alanine and Aspartate were 
chosen due to their relatively similar size and side chain structure to threonine, with 
aspartate containing the negatively charged side chain to mimic the negative phosphate 
group of phosphorylated threonine. The introduction of the mutations was confirmed by 
DNA sequencing (Appendix Fig B.1) and the plasmids purified for transfection into LNCaP 
cells.  
  
Figure 4.11.  Schematic of mouse αβDGflag and the generation of a non-phosphorylatable and 
phospho-mimetic T788 flag tagged αβDG.  Site directed mutagenesis of threonine 788 of mouse βDG to 
an alanine non-phosphorylatable (T788A) and an aspartate phospho-mimetic (T788D) form.  Residue 
788 is highlighted in bold. The transmembrane domain (TM) is depicted in yellow, Nuclear Localisation 
Signal (NLS) in green and the flag tag in red. 
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4.2.7 CHARACTERISATION OF ABDGFLAGT788A AND ADDGFLAGT788D LNCAP 
TRANSGENIC CELLS 
The plasmids encoding αβDGflag, αβDGflagT788A and αβDGflagT788D were electroporated 
into LNCaP cells and grown for 48 hours. Immunoblot analysis with anti-flag M2 antibody 
detected a 43 KDa band representing full length βDG in all three of the flag transfected cell 
populations but not in the empty vector control (Fig 4.12 A). This demonstrates the specificity 
of the antibody and that recombinant protein at the right size is being expressed. Moreover, 
when WCL from LNCaP transiently transfected with wt, T788A and T788D αβDGflag was 
subject to immunoprecipitation with anti-flag M2 resin and immunoblotted with a rabbit anti-
flag (rflag) antibody or with 1709 (pY892 βDG) a band at 43 KDa was detected in the flag 
construct transfected cells but not in the resin only or empty vector control lanes (Fig 4.12 B, 
C). The detection of both the T788A and T788D mutants of βDG by 1709 demonstrates that 
βDG can be phosphorylated at Y890 (mouse) regardless of the phosphorylation status of T788. 
To further verify the flag tagged recombinant protein being detected is βDG, 
immunoprecipitation with βDG antibodies followed by probing with anti-flag antibodies could 
be conducted.  1709 also detected the high molecular weight band between 130-250 KDa in 
all three of the flag construct expressing lysates (Fig 4.12 C). The 26 KDa and 32 KDa fragments 
of βDG were inconsistently detected in lysates from LNCaP cells expressing the αβDGflag wt, 
T788A and T788D constructs (Data not shown). 
In order to investigate the phosphorylation of the mutated βDG constructs, the WCL of 
αβDGflag, αβDGflagT788A and αβDGflagT788D were run on a 20µM phostag gel and probed 
with anti-flag M2 (Fig 4.12 D). All three lysates still displayed two distinct bands between 35-
55 KDa, however, as discussed for Fig 4.9, this experiment lacks the necessary controls to 
investigate if the separation of the bands is due to phosphorylation and should therefore be 
interpreted with caution.  There is very little difference in the migration of the 
αβDGflagT788A, αβDGflagT788D and αβDGflag bands, nor is there a difference in the number 
of βDG bands present, suggesting that there has not been a change in the number of 
phosphorylation modifications on the constructs. However, it is not possible to conclude that 
this indicates that there has not been a change in the phosphorylation status of residue T788 
in αβDGflag as compensatory phosphorylation events may have occurred in the two mutant 
constructs, which would prevent a shift on the Phostag gel. Further site specific analysis such 
as mass spectrometry and phospho site specific antibodies could be used to investigate 









Figure 4.12. Characterisation of αβDGflag, αβDGflagT788A and αβDGflagT788D. LNCaP cells were 
transfected with pcDNA3.1+, αβDGflag, αβDGflagT788A or αβDGflagT788D and grown for 48 hours. 
Total cell lysates were harvested and immunoprecipitated with anti-flag M2 resin. A no lysate control 
was included in the immunoprecipitations. Total cell lysate (A), or M2 affinity resin with 
immunoprecipitated proteins (B) or both (C) were immunoblotted for M2 flag (A), rabbit flag (rflag) 
(B) or pY892 βDG (1709) (C). Full length and high molecular weight species of βDG are indicated with 
arrows. D. Total cell lysates of αβDGflag, αβDGflagT788A and αβDGflagT788D were run on a 20µm 




Confocal immunofluorescence microscopy analysis showed that αβDGflag, as detected by 
anti-flag M2, in LNCaP cells localised strongly to the plasma membrane and displayed 
punctate staining within the cytoplasm and very weakly in the nucleus (Fig 4.13). The 
αβDGflagT788A and αβDGflagT788D mutants also localise to the plasma membrane, 
cytoplasm and weakly to the nucleus. There is nucleoplasmic and brighter foci staining in the 
nucleus. These results suggest that, contrary to the mass spectrometry data, phosphorylation 
at T788 occurs not only in the nucleus of cells and it cannot be said from this data that it 
affects the nuclear localisation of βDG. None of the constructs demonstrate the same strong 
localisation to the nucleoli as detected by the C20 antibody (Fig 4.6) and is more reminiscent 
of MDG2 staining. All three flag constructs also colocalise with 1709 detection of pY892 βDG 
at the PM and within the cytoplasm of the cell (Fig 4.14) All three constructs, when detected 
with anti-flag M2, also contained populations that do not colocalise with 1709 and are 
therefore not phosphorylated at Y892 (Fig 4.14). It is important to remember that 1709 also 
detects proteins other than βDG in immunofluorescence studies (chapter 3). Given that these 
are transient transfections, not stable cell lines, the expression of the recombinant protein 
was variable and it is difficult to detect what might be subtle changes in βDG localisation. 
Whilst quantification of nuclear: cytoplasmic ratio of immunofluorescence images can be used 
to study the nuclear trafficking of proteins, in the case of βDG technical issues arise due to the 
fact that no one area within the cytoplasm, nucleus or confocal slice is representative to 
obtain an accurate average N:C ratio for a cell, for example due to strong staining at the PM 
and basal surfaces of the cell as well as variable staining of intracellular structures such as the 
golgi, vesicles and sub-nuclear structures. Whilst quantification of nuclear to non-nuclear 
ratios of βDG via immunofluorescence has been reported in the literature (Lara-Chacon et al. 




Figure 4.13. Characterisation of αβDGflag, αβDGflagT788A and αβDGflagT788D via 
immunofluorescence confocal microscopy. LNCaP cells were transfected with pcDNA3.1(+), 
αβDGflag, αβDGflagT788A or αβDGflagT788D and grown for 24 hours. Cells were fixed and 
immunostained with anti-flag M2 antibody (green) and the nuclei counterstained with DAPI (blue). All 
three flag constructs localise strongly at the plasma membrane, cytoplasm and very faintly in the 
nucleus. Exogenous protein occasionally accumulated in internal structures, presumably the golgi or 
ER. Images are Z slices taken from the middle of the nucleus. Images were taken at 60x magnification. 




Figure 4.14 αβDGflag, αβDGflagT788A, αβDGflagT788D colocalisation with pY892 βDG. LNCaP 
cells were transfected with pcDNA3.1(+), αβDGflag, αβDGflagT788A or αβDGflagT788D and 
grown for 24 hours. Cells were fixed and immunostained with anti-flag M2 antibody (green), 
pY892 βDG (red) and the nuclei counterstained with DAPI (blue). A population of all 3 flag 
constructs colocalises with pY892 βDG at the plasma membrane, cytoplasm and the nucleus. 
Enlarged images of a nucleus (box, merge). Images are Z slices taken from the middle of the 
nucleus. Images were taken at 60x magnification. Scale bar 10µm. 
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Consequently, as an alternative method to investigate αβDGflag, αβDGflagT788A and 
αβDGflagT788D localisation, LNCaP cells were subject to biochemical fractionation 24 hours 
after transfection and immunoblotted with anti-flag M2 (Fig 4.15). All three forms of flag 
recombinant protein could be detected in the nuclear fraction at 43 KDa, though it was 
strongest detected in the non-nuclear fractions. The band between 130-250 KDa could be 
detected variably in the nuclear and strongly in the non-nuclear fractions. The 31 and 26 KDa 
fragments of βDG were only detected in the nonnuclear fractions (Fig 4.15). The loading of 
non-nuclear and nuclear sample is 20ug of the total protein, rather than proportional which 
would better suit the quantification of a nuclear: non-nuclear ratio. However quantification of 
the nuclear: non-nuclear ratio has been attempted taking into account the volumes of each 
sample loaded on the SDS-PAGE gels as well as the approximate total volumes of the nuclear 
and non-nuclear fractions. It should be noted that this quantification comes with a number of 
caveats, for example the total volumes of the cytoplasmic and nuclear fractionation are 
approximate due to potential loss of sample in the fractionation process, such as sonication. 
Nonetheless the quantification provides an indication as to the levels of FLAG-tagged βDG in 
the nucleus relative to the rest of the cell and therefore if this is altered by the phospho-null or 
phospho mimetic mutation at T788. Whilst the average of the four repeats indicates a 
marginally higher nuclear: non-nuclear ratio in both the αβDGflag T788A (0.29± 0.12) and 
αβDGflag T788D (0.27± 0.05) transfected cells compared to wt αβDGflag (0.22± 0.08) it is 
important to note that there is considerable variability in the nuclear: non-nuclear ratio in each 
of the individual replicates. Statistical significance cannot be tested as the number of replicates 
(4) is not enough to provide power in the non-parametric test to be used given the non-normal 
distribution of the data. To ensure that the nuclear fraction is not contaminated, future 
fractionation experiments should contain a marker of the ER such as calnexin. It is also 
important to take into account potential differences in the transfection efficiency and protein 
stability of each construct on the quantification of nuclear: non-nuclear ratio (see section 
4.2.10). 
 Together these results do not demonstrate a clear role for phosphorylation of T788 in the 
nuclear localisation of βDG. Both the non-phosphorylatable and phospho mimetic versions of 
αβDGflag at T788 could be found at the plasma membrane, cytoplasm and nucleus at variable 
levels. This does not exclude the possibility, however, that phosphorylation at T788 is 
important for a nuclear function of βDG that has not been investigated in the time frame of 
this project. It is also important to note that an aspartate mutation does not have the same 
structure and properties as true phosphorylation and may therefore not be sufficient to 





4.2.8 THE STABILITY OF RECOMBINANT ΑΒDGFLAG, ΑΒDGFLAGT788A AND 
ΑΒDGFLAGT788D 
 
Whilst characterising the αβDGflag recombinant proteins it was observed that the turnover of 
αβDGflag was very rapid. The protein level at 48 hours post transfection, as quantified from 
immunoblots, was approximately a fifth of the level that was expressed at 24 hours post 
transfection and almost gone by 96 hours post transfection (Fig 4.16). Although transfection 
levels vary, this trend in rapidly reducing levels of protein expression was seen through a 
variety of immunoblot and immunofluorescence experiments (Data not shown). The 
Figure 4.15. αβDGflag, αβDGflagT788A and αβDGflagT788D are all detected in the nucleus of 
LNCaP cells. A) LNCaP cells were transfected with pcDNA3.1+, αβDGflag, αβDGflagT788A or 
αβDGflagT788D and grown for 24 hours prior to biochemical fractionation. Non-nuclear and 
nuclear fractions were immunoblotted with anti-flag M2 antibody. Full length 43KDa βDG can be 
seen in the nuclear fraction of each sample. GAPDH and Fibrillarin were included as loading 
controls of the non-nuclear and nuclear fractions respectively. B) Quantification of the mean 
nuclear: non-nuclear ratios of full length 43KDa βDG of αβDGflag, αβDGflagT788A or 
αβDGflagT788D samples. The intensity of the bands was detected by densitometric analysis and 
divided by the volume of sample loaded. The intensity of the non-nuclear sample was adjusted to 
take in to account the 4:1 ratio of the total volumes of the non-nuclear and nuclear samples. The 




αβDGflagT788D mutant however appeared to be expressed at a higher level at these later 
time points. These experiments were all conducted in cells transiently transfected with the 
flag tagged βDG constructs, and although the differing levels of protein could be a 
consequence of differing transfection efficiency or protein expression, an alternative 
hypothesis is that phosphorylation, or at least the phosphomimetic mutation at T788 confers 
stability to βDG protein.  
 
  
Figure 4.16. Expression profile of αβDGflag over a timecourse. LNCaP cells were transfected with 
αβDGflag and total cell lysates harvested at 24, 48, 72 and 96 hours post-transfection. (A) Lysates were 
immunoblotted for M2 flag. Full length, 43KDa βDG is indicated. GAPDH was included as a loading 
control. (B) Quantification of the level of 43 KDa βDG relative to GAPDH by densitometric analysis. N=3. 
Error bars = S.D.  
 
To investigate this hypothesis LNCaP cells were transfected with αβDGflag, αβDGflagT788A 
or αβDGflagT788D, grown for 24 hours and then treated with cycloheximide (CHX), an 
inhibitor of translation elongation, to prevent protein synthesis. WCL were then collected at 
0, 6, 12 and 24 hours post cycloheximide treatment and subject to immunoblot and 
detection by anti-flag M2 (Fig 4.17 A).  The level of full-length βDG was normalised to the 
actin control and calculated as a percentage of the level of normalised βDG at 0hr of 
cycloheximide treatment (24 hours post transfection) (Fig 4.17 B-C).  Whilst the 
αβDGflagT788A protein level was similar to that of αβDGflag across the time course, the 
phospho mimetic T788D mutant showed a trend of increased stability, though the levels 
were more variable (Fig 4.17 B-C). Pairwise comparisons of the levels of each flag construct 
24 hours post CHX treatment by the non-parametric Mann-Whitney U test did not detect a 
statistically significant difference. The band between 130-250 KDa also rapidly reduced in all 
three flag tagged recombinant proteins after 6 hours of cycloheximide treatment suggesting 
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that it is rapidly processed or degraded.  These data could be affected by potentially 
variable transfection efficiency between the wells, further experiments in cell lines stably 
expressing the constructs would validate if the stability of βDG can be regulated by T788 
phosphorylation.   
 
     
Figure 4.17. Cycloheximide pulse chase analysis of αβDGflag, αβDGflagT788A and αβDGflagT788D 
stability.  
LNCaP cells were transfected with αβDGflag, αβDGflagT788A and αβDGflagT788D and grown for 24 
hours. At 24 hours post-transfection cells were treated with 100µg/ml cycloheximide (CHX) or a DMSO 
control. Lysates were collected at 0, 6, 12 and 24 hours after treatment of CHX. The DMSO treated 
sample was collected at 24 hours post treatment. (A) Lysates were immunoblotted for M2 flag. Actin 
was included as a loading control. The level of 43KDa βDG was normalised to the actin loading control 
and then the expression calculated as a percentage of the expression at 0 hours of CHX treatment. 






4.3.1 NUCLEAR MORPHOLOGY IS DISRUPTED IN DAG NULL PRIMARY FIBROBLASTS 
 
The roles of DG in the nucleus are not fully understood, however dystroglycan has been 
reported to play a role in maintaining nuclear architecture and organisation (Lara-Chacon et 
al. 2013). The DAG null fibroblasts obtained from a patient with Walker-Warburg syndrome 
(Riemersma et al. 2015) were used to assess nuclear morphology in the absence of α and βDG. 
The absence of βDG in the patient cells has been confirmed in this study via immunoblot with 
two separate anti- βDG antibodies (Fig 4.2Ai). The absence of alternative splice variants was 
confirmed via reverse transcription PCR of the DAG null fibroblast mRNA in the initial 
characterisation of the cells, moreover, lack of functional α- and βDG in the DAG null 
fibroblasts was confirmed via western blot and by lack of signal detected in a laminin overlay 
(Riemersma et al. 2015). It should be noted that re-expression of DG in the DAG null 
fibroblasts would be a more suitable control as the cells would then be known to be of the 
same origin and ages as opposed to non-isogenic HDF cells.  
 Immunofluorescence analysis and subsequent quantification of ‘abnormal’ nuclear 
morphology of HDF control fibroblasts and DAG null fibroblasts and showed that dramatically 
more DAG null fibroblasts displayed a disrupted nuclear morphology compared to the control 
cells (Fig 4.2 A-K).  The aberrant nuclear morphology in the DAG null fibroblasts was diverse, 
with nuclei showing irregular shapes, blebbing, twisting, micronuclei and multiple nuclei (Fig 
4.2 A-K). This is consistent with the hypothesis that DG is important for maintaining nuclear 
morphology and supports a previous report in which RNAi partial knockdown of DG in C2C12 
myoblast cells resulted in a six-fold increase in aberrant nuclear morphology, with aberrant 
nuclei being irregular blebbed shape or 2-fold larger or smaller (Lara-Chacon et al. 2010).   
The complex functions of βDG are facilitated in part by its inclusion in multiprotein complexes 
and its interaction with a plethora of protein binding partners (Moore et al. 2010). It has 
previously been demonstrated by electron microscopy that βDG localises to the inner nuclear 
membrane whilst immunoprecipitation and pull down assays show that βDG associates with 
structural components of the nuclear envelope such as emerin, lamin A/C and lamin B1 (Lara-
Chacon et al. 2013). The colocalisation of βDG with lamin B1 in LNCaP cells is consistent with 
this (Fig 4.17). Moreover, in C2C12 cells depleted for βDG by RNAi the localisation of lamin B1 
and emerin but not lamin A/C to the nuclear envelope was disrupted and their stability was 
reduced (Martinez- Vieyra et al. 2013). In support of this lamin B1 but not lamin A/C staining 
looks to be slightly reduced and disrupted in DAG null fibroblasts (Fig 4.3). Martinez-Vieyra et 
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al have proposed a model in which βDG targets emerin to the nuclear envelope whereby it 
interacts with lamin B1 promoting their stability and also associating with lamin A/C. 
Interestingly, C2C12 cells depleted for α-dystrobrevin, which also interacts with lamin B1, 
resulted in a reduction of other DAPC components in the nucleus and 45% of the nuclei 
displayed an irregular morphology, including blebbing (Aguilar et al. 2015). Nuclear blebs are 
protrusions from the nuclear surface that are rich in A type lamins and are regions in which 
the fibres of the lamin meshwork display a greater degree of separation (Prokocimer et al. 
2009, Funkhouser et al. 2013). When B-type lamins are depleted, the lamins begin to 
segregate from one another and form an uneven network and subsequent blebbing of the 
nuclear envelope (Funkhouser et al. 2013).  It is therefore possible that βDG contributes to the 
maintenance of the nuclear morphology through its interactions with the nuclear lamina, 
potentially as part of a nuclear DAPC. Future work elucidating the composition of a nuclear 
DAPC and its interactions with the nuclear lamina warrants further investigation.  
A small number of DAG null cells had multiple nuclei or micronuclei (Fig 4.2 H, I). Multiple 
nuclei can arise from issues with segregation of the two daughter cells following cell division. 
Micronuclei are formed as a consequence of improper segregation of chromosomes during 
mitosis with a segment or whole chromosome remaining separate from the other 
chromosomes and is eventually encased in its own nuclear envelope during telophase, 
separate from the main nucleus (Luzhna et al. 2013). DG depletion delays cell cycle 
progression (Sgambato et al. 2006, Higginson et al. 2008, Villarreal-Silva et al. 2010) and also 
plays a mechanical role in the contractile ring and tethering the plasma membrane to the 
cytoskeleton during cytokinesis. (Higginson et al., 2008). Nuclear morphology defects were not 
reported during the study of cytokinesis in the DG knockdown cells (Higginson et al., 2008), 
however, given the interaction of DG with a number of its structural components it would be 
interesting to investigate if βDG affects nuclear membrane assembly following mitosis in more 
detail, for example through microscopy of live cells in mitosis.  
 
There is preliminary evidence that βDG can interact with SUN1, a component of the LINC 
complex in the inner nuclear membrane (personal communication M. Laredo and S. Winder).  
Sun proteins in the inner nuclear membrane bind to emerin and A-type lamins, but not B-type 
lamins (Haque et al. 2006). When lamin A/C is depleted SUN1 remains localised to the nuclear 
envelope with a few nuclei displaying disrupted localisation at the nuclear poles, therefore 
suggesting the presence of other factors anchoring SUN1 in the INM (Haque et al. 2010). The 
LINC complex has important roles in regulating nuclear shape and position (Razafsky et al. 
2009). An interesting line for future work is to investigate an interaction between βDG and 
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SUN proteins, which are components of two key mechanical and structural complexes and the 
implications for this on the structure of the nucleus.     
The importance of lamins and components of the LINC complex in nuclear morphology are 
clear when looking at diseases that affect the nuclear envelope. Laminopathies are a large 
group of diseases caused by mutations in lamins, which can deplete the amount of lamin or 
perturb their interactions with binding partners such as SUN1 and Emerin and result in 
aberrant nuclei. Laminopathy patients display a large array of clinical symptoms including 
muscular dystrophy and neuropathy (Worman, 2012). Further examples of diseases caused by 
mutations in NE proteins include Hutchinson-Gilford progeria syndrome (HGPS) (Chen et al. 
2014) and Emery-Dreifuss muscular dystrophy (EDMD) (Holt et al. 2003), where loss of lamin 
A/C or emerin cause abnormalities in the nuclear envelope and nuclear morphology. Given the 
apparent emerging roles of DG in nuclear architecture and the fact that DG is a component of 
the DAPC, a complex in which mutations often result in muscular dystrophies, it would be 
interesting to investigate nuclear DG in the context of laminopathies and other muscular 
dystrophies. Indeed, it is important to consider that the DAG null fibroblasts came from a 
patient with Walker-Warburg syndrome and if the apparent nuclear defects may have 
contributed to the disease symptoms. 
From this analysis it is not possible to separate the roles of DG at the plasma membrane or 
cytoplasm from DG in the nucleus on the nuclear phenotype. Therefore, it must be considered 
that lack of DG at the plasma membrane could contribute to the aberrant nuclear morphology 
as a consequence of disrupted signalling pathways or cytoskeletal interactions. Both actin and 
microtubules can affect nuclear morphology, furthermore both are important in cell polarity 
and migration and subsequently nuclear positioning (Martins et al. 2012). In DG knockdown 
cells there are no reported gross changes in the cytoskeletal organisation, although when 
overexpressed it can bundle F-actin (Chen et al. 2003). To test the role of non-nuclear βDG on 
nuclear morphology via the cytoskeleton, βDG knockdown cells could be treated with 
cytoskeletal disruptors such as cytochalasin or nocodazole to see if the nuclear morphology is 
altered. Alternatively, βDG with a functional or mutated NLS could be re-expressed in DAG null 





4.3.2 CHARACTERISATION OF THE NUCLEAR LOCALISATION OF ENDOGENOUS ΒDG IN 
PROSTATE CELL LINES 
 
The localisation of βDG to the nucleus in normal and cancerous prostate tissue and cell lines has 
been reported in multiple studies (Mitchell et al. 2013, Mathew et al. 2013, Leocadio et al. 
2016). Here we show that βDG is in the nucleus of multiple prostate cell lines; the immortalised 
normal prostate epithelia line PNT1a and the metastatic prostate cancer lines LNCaP and PC3 
by biochemical fractionation (Fig 4.4) and immunofluorescence microscopy (Fig 4.5, Fig 4.6), in 
agreement with the previously published literature.   
 
The localisation of DG in prostate epithelia is well characterised. In benign prostate epithelia 
there is strong localisation of βDG at the intercellular junctions between luminal cells, basal cells 
and at the site of basal cell attachment to the basement junction (Sgambato et al, 2007, Mitchell 
et al 2013, Mathew et al. 2013).  In prostate tumour cells α and βDG levels are reduced at the 
plasma membrane in correlation with disease progression but is re-expressed at metastatic sites 
(Mitchell et al, 2013, Sgambato et al, 2007, Sgambato et al 2003).  As previously discussed, there 
is an increasing body of work investigating the mechanisms of βDG regulation in normal and 
prostate tissue which have identified a plethora of PTM contribution to the regulation of βDG 
and how these processes may be aberrant in epithelial cancers including hypoglycosylation, 
phosphorylation and proteolytic cleavage (Sgambato et al. 2007, Sgambato et al. 2010, Mitchell 
et al 2013, Mathew et al. 2013, Leocadio et al. 2016, Bao et al 2010).  
The profile of both phosphorylated and non-phosphorylated Y892 βDG was examined in LNCaP, 
PC3 and PNT1A cells following biochemical fractionation (Fig 4.4). Full length βDG, both 
phosphorylated and non-phosphorylated, was found in the nuclear and non-nuclear fractions 
of the cell lines investigated. In addition to full length βDG, high molecular weight species at 60 
and 130-250 KDa of the Y892 phosphorylated form of βDG were sometimes detected in the 
nucleus as well as fragments of βDG and pY892 βDG at 31 and 26KDa, all of which have been 
previously reported in the literature (Losasso et al. 2008, Mitchell et al. 2013, Mathew et al. 
2013, Leocadio et al. 2016).   
The higher molecular weight species indicate the presence of post-translational modifications 
on βDG, one candidate for which is ubiquitination. As previously discussed mass spectrometry 
analysis (Lee et al. 2011), MG132 treatment and pull down by a high- affinity specific ubiquitin 
binding resin, MultiDsk (Leocadio, 2014, Miller et al. 2012) have all provided evidence for DG 
ubiquitination. The presence of these high mw species in the nucleus, although needing 
further verification as ubiquitinated species, may suggest that following its roles within the 
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nucleus, βDG could be ubiquitinated and degraded by the nuclear ubiquitin proteasome or be 
ubiquitinated and exported to be degraded in the cytoplasmic proteasome. This hypothesis 
could be tested using nuclear import and export inhibitors combined with Multidsk and 
inhibitors of the proteasome such as MG132.   
The presence, production and role of the cleavage fragments of βDG in the plasma membrane, 
nucleus and in prostate cancer progression have been addressed in multiple studies from the 
Winder lab and others (Singh et al. 2004, Lossasso et al. 2008, Sgambato et al. 2003, Yamada et 
al. 2001, Mitchell et al. 2013, Mathew et al. 2013, Leocadio et al. 2016). Increased proteolytic 
cleavage of both α and βDG has been reported in correlation with loss of DG from the PM as is 
seen in epithelial carcinoma progression (Lossasso et al. 2008).  Increased cell density results in 
an increase in proteolytic cleavage and nuclear targeting of βDG, particularly the 26 KDa 
fragment, moreover, a recent study shows that this is a consequence of γ-secretase and furin 
cleavage, which may be mediated in a notch dependent manner (Mitchell et al. 2013, Leocadio 
et al. 2016). Future work could aim at investigating a functional role of fragments of βDG in the 
nucleus. As has previously been mentioned the targeting of a cytoplasmic fragment of βDG to 
the nucleus saw the differential regulation of a small number of genes in a microarray, hinting 
at a potential signalling function (Mathew et al. 2013).  
The localisation of βDG to the nucleus in PNT1A, LNCaP and PC3 cells was also corroborated by 
immunofluorescence microscopy. βDG was detected in the nucleus using two different 
antibodies and the three cell lines showed very similar localisation profiles, at the nucleoplasm, 
nuclear envelope, nucleoli and distinct nuclear foci, although the levels at these sites, 
particularly the nucleoplasm, was variable across the cell lines (Fig 4.5, Fig 4.6). The localisation 
profiles of the two antibodies, MANDAG2 (Fig 4.5) and C20 (Fig 4.6) were surprisingly different, 
with C20 strongly localising to the nucleoli. This could potentially be explained by the fact that 
the antibodies detect different epitopes within βDG and therefore may encompass different 
PTM which may regulate specific nuclear localisation or the epitopes may be blocked by binding 
partners at different sites within the nucleus. The epitopes have been discussed in more detail 
in Chapter 3.  
 βDG colocalisation with lamin A/C at the nuclear envelope in LNCaP cells has also been 
demonstrated. These results are in agreement with multiple reports in the literature detailing 
βDG nuclear localisation in several nuclear compartments and its association with protein 
markers of these compartments (Martinez- Vieyra et al. 2013, Fuentes- Mera et al. 2006, 
Mathew et al. 2013, Leocadio et al. 2016). Roles for βDG, and its interactions, at the nuclear 
envelope have been discussed previously (Section 4.3.1) however a role for βDG in thenucleolus 
is less well studied. The nucleolus is the site of rRNA transcription, processing and ribosome 
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assembly (Raska et al. 2006). Interestingly, recent mass spectrometry analysis of proteins 
immunoprecipitated with βDG from biochemically fractionated LNCaP cells detected a number 
of proteins involved in ribosomal processes including CRM1 a nuclear export factor and u3RN, 
a small nuclear RNA, (Leocadio 2014). Although validation is required to confirm these 
interactions, it could hint at a functional role for βDG in the nucleolus as well as the splicing 
speckles and cajal bodies, where it has also been detected (Martinez-Vieyra et al. 2013).   
It is known that lamin A/C and B1 can be found in the nucleolus and are important in maintaining 
its structure and function (Martin et al. 2009). It is also known that βDG associates with nuclear 
lamins and that nucleolar structure is disrupted upon DG knockdown in C2C12 cells (Martinez- 
Vieyra et al. 2013), therefore βDG localisation in the nucleoli may contribute to the structure of 
these subnuclear compartments via components of the nuclear lamina.  Interestingly α-
dystrobrevin has also been identified in the nucleolus and when α-dystrobrevin is 
downregulated there are changes in the nuclear structure as well as a reduction in the levels of 
a number of nucleolar proteins including fibrillarin and Nopp140 (Hernandez-Ibarra et al. 2015). 
It would therefore be interesting to assess if the roles of α-dystrobrevin and βDG in the 
nucleolus are as part of a nuclear DAPC. In order to further elucidate the precise localisation of 
βDG in the nucleus of these cell lines, co-localisation analysis of protein markers of different 
nuclear structures and βDG could be conducted alongside immunoprecipitation and pull down 
assays as has been conducted in other cell lines (Hernandez-Ibarra et al. 2015, Martinez- Vieyra 
et al. 2013).  
The results above also show that LNCaP, PC3 and PNT1A cells can all be used as models to 
investigate the nuclear regulation and functions of βDG.  
4.3.3 FLAG TAGGED ALPHA-BETA DYSTROGLYCAN CAN BE DETECTED IN THE NUCLEUS OF 
LNCAP CELLS 
The addition of a tag can aid in the study of a specific protein, however, it also has its caveats 
with a major concern being that the position or size of a tag may affect the conformation, PTM 
or interaction sites of a protein thus disrupting its normal cellular function. The expression of 
recombinant tagged βDG is no exception. Firstly, the functional processing of βDG is complex, 
with the production of α and βDG from a single propeptide, meaning that recombinant 
expression is best when both α and βDG are encoded for (Ibraghimov-Beskrovnaya et al. 1993, 
Holt et al. 2000). Secondly, the cytoplasmic tail of βDG is proteolytically cleaved and the position 
of the tag therefore needs to be carefully considered (Yamada et al. 2001, Singh et al. 2004, 
Leocadio et al. 2016). Thirdly the cytoplasmic tail is the site of multiple protein interactions and 
functional PTM which a tag could potentially disrupt (Moore et al. 2010, Ilsley et al. 2001, James 
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et al. 2000 Yang et al 1993). Whilst βDG has been expressed with multiple tags including His, 
myc and GFP tags with success it has recently been shown that tags at the C-terminus of βDG 
can affect either the phosphorylation at Y892 or the ability to detect the Y892 phosphorylated 
form of the protein (Leocadio 2014). A flag tag was therefore inserted at a region of no known 
or putative interactions at residue 803, downstream of the NLS (Fig 4.8 A), and has been 
characterised previously by D. Leocadio (Leocadio, 2014). Importantly for this study full length 
43 KDa αβDGflag as well as some high molecular weight species at ~60 and between 130-
250KDa, can be found in the nucleus when transfected into LNCaP cells, as corroborated by Fig 
4.8 B. Low levels of αβDGflag can also be seen in the nucleoplasm, nuclear envelope and nuclear 
foci via confocal microscopy.  Thus αβDGflag can be used to investigate the functions and 
regulation of βDG and its nuclear localisation.  
4.3.4 INVESTIGATING THE PHOSPHORYLATION OF ΒDG 
Phosphorylation is one of the most abundant PTM in the modification of the proteome and the 
reversible nature of the modification often leads to it being referred to as a ‘molecular switch’, 
regulating a diverse array of cellular processes. There was no significant retardation in the 
migration of βDGflag via SDS PAGE when cells were treated with Calyculin A (Fig 4.10), whilst 
this result does not support the reported phosphorylation of βDG at serine and threonine 
residues identified by mass spectrometry studies (Hornbeck et al. 2014) it is unlikely that the 
resolution of the SDS-PAGE gel is sensitive enough to detect changes in migration caused by the 
altered phosphorylation status of a small number of residues. Furthermore a positive control of 
a protein known to be substrates of serine/ threonine phosphatases would verify the activity of 
the Calyculin A. Shifts in migration of βDG have been reported following treatment with both 
Calyculin A and peroxyvanadate together (Leocadio 2014). The identification of two separately 
migrating bands of βDG between 35-55 KDa when run on a phostag gel could indicate 
phosphorylated species of βDG, although additional controls are required to support this 
hypothesis (fig 4.9). Moreover, whilst phosphorylation at Y892 will be represented within these 
bands, as shown by the detection of both bands with pY892 specific 1709 antibody, their 
detection with MDG2, the epitope of which precludes pY892 (James et al. 2000, Ilsley et al. 
2001), suggests the presence of additional sites of phosphorylation of βDG. There is compelling 
evidence for the phosphorylation of additional tyrosine residues to Y892 in the cytoplasmic 
domain of βDG, particularly the evidence presented by Moraz et al. that tyrosine 
phosphorylation but not the Src dependent phosphorylation of Y892 are important for Lassa 
virus internalisation (Ilsley et al 2001, James et al. 2000, Moraz et al 2012). Phosphorylation at 
serine and threonine residues of βDG is less well studied, reciprocal immunoprecipitations for 
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βDG and phospho-serine/ phospho threonine and the use of phospho-site specific antibodies 
would determine if there is further support for phosphorylation at these residues.  
The mapping and validation of sites of phosphorylation of βDG will provide further insight into 
the regulation and functions of βDG and whether these modifications contribute to the 
localisation, stability, signalling scaffold and protein interaction capabilities of βDG.  
4.3.5 CHARACTERISATION OF THE EFFECT OF PHOSPHO-NULL AND PHOSPHO- MIMETIC 
MUTATIONS AT T788 ON THE LOCALISATION OF ΒDG 
To test the hypothesis that phosphorylation at T788 plays a role in the nuclear localisation of 
βDG phospho null (T788A) and phosphomimetic (T788D) mutations were introduced into 
αβDGflag (Fig 4.11).  
The αβDGflag, αβDGflagT788A and αβDGflagT788D all expressed as a band at 43 kDa as well 
as occasional detection of high MW bands at 130- >250 kDa and the 31 and 26 kDa fragments, 
see discussion in previous sections (Fig 4.12 A). After IP for flag proteins the same bands were 
detected with an antibody against βDG and rflag (Fig 4.12 B, C). As to the question of the 
localisation of βDG when mutated at residue T788, it is clear from both biochemical 
fractionation (Fig 4.15) and confocal immunofluorescence microscopy (Fig 4.13, Fig 4.14) that 
the T788D mutant does not target βDG specifically to the nucleus,  but is localised strongly at 
the PM and cytoplasm also. However, it remains possible that phosphorylation at T788 acts 
dominantly and target βDG to the nucleus in a way that T788D is not able to mimic.  Given the 
localisation of αβDGflagT788D, it is possible to hypothesise that phosphorylation at T788 may 
also have a role outside of the nuclear functions of βDG, however this would require 
investigation through further functional analysis. All three αβDGflag constructs have very 
similar localisations and can be detected only faintly in the nucleus. Quantification of the 
biochemical fractionation suggests that the levels of αβDGflag, αβDGflagT788A and 
αβDGflagT788D in the nucleus relative to the rest of the cell is variable and there appears to 
be no effect on the nuclear localisation of βDG in response to the phospho null and mimetic 
mutations at T788. Further in depth confocal analysis alongside markers of subnuclear 
compartments may be useful to assess for any subtle changes to localisation at these sites.  
Although there does not appear to be an overriding role in nuclear localisation for 
phosphorylation at T788, that is not to say that is does not have another functional or 
regulatory role. T788 lies within a stretch of the cytoplasmic domain of βDG that is rich in 
functional binding. In this region there are binding motifs for importin, ezrin and MAPK 
proteins ERK and Mek (Oppizzi et al 2008, Lara-Chacon et al 2010, Spence et al. 2004, 
Batchelor et al. 2007, Moore et al 2010, Vasquez-Limeta et al. 2014). Whilst pT788 is not 
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directly within these sites it is interesting to note that in ELM pT788 is identified as a putative 
binding site, although non-canonical, for Forkhead- associated (FHA) domain containing 
proteins, with another at canonical site at T782. FHA domain proteins have diverse cellular 
functions such as signal transduction and can be found at the PM and in the nucleus where 
they have roles in cell-cycle checkpoint regulation and DNA repair (Weiling et al. 2013). 
Although it is purely speculation it is interesting to consider that pT788 regulates interaction 
with a binding partner, further work would be required to identify if T788 truly is a site of 
protein interaction.  
The migration shift of both T788A and T788D mutants on a phostag gel is minimal and does 
not support a change in the number of phosphorylated species of βDG, however nor it does 
not rule out compensatory  phosphorylation events within βDG (Fig 4.12 D). No evidence has 
been presented to confirm the presence of phosphorylation of βDG at T788, nor how 
accurately the A and D mutants would serve as functional forms of the non-phosphorylated 
and phosphorylated forms of this site respectively. In silico analysis using the NetPhosK 1.0 
server suggests Protein Kinase C (PKC) as a putative kinase responsible for phosphorylation at 
this site, though the surrounding sequence also resembles a non-canonical binding site for 
Polo-like kinase 1 (Plk1) (Kettenbach et al. 2013). In vitro radiolabelling assays could be 
conducted to determine if βDG is a substrate of these kinases. 
4.3.6 THE STABILITY OF RECOMBINANT PROTEINS ΑΒDGFLAG, ΑΒDGFLAGT788A AND 
ΑΒDGFLAGT788D 
It was observed that αβDGflag expression reduced rapidly after transfection (Fig 4.16) whilst 
αβDGflagT788D seemed to persist for longer. The apparent consistency with which this was 
observed led to the hypothesis that the T788D mutation was conferring stability to the 
protein. In CHX chase assays, in which protein synthesis is inhibited, the turnover of αβDGflag 
and αβDGflagT788A were similar whilst αβDGflagT788D, though more variable showed a 
trend of being more stable (Fig 4.17). The half-life of cell surface βDG expressed in HC11 
murine mammary epithelial cells was calculated to be approximately 12 hours (Sgambato et 
al. 2006). Although not a direct comparison of half-life, at 12 hours following CHX treatment 
αβDGflag and αβDGflagT788A are at 43.69 %±1.909 and 48.06 %±3.951 , which is close to the 
50 % level as would be predicted from the previous reports, whilst αβDGflagT788D is at 
75.08± 22.82% of the relative protein level at 0 hours (Fig 4.17 B, C).  There are concerns that 
CHX treatment confers cellular stress and may perturb components of the degradation 
pathway and therefore other measures of protein stability are required.   
It is interesting, however to hypothesise that T788 is part of a phosphodegron motif, 
particularly as it is in close proximity to multiple lysine residues, one of which, K806, is a 
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putative site of ubiquitination (Lee et al. 2011). Further experiments such as the treatment 
with proteasome inhibitor MG132 and identification of ubiquitinated species of αβDGflag, 
αβDGflagT788A and αβDGflagT788D should be investigated to determine if there is a 
differential turnover rate between the mutant forms of βDG.  
The rapid loss of the 130-250 kDa band detected by the flag antibody following CHX treatment 
is interesting and may be that this protein species is being rapidly degraded or proteolytically 
cleaved into smaller fragments.  
4.3.7 SUMMARY 
1. Nuclear morphology is severely aberrant in a DAG null fibroblast cell line.  
2. βDG is in the nucleus of PNT1A, LNCaP and PC3 cells and is localised at the 
subnuclear level at the nuclear envelope, nucleoli and nucleoplasm.  
3. βDG is phosphorylated.  
4. Phospho null and phospho mimetic mutations at T788 do not affect nuclear 
localisation of βDG and both mutants are found localised at the plasma membrane, 
cytoplasm and nucleus.  


















Chapter 5: The cell cycle and nuclear 
dystroglycan 
5.1 INTRODUCTION 
5.1.1 THE CELL CYCLE  
 The cell cycle is a complex series of sequential events that results in the duplication of genetic 
material and division of a cell. The progression of a cell through the division cycle is 
fundamentally interlinked with a vast array of cellular processes including differentiation, 
migration and adhesion (Walker et al. 2005, Shen et al. 2001, Lovisa et al. 2015, Giancotti 
1997, Pugacheva et al. 2006). The correct coordination of these events alongside regulated cell 
death is required for normal development and adult homeostasis (Budirahardja et al. 2009, 
Caldon et al. 2010, Frisch et al. 1994). When the cell cycle process is disrupted it results in the 
aberrant proliferation of cells and is responsible for numerous human diseases, including 
cancer (Sherr. 1996, Stoker et al 1968, Malumbres et al. 2009).  
5.1.1.1 The phases of the cell cycle 
The phases of the eukaryotic cell cycle are well defined, discrete events. Cells spend the 
majority of their life cycle in interphase which consists of GAP phase 0 (G0), GAP phase 1 (G1), 
Synthesis (S) and GAP phase 2 (G2).  During G1 the cell grows in size, synthesises proteins and 
RNA and duplicates cellular organelles in preparation for the division of the cell. During G1 a 
cell can make the decision to exit the cell cycle and exist in a quiescent state in G0, which may 
be as a consequence of terminal differentiation or if the conditions are not favourable to cell 
division. In S phase the DNA is duplicated, resulting in replicates of 2 sister chromatids of each 
chromosome. G2 follows S phase and is a further period of growth. Following interphase the 
cell enters into mitosis (M phase), with the replicated chromosomes being divided into two 
identical nuclei. Mitosis can further be divided into distinct phases, namely prophase, 
prometaphase, metaphase, anaphase and telophase and finally cytokinesis; the division of the 
cytoplasm and the separation of the two daughter cells (Fig 5.1) (Duronio et al. 013, 












5.1.1.2 Regulation of the cell cycle 
The cell cycle proceeds through tightly regulated checkpoints, the purpose of which is to 
monitor if conditions are conducive to cellular proliferation and to prevent propagation of 
damaged or an incorrect amount of DNA (Budirahardja et al. 2009, Malumbres et al. 2009). 
There are three key checkpoints in the cell cycle. A G1 checkpoint, known as the restriction 
point in mammalian cells, in which cells assess nutrients, cell size, DNA damage and growth 
factors, if these conditions are favourable it is at this restriction point that a cell will commit to 
the cell cycle (Malumbres et al. 2009, Duronio et al. 2013). There is also a G2 checkpoint in 
which the cell again verifies cell size and the accuracy of DNA replication and a spindle 
assembly checkpoint in mitosis to verify spindle attachment to the chromosomes which is 
crucial for correct chromosome segregation (Malumbres et al. 2009, Mussachio et al. 2007).  
The basic cell cycle machinery driving unidirectional progression of the cell cycle are the 
heterodimeric complexes of cyclins and cyclin dependent kinases (CDKs) (Nurse et al. 1976). 
Cyclins are the regulatory subunit whilst CDKs are catalytic. The levels of the specific cyclins 
peak at specific stages of the cell cycle, only when bound to its cyclin regulator can the 
constitutively expressed CDKs phosphorylate target proteins to coordinate entry into the next 
phase of the cell cycle. Cyclin dependent kinase inhibitors (CDKIs) are a further subset of cell 
cycle regulatory proteins which inhibit the activity of the cyclin-CDK complexes (Duronio et al. 
2013, Sherr et al. 1999). Crucially the cell must be able to sense the surrounding environment 
and respond appropriately to the external cues with regards to its decision to enter the 
proliferative cycle. This requires the convergence and integration of signals from multiple 
mitogenic signalling pathways, cytokines, Notch and Wnt signalling and signalling from ECM 
receptors all of which can ultimately regulate the cell cycle machinery (Duronio et al. 2013., 
Nelson et al. 2002, Moreno-Layseca et al. 2014, Zhang et al. 2002, Torii et al. 2006) 
5.1.2 THE CELL CYCLE AND ADHESION RECEPTORS 
During the cell cycle cells undergo vast changes in shape, size, metabolism and signal 
transduction (Duronio et al 2013, Budirahardja et al. 2009, Malumbres et al. 2009, Walker et 
al. 2005). Inevitably timely progression of the cell cycle requires the tightly controlled but 
dynamic regulation of numerous proteins (Balk et al. 2008, Moir et al. 2000, Dabauvalle et al. 
1999, Caldon et al. 2010). The interdependence of the cell cycle and adhesion proteins is a 
well-studied process (Pugacheva et al. 2006, Walker et al. 2005.). It is known that the 
attachment of cells to adjoining cells or their substrate modulates the progression of cells 
through the cell cycle (Nelson et al. 2002, Frisch et al. 2001) and concurrently the transition of 
cells into certain phases, is matched by distinct alterations in the adhesion properties of these 
cells (Pugacheva et al. 2006). During mitosis the majority of focal adhesions are disassembled, 
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and the actin skeleton is reorganised, whilst in adherent cells, during cytokinesis, the correct 
localisation of adhesion receptors at the PM is necessary for reattachment (Yamakita et al. 
1999, Walker et al. 2005, Kunda et al. 2009, Pugacheva et al. 2006). Additionally, a number of 
adhesion receptors have been implicated in the signalling pathways required for G1-S 
transition (Giancotti et al. 1997, Tetsu et al. 1999, Hamaratoglu et al. 2006). 
 The integrin family of adhesion receptors are a prime example of the interplay between ECM 
adhesion receptors and the cell cycle. Integrins bind to components of the ECM and recruit 
binding partners such as FAK, talin and even growth factor receptors such as PDGFR or EGFR 
(Pugacheva et al. 2006, Nobes et al. 1995, Walker et al.2005, Moro et al. 1998). Integrins 
mediate cell cycle progression by triggering signalling cascades such as the mitogenic Ras-raf-
MEK-ERK cascade as well as by modulating the signalling of growth factor receptors, ultimately 
contributing to regulation of the cell cycle machinery, particularly the transcription and 
stabilisation of cyclin D and therefore G1 to S phase cell cycle progression (Moro et al. 1998, 
Chambard et al. 2007, Moreno-Layseca et al. 2014, Torii et al. 2006).  
The cadherin family of proteins involved in adherens junctions also demonstrate a role in 
proliferation. Cadherins can inhibit proliferation via lateral contact inhibiton by sequestering 
intracellular binding partners such as β-catenin in the classical cadherin pathway (Pugacheva et 
al. 2006). In response to signals such as the wnt pathway or when adherens junctions are 
disassembled, β-catenin is released from the membrane bound complex (Masckauchan et al. 
2005, George et al. 2004). The cytoplasmic β-catenin can then translocate to the nucleus 
whereby it interacts with members of the T-cell factor (TCF) family of transcription factors to 
initiate transcription of a number of target genes, including those involved in proliferation such 
as cyclin D1 (Tetsu et al. 1999). Interestingly a number of cell surface receptors themselves 
have demonstrated a cell cycle dependent nuclear translocation or to perform specific 
functions. Although not adhesion receptors, some of the best characterised examples are 
EGFR and FGFR, both of which have been detected transiently in the nucleus during G1 
(Planque 2006, Lo et al. 2005, Schausberger et al. 2003).    
Given the overlap between the cell cycle and adhesion, it is not surprising that certain proteins 
can contribute to, and are regulated by, both of these processes. Importantly, the relationship 
between cell attachment and proliferation is implicated in cancer biology and many adhesion 
proteins are aberrantly regulated in cancer. In these cases both the lack of adhesion and 
disrupted regulation of signalling pathways can contribute to the cancer phenotype. Therefore, 




5.1.3 NUCLEAR MORPHOLOGY AND THE CELL CYCLE 
Whilst the cell undergoes vast morphological changes during the cell cycle, so too does the 
nucleus (Foisner 2003, Tsai et al. 2014). In mammalian cells during interphase the nucleus 
maintains an intact nuclear envelope that functions to partition and regulate the exchange of 
proteins, mRNA and DNA between the cytoplasm and nucleus. In interphase the nucleoli are 
present as dense structures (Hernandez-Verdun 2011). During interphase the nuclear 
membrane and the nuclear lamina are relatively stable. There is, however, still a dynamic 
regulation of components for example in G1 there is an increase of Lamin A in the nucleoplasm 
before incorporation into the growing nuclear lamina (Moir et al. 2000a, Moir et al. 2000b).  
The most dramatic changes to the nuclear morphology, however, occur at the onset and 
conclusion of mitosis. In vertebrates open mitosis requires the breakdown of the nuclear 
envelope (Foisner 2003). In this process the nuclear lamina depolymerises, the nuclear 
membrane fragments and the nuclear pore complexes are disassembled. A key regulator of 
nuclear lamina depolymerisation is the phosphorylation of the lamins and lamina proteins by 
mitotic kinases such as Cdk1 and PKC (Moir et al. 2000a, Nikolakaki et al. 1997, Ottaviano et al. 
1985). Phosphorylation promotes disassembly of the lamins and dissociation of lamina 
proteins from the chromatin (Foisner et al. 1993). Microtubules are believed to play a role in 
the fragmentation of the nuclear envelope, creating a tension that pulls the nuclear membrane 
apart (Gonczy 2002, Salina et al. 2002, Beaudouin et al. 2002). During mitosis A type lamins are 
released into the cytoplasm and diffuse whereas B type lamins remain associated with 
membrane fragments and potentially with the lamin B receptors (LBR) via their C-terminal 
farnesyl modification (Foisner 2003, Meier et al.1994, Ye et al. 1994). The membrane 
fragments merge into the ER with a few studies suggesting that the nuclear membrane can be 
incorporated into vesicles with differing populations accommodating membrane fragments 
from different origins (Dabauvalle et al. 1999, Ellenberg et al. 1997, Yang et al. 1997, Maison et 
al. 1993). Similarly, the nucleolus is disassembled in early prophase prior to NEBD (Hernandez-
Verdun 2011). Components of the ribosomal machinery around which the nucleolus is formed 
are phosphorylated by mitotic kinases promoting their release (Negi et al. 2006). A number of 
proteins normally associated with the nucleolus form a perichromosomal matrix during 
mitosis, hinting at some form of remaining association (Gautier et al. 1992). 
During the formation of the new daughter cells the nuclear envelope must be reformed 
around the divided chromosomes. This requires the targeting of the nuclear envelope 
components to the surface of the chromosomes and the fusion of the membranes. It has been 
shown that the reformation of the nuclear envelope is a tightly regulated, sequential process 
requiring a complex array of interactions between the chromatin and nuclear envelope 
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components (Foisner 2003). For example, it has been shown that as early as late anaphase, 
LEM domain containing lamina binding proteins such as lamina associated polypeptide 2 
(LAP2), and emerin accumulate around the chromatin whereby they can bind to the 
chromosomal protein barrier-to-autointegration factor (BAF) (Haraguchi et al. 2001, 
Dabauvalle et al. 1999, Lee et al. 2001, Manilal et al. 1998, Foisner 2003) LBR can also associate 
with chromatin binding proteins and bind to the DNA itself, thus targeting components of the 
nuclear envelope to the chromatin (Ye et al. 1994). A hierarchical recruitment of other NE 
components then follows with components of the nuclear pore complex, then B type lamins 
followed by A type lamins being assembled into the nuclear envelope (Bodoor et al. 1999, 
Haraguchi et al. 2000). The early stages of nuclear envelope assembly are often regulated by 
dephosphorylation events (Thompson et al. 1997), whilst the later events of membrane fusion 
have been shown to require Ran GTPase activity (Hetzer et al. 2000). The nucleoli start to 
reform in telophase and require the coordinated recruitment and activation of rDNA 
transcription and RNA processing complexes around which the dense nucleoli structures form 
(Hernandez- Verdun 2011, Tsai et al. 2014). 
5.2 DAPC COMPONENTS AND THE CELL CYCLE 
The interplay of components of the DAPC and the cell cycle has been studied by multiple 
groups. It has been shown that depletion of Dp71 in PC12 cells caused a delay in cell 
proliferation, with flow cytometric analysis identifying a subtle delay at the G0/G1 transition 
(Villarreal-Silva et al. 2011). Furthermore, during cytokinesis Dp71 was found to localise to the 
midbody and cleavage furrow where it colocalised with lamin B1 and βDG (Villarreal-Silva et al. 
2011). Additionally, β-dystrobrevin depletion in C2C12 myoblasts perturbed cell cycle 
progression with an increased number of cells in G0/G1 and reduced cells in S phase relative to 
the controls (Aguilar et al. 2015). Furthermore, there was a decrease in cells actively 
synthesising DNA, as detected by BrdU analysis, in the β-dystrobrevin knockdown cells (Aguilar 
et al. 2015).  
5.3 DYSTROGLYCAN AND THE CELL CYCLE 
5.3.1 Dystroglycan and proliferation 
There are multiple studies linking the cell cycle to dystroglycan expression and localisation.  An 
initial study by Hosokawa et al. demonstrated that overexpression of full length βDG reduced 
the growth rate of bovine aortic endothelial cells (BAE), whilst expression of a cytoplasmic 
fragment of βDG increased proliferation, an early hint at a complex relationship between the 
cell cycle and βDG (Hosokawa et al. 2001). The study went on to further show that βDG levels 
increased in proliferating cells compared to quiescent cells and that this level fluctuated in 
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synchronised cells, increasing as the cells entered S phase and then decreasing (Hosokawa et 
al. 2001). A dynamic regulation of βDG in the cell cycle was further supported by Sgambato et 
al. working on murine mammary HC11 cells.  The authors demonstrated that in synchronised 
cells the level of DG at both mRNA and protein levels fluctuated in a cell cycle dependent 
manner, again peaking at S phase (Sgambato et al. 2006). Interestingly, whilst βDG peaked at S 
phase, the levels of αDG appeared to decrease progressively after release into the cell cycle, 
thus suggesting differential regulation of the two subunits, and indicating that regulation is 
occurring at the post-transcriptional and post-translational level (Sgambato et al. 2006). The 
reduction in levels of αDG upon growth stimulation has also been seen when rat thyroid cells 
were stimulated by thyrotropin (TSH) (Collins et al. 2001).  In the case of the HC11 cells, 
reduction of βDG via RNAi resulted in a slower rate of proliferation with an increased number 
of cells in S phase and accordingly there was increased levels of cyclin D and E and a reduction 
of CDKI p27Kip in these cells (Sgambato et al. 2006). 
 Multiple other groups have also reported altered proliferation rates upon modulating the 
levels of βDG. In swiss 3T3 cells reduced levels of DG resulted in lower proliferation rates, 
further analysis demonstrated that these cells had a delayed entry into S phase where they 
then persisted longer, also demonstrating a delayed transition into G2M (Higginson et al. 
2008). Mitchell et al. demonstrated a complex relationship between DG levels and 
proliferation rate, in prostate cancer cell line PC3 both RNAi depletion and overexpression of 
βDG resulted in similarly reduced proliferation rates, proliferation was also reduced in DU145 
prostate cancer line upon RNAi KD of DG (Mitchell, 2010, thesis). In the case of LNCaP cells 
overexpression of DG reduced proliferation whilst knockdown increased proliferation by 
approximately 25%.  
5.3.2 Dystroglycan modulation of cell cycle signalling cascades 
The ways in which DG could exert its influence on the cell cycle are not well understood 
however, one route is through its signal transduction properties. DG acts as a scaffold for 
MAPK signalling cascade molecules MEK and ERK, modulating their spatial and temporal 
activity (Spence et al. 2004). In Swiss 3T3 cells in which DG was depleted by RNAi and the cell 
cycle disrupted, there was also a 50% reduction in the levels of ERK. Similarly, a reduction in 
the phospho-ERK and phospho Mek was detected in HC11 cells depleted for DG via RNAi 
(Higginson et al. 2008, Sgambato et al. 2006). The Ras-MEK-ERK MAPK signalling cascade is a 
well characterised regulator of cellular proliferation (Chambard et al. 2007, Zhang et al.2002) 
and it is therefore tempting to speculate that DG may in part affect the cell cycle through its 
modulation of ERK signalling pathways. 
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 Additionally, levels of PTEN were decreased whilst Akt and phospho-Akt levels were increased 
in DG depleted HC11 cells (Sgambato et al. 2006). PTEN is a phosphatase agonist of PI3K 
activity and can induce arrest in G1 via its inhibition of the Akt pathway (Ramaswamy et al. 
1999, Radu et al. 2003). The DGC and βDG have previously been shown to modulate the 
PI3K/Akt signalling pathway when inhibited from binding to laminin (Langenbach et al. 2002, 
Yongmin et al. 2009). Activated Akt has been implicated in the inhibition of CDKI p27kip1 as 
well as promoting translation and nuclear localisation of cyclin D1 (Duronio et al. 2013). Thus 
demonstrating another pathway linking DG and the cell cycle. 
The contribution of DG to signalling cascades is likely to be complex to dissect given its ability 
to modulate multiple pathways directly as well as indirectly through other DGC components 
and even more so given the high levels of cross-talk between the signalling pathways. For 
example, integrins also modulate the Ras-MEK-ERK signalling cascade and it has been shown 
that DG can act as a suppressor of laminin mediated integrin α6β1 activation of the ERK 
signalling pathway (Ferletta et al. 2003). 
5.3.3 A role for Dystroglycan in cytokinesis 
βDG has been reported to localised to the midbody and cleavage furrow during cytokinesis in a 
number of cell lines including swiss 3T3, Ref52 and Hela cells, colocalising with the contractile 
F-actin ring in dividing cells (Higginson et al. 2008). DG and ezrin are known interacting 
partners and were found to colocalise at the midbody and cleavage furrow (Batchelor et al. 
2007, Higginson et al. 2008). Ezrin and other ERM family members have been shown to 
organise the actin cytoskeleton and recruit other transmembrane adhesion receptors, such as 
CD43, to the midbody during cytokinesis (Fehon et al. 2010, Solinet et al. 2013, Yonemura et 
al. 1998, Yonemura et al. 1993). When the cytoplasmic ezrin binding site of βDG was deleted 
the localisation at the midbody at later stages of cytokinesis was reduced (Higginson et al. 
2008). In the DG knockdown cells there was, however, no disruption to the actin, microtubule 
or intermediate filament cytoskeletons and no observed cytokinetic defects, demonstrating 
that low levels of DG do not prevent cytokinesis (Higginson et al. 2008). Interestingly, ERK 
signalling has also been reported to be important for midbody abscission (Kasahara et al. 
2007), thus it is tempting to speculate that βDG could contribute mechanically and via its 
signalling capabilities to midbody function in cytokinesis. 
In the small number of studies in which the localisation of βDG in mitosis has been addressed, 
the focus has been largely of the dominant pool of βDG at the plasma membrane, as described 
above. However, given the emerging role of a small population of βDG at the nuclear envelope 
and its interactions with components of the nuclear lamina it would be interesting to try to 
address the localisation and dynamics of this population of βDG during mitosis. 
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5.3.4 A role for the cell cycle in the nuclear accumulation of βDG? 
In a number of studies it has been reported that the level of nuclear βDG is variable within an 
asynchronous population (Mitchell et al. 2013, Mathew et al. 2013, Leocadio et al. 2016, 
Martinez-Vieyra et al. 2013). As previously mentioned, in a recent study in the Winder lab it 
was observed that stimulation of the androgen sensitive prostate cancer cell line, LNCaP, with 
the androgen dihydrotestosterone (DHT) stimulated a strong nuclear accumulation of βDG and 
that this nuclear accumulation fluctuated in a time dependent manner after androgen 
stimulation (Mathew et al. 2013, Mathew 2011 Thesis).  Roles for AR regulation of βDG have 
previously been reported. Sgambato and colleagues observed that primary tumour samples 
from prostate cancer patients treated with the anti-androgen flutamide demonstrated 
reduced levels of α- and βDG at the cell surface (Sgambato et al. 2007). Studies in LNCaP cells 
showed that upon androgen stimulation both DG mRNA and βDG protein levels increased in a 
dose and time dependent manner indicating that androgens were regulating DG at a 
transcriptional level (Sgambato et al. 2007). The effect of androgens could be explained by the 
finding that, the DAG1 gene contains an Androgen Responsive Element (ARE) in its promoter 
region (Sgambato et al. 2007, Mathew et al. 2013). 
When a ligand binds to the androgen receptor (AR) the receptors dimerise to form AR 
homodimers. The homodimers are then phosphorylated, after which the ARs translocate to 
the nucleus, binding to AREs of target genes promoting their transactivation (Balk et al. 2008, 
Koryakina et al. 2015). It has been shown that the AR can act as shuttle to transport proteins 
into the nucleus as is the case with β-catenin (Mulholland et al. 2002). It is tempting to 
propose a similar hypothesis regarding AR shuttling of βDG to the nucleus, however, rigorous 
investigation did not detect an interaction between the AR and βDG (Mathew et al. 2013).                                                                                                                                                                                                                                                                                                                                                                                          
LNCaP cells are androgen responsive and are stimulated to proliferate upon DHT treatment 
(Horoszewicz et al. 1983, Murthy et al. 2013). There is a large amount of cross talk between 
the AR signalling axis and the cell cycle pathways, with AR both contributing to and being 
modulated by the cell cycle. p21cip ,a cyclin is a direct target of the AR and is transcriptionally 
upregulated upon AR activation. Cyclin D expression is increased upon AR stimulation through 
increased translation through the mTOR pathway as well as through promoting the activity of 
mitogenic signal transduction pathways such as MAPK. (Koryakina et al. 2015, Balk et al. 2007). 
The androgen studies required the serum starvation and consequently synchronisation of the 
LNCaP cells at G0/G1 and are subsequently released into the cell cycle upon DHT treatment 
(Mathew et al. 2013). Fluctuation of nuclear βDG levels was also observed when serum starved 
and synchronised LNCaP cells were released into the cell cycle via addition of serum (Mathew 
2011. Thesis). Importantly, βDG can be found in the nucleus at varying levels in cell lines that 
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do not express AR such as the AR negative prostate cancer PC3 cells, C2C12 myoblasts and 
Hela cells (Mitchel et al. 2013, Martinez- Vieyra et al. 2013, Lara- Chacon et al. 2010). Thus 
whilst AR and βDG association in complexes along with other proteins and a role for this in the 
nuclear translocation of βDG cannot be excluded, it is interesting to hypothesise that the 
fluctuating levels of βDG in the nucleus were a consequence of the mitogenic effects of the 
androgen and the progression of the cells through the cell cycle, rather than a direct response 
to the androgen pathway itself.  
Given the high level of interdependence between βDG expression and localisation with the cell 
cycle and the observation of fluctuating level of nuclear βDG in synchronised proliferating cells 
we therefore hypothesised that there is a cell cycle dependent nuclear translocation of βDG. 
5.1.4 CHAPTER AIMS 
The aims of the research conducted in this chapter are: 
- To investigate the levels and localisation of β-dystroglycan at different stages of cell 
cycle progression in prostate cell lines. 
- To investigate if the level of β-dystroglycan in the nucleus is regulated in a cell cycle 
dependent manner. 
- -To investigate the localisation of βDG in mitotic LNCaP cells. 
   
5.2 RESULTS 
5.2.1 PROLIFERATION OF LNCAP CELLS 
The level of βDG in the nucleus of LNCaP cells in an asynchronous population is variable 
(Mitchell et al. 2013, Leocadio et al. 2016). Furthermore, a time dependent fluctuation in the 
nuclear levels of βDG could be detected upon the stimulation of synchronised cells with 
androgen or serum (Mathew et al. 2013). Given these observations, LNCaP cells were chosen 
as the main model in which to test the hypothesis of a cell cycle dependent regulation of 
nuclear βDG in this project. Growth curves of LNCaP cells in standard growth conditions of 
RPMI media supplemented with 10% FBS were conducted to determine the proliferation 
profile and rate of LNCaP cells. LNCaP cells were seeded at a density of 2.5 x103 cells/ cm2 in 12 
well plates. The cell number per well was calculated every two days for 12 days with an 
average of 4 wells taken per time point (Fig 5.2). 2.5 x103 cells/ cm2 is a low density of cells and 
in these conditions the lag phase of growth is relatively long with a slow increase in growth up 
to 6 days after seeding (Fig 5.2). Cells reach exponential growth between 8 and 10 days (Fig 
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5.2) when seeded in these conditions and the doubling time during this phase was calculated 
to be 33.62 hours, which is within the 32-34 hour doubling time of LNCaP cells reported in the 










Figure 5.2. LNCaP growth curve. LNCaP cells were seeded at a density of 2.5 x 103 cells per cm2 in a 12 
well plate and grown in RPMI, 10% FBS for 12 days. The number of cells per well were counted every 2 
days using the automated CasyCounter and the number of cells per cm2 calculated. In each experiment 
the number of cells from 4 wells was counted at each time point and an average calculated. The graph 
depicts the averages of 4 independent experiments. Error bars are S.E.M.  
5.2.2 THE LEVEL OF Β-DYSTROGLYCAN FLUCTUATES IN A CELL CYCLE DEPENDENT MANNER IN 
THYMIDINE SYNCHRONISED LNCAP CELLS 
A useful tool in the study of cell cycle events is the synchronisation of cell populations, 
enabling the clarification and enrichment of specific cell cycle stages. Preliminary studies with 
serum starvation resulted in poor synchronisation and slow progression of the LNCaP cells 
back into the cell cycle (Data not shown) therefore synchronisation of LNCaP cells with a 
double thymidine block was implemented. Thymidine is a pyrimidine nucleoside, high 
concentrations of which disrupt the deoxynucleotide metabolism pathway and DNA 
replication, thus arresting the cells at the G1/S phase border in the cell cycle (Bootsma et al. 
1964). Thymidine synchronisation of cells is well studied and is useful in the study of S phase 
events (Bostock et al. 1971, Thomas et al. 1975), an additional reason it was chosen for this 
study given previous reports of increased levels of βDG in S phase (Sgambato et al. 2008, 




5.2.2.1 Double thymidine block and synchronisation of LNCaP cells. 
LNCaP cells were treated with 2mM thymidine for 18 to 32 hours to investigate the effect of 
thymidine treatment on LNCaP cell cycle distribution and determine the optimal length of 
treatment for subsequent synchronisation experiments. In asynchronous populations of LNCaP 
cells the majority of the cells exist in G1/G0 phase (~75- 80%), with small populations in S 
Phase (9.3-13.2%) and ~ 10% in G2M. Upon treatment with thymidine there was an increase in 
the population of cells in S phase, which increased with longer thymidine treatment (Appendix 
C, Fig C.1). At 32 hours of thymidine treatment 33.4% of the cells were in S phase, 60.9 % in G1 
and 5.8% in G2M. It would be expected that upon thymidine treatment cells would arrest at 
G1/S transition, with the cells in S phase at the time of treatment arresting in S phase. It can be 
seen, however, in the longer treatments of thymidine that there is an increase in the number 
of cells progressing further into S phase, suggesting a ‘leakiness’ of the synchronisation at the 
G1/S phase transition as has previously been described by Bostock et al. (Bostock et al. 1971). 
Double thymidine blocks are often used to achieve a greater synchrony of a population of cells. 
LNCaP cells were blocked first with thymidine for 32 hours. 32 hours was chosen because it 
resulted in a high number of cells in G1 and S phase and because this is the proposed length of 
LNCaP doubling time, therefore, during the treatment, the majority of the cells should have 
passed through the cell cycle to reach the G1/S transition at which the thymidine block acts. 
The cells were then washed and incubated with fresh media. A release period of 9 hours was 
chosen as this should be sufficient for the cells to progress out of S phase before a second 
2mM thymidine treatment of 22 hours to enable the cells to move through G2 and M into G1 
to arrest at the G1/S boundary (Murthy et al.2013). Cells were then released into the cell cycle 
and populations collected every 2 hours for 14 hours. (Fig 5.3A). The cell cycle distribution and 
progression of the LNCaP populations following release was monitored via propidium iodide 
staining and flow cytometry analysis (Fig 5.3.B.C and Appendix C, Fig C.2) and immunoblots for 
the phase specific cyclins. The intensity of the bands was determined by densitometry analysis 
and normalised to the GAPDH loading control. In order to combine the replicates, for each 
independent experiment each normalised intensity value was then calculated relative to the 
highest normalised intensity in the time course. Cyclin A1 was not quantified because of the 





Figure 5.3. Double thymidine block synchronisation of LNCaP cells and cell cycle progression. A) 
Cells were grown for 48 hours and then treated with 2mM Thymidine for 32 hours. Cells were 
released by addition of fresh media for 9 hours and then blocked for a further 22 hours with 2mM 
Thymidine. Cells were released into the cell cycle via the addition of fresh media and collected every 
two hours over 14 hours. Control 1 and control 2 were PBS control treatments at 0 hr and 14 hours 
respectively.  The collected cells were harvested for lysate collection or ethanol fixed, stained with 
propidium iodide and analysed for cell cycle distribution via flow cytometry. B , C)The average 
number of cells at each phase of the cell cycle at each time point. N=4. D) Representative image of 
immunoblots of total cell lysates collected from double thymidine block synchronised LNCaP cells at 
each time point and immunoblotted for cyclins D3, E1, A2 and B1 and a GAPDH loading control. E) 
Quantification of cyclin immunoblot levels. The intensity of the bands was determined via 
densitometric analysis and was normalised to GAPDH. Each time point was then found relative to the 
level of the highest expression in each experiment. Mean values and S.E.M are displayed. Cyclin E1 




There was a tighter accumulation of cells at the G1/S transition at 0 hours than seen with the 
single treatments. The LNCaP cells had the highest population of cells in S phase (~25%) at 2 to 
4hours post release which tallied with cyclin E1 expression (marker of G1-S transition), which 
was present in all of the samples, but was strongest at 0 to 4 hours (Fig 5.3). Cells peaked at 
G2M at 6- 8 hours post release, with 28.2-35.6 % in G2M population with cyclin A (late S 
through M) and cyclin B1 (M) detected at 6-10 hour and 6-8 hours respectively before moving 
back into G1 (~76%) at 12 hours (Fig 5.3). Cyclin D1 expression was variable throughout which 
can be expected given the high levels of G1 population see throughout the time course. 
Although the results were relatively reproducible it must be noted that at each time point the 
majority of the cells were in G1 phase, which does not fall below 50% (Fig 5.3). Therefore, 
when interpreting results of the double thymidine synchronisation, it must be remembered 
that it is a mixed population of cell cycle phases, with what appears to be the synchronised 
progression of a sub-population of the cells through the cell cycle. Further optimisation of 
timing or different synchronisation techniques such as Isoleucine or nocodazole block, would 
likely enhance the synchronisation of the cell cycle enrichment of specific cell cycle phases.   
5.2.2.1 βDG protein levels fluctuate in double thymidine synchronised LNCaP cells. 
There is a complex relationship between dystroglycan and the cell cycle, including a role for 
the cell cycle in the expression of DG (Sgambato et al. 2008, Hosokawa et al. 2001). In order to 
determine if the βDG protein level varied as LNCaP cells progressed through the cell cycle after 
release from the thymidine block total cell lysates were collected at each time point and 
immunoblotted for both βDG and pY892 βDG. There is a strong expression of full length βDG 
and pY892 βDG across all of the time points collected with a slight, variable increase at 2 to 6 
hours (Fig 5.4). There did not appear to be any clear changes in the faint high and low 
molecular weight species of βDG or pY892 βDG detected. When the levels of 43 KDa βDG and 
pY892 βDG were quantified as described above for the cyclins and the mean calculated, it 
showed an increase at 4 hours post release, correlating to a time point at which the amount of 
cells in S phase was at its highest at 25.8%±1.2 (Fig 5.4, Fig 5.3). The relative level of βDG and 
pY892 βDG following densitometric quantification at each time point is variable and for each 
independent replicate the highest expression level did not always correlate with the highest S 
phase containing time point (Fig 5.4, Appendix C.3). Given the variability between the 
independent replicates this experiment does not provide conclusive support for an increased 
level of βDG at S phase in LNCaP cells. The GAPDH levels are also variable within and between 
the individual replicate experiments and may be a contributing factor to the trend observed in 





Figure 5.4. βDG and pY892 βDG levels in total cell lysates from thymidine synchronised LNCaP cells. A) 
Immunoblot of total cell lysates collected from double thymidine block synchronised LNCaP cells at each 
time point and immunoblotted for βDG and pY892 βDG and a GAPDH loading control. Arrows indicate 
full length 43 KDa βDG. B) Quantification of 43 KDa βDG and pY892 βDG immunoblot levels. The 
intensity of the bands was determined via densitometric analysis and was normalised to GAPDH. Each 
time point was then found relative to the level of the highest expression in each experiment. Mean 









Figure 5.5. βDG and pY892 βDG levels relative to cell cycle phase percentages. The relative level of βDG 
(left) and pY892 βDG (right)as determined via immunoblot were plotted against the percentage of cells 
in G1 (top), S (middle) or G2M (bottom) as determined by flow cytometry at each time point. Data from 
each replicate are represented by a different shape. Correlation and statistics were calculated via 








To assess the relationship between βDG level and the cell cycle phases in further detail, the 
relative level of full length βDG and pY892 βDG was plotted against the percentage of cells in 
each of the cell cycle phases at that time point for each individual experiment (Fig 5.5). The 
scatter plots all show relatively dispersed data. Spearmans correlation test was used to 
determine if there was a correlation between the level of βDG and the percentage of cells in a 
specific phase of the cell cycle. A non-parametric test was used as not all of the data sets were 
normally distributed, as determined by two different normality tests and frequency 
distribution histograms (not shown). The rs value provides a measure of the degree of 
correlation with 1 being a strong, positive correlation and -1 being a strong, negative 
correlation. Weak, positive correlations were found to be statistically significant in S phase for 
both βDG and pY892 βDG. In G1 and G2M analyses the correlations were very weak and not 
statistically significant (Fig 5.5). Although this analysis must be interpreted carefully, as the 
protein level is a combination of the entire population of cells and has been normalised to 
GAPDH, it hints at an increased level of βDG within cells with higher S phase populations, this 
is supported by the previous reports in the literature in which βDG is increased at both the 
DNA and protein level in S phase in HC11 and BAE cells (Sgambato et al. 2008, Hosokawa et al. 
2001). If time permitted it would be important to repeat the western blot experiments with 
populations better synchronised or enriched for the specific cell cycle phases in LNCaP and 
other cell lines to see if the changes in βDG expression level could be verified further. 
Furthermore, it would have been interesting to assess the levels of mRNA to determine if the 
cell cycle dependent regulation was occurring at the transcriptional level. 
5.2.3 THE LEVEL OF NUCLEAR Β DYSTROGLYCAN IN CELL CYCLE PROGRESSING CELLS 
FOLLOWING THYMIDINE SYNCHRONISATION. 
 
In order to determine if the level of βDG in the nucleus varied as the LNCaP cells progressed 
through the cell cycle the LNCaP cells were synchronised with a double thymidine block as 
described above and subject to biochemical fractionation to obtain non-nuclear and nuclear 
fractions at each time point. The cell cycle distribution was determined at each time point via 
fixation and propidium iodide staining of the populations, followed by flow cytometry analysis 
(Fig 5.6). The non-nuclear and nuclear fractions were immunoblotted for βDG and pY892 βDG 
(Fig 5.7, Fig 5.9). GAPDH and lamin A/C were included as markers of the purity of the 
fractionation for the non-nuclear and nuclear fractions respectively and showed clean 
fractionation. It should be noted that in the G2M populations, whilst G2 nuclei are likely to be 
fractionated cleanly, there is not an intact nucleus to separate in mitotic cells. Further 




Figure 5.6 Double thymidine block synchronisation of LNCaP cells and cell cycle progression for 
fractionation experiments. Cells were synchronised via double thymidine block as previously described, 
The collected cells were harvested for fractionation or ethanol fixed, stained with propidium iodide and 
analysed for cell cycle distribution via flow cytometry.A, B)The average number of cells at each phase of 
the cell cycle at each time point. N=2.  
Full length 43 KDa βDG in the non-nuclear fraction was slightly higher at 0 to 6 hours post 
release before decreasing variably between the two repeats (Fig 5.7, Appendix C.4). In the 
nuclear fractions the level of full length βDG was more variable both within and between 
replicates (Fig 5.7, Appendix C.4). Whilst the expression of βDG was consistently high at 4 
hours and reduced at 0 and 14 hours, the remaining time points demonstrated significant 
variability. The increase in the level of βDG again overlapped with the time points of the 
highest levels in S phase at 22.5-23.4% at 2-4 hours post release (Fig 5.7, Fig 5.6). The intensity 
of the full length βDG was determined by densitometry analysis and normalised to GAPDH or 
the top band of the lamin A/C for the non nuclear and nuclear fractions respectively and then 
found relative to the highest intensity in that experiment (Fig 5.7 B, C). Normalising to lamin 
A/C is not an ideal loading control as lamins are regulated in a cell cycle dependent manner 
with regards to their phosphorylation and distribution (Moir et al. 2000). The effect of the cell 
cycle on the level of lamin total expression is less clear and thus this quantification should be 
interpreted critically as a means to normalise the expression for loading. However, it was 
attempted to load the same amount of nuclear extracts and quantification without 
normalisation and normalising to nucleolin, which also is dynamically regulated in the cell 
cycle, shows the same trend (Data not shown). To gain more confidence in the observation of 
a potential increased nuclear level of βDG at time points correlating with higher levels of S 
phase cells more repeats are needed unfortunately, despite repeated attempts, only two 






Figure 5.7. βDG levels in non- nuclear and nuclear fractions of thymidine synchronised LNCaP cells. A) 
Immunoblot of non-nuclear (left) and nuclear (right) lysates collected from double thymidine block 
synchronised LNCaP cells at each time point and immunoblotted for βDG. GAPDH and Lamin A/C were 
included as purity markers of the fractionation and loading controls of the non-nuclear and nuclear 
fractions respectively. Arrows indicate the full length 43 KDa βDG. B) Quantification of 43 KDa βDG in 
the non-nuclear and nuclear fractions. The intensity of the bands was determined via densitometric 
analysis and was normalised to the loading control. Each time point was then found relative to the level 








Figure 5.8. βDG levels in non-nuclear and nuclear fractions relative to cell cycle phase percentages. 
The relative level of βDG in non-nuclear (left) and nuclear (right) fractions as determined via 
immunoblot were plotted against the percentage of cells in G1 (top), S (middle) or G2M (bottom) as 
determined by flow cytometry at each time point. Data from each replicate are represented by a 
different shape. Correlation and statistics were calculated via Spearman non-parametric test. N=2.  * in 






Figure 5.9. pY892 βDG levels in non- nuclear and nuclear fractions of thymidine synchronised LNCaP 
cells. A) Representative image of immunoblots of non-nuclear (left) and nuclear (right) lysates collected 
from double thymidine block synchronised LNCaP cells at each time point and immunoblotted for pY892 
βDG. GAPDH and Lamin A/C were included as purity markers of the fractionation and loading controls of 
the non-nuclear and nuclear fractions respectively. Arrows indicate the full length 43 KDa pY892 βDG. B) 
Quantification of 43 KDa βDG in the non-nuclear and nuclear fractions. The intensity of the bands was 
determined via densitometric analysis and was normalised to the loading control. Each time point was 
then found relative to the level of the highest expression in each experiment. Mean values and S.E.M 








Figure 5.10. pY892 βDG levels in non-nuclear and nuclear fractions relative to cell cycle phase 
percentages. The relative level of pY892 βDG in non-nuclear (left) and nuclear (right) fractions as 
determined via immunoblot were plotted against the percentage of cells in G1 (top), S (middle) or G2M 
(bottom) as determined by flow cytometry at each time point. Data from each replicate are represented 
by a different shape. Correlation and statistics were calculated via Spearman non-parametric test. N=2.  





To get a more detailed analysis of the relationship between the level of βDG and the cell cycle, 
scatter plots for each time point detailing the percentage of cells in a specific phase and the 
level of βDG were plotted (Fig 5.8). Only the relative level of non-nuclear βDG in S phase 
showed a statistically significant weak, positive correlation as determined by spearmans 
parametric correlation analysis (Fig 5.8). Although there is no statistically significant correlation 
in the nuclear S phase levels of βDG, it is interesting to note that the samples with the highest 
levels of βDG were also the samples that had the highest levels of S phase cells. Again further 
replicates with increased enrichment of S phase cells as well as quantification relative to 
additional loading controls would be required to further test a hypothesis of increased nuclear 
βDG in S phase cells.  
In the case of pY892 βDG, via immunoblot and quantification, the levels of full length pY892 
βDG do not vary greatly over the time course in the non-nuclear fractions (Fig 5.9). The 
expression increases slightly after the initial release into the cell cycle but then decreases 
slightly and remains relatively constant. In the nuclear fractions there is a greater increase 
after entry into the cell cycle, with an  increase at 4 hours then reducing for the remaining time 
points, although, once again there is variability between the replicates (Fig 5.9 A). The 
quantification must be treated critically due to the normalisation against lamin AC and GAPDH. 
The mean nuclear level of pY892 βDG peaks at phase when there is the highest proportion of 
cells in S phase. If the increase was due to number of cells in S phase alone, however, you 
would expect to see a larger increase at 2 hours compared to 6 hours as the percentage of 
cells in S phase at 2 hours is 22% compared to 10% at 6 hours (Fig 5.6). It may be that there is a 
more specific timing or event that sees an increased level of nuclear βDG in the cell cycle.  In 
the scatter plots of pY892 βDG intensity against cell cycle phase percentage the correlations 
were again relatively weak (Fig 5.10). Interestingly, in the nuclear fractions there was a weak, 
statistically significant positive correlation of pY892 βDG relative to the number of cells in S 
phase, but also a stronger, statistically significant negative correlation between pY892 βDG and 
populations with a larger percentage of cells in G1 phase (Fig 5.10). Although further 
experiments with clearer populations of specific cell cycle phases is needed it appears that the 
pY892 βDG has more of a cell cycle dependence on its nuclear level rather that the non-
phosphorylated or non-nuclear form.  
From the immunoblot it is interesting to note that there is the presence of additional high 
molecular weight bands in the nuclear fraction that are not present or reduced in the non-
nuclear fractions. Furthermore, the levels of some of these bands are clearly increased at 
different time points. For example, a band at approximately 60 KDa is particularly high at 0 
hours and 6 hours post release, whilst the high molecular weight band >250KDa is increased at 
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6 and 12 hours (Fig 5.9). It would be interesting to use mass spectrometry to determine if 
these bands are post-translationally modified species of βDG and if these occur in a cell cycle 
dependent manner that contributes to βDG fate or function. 
Although there are a number of caveats to these thymidine synchronised experiments, they do 
hint at a fluctuating level of βDG as the cells progress through the cell cycle. There is an 
indication that dystroglycan levels are increased in correlation with higher number of cells in S 
phase and that this may also be the case for nuclear βDG, particularly the pY892 
phosphorylated form, which also seems to have an inverse relationship with populations of 
cells with higher proportions of G1 cells. 
5.2.4 NUCLEAR ΒDG LEVELS IN BRDU POSITIVE LNCAP CELLS ARE NOT INCREASED 
 
Because of the variability seen with in the thymidine experiments it was important to 
investigate the nuclear level of βDG in the cell cycle using different methods. An alternative 
method to investigate if the nuclear level of βDG was increased in S phase cells is via 
immunofluorescence intensity analysis. An asynchronous population of LNCaP cells was 
incubated with BrdU for 1 hour and then immunostained for BrdU and βDG (Fig 5.11.A). BrdU 
is a synthetic nucleoside that is incorporated into the DNA during DNA replication, thus 
subsequent immunodetection of BrdU positive cells enables identification of cells in S phase. 
Image J was used to make masks of the nuclei of images taken on an epifluorescence 
microscope.  The intensity of βDG within the nucleus was normalised to the area and scored as 
a BrdU positive (S phase) or BrdU negative (non-S phase) nuclei. Quantification showed a 
broader spread of the intensity of βDG in BrdU negative cells relative to the positive cells (Fig 
5.11.B). The mean of the BrdU negative cells was found relative to the BrdU positive cells for 
each replicate. There was no difference in the means of the two populations (Fig 5.11.C). This 
agrees with the thymidine treated LNCaP fractionation data in which no statistically significant 
correlation was detected between βDG and the percentage of cells in S phase. Unfortunately, 
1709, the antibody that detects pY892 βDG, has been shown to detect the nucleus non-
specifically when used for immunofluorescent studies (Section 3.2.4) and therefore could not 
be used accurately in the BrdU assay. The experiment should be repeated with antibodies that 
can detect the total population of βDG or tagged versions of βDG to account for the Y892 
phosphorylated population. The BrdU immunofluorescence analysis was conducted on images 
taken from an epifluorescence microscope thus is also taking into account βDG expressed at 
the plasma membrane or cytoplasm that are included in the region of interest. Conversely it is 




Figure 5.11 Nuclear βDG levels in BrdU positive LNCaP cells A) LNCaP cells were grown for 48 hours 
before being incubated with 10 µM BrdU for 1 hour at 37°C. Cells were immunostained for βDG (green) 
and BrdU (red). Nuclei were counterstained with dapi (blue). Images taken on an epifluorescence 
microscope, 63 x magnification. Scale bar 15µm. Fiji was used to create masks of the nuclei and the 
fluorescence intensity of βDG in the nuclei was measured. Intensity was normalised to the area of the 
nuclei. B) Representative graph from one replicate experiment of the fluorescence intensity of βDG 
normalised to the area of the nucleus in BrdU positive and BrdU negative LNCaP cells. Mean and S.E.M 
are depicted. C) The means of the fluorescence intensity of βDG normalised to the area of the nuclei in 





5.2.5 ΒDG LOCALISATION IN THE NUCLEUS OF BRDU POSITIVE LNCAP CELLS 
 
Although there was no detected change in the levels of βDG between the BrdU positive and 
BrdU negative cells, it was decided to characterise the localisation of βDG in S phase cells that 
were participating in DNA replication.  LNCaP cells were incubated with BrdU and 
immunostained as described above and then imaged via confocal microscopy (Fig 5.12). BrdU 
was detected in specific foci in the nucleus at sites of DNA replication. βDG was detected 
strongly at the plasma membrane as expected and also at the nuclear envelope as previously 
described (Chapter 3). βDG was also detected as a faint nucleoplasmic stain with some 
stronger nuclear foci. The strongest foci did not appear to colocalise with the bright BrdU 
staining and were localised at sites likely to be the nucleoli as determined by the nuclear 
morphology in the DAPI staining. There was however a small degree of colocalisation of the 
BrdU with some of the weaker βDG foci (Fig 5.12). The localisation of βDG at the nuclear 
envelope and in the nucleoli did not appear to be increased in the BrdU positive cells 
compared to the BrdU negative cells although this was not quantified. It has been reported 
that the HCl treatment used in the immunofluorescence process to enable the antibody access 
to the BrdU might distort the localisation detected (Tang et al. 2007) and the analysis should 
be confirmed with 5-ethynyl-2’-deoxyuridine (EdU) incorporation, a modified thymidine 
analogue which does not require HCl treatment (Buck et al. 2008). 
5.2.6 ANALYSIS OF ΒDG EXPRESSION AT DIFFERENT CELL CYCLE PHASES FROM AN 
ASYNCHRONOUS POPULATION 
 
When synchronised with the double thymidine block, the LNCaP cells provided enriched 
populations of the different phases of the cell cycle, however, the proportions of S phase and 
G2M populations of cells were still low. Furthermore, whilst synchronisation is a useful tool, it 
can be argued that the addition of agents such as thymidine or nocodazole have broader 
effects on cell behaviour than just cell cycle synchronisation. Therefore, asynchronous, 
exponentially growing populations of LNCaP cells were stained with DNA dyes Hoechst 33342 
(H33342) or propidium iodide prior to FACS analysis into G1, S and G2M populations for 








Figure 5.12. Confocal immunofluorescence of βDG in BrdU positive LNCaP cells. LNCaP cells were 
grown for 48 hours and incubated with BrdU as previously described. Cells were fixed and 
immunostained for βDG (green) and BrdU (red). Nuclei were counterstained in DAPI (blue). Images were 
obtained on Nikon A1 confocal. Slices from the middle of the nuclei are presented. Enlarged images of a 
BrdU positive nuclei (box in merged image) are shown in the panel on the right. White arrows indicated 
βDG at the nuclear envelope and internal nuclear foci. Scale bar 15µm and 5µm in enlarged image. 
 
5.2.6.1 Optimisation of FACS sorting of asynchronous populations of prostate cells for cell cycle 
analysis 
 
During the course of the project multiple attempts at optimising the conditions of the FACS 
analysis of asynchronous populations of cells were conducted.  
As a receptor at the plasma membrane, the extracellular domain of βDG is exposed to external 
enzymes. Cells are commonly detached using trypsin-EDTA. Trypsin is a serine protease which 
cleaves peptide chains C-terminal to lysine or arginine residues, except when either is followed 
by a proline (Olsen et al. 2004). Analysis of the peptide sequence of βDG highlights multiple 
potential sites of trypsin cleavage within the external domain of βDG (Appendix C, Fig C.3).  
Indeed, lysates obtained from cells detached by trypsin incubation and immunoblotted for 
βDG or pY892 βDG showed a dramatic reduction in the level of full length 43 KDa βDG and an 
increase in the 35 KDa band. Cells detached with two different enzyme free dissociation 
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buffers retain the majority of the protein as 43 KDa βDG though there is a small increase in 
bands at 26 KDa (Appendix , Fig C.5). Subsequent FACS analysis used the Gibco enzyme free 
dissociation buffer so as not to cleave βDG prior to analysis. 
Initial attempts at FACS sorting of LNCaP cells in which the LNCaP cells were detached with 
enzyme free dissociation media, stained with H33342 for 30 minutes prior to sorting and 
collected in PBS resulted in low yields of cells returned with a large number of cells were dying 
in the process of detaching and sorting the cells. Consequently, sufficient lysate extraction 
from the resultant populations was inconsistent (data not shown). Increasing the number of 
cells in the FACS experiment did not increase the yield.   
It has previously been shown that reduced cell-matrix interactions in epithelial and endothelial 
cells can result in apoptosis in a process known as anoikis (Frisch et al. 1994, Frisch et al. 2001). 
It was hypothesised that the prolonged detachment of the cells necessary in the sort process 
was causing the cells to undergo apoptosis. In an attempt to reduce the time of detachment, 
cells were stained with H33342 prior to detachment with enzyme free dissociation buffer and 
sent immediately for sorting. In addition, the length of H33342 stain (25 minutes to 1 hour), 
the temperature (room temperature, ice or 37°C) and length of detachment (3- 15 minutes) 
and the collection temperature of the FACS sort (room temperature, ice or 37°C) were all 
varied in an attempt to improve accuracy and yield but showed little improvement or 
inconsistency in yield of cell number or lysate quality. As well as LNCaP cells, the prostate cell 
lines PC3 and PNT1A were also investigated. However, in all of the above cases the majority of 
cells still underwent apoptosis during the detachment or FACS sorting process with low yields 
of cells and inconsistent lysate quality. Live cell analysis was initially used as fixation can affect 
the quality of the protein extracted and fixation prior to FACS can alter the wavelengths and 
detection of dyes, however, the specificity of the phases in the live cell sorts was inconsistent, 
potentially as a consequence of poor H33342 staining or of a drifting population during and 
after sorting. 
To attempt to reduce the apoptosis of the cells and to maintain the cells in their respective cell 
cycle phases, cells were fixed in EtOH and stained with propidium iodide prior to FACS sorting. 
Once again the return yields were very low. The cells are likely undergoing apoptosis during 
cell detachment or fixation and may be damaged during the sort process. Fixatives such as 
EtOH and PFA can cause difficulties for subsequent protein extraction causing protein 
precipitation and cross-linking respectively and EtOH fixation has been reported to result in 
the leaking of cytoplasmic proteins (Pollice et al. 1992). However, immunoblots following EtOH 
fixation of unsorted populations showed strong detection of βDG indicating a problem with 
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low cell yield rather than protein extraction. Further experiments combining PFA fixation with 
EtOH or MeOH permeabilisation may result in increased cell yield.  
5.2.6.2 βDG and pY892 βDG protein expression in specific cell cycle phases from a FACS sorted 
asynchronous population 
 
Although cell return yields remained low and inconsistent, it was possible to assess the levels 
of βDG and pY892 βDG via immunoblots in the populations of the cell cycle phases that were 
obtained. In the majority of cases there was little variation in the levels of βDG and pY892 βDG 
in the asynchronous, G1, S and G2M populations. This was the case for the LNCaP, PC3 and 
PNT1a cell lines tested. Figure 5.13 is an example blot from cells that were stained with 
H33342 for 30 minutes at 37°C whilst adhered and then sorted. The yield of G2M population in 
LNCaP cells was also very low and provided very low lysate concentration. Markers of different 
cell cycle phases for G1 (cyclin D3) S/G2 (cyclin A) and mitosis (Cyclin B1 and phospho histone 
H3) were included to assess the accuracy of the sorted populations (Fig 5.13). The specificity of 
the phases in the sorted populations was low, a recurring problem in the FACS sorts, it is 
therefore difficult to draw robust conclusions, however, there is no clear difference in the 
levels of βDG or pY892 βDG at any stage of the cell cycle.   
5.2.6.3 pY892 βDG expression level in non-nuclear and nuclear fractions of cell cycle sorted 
populations of LNCaP cells. 
 
When the cell yields were sufficiently high following the FACS sort the resultant populations 
were subject to biochemical fractionation in order to determine if there was a difference 
nuclear βDG in the different cell cycle phases. There was no apparent increase in the nuclear 
levels of full length pY892 βDG (Fig 5.14) in the nuclear fractions in asynchronous, G1 or S 
phase populations (Fig 5.14). Similarly, the non-nuclear levels of full length pY892 βDG did not 
seem to vary between the populations. It was apparent from the immunoblots that the 
expression profiles between the non-nuclear and nuclear fractions were strikingly different (Fig 
5.14), as has been reported widely in the literature and elsewhere in this thesis (Chapter 4). 
The lower molecular weight 35 and 26 KDa bands could be detected in the non-nuclear but not 
the nuclear fractions (Fig 5.14). There were also high molecular weight bands that were 
present or at different strengths in the non-nuclear and nuclear fractions. The expression of 
these high and low molecular weight species do not appear to alter between the cell cycle 
phases, with the exception of the presence of some higher molecular weight species in the 
asynchronous nuclear fractions but not the specific cell cycle phase populations (Fig 5.14). The 
potential post-translational modifications resulting in the high molecular weight species and 
their significance have been discussed elsewhere in this thesis (Chapter 4). Further validation 
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of the specificity of the cell cycle stages in each population, for example by cyclin expression, is 
required before strong conclusions can be drawn regarding the levels of βDG in each of the 
phases. Furthermore, staining for βDG was weak and inconsistent in the fractionation 
experiments (Data not shown) and requires further optimisation.  
 
 
Figure 5.13 βDG and 
pY892 βDG levels at 
different cell cycle 
phases in FACS sorted 
asynchronous 
populations of prostate 
cell lines. Adhered 
LNCaP, PC3 and PNT1A 
cells were incubated with 
5µg/ml H33342 for 40 
minutes at 37°C. Cells 
were then detached with 
Gibco enzyme free 
dissociation buffer and 
sorted into G1, S and 
G2M populations on the 
BD Jazz FACS machine. A 
portion of the cells was 
not sorted and 
maintained as an 
asynchronous 
population. Total cell 
lysates were extracted 
from the resultant 
populations. Protein 
lysates were separated 
via SDS-PAGE and 
immunoblotted. 
Membranes were 
immunoblotted for βDG 
(top) and pY892 βDG 
(bottom) as well as cell 
cycle markers Cyclin D3, 
Cyclin B1, Cyclin A2 and 
phospho-histone H3. 






Figure 5.14. pY892 βDG levels in non-nuclear and nuclear fractions at different phases of the cell cycle. 
LNCaP cells were detached from the culture vessel using enzyme free dissociation buffer and incubated 
with 5µg/ml H33342 for 30 minutes. A) DNA histogram of H33342 stained LNCaP cells obtained from 
MoFlow FACS machine. Cells were sorted into G1 (R3 gate), S (R4 gate) and G2M (R5 gate) populations 
and an unsorted, asynchronous population was retained. B) Resultant populations underwent 
biochemical fractionation to obtain a non-nuclear and nuclear fraction. Fractions were run on an SDS-
PAGE gel and immunoblotted for pY892 βDG. GAPDH and Lamin AC were included as loading controls 




5.2.7 ΒDG AND PY892 ΒDG PROTEIN LEVELS AND LOCALISATION IN MITOTIC LNCAP CELLS. 
  
The division of the cell through mitosis sees dramatic rearrangements in cellular architecture, 
with the detachment of cells from their extracellular environment, rounding up of the cells, 
condensation of the DNA and breakdown of the nuclear envelope (Foisner 2003, Moir et al. 
2000a, Pugacheva et al. 2006, Kunda et al. 2009). The localisation of many proteins during 
mitosis, particularly those within the nucleus or those actively involved in the division process 
is also radically different from interphase cells (Foisner 2003, Hernandez-Verdun 2011). Post-
translational modifications, particularly phosphorylation events are often key regulators of the 
changes in cellular architecture or protein localisation (Nikolakaki et al. 1997, Ottaviano et al. 
1985). Given the roles for βDG at both the plasma membrane and the nuclear envelope we 
decided to investigate the levels of βDG in mitotic enriched versus asynchronous populations 
of LNCaP cells. 
5.2.7.1 Nocodazole induced G2M arrest of LNCaP cells 
In order to arrest cells in mitosis, cells were treated with nocodazole. Nocodazole binds to β-
tubulin, inhibiting di-sulphide bridge formation thus disrupting microtubule polymerisation. 
Disrupting microtubule polymerisation causes cells to arrest in G2/M due to defects in mitotic 
spindle formation (De Brabander et al. 1976, Jordan et al. 1992). The optimal concentration to 
arrest LNCaP cells in G2/M was determined by treating cells with a range of Nocodazole 
concentrations (50-500ng/ml) over a range of times (12, 18, 24 and 30 hours). Cells were then 
fixed in EtOH, stained with P.I. and the cell cycle profile determined by flow cytometry 
(Appendix C, Table C.1). Treatment of LNCaP cells for 30 hours with 100ng/ml nocodazole was 
optimal, resulting in ~72% of the cells in G2M compared to ~ 20% G2M cells in a population of 
cells treated with DMSO for the same length of time (Fig 5.15 A).   
5.2.7.2 βDG and pY892 βDG levels in Nocodazole G2M arrested mitotic cells 
 To investigate if the expression levels or profiles of βDG are altered in mitotic cells LNCaP cells 
were treated with 100ng/ml Nocodazole for 30 hours and then the total cell lysates collected 
and subject to immunoblot for βDG or pY892βDG to cover the total population of βDG (Fig 
5.15 B). Phospho-histone H3 was included as a marker of mitotic cells and shows a dramatic 
increase upon Nocodazole synchronisation of the cells. Although the immunoblots hinted at 
small differences between the levels of βDG and pY892βDG in the two populations, 




Figure 5.15 βDG and pY892 protein levels in Nocodazole induced mitotic cells. A) DNA histograms from 
flow cytometry analysis of propidium iodide stained, EtOH fixed LNCaP cells that had previously been 
treated with 100ng/ml Nocodazole or DMSO for 30 hours. B.) LNCaP cells were treated with DMSO (-) or 
100ng/ml Nocodazole (+) for 30 hours. Total cell lysates were collected, run on SDS PAGE and 
immunoblotted. Membranes were probed for pY892 βDG, βDG with the JAF1 antibody and βDG with 
the MDG2 antibody. Arrows indicate bands at high molecular weight species that differ in expression 
between Nocodazole treated or untreated lysates. P-histone H3 (phospho histone H3) was included as a 
marker of mitotic cells. GAPDH was included as a loading control. C.) Quantification of 43 KDa βDG 
(MDG2) and pY892 βDG (1709) of DMSO and Nocodazole treated LNCaP cells. The intensity of the bands 






Figure 5.16 Localisation of βDG and pY892βDG in mitotic LNCaP cells. LNCaP cells were grown for at 
least 48 hours and then fixed for immunofluorescence analysis. Cells were immunostained for βDG (left, 
green) or pY892 βDG (right, green) as well as the mitosis marker phospho-histone H3 (red). DNA was 
counterstained with DAPI (blue). Images were obtained on an epifluorescence microscope at 63x 
magnification. Representative images of cells in the different phases of mitosis; prophase, pro-




Figure 5.17. Confocal microscopy analysis of βDG localisation in mitotic LNCaP cells. LNCaP cells were 
grown for 48 hours then fixed for immunofluorescence analysis. Cells were immunostained with βDG 
(green) and the DNA counterstained with DAPI (blue).  Representative confocal slice images of cells at 






Figure 5.18. Confocal microscopy analysis of pY892 βDG localisation in mitotic LNCaP cells. LNCaP cells 
were grown for 48 hours then fixed for immunofluorescence analysis. Cells were immunostained with 
anti pY892 βDG (green) and the DNA counterstained with DAPI (blue).  Representative confocal slice 
images of cells at each stage of mitosis. Images taken at 60x magnification, scale bar 10µm. 
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significant difference in the expression levels between the cells treated with nocodazole or 
DMSO (Fig 5.15 C). Only one repeat using JAF1 was available and therefore was not quantified. 
Upon increasing the exposure, high molecular weight species of pY892 βDG could be identified 
in control and mitosis enriched fractions (Fig 5.15 B). The level of a 130 KDa band was greatly 
reduced in the nocodazole treated population whilst a band at 100 KDa was slightly increased. 
There was also the presence of an additional band between 130-250 KDa in the control 
population (Fig 5.15 B). It would be interesting to determine the post-translational 
modifications responsible for these bands by mass spectrometry and to further investigate if 
these modifications can be regulated in a cell cycle dependent manner and if these modified 
forms of βDG have a cell cycle specific role. For example, it would be of interest to determine if 
βDG is phosphorylated by a mitotic or phase specific kinases which may in turn affect other 
PTM, including pY892 or ubiquitination. 
5.2.7.3 Localisation of βDG and pY892 βDG in mitotic LNCaP cells. 
 
To investigate the localisation of βDG during mitosis, LNCaP cells were fixed and 
immunostained for βDG prior to viewing via both epifluorescence and confocal microscopy (Fig 
5.16, Fig 5.17). As has previously been reported, βDG localised very strongly at the plasma 
membrane during mitosis and can be seen in the cell protrusions and neighbouring cells 
(Higginson et al. 2008) (Fig 5.16, Fig 5.17). The strong βDG localisation at the cell periphery 
colocalises with the actin cortex formed in mitotic cells, as seen in figure 5.19 in confocal 
analysis of LNCaP cells co-immunostained with βDG and a fluorescently labelled phalloidin, 
which binds to F-actin filaments. During telophase βDG starts to accumulate at the site of 
formation of the cleavage furrow and localises strongly where the furrow will start to form on 
the apical surface of the cell and can be best seen in the orthogonal view in figure 5.19. During 
cytokinesis βDG localises strongly to the midbody where there is an accumulation of actin prior 
to abscission and the formation of the two daughter cells. The localisation at the periphery, 
mid body and cleavage furrow have all been described previously in the literature and can be 
linked to the role of βDG at the plasma membrane where it can interact with the cytoskeleton 
(Higginson et al. 2008). 
βDG also localises to the nuclear envelope, nuclear speckles and nucleoplasm in interphase 
cells (Martinez-Vieyra et al, 2013, Mathew et al. 2013), however the localisation of this pool of 
βDG is less clear in mitotic cells. During mitosis the fate of nuclear envelope and nuclear 
proteins is varied being resorbed into the ER or dispersed in the cytoplasm (Foisner 2003). 
Analysis of confocal slices of mitotic LNCaP cells shows very faint cytoplasmic distribution of 




Figure 5.19 βDG and actin colocalisation in mitotic LNCaP cells. A) Representative images of confocal 
slices of LNCaP cells fixed and immunostained for βDG and actin (phalloidin). Arrow indicates strong 
localisation of βDG and actin at the midbody in a cell in late telophase/ cytokinesis. B) Merged image of 
mitotic LNCaP cells immunostained for βDG (green), Actin (red) and DNA (blue). Orthogonal slices along 
xz and yz axis are shown. White arrow in yz panel indicated βDG localisation to the top of the cleavage 
furrow in the late anaphase cell (white * in xy view). Xy images are confocal slices, images taken at 60x 
magnification, scale bar 10µm. 
 
Co-staining of βDG with calnexin, a marker of the ER, in mitotic cells did not show a strong 
colocalisation (Fig 5.20). The level of βDG at the nuclear membrane is low and therefore it may 
be difficult to detect once the nuclear envelope has been disassembled. To further investigate 
the fate of βDG in mitotic cells it would be interesting to co-stain with proteins with which it 
colocalises in the nucleus, such as lamin A/C or B and emerin to see if they remain associated. 
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During the immunofluorescence analysis of mitotic cells the LNCaP cells were also stained with 
1709, the antibody that detects the pY892 species of βDG (James et al. 2000) (Fig 5.17). pY892 
βDG accumulated around the condensed DNA in mitotic cells, particularly during metaphase 
and anaphase (Fig 5.17). The strong accumulation of pY892 βDG around the condensed DNA 
was not detected in confocal analysis of 1709 stained LNCaP cells although occasionally a small 
increase in the diffuse perichromosomal staining of metaphase, anaphase and telophase 
LNCaP cells could be detected (Fig 5.18). It is not surprising that the accumulation is harder to 
detect in confocal slices, as these represent thin section of the cell compared to the sum stain 
observed through the total cell in the epifluoresence images. A number of proteins involved in 
adhesion processes, such as merlin and samp1, colocalise with mitotic spindles in mitosis, 
stabilising the microtubules (Solinet et al. 2013, Buch et al. 2009). 1709 detection of pY892 
βDG did not colocalise strongly with the mitotic spindles themselves, as detected by co-
localisation analysis with α-tubulin although a diffuse perichromosomal detection of pY892 
βDG did overlap with the site of the mitotic spindle in the metaphase cells (Fig 5.21). Strikingly 
1709 strongly detected the microtubule organising centre (Fig 5.21, arrows) and is discussed in 
detail in Chapter 6. 
It was subsequently shown that 1709 exhibited non- βDG specific staining in 
immunofluorescence protocols however it is unclear if this localisation at the condensed 
chromatin is a true result or an artefact. Nuclear envelope proteins start to associate with the 
chromosomes as early as anaphase to initiate the reformation of the nuclear envelope after 
mitosis (Gautier et al. 1992, Haraguchi et al. 2001, Ye et al. 1994). Staining of mitotic DG null 
cells, or cells treated with anti-DG RNAi, with 1709 or the use of an affinity purified 1709 would 
be important in determining if the staining is artefactual. Alternatively, the localisation of a 

























































































































































































































































5.2.8 EXPRESSION OF ΑΒDGFLAG REDUCES PROLIFERATION OF LNCAP CELLS 
 
Immunoblot studies indicated that pY892 βDG may undergo greater nuclear fluctuations than 
βDG. Unfortunately, the 1709 antibody exhibits non-specific staining when used for 
immunofluorescence analysis (Chapter 3). A flag-tagged version of βDG, αβDGflag, can be 
detected in the nucleus as well as at the plasma membrane and detects both pY892 βDG and 
βDG (Section 4.2.9). Therefore, LNCaP cells were transiently transfect with αβDGflag for 
immunofluorescence analysis of cells at specific phases of the cell cycle. Very few αβDGflag 
expressing mitotic cells or cells in S phase as detected by BrdU (not shown) could be detected.  
Manipulating the levels of βDG in a cell has been shown to alter the proliferation rates and cell 
cycle progression of a variety of cells (Sgambato et al. 2006, Hosokawa et al. 2001, Higginson 
et al. 2008, Mitchell et al. 2013). The proliferation of LNCaP cells transfected with αβDGflag 
was investigated by co-immunostaining for flag-tagged βDG and ki67, a marker of 
proliferation. In the non-transfected cells the number of ki67 positive and negative cells was 
Figure 5.21. pY892 βDG does not colocalise with the mitotic spindles in mitotic LNCaP cells. 
LNCaP cells were fixed and co-immunostained for pY892 βDG (1709, Green) and α-tubulin (red). 
DNA was counterstained with DAPI. Cells in metaphase (top) and Telophase (bottom) are shown. 




each about half of the population (Fig 5.22). In the case of the aβDGflag transfected cells, of 
which there were considerably fewer, only 15.2% of the population was ki67 positive. A DG-
GFP construct and a GFP control construct was also included in the analysis to determine if the 
result was a consequence of the transfection process or increased DG levels. Again for both 
constructs, the non-transfected cells were split with approximately half of the population as 
either ki67 positive or negative. Both GFP and DG-GFP transfected cells had a reduced number 
of proliferating cells at 34.6% and 35.64% respectively, this suggests that it is the transfection 
process that is resulting in reduced proliferation (Fig 5.22). Having said that, the proliferation 
of the αβDGflag cells is about half that of the DG-GFP and GFP cells, which could be a 
consequence of the high levels of αβDGflag expressed. Mitchell et al. previously demonstrated 
a reduced rate of proliferation in LNCaP cells overexpressing βDG (Mitchell et al. 2013). 
In confocal immunofluorescence analysis of αβDGflag in ki67 positive cells, βDG was detected 
accumulation at distinct foci within the nucleus however there was very little colocalisation 
with the ki67 positive structures (Fig 5.22 B). There is also a faint nucleoplasmic and nuclear 
envelope stain. The localisation of βDG within the nucleus did not appear to differ between 
Ki67 positive and negative cells. It is difficult to quantify the levels of βDG in the nucleus with 
the αβDGflag transfected cells due to the variable levels of expression in the transiently 
transfected population. Stably expressing cell lines may give a clearer indication on if there is a 
quantifiable change in the levels of βDG in the nucleus of proliferating cells.  
5.2.9 ΑΒDGFLAG LOCALISATION IN NOCODAZOLE ARRESTED MITOTIC LNCAP CELLS.  
In order to assess if the perichromosomal accumulation of pY892 βDG detected by 1709 
antibody in mitotic cells is a true localisation αβDGflag immunofluorescence studies were 
conducted. To enrich for mitotic cells, LNCaP cells were transfected with αβDGflag and grown 
for 24 hours prior to 18 hours treatment with 100ng/ml nocodazole. The treatment time was 
chosen as a balance between LNCaP recovery time after transfection, sufficient length of 
nocodazole treatment for mitotic arrest and to retain good expression level of αβDGflag, 
which has been shown to degrade rapidly (Section 4.3.6). Cells were then fixed and 
immunostained with anti-flag and viewed via confocal microscopy (Fig 5.23). Very few mitotic 
cells were observed and non-quantified observations indicated high levels of apoptosis. This 
may be because the combination of transfection and nocodazole treatment was too stressful 
for the cells or because increased levels of βDG make the cells sensitive to nocodazole 
treatment. Nocodazole disrupts microtubules and inherently causes an ‘abnormal’ mitosis, 
which may affect the localisation of βDG (De Brabander et al. 1976, Jordan et al. 1992). 
Nonetheless βDG localisation once again was strong at the periphery of the cells. The 
cytoplasmic stain was more punctate than observed with MDG2 staining. Whilst there was no 
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strong stain around the condensed DNA in the nocodazole treated cells (Fig 5.23), it is 
important to note that these cells are not in the mitotic phases (metaphase, anaphase and 
telophase) where the accumulation of endogenous protein was previously detected by anti- 
pY892 βDG antibody(Fig 5.16). Unfortunately, likely due to the low number of transfected cells 
and the time course of the experiment, only LNCaP cells in prophase and prometaphase were 
detected. 
 
Figure 5.22 Proliferation and βDG localisation in βDG overexpression LNCaP cells. A) Proliferation of 
DG transfected LNCaP cells. LNCaP cells were transfected with αβDGflag, GFP or DG-GFP and grown for 
48 hours. Cells were then immunostained for proliferation marker ki67 and αβflag in the case of the flag 
tagged DG construct. Images were obtained via epifluorescence microscopy. Cells were then quantified 
as transfected or non-transfected and within these populations as Ki67 positive (+) or Ki67 negative (-). 
The percentage of ki67 + or – cells was then calculated for the transfected and non-transfected 
populations. N=2, ≥ 300 cells per construct, Error bars SEM. B) Localisation of αβDGflag in Ki67 positive 
cells.  LNCaP cells transfected with αβDGflag for 48 hours were fixed and immunostained for αβDGflag 
(green) and ki67 (red) nuclei were counterstained with DAPI (blue). Images are confocal slices taken at 




Figure 5.23. αβDGflag localisation in Nocodazole induced mitotic LNCaP cells. LNCaP cells were 
transfected with αβDGflag and grown for 24 hours. Cells were then treated with 100ng/ml Nocodazole 
for 18 hours. Cells were fixed and immunostained for αβDGflag (M2 flag, green). DNA was 
counterstained with DAPI (blue).  Two representative images are shown with enlarged images of the 





Different stages of the cell cycle see vast changes in cell morphology, interaction with the 
extracellular environment, DNA replication, signal transduction pathways and growth (Walker 
et al. 2005, Pugacheva et al. 2006 Budirahardja et al. 2009, Caldon et al. 2010, Frisch et al. 
1994). Accordingly, the levels, localisation and activity of proteins involved in these processes 
is often regulated in a cell cycle dependent manner (Pugacheva et al. 2006, Dabauvalle et al. 
1999, Balk et al. 2008, Muranen et al. 2005). A complex relationship between βDG and the cell 
cycle has long been reported but is by no means fully understood (Sgambato et al. 2006, 
Hosokawa et al. 2001, Higginson et al. 2008). It has been shown that modulating the levels of 
βDG can increase or decrease the rate of proliferation (Sgambato et al. 2006, Hosokawa et al. 
2001, Higginson et al. 2008, Mitchell et al. 2013). An increased level of βDG has been reported 
in proliferating cells, furthermore, the levels of βDG mRNA and protein have been shown to be 
regulated in a cell cycle dependent manner in different cell lines, increasing in S phase 
(Sgambato et al. 2006, Hosokawa et al. 2001).  Interestingly, there is a differential expression 
of βDG in the nuclei of cells in an asynchronous population of proliferating cells (Mitchell et al. 
2013, Mathew et al. 2013, Leocadio et al. 2016, Martinez-Vieyra et al. 2013).  Moreover, in 
growth arrested LNCaP cells stimulated into proliferation either by addition of androgen or 
serum there was a time dependent fluctuation in the nuclear levels of βDG (Mathew et al. 
2013, Mathew 2011 Thesis). We therefore hypothesised that there was a cell cycle dependent 
regulation of the nuclear localisation of βDG.  
5.3.1 A POTENTIAL FLUCTUATION IN THE TOTAL LEVELS AND NUCLEAR ACCUMULATION OF 
ΒDG AND PY892 IN A CELL CYCLE DEPENDENT MANNER 
 
In this work we demonstrate mild fluctuation in the levels of full length βDG and pY892 βDG 
total cell lysates as well as in non-nuclear and nuclear lysates following the thymidine 
synchronisation and release of LNCaP cells into the cell cycle (Fig 5.4, Fig 5.7, Fig 5.9). 
Furthermore, following quantification of immunoblots, a weak, positive correlation was found 
between the levels of full length βDG and pY892 βDG within populations of cells with higher 
percentages of S phase cells (Fig 5.5) in support of the previously reported observations of 
increased levels of βDG in S phase cells in the literature (Sgambato et al. 2008). Interestingly, 
this correlation extended to the levels of pY892 βDG within the nucleus of S phase cells, 
though not the non-phosphorylated Y892 species of nuclear βDG. It is important to note that 
there is a report that GAPDH levels may be regulated in a cell cycle dependent manner in 
normal human cells, with slightly reduced levels in S phase (Mansur et al. 1993). It is therefore 
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possible that the GAPDH normalised data may over report the increased levels of βDG in S 
phase. It would therefore be important to repeat these experiments with an alternative 
loading control, such as the total protein loaded onto the gel to verify the potential fluctuation 
of the levels of βDG. Furthermore, the potential S phase dependent changes on the levels and 
localisation of βDG and pY892 βDG were not supported in analysis of lysates from cell cycle 
phase populations sorted by FACS analysis of an asynchronous population, in which the levels 
of both phosphorylated and non-phosphorylated species of βDG stayed relatively constant (Fig 
5.14, Fig 5.13).  
As previously discussed a problem encountered throughout this analysis was obtaining LNCaP 
populations sufficiently enriched for specific phases of the cell cycle (Fig 5.3, Fig 5.13), thus 
making it difficult to draw strong conclusions regarding the levels of βDG and potentially 
masking subtle changes in βDG distribution.    
LNCaP cells have a relatively long doubling time of 32-34 hours and a long lag phase whilst they 
recover and adhere to the substrata following seeding. Whilst the LNCaP cells were grown for 
the 48 hours normally required to exit lag phase (Van Steenbrugge et al. 1991, Cunningham et 
al. 2015), it is possible that the LNCaP cells are not at exponential growth at the time of 
treatment, thus maintaining a sub population in G0 that are not synchronised by the thymidine 
block. Timing is crucial for tight synchronisation of cells (Bostock et al. 1971). Although a 
double thymidine block appeared to tighten the synchronisation, the synchronised 
subpopulation remained relatively small (Fig 5.6). Following thymidine block, cells are not 
arrested completely at the G1/S phase border, rather the rate of DNA synthesis slows and the 
length of S phase increases (Bostock et al. 1971, Thomas et al. 1975). The long doubling time of 
LNCaP complicates the timings of thymidine treatment as it must be long enough for the 
majority of cells to reach the G1/S restriction site but not too long for cells to progress out of S 
phase. Alternative methods of synchronisation of cells such as isoleucine blocks or Nocodazole 
blocks in mitosis are also available (De Brabander et al. 1976, Cifuentes et al. 2003). It would 
also be beneficial to use different cell lines with higher rates of proliferation, such as PC3 or 
PNT1A, to assess the levels of βDG in a synchronised population of cells. 
In the case of the FACS sorted asynchronous cells the main problem was a low yield of return 
of cells as previously discussed. In an asynchronous population of LNCaP cells approximately 
75% are in G1/G0, therefore there is already a low collection of S phase and G2M populations 
(Fig 5.3). In the case of unfixed samples, the cells may have undergone anoikis (Frisch et al. 
1994, Frisch et al. 2001). The specificity of the live cell sorts was poor despite varying the 
conditions of treatment with H33342 (Fig 5.13) potentially as a consequence of the wavelength 
detection or cell populations drifting after sorting. It is likely that the length of the sort and the 
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forces applied during the process to cells that are already delicate following detachment or 
fixation causes further damage or apoptosis (Pollice et al. 1992). There are cell cycle reporter 
constructs, such as Fluorescent-ubiquitin based cell cycle indicators (FUCCI) that fluorescently 
report different phases of the cell cycle in live cells (Sakaue-Sawano et al. 2008). The fucci 
construct could be used as an alternative to the DNA ploidy based FACS sorting and may result 
in improved phase specificity. 
In immunofluorescence analysis an increase of βDG in the nucleus of S phase cells, BrdU 
positive LNCaP cells was not detected (Fig 5.11). This correlated with the results from the 
thymidine synchronisation data that βDG levels in the nucleus fluctuated very little. Affinity 
purification of 1709 or analysis with a tagged construct of βDG will be important in analysing 
the nuclear levels of βDG in the future. Transfection of LNCaP with a flag tagged version of 
βDG resulted in reduced proliferation, thus very low numbers of S phase cells, and inconclusive 
results for BrdU analysis. The co-transfection of a fluorescently tagged βDG along with a cell 
cycle reporter such as fucci is an attractive option to look at the fluorescent levels of βDG in 
the nucleus in real-time, provided the issue of where to place the tag could be resolved. 
Although no definitive conclusion can be reached from the analyses in this chapter regarding a 
cell cycle dependent regulation of nuclear βDG that does not mean it can be excluded. There 
may be a fluctuation within a tight time frame that is missed in these experiments because of 
the time points or sensitivity of the experiments. A number of proteins undergo sudden 
fluctuations in nuclear localisation. Merlin, a protein that is structurally related to the ERM 
proteins, accumulated in the nucleus in early G1 in a manner that was dependent of cell 
attachment but was exported from the nucleus in late G1 (Muranen et al. 2005).  
The levels of pY892 βDG in the nucleus are more variable than the non-phosphorylated form 
(Fig 5.9, Fig 5.10). It would be interesting to determine if a cell cycle specific nuclear 
localisation or role requires phosphorylation at this residue. Mutating pY892 did not prevent 
the nuclear localisation of βDG in LNCaP or HeLa cells (Lara-Chacon et al. 2010, Leocadio 2015, 
Thesis), however these studies were in asynchronous populations, thus any cell cycle subtleties 
may have been masked. Phosphorylation at Y892 modulates the interaction of βDG with 
binding partners of its cytoplasmic domain (Ilsley et al 2001, James et al. 2000, Yang et al. 
1995) and this may also be the case in the nucleus, with potential cell cycle dependent roles. 
An important question is if the increased nuclear pool of βDG has been internalised from the 
plasma membrane or is a separate population of βDG. A number of cell surface proteins, such 
as the growth factor receptors FGFR and EGFR, are internalised from the plasma membrane 
and subsequently translocate to the nucleus (Planque 2006, Lo et al. 2005, Schausberger et al. 
2003). Phosphorylation at Y892 occurs in an adhesion dependent manner and promotes the 
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internalisation of βDG (James et al. 2000, Sotgia et al. 2003, Miller et al. 2012).  It is therefore 
possible that the increased pY892 form in the nucleus is a consequence of its internalisation 
from the membrane rather than its cell cycle dependent nuclear targeting per se, though 
either or both of these processes could still be occurring in a cell cycle dependent manner or to 
facilitate cell cycle dependent nuclear functions. Biotinylation studies suggest that at least a 
pool of βDG is internalised from the PM (Vasquez-Limeta et al. 2014). It would be interesting 
to perform a pulse chase biotinylation study in cell cycle phase specific conditions to 
determine if internalisation and nuclear accumulation of βDG from the PM is altered between 
the phases.  
Alternatively, there may be additional phosphorylation or other post-translational modification 
events that could regulate βDG in a cell cycle manner independently of, or in tandem with, 
phosphorylation at Y892. Indeed, in the nuclear fractions, higher molecular weight species of 
βDG were detected with an antibody recognising pY892 βDG and the levels of these species 
varied in the thymidine treated synchronised cells but not the FACS sorted populations (Fig 
5.9).  Interestingly, ELM analysis identifies two potential sites of phosphorylation by CDKs 
within the cytoplasmic tail of βDG at residues T850 and T884 (Gould et al. 2010). CDKs are 
proline directed kinases with a consensus sequence of xx[S/T]Px[K/R] (Songyang et al. 1994). 
Whilst there are no reported incidences of βDG phosphorylation at T850, multiple studies have 
identified phosphorylation at T884, as reported by phosphosite plus (Hornbeck et al. 2014).  
Furthermore, there are two identified consensus sequence sites for recognition by cyclin 
proteins within βDG (Gould et al. 2010). Binding of cyclins at these sites increases the 
interaction of a substrate with cyclin-CDK complexes thus facilitating their phosphorylation. 
The potential for βDG interaction with or modulation by key components of the cell cycle 
regulatory machinery is interesting and the introduction of mutations at these sites might 
highlight a cell cycle dependent role or regulation of βDG.  
βDG can be seen at the nuclear envelope, nuclear foci and nucleoplasm of cells across 
different phases in an asynchronous population (Fig 5.11) (Martinez-Vieyra et al. 2013, Lara-
Chacon et al. 2010, Mathew et al. 2013, Mitchell et al. 2013, Oppizzi et al. 2008).  One could 
hypothesise from these observations that there is a basal level of βDG in the nucleus fulfilling a 
role that is not cell cycle phase dependent, for example, the proposed structural function of 
βDG at the NE, whereby βDG plays a role in maintaining nuclear morphology (Martinez-Vieyra 
et al. 2013). A role for βDG at a specific phase of the cell cycle may not necessitate a 
detectable change in the level of the protein in the nucleus or there may then be an influx of 
βDG to perform an as yet unidentified specific role at a certain phase of the cell cycle. 
Correlation analysis of the levels of βDG in the nucleus of thymidine synchronised cells hinted 
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at a potential increase with a higher population of cells in S phase, although this was not 
confirmed in FACS sorted populations or immunofluorescence quantification in BrdU cells. 
Increased levels of βDG at S phase of HC11 and BAE cells have previously been reported 
(Sgambato et al. 2006, Hosokawa et al. 2001). Furthermore, cells in which the DG level has 
been reduced by RNAi have displayed delays in entering or exiting S phase (Sgambato et al. 
2008, Higginson et al. 2008). It is therefore interesting to speculate at a role for βDG in the 
nucleus of S phase cells or S phase progression. 
As previously discussed, dystroglycan has been reported to modulate the activity of ERK in 
both a spatial and temporal manner. ERK has vital roles in G1 to S phase progression of the cell 
cycle (Chambard et al. 2007, Torii et al. 2006). Importantly a biphasic activity of ERK is required 
for cell cycle progression with an initial brief period of activity being sufficient to stimulate the 
expression of early genes such as c-fos, however a longer, sustained activity of ERK is necessary 
for the stabilisation and activity of the gene products and only in these conditions can cells 
progress through G1 phase of the cell cycle (Torii et al. 2006, Murphy et al. 2004). It is 
interesting to hypothesise, therefore that βDG could act as a scaffold to modulate ERK 
localisation or activity in the nucleus which may ultimately have a role on cell cycle 
progression. It would be particularly interesting to study the nuclear localisation of βDG and 
ERK in parallel throughout the progression of synchronised cells. 
βDG may play an active role in the nucleus during S phase and this may not necessarily require 
an increase in its protein level. In a mass spectrometry study of proteins identified from an IP 
with αβflag in the nuclear fractions of LNCaP cells proteins involved in DNA replication were 
identified. Namely these were proteins of the mini-chromosome maintenance (mcm) complex; 
mcm2, 4, 5 and 7 (Leocadio, 2014). The mcm complex consists of 6 related helicase proteins 
and is important for initiation and elongation of DNA replication. The mcm genes are 
transcribed during late M and G1 phase whereby they are translocated to the nucleus and 
loaded onto origins of replication (Lei 2005). Here we show that βDG does not colocalise to 
active sites of DNA synthesis, as detected by BrdU labelling, supporting the observation 
previously published in C2C12 cells (Martinez-Vieyra et al. 2013). However, it has been 
reported that whilst a subset of mcm complex travels along the DNA with the replication fork, 
the majority of mcm proteins are not found colocalised with sites of DNA synthesis but as 
speckles within the nucleus where they modulate chromosome dynamics (Forsburg 2004, 
Krude et al. 1996). βDG may therefore interact with mcm proteins at these sites, though the 
putative interaction requires further colocalisation and binding studies. 
 Interactions between βDG and LINC complex components have been proposed (M. Laredo 
and S. Winder).  MEFs from SUN1-/- SUN2-/- mice displayed an early cell cycle arrest in S phase 
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and an increased number of apoptotic cells compared to controls (Lei et al. 2012). The arrest in 
S phase was attributed to disrupted DNA damage response in these cells through interaction 
with DNA-dependent protein kinase (DNAPK) and ultimately through an ATM mediated 
response (Lei et al. 2012). Cells in which βDG has been reduced displayed an accumulation of 
cells in S phase and high levels of apoptosis (Sgambato et al. 2006, Higginson et al. 2008). In 
the mass spectrometry study D. Leocadio also identified DNAPK to be pulled down in IP with 
βDG (D. Leocadio, 2014). The interaction remains to be validated and could be direct or 
indirect through complexes potentially involving SUN proteins.  
βDG may also have more passive roles in interphase and S phase in its role in the structure of 
the NE. Lamins and their interacting proteins LAPs can interact with the chromatin and whilst 
there is a structural element to this there may also be a regulatory role (Cai et al. 2001, Spann 
et al. 1997, Foisner 2003). Correct lamin organisation is required for DNA synthesis during S 
phase with arguments for both indirect or direct roles (Moir et al. 2000a, Spann et al. 1997). 
Those in support of an indirect role suggest that the lamina provide support to the nuclear 
envelope thus allowing for efficient accumulation of replication factors in the nucleus and thus 
DNA synthesis (Walter et al. 1998). However, there is strong evidence in support of a direct 
role based partly upon the observation of colocalisation of lamin B at nucleoplasmic foci with 
markers of DNA replication such as PCNA (Spann et al. 1997). Furthermore, expression of 
dominant negative lamin helped to identify a specific role in the elongation phase of DNA 
replication for organised lamins (Moir et al. 2000c). Whilst βDG does not localise to regions of 
active elongation it does help to regulate lamin organisation. Thus delays in S phase in DG RNAi 
cells may, in part, be attributed to disruption of lamins within the nucleus. 
When studying proliferation in LNCaP cells it would be remiss to not discuss the role of the 
androgen receptor. During normal tissue development and homeostasis the androgen 
receptor plays an important role in driving epithelial cell proliferation (Balk et al. 2008, 
Koryakina et al. 2015). In prostate cancer, during the process of transformation the 
proliferation of cells through the AR pathway become autonomous (Balk et al. 2008, Yuan et 
al. 2006). LNCaP cells contain functionally active AR and respond to DHT treatment 
(Horoszewicz et al. 1983).  A prerequisite of AR action is its translocation to the nucleus 
whereby it can bind to ARE in target genes or interact with co-activators or repressors (Balk et 
al. 2008). There are a number of potential ways in which the AR could influence the nuclear 
accumulation of βDG 
As previously mentioned, androgen stimulation results in increased levels of cyclin D and cell 
cycle progression (Koryakina et al. 2015). Given the presence of putative cyclin interaction and 
CDK consensus sequences in βDG it would be interesting to investigate if cyclin D-CDK4/6 
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complexes can interact with and regulate βDG and potentially its nuclear localisation. To 
further dissect the roles of the AR and the cell cycle the nuclear translocation of βDG in 
synchronised or cell cycle phase sorted populations of cells negative for the AR should be 
tested. The later was attempted with H33342 FACS sorts of PC3 cells, however the results were 
inconclusive. 
It is known that androgen treatment results in an increase in βDG at both the transcriptional 
and protein level. There is also a degree of cross-talk between the AR and pathways known to 
regulate βDG. In a study in mouse prostate epithelium when both c-src and AR levels were 
enhanced there was strong activation of the src kinase signalling pathway and enhanced AR 
activity (Cai et al. 2011). Src is the kinase responsible for phosphorylation at Y892 and as 
previously discussed there is a greater fluctuation in the nuclear levels of this species of βDG. It 
is possible to speculate c-src activity further modulated by AR activity in androgen responsive 
cell lines could contribute to the nuclear translocation of βDG to the nucleus.  Additionally, 
stimulation of AR activity in LNCaP cells also sees induction of ezrin phosphorylation at 
residues T567 and Y353 by PKC and src kinases respectively (Chuan et al. 2006). Interestingly 
overexpression of a T567D phosphomimetic active form of ezrin resulted in an increased 
nuclear translocation of βDG (Vasquez-Limeta et al. 2014). This ezrin mediated translocation of 
βDG to the nucleus appeared to require F-actin and moreover was only a means of nuclear 
translocation for cytoplasmic, not membrane associated βDG (Vasquez-Limeta et al. 2014). It is 
therefore possible that the androgen activity, which varies throughout the cell cycle, could 
influence the nuclear translocation of a pool of βDG in an ezrin dependent manner.  
Although no interaction between βDG and the AR was detected in a previous study it is still 
possible that they could enter the nucleus as part of a complex (Mathew et al. 2013). The 
nuclear translocation of both βDG and the AR to the nucleus occurs in a manner dependent on 
importin and Ran pathways (Lara-Chacon et al. 2010, Kaku et al. 2008). RanBPM is an AR 
coactivator and interestingly RanBPM has been identified as an interacting partner of βDG in a 
yeast-two hybrid screen (Winder lab, unpublished observations). It is therefore possible that 
βDG could form a complex with RanBPM and the AR and be shuttled to the nucleus in an AR 






5.3.2 DYSTROGLYCAN LOCALISES TO THE CELL PERIPHERY AND MIDBODY IN MITOTIC LNCAP 
CELLS 
 
During mitosis a large number of proteins see vast changes in their regulation and localisation. 
This is particularly the case for cell adhesion molecules as the cell contacts with the substrate 
are minimal during mitosis as the cell rounds up (Pugacheva et al. 2006, Kunda et al. 2009), 
and for components of the nuclear envelope which must break up and reform in a timely 
manner to allow for cell division (Fosnier 2003). βDG is a protein that has functions at both of 
these localisations thus we were interested in its localisation throughout mitosis, which may 
hint at the fate and potential additional cell cycle roles for this multifunctional protein. 
In LNCaP cells arrested in mitosis by nocodazole treatment there was very little change the 
non-phosphorylated or pY892 forms of βDG (Fig 5.15). There were small changes in the levels 
of some of the higher molecular weight species of βDG between nocodazole treated and 
untreated samples as detected by this antibody. The modification and functions of these high 
molecular weight species of βDG are unknown. 
βDG has multiple sites of phosphorylation with as yet unassigned roles. βDG has putative CDK 
phosphorylation sites that may regulate βDG in a cell cycle dependent manner (Gould et al. 
2010). Phosphorylation by mitotic kinases is the principle means behind the control of a 
number of mitotic processes (Ottaviano et al. 1985, Moir et al. 2000a, Nikolakaki et al. 1997, 
Goss et al. 1994). As previously described, lamin phosphorylation in NEBD has been extensively 
studied (Ottaviano et al. 1985). Similarly, phosphatase activity is required for reassembly of the 
nuclear lamina with protein phosphatase 1 important for B-type lamin reassembly (Thompson 
et al. 1997). Emerin is reported to be phosphorylated at 26 sites during mitosis by multiple 
kinases, furthermore aberrant cell cycle dependent phosphorylation of emerin and altered 
subcellular localisation has been implicated in patients with EDMD (Berk et al. 2013). Yet 
another potential NE binding partner of βDG to display mitotic phosphorylation events is 
SUN1. Phosphorylation events catalysed by Cdk1 and Plk1 are important for reducing the 
interactions of SUN1 with lamin A/C, emerin and short isoforms of nesprin2 (Patel et al. 2014). 
It would therefore be interesting to test if mutations to the putative βDG CDK sites affects 
NEBD or reformation or DG localisation to the reformed nuclear envelope. Similarly, it could be 
important to see it different mitotic phosphorylation events of βDG’s nuclear binding partners 
affects their interaction. 
Separate from its roles at the nuclear membrane, βDG at the plasma membrane is known to 
play a role in cytokinesis and has been fairly extensively characterised (Higginson et al. 2008). 
As seen here and reported elsewhere in multiple cell lines, βDG localises strongly to the cell 
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periphery throughout mitosis (Fig 5.16, Fig 5.17). During late anaphase and telophase βDG 
localises at the site of the forming cleavage furrow and during cytokinesis localises strongly at 
the midbody, colocalising with the actin contractile ring (Fig 5.20). βDG has been shown to 
colocalise with ezrin at the cleavage furrow and midbody (Higginson et al. 2008). At the 
midbody βDG may play a role in tethering the plasma membrane to the actin contractile ring 
and either directly via βDG interaction with F-actin or through an indirect interaction with ezrin 
through a dbl/ezrin complex (Batchelor et al. 2007, Higginson et al. 2008). During mitosis ERM 
proteins, such as ezrin, help to facilitate cell rounding through the organisation and stiffness of 
the actin cortex. Thus βDG may be contributing to this process through its interactions with 
ezrin. The localisation of Dp71, another component of the DAPC has also been identified at the 
midbody during cytokinesis and when depleted results in reduction of βDG immunoreactivity 
at the midbody (Villarreal-Silva et al. 2011), hinting that the DAPC is important in this function. 
It is important to note however that cells which were depleted for βDG did not display 
detectable cytokinetic defects. DG null fibroblasts display abnormally shaped nuclei, however 
it is not known if this is due to cytokinetic defects in βDG or mislocalisation of components of 
the nuclear lamina 
In mitotic cells βDG displayed a faint cytoplasmic stain and appeared to be excluded from the 
chromosome regions however the pY892 form of βDG accumulated around the condensed 
chromosome particularly through metaphase to telophase and may overlap with the site of 
the mitotic spindle (Fig 5.16, Fig 5.18, Fig 5.21). This accumulation remains to be verified as 
1709 specificity is questionable, and attempts to assess the localisation of αβDGflag in mitotic 
cells was hampered by low numbers despite Nocodazole treatment (Fig 5.22, Fig 5.23). In the 
few mitotic cells there did not appear to be an accumulation of βDG around the condensed 
DNA however further investigation is warranted. Additionally, Nocodazole disrupts 
microtubules and therefore may disrupt any localisation to the mitotic spindles anyway (De 
Brabander et al. 1976). A number of cell membrane or cell adhesion molecules, such as Merlin, 
have been seen to associate with the mitotic spindles or kinetochores during mitosis. 
During mitosis the components of the nuclear envelope are dissociated and undergo various 
fates. Fragments of the nuclear membrane and proteins that remain attached have been 
reported to be resorbed into the ER (Meier et al.1994, Dabauvalle et al. 1999, Ellenberg et al. 
1997, Yang et al. 1997, Maison et al. 1993). Colocalisation with ER marker calnexin in mitotic 
LNCaP cells did not display a clear localisation. Other NE proteins such as lamin A/C are 
dispersed into the cytoplasm during interphase which may be the case with βDG. A number of 
NE proteins, including SUN1, LAP2β and lamin B1 have been shown to colocalise to the spindle 
poles in the early stages of mitosis (Haque et al. 2006, Beaudouin et al. 2002). The movement 
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towards the poles is in a microtubule dependent manner and is consistent with the NE 
proteins remaining attached to the nuclear membrane fragments after the NE is pulled apart 
forcibly by microtubules (Beaudouin et al. 2002). The reformation of the nuclear membrane 
around the chromosomes is a tightly regulated processes (Haraguchi et al. 2001). As early as 
late anaphase nuclear envelope proteins are recruited to the surface of condensed 
chromosomes (Gautier et al. 1992). In many cases this is facilitated through BAF which 
interacts with proteins such as Emerin and LAP2 through their LEM domains (Lee et al. 2001). 
Given the interaction of βDG with components of the nuclear envelope and the disruption in 
their organisation upon βDG depletion, it would be interesting to monitor the assembly of the 
nuclear envelope in βDG depleted cells following mitosis to see if there are any delays or 
abnormalities and could be done via live imaging of these cells. 
Additionally, a proposed interaction between βDG and MAD2L2 has been identified in a yeast 
2 hybrid screen (S. Winder, Personal communication). MAD2L2 is an adaptor protein involved 
in the spindle assembly checkpoint acting as an inhibitor or the anaphase promoting complex 
and preventing metaphase to anaphase transition until the chromosomes are aligned along 
the metaphase plate. MAD2L2 localises on the spindle during mitosis. Therefore, it would be 
interesting to investigate a potential MAD2L2- βDG complex at the mitotic spindle through 
interaction studies such as IPs and proximity ligation. 
5.3.3 SUMMARY 
 
1. Although highly variable, small fluctuations in the levels of βDG and pY892 βDG can be 
detected as synchronised LNCaP cells progress through the cell cycle upon release 
from thymidine block. 
2. There is a weak positive correlation between the quantified level of full length pY892 
βDG and the percentage of LNCaP cells in S phase in synchronised cells however this is 
not seen in FACS sorted populations or via immunofluorescence in BrdU S phase 
populations. 
3. βDG does not localise to foci of DNA replication in BrdU positive cells. 
4. βDG colocalises to the cell periphery, midbody and cleavage furrow in mitotic LNCaP 
cells and does not localise with the ER in the cytoplasm. 
5. pY892 βDG may localise to the perichromosomal region of LNCaP cells in metaphase, 




Chapter 6: Analysis of β-Dystroglycan 
localisation at the centrosome 
 
6.1INTRODUCTION 
6.1.1 THE CENTROSOME: FUNCTION, STRUCTURE AND BIOGENESIS 
First described by Boveri in the early 20th century (Boveri, 1914), the centrosome is a small 
organelle located near to the nucleus with an essential function as a microtubule organising 
centre (MTOC) (Luders et al. 2007). As a MTOC the centrosome plays important roles in 
organising the polarity and orientation of microtubules in interphase cells, whilst in dividing 
cells, a duplicated pair of centrosomes act as the poles of the mitotic spindle, nucleating the 
growth of the microtubules and controlling assembly of the mitotic spindle (Reviewed in 
Azimzadeh et al. 2007, Luders et al. 2007). Consequently, the centrosome influences cell 
shape, polarity and migration as well as cell division and chromosome segregation (Chang et al, 
2013, Obino et al. 2015). In addition to its structural roles the centrosome may also act as a 
signalling scaffold and, although there is no definitive evidence, it is thought to contribute to 
cell cycle progression and DNA damage response (Arquint et al. 2014, Terrin et al 2012, Barr et 
al. 2010.). Moreover, perturbation of centrosome structure and function has been implicated 
in carcinogenesis and chromosome instability (Boveri, 1914, D’ Assoro, et al. 2002, Ganem et 
al. 2009). Given the important functions of the centrosome there is a great deal of interest in 
understanding the mechanisms that govern its function and regulation. 
The centrosome consists of two perpendicular cylindrical centrioles, each centriole consisting 
of nine microtubule triplets (Fig 6.1A) (Paintrand et al. 1992, Gonczy. 2012, Nigg et al. 2011). 
Of the two centrioles, the older centriole, known as the mature, or mother, centriole also has 
subdistal and distal appendages required for its functions (Fig 6.1B) (Piel et. al. 2000). The 
centriole pair is embedded within the pericentriolar material (PCM), an electron dense cloud 
of many proteins which are important for the integrity and function of the centrosome (Fig 
6.1.B). Extensive work has been undertaken to elucidate the identity, organisation and 
functions of the plethora of proteins constituting the PCM (Andersen et al. 2003, Lawo et al. 
2012), an important example being gamma tubulin (Oakley 1990, Moudjou et al. 1996). γ-
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tubulin is recruited to the PCM and forms the γ-tubulin ring complex (γ-TURC), mediating 
microtubule nucleation and capping (Oakley 1990, Weise et al., 2000, Moritz, et al. 1995, 
Teixido-Travesa et al. 2012) but is also associated with the centrioles themselves (Fuller et al. 
1995, Moudjou et al., 1996).  
 
Figure 6.1: Centrosome structure and organisation. A. Schematic diagram of a cross-section view of a 
centriole, consisting of 9 microtubule triplets in a ‘cartwheel’ organisation. B. Schematic diagram of a 
centrosome in G1. A centriole pair consisting of a mother and daughter centriole tethered at their 
proximal ends by linker proteins. The mother centriole has both distal and subdistal appendages/ The 
centriole pair is embedded within the pericentriolar material (PCM), simplified here as a green circle. 
Microtubules nucleate from γ-TURC complexes recruited to the PCM. 
The number of centrosomes and their position in a cell must be tightly regulated and largely 
depends on the cell cycle (Nigg, et al. 2011).  Normally, in cycling cells, the centrosome is 
duplicated once per cell cycle in a manner closely synchronised with cell cycle progression 
(Tsou et al. 2006). Briefly, the centrosome duplication cycle starts at the G1-S transition 
(Robbins et al. 1968). In G1 the existing mother and daughter centriole are tethered at their 
proximal ends. At the G1-S transition a new daughter centriole (procentriole) begins to form at 
one site on the lateral side of each existing (mother) centriole (Robbins et al. 1968). The 
procentriole is connected to the mother centriole by a linker. The procentrioles elongate 
throughout S and G2. Then in M phase the tether between the two mother centrioles is 
released and the new centriole pairs disengage. The two newly formed centrosomes form the 
poles of the mitotic spindle whereupon each is segregated into the new daughter cells 
(Reviewed in Nigg et al. 2011). Importantly, in quiescent (G0) cells the mother centriole can 
migrate to the cell surface whereby it associates with the plasma membrane and forms the 
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basal body from which the axoneme extends to form the primary cilium (Sorokin. 1962, Nigg, 
et al., 2011).  
 It is crucial that every centriole duplicates just once per cell cycle and that each pre-existing 
centriole forms just one new, adjacent centriole (Tsou et al. 2006). If there is multiple 
replication of centrioles there will be centrosome amplification (Ganem et al. 2009). 
Centrosome amplification was defined by D’Assoro et al. as centrosomes that are larger than 
normal, a cell with more than four centrioles or with more than two centrosomes present 
(D’Assoro et al., 2002). Centrosome amplification results in the formation of multipolar 
spindles and subsequent chromosome missegregation (Ganem et al. 2009). Boveri observed 
the formation of multipolar spindles in tumour cells with chromosome amplification and 
hypothesised the resultant chromosome missegregation contributed to the chromosome 
instability seen in malignant tumours (Boveri. 1914), a process now commonly reported to 
contribute to the disease phenotype in cancer cells (Ro et al. 2004). 
6.1.2 ATTACHMENT OF THE CENTROSOME TO THE NUCLEAR ENVELOPE 
 In most metazoan cells the centrosome is positioned very close to the nucleus. There has long 
been the hypothesis that a physical tether connects the centrosome to the nuclear envelope, a 
hypothesis that was seemingly supported by the observation that the centrosome remained 
closely associated with the nucleus after disruption physically, after gentle homogenisation, or 
biochemically, after disruption of the nuclear membrane with triton-x-100 (Nadezhdina et al. 
1979.).  
The positioning of the centrosome close to the nucleus could be important for a number of 
reasons such as maintaining a close location to the chromosomes for the formation of mitotic 
spindle following nuclear envelope breakdown (Burakov et al. 2013). Moreover, it is known 
that centrosome position relative to the nucleus is important for cell polarity and migration 
(Luxton et al. 2011). For example, in migrating myoblasts it has been shown that the 
centrosome was positioned between the nucleus and the leading edge of the cell, as a 
consequence of active rearwards movement of the nucleus in an actomyosin dependent 
mechanism (Gomes et al. 2005). In the case of cell polarisation, the repositioning of the 
centrosome and the consequent reorganisation of the microtubule network allows the 
asymmetrical positioning of cellular organelles. For example, there is F-actin mediated 
retrograde transport of the nucleus and subsequent centrosome repositioning in polarised 
fibroblasts (Chang et al. 2013). In addition to the role of F- actin, the microtubule network and 
the microtubule motors, dynein and kinesin, regulate centrosome position. It is thought that 
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dynein brings the nucleus towards the centrosome, moving along microtubules towards the 
minus end at the centrosome (Burakov et al. 2003).  
Once the centrosome is juxtaposed at the nuclear envelope the mechanisms by which the two 
organelles are tethered are not fully understood. In recent years, however, a number of 
proteins have been identified which play a role in the centrosome association to the nucleus. 
An early example came from Caenorhabditis elegans (C. elegans) in which ZYG-12, a KASH 
domain containing protein, was found to localise at the nuclear envelope and centrosome 
(Malone et al. 2003). ZYG-12 was proposed to anchor the centrosome to the nucleus by 
associating with itself on these two organelles whilst being anchored to the nuclear envelope 
via LINC complex component SUN-1 (Malone et al. 2003, Minn et al. 2009). This mechanism is 
true up until early embryogenesis however later does not appear to be the sole mechanism of 
nucleus-centrosome coupling (Zhou et al. 2009). In neuronal cells deletion of Hook3, the 
mammalian homolog of ZYG-12, led to disrupted assembly of proteins at the centrosome and 
attachment of microtubules to the centrosome (Ge et al. 2010). The connection between ZYG-
12 and the centrosome itself remains unclear although it is known that Hook3 interacts with 
the PCM protein PCM-1 (Ge et al. 2010).  
Since the C. elegans study there have been a number of reports implicating components of the 
LINC complex and its interacting proteins with the nuclear- MTOC attachment. The LINC 
complex is an important facilitator of interaction between the nucleoskeleton and the 
cytoskeleton (Reviewed in Razafsky et al. 2009). The cellular processes in which the LINC 
complex has roles is steadily expanding, with roles in cellular rigidity (Lombardi et al. 2011, 
Stewart-Hutchinson 2008), nuclear shape (Luke et al. 2008), nuclear movement, which is 
facilitated through the interaction of the LINC complex actin cables known as TAN lines (Luxton 
et al. 2010) and centrosome attachment to the NE (Malone et al. 2003), though there is still 
much to be explored in the mechanisms through which these are achieved. 
In yeast Schizosaccharomyces pombe (S. pombe) it was found that microtubules were 
physically interacting with the nucleus, and the heterochomatin within, through a SUN- KASH 
complex of Kms2 in the outer nuclear membrane and Sad1 and Ima1 in the inner nuclear 
membrane (King et al. 2008). When Ima1 was disrupted or depleted the site of attachment of 
the MTOC to the nuclear membrane was disrupted (King et al. 2008). The mammalian homolog 
of Ima is Samp1. Samp1 can localise to the inner nuclear membrane where it interacts with 
component of the LINC complex SUN2 and lamins A/C (Borrego-Pinto et.al. 2012). 
Interestingly, Samp1 has also been detected at the spindle matrix and polar region of the 
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mitotic spindles during mitosis (Buch et al. 2009). Depletion of Samp1 led to an increased 
centrosome to nuclear envelope distance (Buch et al. 2009). 
It has been shown that the nuclear envelope protein emerin couples the centrosome to the 
nucleus (Salpingidou et al., 2007). Emerin is predominantly thought of as an INM protein 
however it has been demonstrated that a pool of emerin is also found localised at the ONM. 
Salpingdiou et al.  have demonstrated that an ONM pool of emerin can interact with β-tubulin 
and mediate the attachment of the centrosome to the NE (Salpingidou et al., 2007). Further 
support for the role of emerin in maintaining the connection between the centrosome and the 
nucleus can be seen in mice models of EDMD and fibroblasts from patients with x-EDMD, both 
lacking emerin protein, in which the distance between the centrosome and the nucleus was 
also increased (Hale et. al.  2008, Salpingidou et al., 2007). It was also found that centrosome 
to nucleus distance was increased in cells in which A-type lamins were deficient or reduced, 
such as is the case in laminopathies (Hale et. al.  2008).  Emerin localisation is regulated by 
lamin A and the increased distance was attributed to mislocalisation or loss of emerin from the 
nuclear envelope in these cells (Hale et. al.  2008). Interestingly the multifunctional structural 
protein 4.1R was shown to immunoprecipitate with emerin and lamin A/C and furthermore 
when 4.1R was depleted both these proteins were mislocalised (Meyer et al. 2010). In these 
cells the centrosome to nucleus distance was also increased, again likely due to the disrupted 
localisation of emerin (Meyer et al. 2010). 
It has also been shown that when nesprin 3, a KASH domain protein, is depleted in endothelial 
cells, centrosome polarisation and nucleus-centrosome distance is increased (Morgan et al. 
2011). Nesprin 3 is smaller than the Nesprin 1 and 2 isoforms and contains a plectin binding 
domain rather than an actin binding domain at its N-terminus (Razafsky et al. 2009). 
Interestingly it has also been shown that BRCA2 interacts with plectin and mediates 
centrosome localisation (Niwa et al. 2009). Morgan et al therefore hypothesised that nesprin 3 
mediates centrosome positioning through this plectin mediated interaction with the 
intermediate filaments (Morgan et al. 2011). 
Centrosome coupling to the nucleus has also been shown to be regulated by Sun1 and Sun2 in 
complex with syne-2 in mice (Zhang et al. 2009).  Knockouts of the aforementioned 
components resulted in large increases in nucleus- centrosome distance (Zhang et al. 2009). 
The connection between syne-2 and the centrosome is mediated through interactions with the 
microtubule motors dynein and kinesin (Zhang et al. 2009). Dynein and kinesin are thought to 
be important in the movement of the nucleus along the microtubules towards or away from 
the centrosome respectively (Razafsky et al. 2009, Zhang et al. 2009, Meyerzon et al. 2009). It 
187 
 
is, therefore, difficult to dissect a direct role of tethering from the disruption of the 
dynein/kinesin role in positioning in the SUN or Syne knock out animals and there may be as 
yet undiscovered connections between the LINC complex and the centrosome.  
In addition to interactions with the microtubule network, the LINC complex is also well known 
to interact with the actin cytoskeleton (Zhang et al. 2002, Razafsky et al. 2009), and a role of 
actin in centrosome positioning is by no means new (Shay et al. 1974). A recent paper indicates 
a role for F-actin filaments nucleating from the centrosome in connecting the centrosome to 
the nucleus (Obino et al. 2015). It was hypothesised that Arp 2/3 dependent nucleation led to 
a network of F-actin filaments emanating from the centrosome that were bound by nesprin, 
holding the centrosome at the nucleus in lymphocytes (Obino et al. 2015). When Arp 2/3 was 
depleted at the centrosome during lymphocyte activation, resulting in reduced F-actin at the 
centrosome or when a dominant- negative form of nesprin unable to bind actin was expressed 
the centrosome was able to move further from the nucleus (Obino et al. 2015). 
Thus there is an emerging web of complex interactions of nuclear proteins and cytoskeletal 
components involved in the tethering of the centrosome to the nuclear envelope. 
6.1.3 DG AND THE CENTROSOME 
There is little published work available regarding a role for dystroglycan at the centrosomes 
however in C2C12 cells in which DG had been reduced by RNAi the distance of the 
centrosomes from the nucleus was increased and there was also a significant increase in the 
number of cells with amplified (3-6) centrosomes (Martinez- Vieyra et al. 2013). Furthermore, 
DG has been shown to affect the localisation of nuclear envelope protein, emerin and 
potentially interact with components of the LINC complex, all of which modulate centrosome 
position, as described above (Martinez- Vieyra et al. 2013). Interestingly, in 
immunofluorescence studies conducted as part of this thesis pY892 βDG was observed to 
localise at the spindle poles in mitotic cells (Fig 5.20) and also displays a bright punctate stain 
in interphase cells (Data not shown, S. Winder personal communication). It was therefore 
decided to investigate βDG localisation and function at the centrosome. 
6.1.4 CHAPTER AIMS 
The aims of the research conducted in this chapter are: 
-to investigate the localisation of βDG at the centrosomes. 




6.2.1 IMMUNOFLUORESCENCE ANALYSIS OF PY892 BDG LOCALISATION AT THE CENTROSOME  
 Whilst analysing the localisation of βDG in interphase it was observed that the antibody 1709, 
which recognises pY892, often displayed a bright punctate stain at one or two locations in the 
cell (Fig 6.2, arrows). The bright punctate stain was strongest in cells fixed via MeOH/ acetone 
fixation as used when observing microtubules (Chapter 5, Fig 5.20). Interestingly in mitotic 
cells there was a strong localisation of 1709 antibody signal at the mitotic spindle at a location 
where the MTOC would be expected to be (Chapter 5, Figure 5.20). These observations 
warranted further investigation into βDG localisation at the centrosome. 
 
Figure 6.2 Punctate localisation of pY892 βDG in LNCaP cells. LNCaP cells were fixed with 3.7% PFA and 
stained for pY892 βDG with the 1709 antibody (green) nuclei were counterstained with DAPI (blue). 
Images were obtained via epifluorescence microscopy. Arrows indicate bright punctate structure 







6.2.2 ANTI B-DG ANTIBODIES 1709 AND JAF1 LOCALISE AT THE CENTROSOME IN 
INTERPHASE AND MITOTIC CELLS. 
It was decided to investigate if βDG was localising to the centrosomes and to see if this was 
also the case for βDG that was not phosphorylated at pY892. LNCaP cells were fixed with 
MeOH/ Acetone and stained with one of three βDG antibodies, MDG2 and JAF1, the epitopes 
of which are non-phosphorylated βDG at Y892, or 1709, which detects the pY892 form of βDG. 
The cells were co-stained with γ-tubulin, a marker of the centrosome. MDG2 did not co-
localise with γ-tubulin in either interphase of mitotic cells (Fig 6.3). 1709 and JAF1, however, 
both co-localised with the centrosome marker in both interphase and mitotic cells (Fig 6.3). 
This suggests that both phosphorylated and non-phosphorylated Y892 βDG may localise to the 
centrosome. The fact that JAF1 but not MDG2 localised at the centrosome despite having 
overlapping and very similar epitopes may be due to JAF1 recognising slightly different epitope 
that may be independent of Y892. 1709 and JAF1 localised to the centrosome at all stages of 
mitosis (not shown) but was particularly strong in metaphase cells (Fig 6.3). The colocalisation 
of 1709 and JAF1 but not MDG2 with γ-tubulin was also observed in PNT1A and PC3 cells (data 





Figure 6.3 anti-βDG antibodies 1709 and JAF1 localise at the centrosomes in interphase and mitotic 
cells. LNCaP cells were fixed with MeOH and stained for βDG with two different antibodies (MDG2) (top) 
and JAF1 (bottom) or pY890 βDG (1709) (middle) (Green). Cells were costained for gamma tubulin (red) 
and the nuclei counterstained with DAPI (blue). Images are Z slices from confocal microscopy taken at 
the clearest Z slice of the centrosome. Images were taken at 60 x magnification. Scale bar is 10 µm. 
Enlarged images of the centrosome (white box) are included. Arrow indicates the centrosome. Scale bar 






6.2.3 TAGGED FORMS OF ΒDG DO NOT LOCALISE TO THE CENTROSOME 
 
A problem when studying the proteins at the centrosomes is the false positive detection of 
proteins as a consequence of antibody cross-reactivity or non-specificity (Moudjou, et al. 
1996). In order to ascertain if βDG truly localises to the centrosome, tagged versions of βDG 
were analysed via co-immunostaining and confocal microscopy to determine if the tagged 
versions could be detected at the centrosome independent of the βDG antibodies. 
 
Figure 6.4 Myr-CβDG-GFP does not colocalises to the centrosomes in LNCaP cells. LNCaP cell lines 
stably expressing Myr-CβDG-GFP (green) were fixed and co-stained with γ- tubulin (red). DNA was 
counterstained with DAPI (blue). Z slice Images of interphase (top) and mitotic (bottom) cells were taken 
via confocal microscopy. Scale bar is 10 µm. Inset are enlarged regions of the white box. Asterisk 








6.2.3.1 Myr-cβDG-GFP does not localise to the centrosome 
One well studied tagged βDG construct available in the Winder lab is a myristoylated 
cytoplasmic fragment of βDG with a c-terminal GFP (Myr- cβDG-GFP) (Batchelor et al., 2007, 
Mathew et al., 2013). Stable LNCaP cells expressing this construct were fixed and co-stained 
with γ-tubulin and imaged via confocal microscopy. Despite a clear localisation to the PM as 
expected (Batchelor et al, 2007) Myr- cβDG-GFP did not colocalise with γ-tubulin in either 
interphase or mitotic cells (Fig 6.4). There a few caveats to consider when using this construct. 
Firstly, although Myr- cβDG-GFP has been shown to localise βDG efficiently to the plasma 
membrane and the nucleus, partly facilitated by the myristoyl tag, it is unknown if the 
construct fully mirrors wildtype βDG localisation. Indeed, it should be considered that the 
myristoyl tag may be targeting βDG to membranes and could therefore affect its potential 
localisation to the centrosome.   Furthermore is only a fragment of βDG which may have 
unknown consequences on βDG behaviour or localisation. Secondly, Myr- cβDG-GFP contains a 
c-terminal GFP which has been reported to perturb βDG phosphorylation at Y890 and 
potentially other functional properties of the crowded C-terminal tail of βDG (D. Leocadio, 
2014). This may be particularly relevant in the context of this experiment given the strong 
localisation of pY890 specific antibody 1709 to the centrosome.  As such the localisation of a 
second tagged-version of βDG at the centrosome was also investigated. 
6.2.3.2 αβDG flag does not localise to the centrosome in LNCaP cells 
 LNCaP cells were transiently transfected with αβDG-flag and immunostained with anti-flag 
and γ-tubulin. The αβDG-flag construct has been described in previous chapters of this thesis.  
αβDG-flag did not colocalise with γ-tubulin in the interphase LNCaP cells (Fig 6.5). 
Unfortunately, no mitotic cells were observed as a consequence of the low proliferation seen 
in the transfected cells (Chapter 5, Fig 5.21). The flag tag is not thought to interfere with any 
known or putative interactions of βDG however there is the possibility of the tag interfering 
with as yet undescribed modifications or interactions that may perturb its function. Together 











Figure 6.5 αβDG flag does not colocalises to the centrosomes in LNCaP cells. LNCaP cells were 
transiently transfected with αβDG flag fixed and co-stained anti-flag (green) and γ- tubulin (red). DNA 
was counterstained with DAPI (blue). Z slice Images of interphase cells were taken via confocal 
microscopy. Scale bar is 10 µm. Inset are enlarged regions of the white box. Arrows indicate the 
centrosome. Scale bar is 2 µm. Images were taken at 60x magnification. 
6.2.4 B-DG ANTIBODIES STAIN THE CENTROSOMES IN DAG1 NULL SYSTEMS 
A complementary approach to assess if the localisation of βDG at the centrosome is specific or 
an artefact of the antibody is to look at the expression pattern of the antibodies in a system 
lacking βDG protein expression. 
6.2.4.1 1709 colocalises with γ-tubulin in DAG1-/- zebrafish embryos 
One available DAG null system that has previously described in this thesis and elsewhere is the 
DAG1 zebrafish line. DAG1 fish have a point mutation in the DAG1 gene and do not express 
βDG protein (Lin et al 2011, Gupta et al 2011). DAG1-/-  fish have a dystrophic phenotype and 
this was used to sort the zebrafish embryos via birefringence into populations of DAG1+/+ and 
DAG1+/- fish or DAG1-/-  at 4 d.p.f. Zebrafish embryos from each group were then 
immunostained with 1709 and γ-tubulin and viewed via confocal microscopy. In both the 




Figure 6. 6. 1709 antibody localises to the centrosomes in DAG-/- zebrafish embryos. At 4 d.p.f 
zebrafish embryos were identified as DAGsib or DAG-/-, fixed and stained for pY892 βDG (1709) (green) 
and γ-tubulin (red). Nuclei were counterstained with DAPI (blue). Confocal images at 60 x magnification 
were taken with a water- dipping lens. Enlarged images of the white box are included, arrows indicate 
the centrosomes. 
 
6.2.4.2 1709 and JAF1 localise to the centrosomes in DAG null fibroblasts 
The recent isolation of DAG null fibroblasts from a patient with Walker-Warburg syndrome 
(Riemersma et al. 2015) presents a second DAG null system in which to assess if βDG 
localisation at the centrosome is an artefact of the antibodies. HDF control cells and DAG null 
fibroblasts were co-stained with 1709 or JAF1 alongside γ-tubulin. In interphase cells 1709 and 
JAF1 colocalised with γ-tubulin in the HDF controls but also the DAG null fibroblasts (Fig 6.7 A, 
B). As there is no βDG in the DAG null cells to be detected, this clearly demonstrates an 
artefactual staining of the antibodies at the centrosome. A secondary antibody control shows 
very faint background staining, showing that it is an artefact of the primary antibody and not 







Figure 6.7 βDG antibodies localise to the centrosome in HDF and DAG null fibroblasts. HDF and DAG 
null fibroblasts were fixed with MeOH/ Acetone and stained for pY890 βDG (1709) (A) or βDG (Jaf1) (B) 
(green). Centrosomes were stained with γ-tubulin (red) and the nuclei counterstained with DAPI (blue). 
Images are z slices taken via confocal microscopy at 60x magnification. Scale bar 10 µm. Inset are 
enlarged images of the white box.  Arrows indicate centrosome location. Scale bar 2 µm.  C) Secondary 
antibody control. DAG null fibroblasts were immunostained with secondary antibodies Alexa 488 and 




6.2.5 CENTROSOME POSITION AND NUMBER IN DAG NULL FIBROBLASTS 
Although the above results indicate that βDG does not localise at the centrosomes, there is still 
the potential for a role for βDG in regulating centrosome function or localisation indirectly. 
βDG has been proposed to interact with the LINC complex at the nuclear envelope (Personal 
communication S. Winder and M. Laredo), a complex with roles in tethering the centrosome to 
the nuclear lamina. Moreover, Martinez-Vieyra et al. reported an increased nucleus-
centrosome distance and centrosome duplication in DG RNAi C2C12 cells in which nuclear 
morphology and nuclear envelope proteins were disrupted (Martinez- Vieyra et al. 2013). 
Nuclear morphology is severely disrupted in the DAG null fibroblasts (Section 4.2.1), we 
therefore investigated if centrosome amplification and positioning was also affected in these 
cells. 
6.2.5.1 Centrosome to nucleus distance  
HDF and DAG null fibroblasts were fixed and the centrosome stained for γ-tubulin and the 
nucleus counterstained with DAPI (Fig 6.8, A-F). The distance between the centrosome 
(measured from the closest centriole) to the nuclear envelope was measured in Fiji. The mean 
distance was 1.795µm in HDF cells compared to 2.483 µm in the DAG null fibroblasts but this 




Figure 6.8. Centrosome to nucleus distance in HDF and DAG null fibroblasts. Representative confocal 
images of HDF (A-C) and DAG null fibroblasts (D-E). Nuclei (blue) are stained with DAPI and the 
centrosomes are stained with γ-tubulin (red). The distance between the centrosome and the nuclear 
envelope were measured using image J. (white line). Scale bar 10um. G) Mean distance ± SEM of 2 
replicates each with at least n=100 per cell type. Mann-Whitney U test, P=0.0592. H) Scatter plot of total 
distance ± SEM between the centrosome and the nucleus. 2 replicates, each with at least n=100 per cell 
type 
 
6.2.5.2 Centrosome number 
Centrosome amplification was also analysed from the experiments described above.  γ-tubulin 
antibodies detect the centriole pair within the centrosome (Fuller et al. 1995), thus one 
centrosome is detected as two centrioles. No HDF cells were observed with multiple 
centrosomes whilst a small number of DAG null fibroblasts at 1.57 ±0.84 % had multiple 
centrosomes (3 or more) (Fig 6.9 A-C).  The majority of cells of both HDF and DAG null 
fibroblasts had 1 centrosome with a small percentage of cells with 2 centrosomes as would be 
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expected from a population of dividing cells. These results show a trend towards increased 
nucleus to centrosome distance and centrosome amplification in the DAG null fibroblasts, 
however the results are not statistically significant (Fig 6.9 B, C).  
 
Figure 6.9. Centrosome number in HDF and DAG null cells (A)Representative confocal images of DG null 
nuclei with 1 (left) or >2 centrosomes (right) stained with DAPI and the centrosomes stained with γ-
tubulin (red). Inset; enlarged centrosome image. Scale bar is 10 µm. 2 replicates, each with at least 








The centrosome is an important organelle regulating a number of cellular processes including 
cell polarity, migration and division (Azimzadeh et al. 2007, Luders et al. 2007). A functional 
centrosome requires the cooperation of a large number of diverse proteins in the PCM 
(Andersen, et al. 2003, Lawo et al. 2012) but also of interacting partners that regulate 
centrosome positioning and interaction with other organelles, such as the nucleus (Burakov et 
al. 2013). The functions and mechanisms of these proteins are gradually resolving however are 
not completely understood. It has been reported that centrosome number and distance from 
the nucleus are disrupted in C2C12 myoblast cells treated with DG RNAi (Martinez- Vieyra et al. 
2013).  Furthermore, βDG interacts with, and modulates the localisation of emerin and lamin 
(Martinez- Vieyra et al. 2013), components of the nuclear envelope that are established as key 
proteins in the tethering of the centrosome to the nucleus (Salpingidou et al. 2008, Hale et al. 
2008). We have also observed the localisation of βDG antibodies to punctate foci within a 
variety of cells, hypothesised to be the centrosome or primary cilia (Fig 6.2). In light of these 
observations we set out to investigate the localisation or functional roles for βDG with the 
centrosome. 
6.3.1 THE LOCALISATION OF ΒDG AT THE CENTROSOME IS AN ARTEFACT OF THE PRIMARY 
ANTIBODIES 
We have shown that βDG antibodies 1709 and JAF1, but not MDG2, localise to the 
centrosomes in both interphase and mitotic cells (Fig 6.3). However subsequent investigation 
has shown this to be an artefact of the antibodies rather than βDG localisation at the 
centrosomes. This was concluded from two different experimental approaches. Firstly, two 
different tagged forms of βDG, a cytoplasmic fragment (Myr-CβDG-GFP) (Fig 6.4) and a flag 
tagged full length βDG (αβDGflag) (Fig 6.5) did not localise to the centrosomes. Although there 
are arguments that tags can affect the behaviour of proteins and that the fragment may not 
localise to the centrosome endogenously, the artefactual staining of the antibodies was 
supported by analysis in DAG null systems. In two different DAG null systems, the DAG1-/- 
zebrafish embryos (Lin et al. 2011, Gupta et al. 2011) (Fig 6.6) and DAG null fibroblasts from a 
patient with Walker Warburg syndrome (Riemersma et al. 2015) (Fig 6.7), the DG antibodies 
1709 and JAF1 stained the centrosomes. The staining of the centrosomes in the absence of DG 
confirms that the localisation at the centrosome of these antibodies is not specific to βDG. 
The artefactual staining of the centrosomes by antibodies, especially with those derived from 
rabbit sera as is the case with 1709 and JAF1, is a notorious problem in the study of 
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centrosomal proteins (Moudjou et al. 1996). Sera from rabbits can contain pre-immune activity 
against proteins in centrosomes and basal bodies. This is best demonstrated in a study in 
which a γ-tubulin antibody was being developed where the detection of the centrosome via 
immunofluorescence was observed in the preimmune sera of all 12 rabbits used Moudjou et 
al. 1996.  In fact, the discovery of a number of centrosomal proteins has stemmed from the 
activity of autoimmune sera. For example, the rabbit 0013 serum (Gosti-Testu et al. 1986) led 
to the identification of AKAP350, a protein kinase A anchoring protein found in the 
centrosomes (Keryer et al. 1993) whilst human autoimmune sera 5051 (Calarco-Gilam et al. 
1983) led to the identification of pericentrin (Doxsey et al. 1994). Alternatively, there may be 
epitope similarity of 1709 and JAF1 in other proteins that are localised at the centrosome. 
Thus, the direct interaction of a protein at the centrosome should always be confirmed 
through biochemical techniques. The non-specific staining at the centrosome and the now 
apparent problems of broader non-specific staining of 1709 and JAF1 (as discussed in Chapter 
3) highlights the necessity of rigorous controls for antibodies for their use in various 
techniques. Affinity purification of the antibodies 1709 and JAF1 with their respective antigens 
should be conducted to reduce the non- βDG specific detection of these antibodies for use in 
future applications. 
6.3.2 CENTROSOME TO NUCLEUS DISTANCE AND AMPLIFICATION IN DAG NULL FIBROBLASTS 
It is not necessarily surprising that βDG does not localise at the centrosome itself and it is 
perhaps more intuitive that βDG may exert its influence over the centrosomes through its 
localisation and roles at the nuclear membrane. A number of components of the nuclear 
envelope such as emerin, Lamins, nesprins and SUN proteins have all been implicated in 
centrosome positioning near to the nucleus (Burakov et al 2013, Salpingidou et al. 2008, Hale 
et al. 2008, Malone et al. 2003, King et al. 2008, Zhang et al. 2009). The contribution of these 
proteins to centrosome positioning can be through their interaction with the microtubule or 
actin cytoskeleton or their roles in maintaining localisation of other components of the nuclear 
envelope which in turn interact with the centrosome through the cytoskeleton or microtubule 
motors such as dynein (Burakov et al 2013). Depletion of DG via RNAi in C2C12 cells led to both 
mislocalisation of nuclear envelope components emerin and lamin A/C but also an increase in 
the distance from the centrosome to the nucleus and centrosome number in cells, likely as a 
consequence of the disrupted nuclear envelope (Martinez- Vieyra et al. 2013). In this study we 
asked if nucleus to centrosome distance was also increased in the human patient primary DAG 
null fibroblasts. In this instance, although there was a trend towards an increase in the 
distance (Fig 6.8) and a small number of cells with amplified centrosomes (Fig 6.9), it was not 
statistically significant. In the report by Martinez-Vieyra et al. the number of cells with 
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amplified centrosomes increased from 2% to 17% whilst the distance between the centrosome 
and the nucleus increased from 0.75µm to 1.8µm from wildtype C2C12 to DG RNAi C2C12 cells 
(Martinez- Vieyra et al. 2013). The difference between the significance of the results may be 
due to the cell types in which the experiments were conducted, although the importance of 
nuclear envelope proteins in tethering the centrosome has been seen in multiple cell types. It 
is also important to consider whether HDF cells are the best controls for the DAG null 
fibroblasts as they are from a different source and may be of a different age, thus a subtle 
change in distance may not be detected between these cells. It would be better to compare 
the DAG null fibroblasts to the same cells in which DG has been reexpressed.  
The nuclear morphology of the DAG null fibroblasts is clearly disrupted (Section 4.2.1) it, would 
therefore be interesting to fully investigate the localisation of emerin, lamins and LINC 
complex components in these cells, which may shed light on both the nuclear morphology and 
centrosome positioning. It will also be important to investigate these localisations and 
interactions in a number of different cell types which have different adhesion and migration 
properties, which may have different contributions to nucleus and centrosome positioning. 
DG can directly bind f-actin (Chen et al. 2003), it would therefore be interesting to investigate 
if DG influences centrosome position through emerin or another NE protein or itself through 
its cytoskeleton binding abilities. For example, this could be addressed through the expression 
of DG mutants with the inability to bind F-actin. As discussed in chapter 4, it is however, 
difficult to dissect roles of DG on the cytoskeleton from its localisation at the plasma 
membrane, from its roles in the nucleus. 
Investigating the proteins contributing to nucleus- cytoskeletal connections at the centrosome 
is also important for our understanding of a number of diseases. There are a number of 
diseases stemming from mutations of nuclear envelope proteins, including laminopathies such 
as Hutchinson- Gilford progeria syndrome (HGPS) or emerin deficient X-linked EDMD (Worman 
2012). Centrosome detachment from the nucleus and subsequent loss of the ability to polarise 
has been reported in mice models of these diseases (Hale et al. 2008). Centrosome 
amplification and abnormalities have also been reported with carcinogenesis (Boveri, 1914, 
D’Assoro et al. 2002, Ro et al, 2004). Thus understanding the mechanisms of centrosome 





1. Anti- βDG antibodies 1709 and JAF1 localise to the centrosome in interphase and mitotic 
cells. 
2. The localisation of 1709 and JAF1 at the centrosome is an artefact of the primary antibodies 
as determined by studies of tagged βDG protein and DAG null systems. 
 -Myr-cβDG-GFP and αβDGflag do not localise to the centrosomes 
 -1709 and JAF1 detect the centrosomes in DAG1-/- zebrafish embryos and DAG null 
fibroblasts. 
3. There is a small but not statistically significant increase in the distance between the nucleus 
and the centrosome in DAG null fibroblasts compared to HDF cells and a very small number of 

























The data presented in this thesis concur with and expand upon the current knowledge of a 
dynamic localisation of βDG within the nucleus and its mechanisms of regulation and functions 
therein. βDG is localised to multiple nuclear compartments including the NE, nucleoplasm and 
nucleoli in cancerous and ‘normal’ prostate cell lines and primary fibroblasts and, in 
conjunction with previous reports in the literature, indicates a role for βDG within the nucleus 
across multiple cell types (Oppizzi et al. 2008, Lara-Chacon et al. 2010, Martinez-Vieyra et al. 
2013, Mathew et al. 2013). The severely disrupted nuclear morphology seen in DG null 
fibroblasts supports the hypothesis of a structural function of βDG within the nucleus which, 
although not addressed directly in this study, is potentially a consequence of the loss of the 
reported interactions of βDG with structural components of the NE including emerin and 
lamins (Martinez-Vieyra et al. 2013). Disruptions to the nuclear envelope organisation and 
proteins can result in mislocalised centrosomes. However, in contrast to a report in myoblasts, 
depleted levels of DG did not cause a significant increase in the NE to centrosome distance or 
centrosome number in the DG null fibroblasts. The disparity may be a consequence of differing 
contributions of DG to the role in different cell types cell types, migration status of the cells, or 
experimental caveats as addressed in chapter 6. Furthermore, it was shown that βDG does not 
localise to the centrosome itself and that the staining observed at the centrosomes with two 
separate anti- βDG antibodies was artefactual. Therefore, any potential role for DG in 
centrosome regulation could be through dystroglycan’s interactions within other cellular 
structures such as the nuclear envelope or the cytoskeletal network. 
Phosphorylation and the cell cycle were also investigated as potential regulatory mechanisms 
of the dynamic nuclear localisation of βDG. The phosphorylation status of residue T788 βDG 
did not appear to affect its nuclear localisation although may have roles in protein stability, 
thus opening an avenue for future research into the behaviour and regulation of βDG. 
Although DG regulation and the cell cycle are undoubtedly linked, a role for the cell cycle in the 
nuclear localisation of βDG remains inconclusive, although there is some evidence to suggest 
fluctuating levels of βDG at different stages of the cell cycle. Some caveats and further 
implications of the data obtained in this project are discussed below. 
PTM are crucial regulators of protein localisation, including nuclear targeting. Antibodies raised 
against unphosphorylated and phosphorylated Y892 βDG epitopes detected βDG within the 
nucleus, suggesting that this modification is not essential for its nuclear targeting, in support of 
observations from previous studies in which Y892 has been mutated (Lara-Chacon et al. 2010, 
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Leocadio. 2015). Phosphorylation at residue T788(mouse)/ T790 (human) was hypothesised as 
a candidate for the nuclear targeting of βDG however neither phospho-mimetic or phospho-
null mutations at this site altered the nuclear localisation of βDG, however there is preliminary 
evidence to suggest that a phospho-mimetic mutation at this site increases the protein’s 
stability.   
Phosphorylation involvement in the regulated degradation of proteins is widely reported and 
can be via phosphodegrons, in which phosphorylation of a short motif promotes subsequent 
ubiquitination and degradation, or alternatively phosphorylation can prevent degradation by 
modifying a constitutively active degradation motif (Ravid et al. 2008, Holt et al. 2012). 
Ubiquitination of βDG has been reported by multiple groups and, interestingly, the E3 ligase 
NEDD4L has been identified as interacting with βDG via both mass spectrometry and Y2H 
screens (Leocadio 2015 and S. Winder personal communication). Moreover, using in vitro 
studies with peptide arrays and recombinant proteins, an interaction between the WW 
domains on NEDD4L and the peptide sequence LEDQATFIKKGVPI, corresponding to residues 
883-896 of βDG, was identified (Piggott, 2014). The T788 phosphorylation site lies within this 
sequence and it could therefore be possible that phosphorylation at this site could modulate 
an interaction between βDG and the E3 ligase and ultimately the proteasome mediated 
degradation of βDG. However, further in vivo studies in H2K cells and pull downs with 
recombinant fragments of NEDD4L and βDG did not demonstrate an interaction. It is possible 
that NEDD4L is interacting at different sites of βDG for example with one of the three PEST 
(Pro, Asp, Ser, Thr) motifs within its sequence or it may not be a direct interaction between the 
two proteins (Piggott, 2014). An avenue of future research could aim to assess the role of 
phosphorylation at T788 on the degradation of βDG via cell lines stably expressing the T788 
mutant constructs in parallel with proteasome inhibitors, ubiquitin-specific resins such as 
Mdsk and interaction studies with E3 ligases.  
Whilst it is important to understand the mechanisms of nuclear translocation, this project also 
aimed at identifying the cellular cues that result in a fluctuating level of nuclear DG. Although 
by no means conclusive, there is some evidence to suggest a role for the cell cycle in regulating 
the nuclear levels of βDG. There was a slight correlation between the percentage of cells in S 
phase and an increase in the quantified levels of total DG, this seemingly agrees with two 
separate reports in which DG increased in proliferating cells, particularly at S phase (Sgambato 
et al. 2006, Hosokawa et al. 2001). However, as previously discussed there are caveats 
regarding the quantification and variability of the expression of βDG in the thymidine 
synchronised populations and thus the potential slight fluctuation of βDG should be 
interpreted with caution requires further investigation. The reports by Sgambato et al and 
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Hosokawa et al. indicate that the cell cycle dependent regulation is at the level of 
transcription, through as yet unknown mechanisms (Sgambato et al. 2006, Hosokawa et al. 
2001). Furthermore, in this study, βDG species with different Y892 phosphorylation statuses 
displayed varying degrees of fluctuation in their nuclear levels and correlation to cell cycle 
phases.  
One can suggest a scenario in which the total levels of βDG are increased at a certain point in 
the cell cycle, seemingly S phase. There is a corresponding increase in the levels of 
phosphorylated Y892 βDG. pY892 promotes the internalisation of βDG from the membrane 
(Sotgia et al. 2003, Miller et al. 2012) the observed increased in this modified form of βDG may 
simply be a consequence of an increased level of DG substrate for the kinase or actively 
increased phosphorylation in response to a cellular cue. For example, an increase in 
phosphorylation at Y892 might be important in reducing the amount of βDG within cell 
adhesions at the cell surface when the cell rounds up and reduces adhesions during mitosis. 
Internalisation from the membrane is presumably a necessary step in the process of nuclear 
translocation of βDG if the source is the plasma membrane. In this scenario there would 
therefore be an increased intracellular pool of βDG available for interaction with nuclear 
import proteins. Once internalised there are likely specific PTM promoting or disrupting 
interactions with proteins that regulate nuclear transport or cytoplasmic or nuclear retention. 
The nature of the PTM or interactions promoting nuclear translocation at this time point and 
whether they are actively regulated by the cell cycle or just increased activity of the basal 
machinery as a consequence of increased internalised levels of DG is unclear. The fate of the 
nuclear DG is yet to be determined and it may be targeted for degradation or may play a role 
in cell cycle or nuclear processes. Any hypothetical role for DG in the cell cycle is clearly not 
vital as in DG null or knockdown systems cell still progress through the cell cycle, albeit with 
delays (Higginson et al. 2008, Sgambato et al. 2006).  
The non-nuclear levels of pY892 βDG do not fluctuate significantly in the synchronised 
populations or decrease at the time point corresponding to increased levels in the nuclear 
fraction, a result which could suggest that the excess internalised βDG is targeted to the 
nucleus. Conversely a significant correlation with S phase is seen in the non-nuclear but not 
the nuclear levels of non-phosphorylated Y892 βDG. This observation may support the 
hypothesis that the nuclear translocation follows an increased internalisation from the PM as a 
result of its phosphorylation, whilst the non-phosphorylated population remains largely at the 
cell surface.  Unfortunately, the dynamic localisation of pY892 βDG could not be validated via 
immunofluorescence analysis studies due to the artefactual staining demonstrated by the 
1709 antibody in this technique. 
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A useful tool in the study of the behaviour of proteins in a dynamic process such as the cell 
cycle is live cell imaging. This process ideally requires a fluorescent tag. Whilst live cell analysis 
has been carried out with βDG before, the focus was not on the nuclear levels of βDG and 
moreover there are important caveats with the system. A C-terminal GFP tag impairs Y892 
phosphorylation, and therefore interferes with an important regulatory site of interactions and 
localisation (Leocadio, 2014). Unfortunately, it is difficult to propose a site within βDG to insert 
a tag without disrupting a functional or regulatory site. A key caveat with this project was the 
inability to achieve higher purity or synchronised populations of cells for cell cycle analysis and 
the results should be analysed critically accordingly as discussed in detail in chapter 5. Future 
work in this field will require investigation with alternative cell cycle analysis techniques with 
optimised synchronised or sorting. An attractive alternative option is to use a protocol 
combining immunofluorescence staining, with biochemical fractionation of isolated nuclei that 
are then analysed on the flow cytometer to determine cell cycle phase (Rosner et al. 2013). 
This approach has been reportedly successful in the study of nucleocytoplasmic shuttling of 
proteins in the unperturbed mammalian cell cycle of multiple cell lines (Rosner et al. 2013). 
Whilst neither phosphorylation at Y892 (human) and T788 (mouse) appear to have clear direct 
roles in the nuclear translocation of βDG there are multiple other PTM which may regulate the 
nuclear localisation of βDG. Given the potential for cell cycle regulation, putative sites of CDK 
phosphorylation remain interesting candidates, however it is not immediately clear how 
phosphorylation at the predicted residues could affect the nuclear transport as the sites do not 
overlap with sites of known interactions (Moore et al. 2010). However, it is possible that 
phosphorylation disrupts an unknown interaction involved in nuclear or cytoplasmic retention 
or transport. 
 Phosphorylation by CDK1 is an important regulator of chromatin organisation, cytoskeletal 
rearrangements and NEBD and reformation during mitosis (Foisner 2003, Enserink et al. 2010). 
There are multiple reports in the literature of specific localisation of DG and other DAPC 
components at distinct locations at the cell periphery, forming cleavage furrow and midbody 
during mitosis and cytokinesis (Higginson et al 2008, Villareal-Silva et al. 2011), which is 
supported by the data presented in chapter 5. These distinct localisations suggest a specific 
regulation of DG during this phase of the cell cycle, as is the case with many cytoskeletal 
interacting or NE proteins and one could hypothesise that CDK1 phosphorylation may play a 
role in the regulation or localisation of βDG. An obvious first step would be to validate if βDG is 
a target of CDKs whilst site specific mutations might provide functional clues. 
An example of CDK1 activity mediating cytoskeletal regulation in mitosis is the CDK1 mediated 
phosphorylation of filamin-A, an actin cross-linking protein. Phosphorylation regulates the 
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actin binding ability of filamin-A, moreover, mutations at the sites of CDK1 phosphorylation of 
filamin-a disrupt daughter cell separation in cytokinesis (Cukier et al. 2007, Szeto et al. 2015). 
βDG can also bind to actin via its C-terminal tail and it remains a possibility that 
phosphorylation at residues within this domain may modulate its actin binding ability and 
ultimately modulate actin dynamics (Chen et al. 2003). However, studies in which DG has been 
depleted by RNAi and the DAG null fibroblasts show normal cytoskeletal features (Batchelor et 
al. 2007, Higginson et al. 2008), and it is difficult to reconcile these observations with a role for 
βDG in cytoskeletal rearrangements in mitosis. 
 Of particular interest in terms of this project is the regulation of NE proteins in mitosis. NE 
proteins including SUN1, emerin and Man1 as well as nuclear lamins are regulated in NEBD 
and NE reformation in part through their phosphorylation by CDKs and other mitotic kinases 
(Foisner 2003, Patel et al. 2014, Ottaviano et al. 1985, Nikolakaki et al. 1997). Whilst 
immunoblot analysis of mitotic enriched populations did not identify an altered 
phosphorylation status of DG in mitotic cells this technique might not have been sensitive 
enough. Mass spectrometry of mitotic enriched populations might identify specific sites of 
mitotic phosphorylation. Indeed, a number of the entries of phosphorylated βDG in the 
phosphosite database are as a consequence of studies of the global phospho profile of mitotic 
populations of cells (Hornbeck et al. 2104, Kettenbach et al. 2011). In addition to its strong 
localisation at the cell periphery in mitotic cells the non-phosphorylated Y892 form of βDG was 
faintly dispersed in the cytoplasm.  The reformation of the NE is a hierarchical process (Foisner 
2003, Haraguchi et al. 2000). The fact that NE are reformed in DG null cells hints that DG is not 
vital in this process, on the other hand some of the severe morphological defects observed in 
DG null cells may be a consequence of disruptions in the NE assembly process. Analysis in live 
cell imaging of NE markers in mitotic DG null cells might highlight if this is indeed the case.  
Key to understanding the behaviour of DG in the nucleus will be the identification of its nuclear 
binding partners. At the plasma membrane βDG has been shown to interact with a plethora of 
proteins, thus broadening our knowledge of the varying pathways and functions in which βDG 
is involved (Moore et al. 2010). However, unravelling the interactions of βDG within the 
nucleus is unlikely to be a simple task. In proteomics studies a vast number of nuclear 
membrane proteins have been identified (Wilkie et al. 2007, Worman et al. 2015). Whilst some 
of these NE proteins are ubiquitously expressed, such as emerin and lamins, their functionality 
is modulated by specific PTM but also the temporal expression and tissue specificity of their 
binding partners (Worman et al. 2015). It is not unreasonable to predict that nuclear DG is a 
ubiquitous phenomenon given its ubiquitous expression profiles in tissues and its widespread 
reports of its presence in the nucleus (Ibraghimov-Beskronaya et al. 1993, Oppizzi et al. 2008, 
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Lara-Chacon et al. 2010, Mitchell et al. 2013, Mathew et al. 2013). It is also likely to form 
multiple interactions, especially given its diverse nuclear localisation at the NE, nucleoplasm 
and other nuclear organelles (Martinez-Vieyra et al. 2013). Indeed, studies of DAPC 
components within the nucleus revealed slightly different members in different cell types 
(Villarreal-Silva et al. 2010, Gonzalez-Ramirez et al. 2008, Fuentes-Mera et al. 2006). 
Immunoprecipitation experiments have already indicated interactions with the important 
nuclear proteins lamins, emerin (Martinez-Vieyra et al. 2013) and potentially SUN1 (M. Laredo 
and S. Winder, personal communication) through which βDG may contribute to both structural 
and signal transduction pathways in the nucleus. Analogous to the behaviour of βDG at the 
PM, DG may interact with signalling pathway components such as ERK and adaptor proteins in 
the nucleus. Mass spectrometry studies of nuclear samples have been conducted in LNCaP 
cells indicating a range of PTM and binding partners that remain to be validated (Leocadio, 
2014). Further insights may well be gained through similar mass spectrometry approaches in 
samples from different tissue types or enriched for cell cycle phases.    
An important βDG interaction not addressed in this study is whether αDG is also found in the 
nucleus and moreover if it interacts with nuclear βDG and regulates its function? αDG is a 
secreted protein and contains no TM domain or predicted NLS, furthermore a functional role 
for this protein in the nucleus is difficult to conceive, however it cannot be dismissed. αDG is 
difficult to detect because of its many glycosylation moieties and indeed some of the perceived 
loss of αDG from the PM in cancer studies may be as a consequence of loss of specific 
glycosylation epitopes rather than core protein. A study by Oppizzi et al. did not detect αDG in 
the nucleus, although this study used the aforementioned glycosylation dependent antibodies 
(Oppizzi et al. 2008). A different study has detected the presence of an exogenously expressed 
myc tagged αDG in the nucleus of LNCaP cells following fractionation however if this is true of 
endogenous αDG remains unclear (Leocadio, 2015).  
To expand upon the findings from this project it would be important to investigate nuclear DG 
in different experimental systems. Whilst cells in 2D culture are easy to manipulate and study, 
providing valuable insights into the function and regulation of a protein and its subsequent 
role in cellular behaviour, it is important to recognise their limitations. In vivo a cell is highly 
influenced by its 3D microenvironment via ECM-interactions, cell-cell interactions and differing 
nutrient profiles (Edmondson et al. 2014, Hakkinen et al. 2011, Loessner et al. 2010). Typically 
cells in 3D culture grow as aggregates or spheroids with a hierarchical structure and 
heterogeneity demonstrating a closer resemblance of cell morphology, functions and 
interactions to cells in vivo (Kim et al. 2005, Lin et al. 2008). It has been shown that cells in 3D 
systems can display a different spatial organisation of surface receptors than in 2D and can 
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show different expression patterns of proteins (Hakkinen et al. 2011, Luca et al. 2013). βDG 
localisation in LNCaP, PC3 and PNT1A cells in 3D cultures has been characterised previously, 
broadly demonstrating a peripheral localisation and variable levels within the nuclei within a 
spheroid structure (Mathew, 2011). In light of the observations that nuclear levels of βDG may 
fluctuate in a cell cycle dependent manner it would be interesting to readdress the nuclear 
localisation of βDG in the 3D populations with regards to proliferation status of the cells to 
validate this observation in more representative conditions. A 3D system may be of particular 
interest in understanding the distribution of βDG in tumours as the cell aggregates or 
spheroids grown in culture often mimic tumour organisation with more proliferating cells in 
the outer layers with increased numbers of quiescent cells in inner layers and a necrotic core 
(Laurent et al. 2013, Kim et al. 2005, Edmondson et al. 2014).  In a similar vein it should be 
acknowledged that the majority of the work in this project was conducted in cancer cell lines, 
therefore to ascertain the ‘normal’ processing of DG would require repeats in non-neoplastic 
cell lines. 
Beyond cell culture systems it could be useful to assess the role of βDG in the nucleus using 
the available DAG1 null or mutant DG animal models available. The aberrant nuclear 
morphology seen in the DAG1 null fibroblasts and other reports in DG KD cell systems 
(Martinez- Vieyra et al. 2013) has not been reported in the studies of DAG1 null tissues of 
chimeric mice, nor in the null zebrafish or fly models. However, it should be noted that the 
majority of these studies focussed at the tissue not the subcellular level. Investigations in 
animal models would also allow enable the investigation of how a nucleus absent for DG fares 
under the more dynamic mechanical stresses experienced in a living animal. 
In the models addressed so far it is difficult to dissect the roles of DG at the PM from the 
nuclear population of DG on nuclear structure but also signalling. These studies have been 
hindered by the lack of a full knockout cell model. Expression of βDG with mutations in the NLS 
or of fragments which target strongly to the nucleus in systems such as the DG null fibroblasts 
could help in identifying the consequences of nuclear DG in the absence of endogenous 
protein. Furthermore, the exogenous protein could be expressed without a tag thus limiting 
potential interference with interacting partners. The development of a CRISPR/Cas9 model to 
produce cells lacking DG would also provide a useful experimental system to investigate the 
roles of nuclear DG. 
The localisation of βDG in the nucleus and its emerging role in maintaining nuclear structure 
could have broad disease implications. A number of nuclear envelope proteins and lamins have 
been implicated in a range of diseases from muscular dystrophy to accelerated aging disorders 
(Worman et al. 2010).  For example, different forms of EDMD can arise as a consequence of 
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mutations in lamins A and C, emerin and nesprin1 (Bonne et al. 1999, Bione et al. 1994, Zhang 
et al. 2007). Multiple molecular mechanisms have been proposed to underlie the pathology of 
NE diseases including mechanical instability by perturbing interactions between the nucleus 
and cytoskeleton, altered gene expression as a consequence of disrupted NE and disruption of 
the cell cycle (Wilkie et al. 2011, Worman et al. 2010). Disruption of individual components of 
the DAPC can result in the dissociation of the complex with reduced localisation at the PM and 
a reduction in the levels of the proteins, including DG (Villarreal-Silva et al. 2010). Given the 
evidence for a nuclear DAPC and its NE localisation reported elsewhere (Martinez- Vieyra et al. 
2013, Leocadio et al. 2016) and in this study, it is not unreasonable to hypothesise that the 
nuclear DAPC could also be disrupted upon mutations or reduced levels of an individual 
component. Subsequent loss of nuclear DAPC components and their interactions with NE 
proteins, such as DG with lamins, emerin and the LINC complex could contribute to disease 
pathology through any of the aforementioned mechanisms. The aberrant nuclear morphology 
seen upon loss of DG is similar to that seen in cells deficient in lamins or emerin (Lammerding 
et al. 2005, Fidzianska et al. 1998, Funkhouser et al. 2013), reinforcing the role for DG in NE 
structure. It is not known if the interactions with NE proteins play a role in retaining DG within 
the nucleus, however it is also possible that disruption to the levels or correct functioning of 
NE proteins such as emerin and lamins could also perturb nuclear DG localisation, thus 
exacerbating the instability of the NE in a range of diseases.  
The data presented throughout this thesis supports the presence of βDG in the nucleus of 
cancer cells as well as non-cancerous cells. Loss of α and βDG from the PM have been reported 
as early steps in the EMT and metastatic process in epithelial cancers including breast and 
prostate, with reexpression in tumours at secondary sites (Cross et al. 2008, Mitchell et al. 
2013, Mathew et al. 2013). The loss of DG from cells correlating with cancer progression is 
similar to that seen with other adhesion molecules such as E-cadherin and catenins. Prostate 
cancers with lower expression of α-catenin correlated with higher mitotic indexes, higher S 
phase factions and reduced survival (Aaltomaa et al. 1999, Morita et al. 1999). Whilst potential 
mechanisms of DG contribution to cancer progression at the PM are perhaps more intuitive 
given its roles in adhesion, migration and proliferation, a potential nuclear contribution 
remains less clear. The 31 and 26Kda fragments of βDG have been reported in cancer cells 
(Singh et al. 2004, Cross et al. 2008, Mitchell et al. 2013, Leocadio et al. 2016), and pY892 βDG 
has been identified in the nucleus of prostate tissue microarrays (TMA) (Mathew et al. 2013) 
however a further in depth analysis of nuclear DG in patient tissue samples at different stages 
of disease progression or at different stages in animal cancer models may provide further 
insight into nuclear levels of DG at different stages of cancer progression.  Differential 
regulation of βDG at the PM is likely a consequence of cancer but can also then contribute to 
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disease phenotypes and this scenario possibly extends to βDG within the nucleus. A potential 
correlation between proliferating cells and nuclear DG levels may result in an increased level of 
nuclear DG in the inherently highly proliferative tumour cells, in combination with increased 
nuclear targeting as a result of aberrant glycosylation and increased proteolytic cleavage at the 
cell surface. As to contribution to disease progression, although at this stage purely 
speculative, one may hypothesise that βDG could modulate signalling pathways by 
sequestering pathway components in the nucleus, in this way βDG could influence the 
regulation of a variety of target genes which may ultimately contribute to disease progression, 
including early cell cycle genes through the ERK pathway or ETV1 in prostate cancers. 
Research into the role of DG at the PM has long been a focus for multiple groups, however the 
localisation of DG at internal structures should not be ignored. Whilst this study has 
demonstrated that the localisation of DG at the centrosomes is artefactual, the nuclear 
functions and mechanisms of regulation of βDG are still emerging. Many questions remain 
with regards to nuclear DG however this thesis has addressed PTM that were hypothesised to 
play a role in the nuclear localisation of βDG, providing a basis for future studies in 
understanding the complex regulation of DG. Furthermore, the investigation of the nuclear 
levels of DG in the cell cycle expands the knowledge of the relationship between this 
fundamental cellular process and DG, although further work is required to validate a specific 
mechanism linking the nuclear localisation of DG to the cell cycle. Given the many roles of DG 
in normal and disease processes it is important to continue research to improve the 
















Appendix A: Buffers and Recipes 
 
Buffer Components Notes/ Reference 
Blocking Buffer 
(immunofluorescence) 
5% FBS (v/v), 3% BSA (w/v) Made in 1x PBS pH7.4 
Blocking Buffer 
(Western Blot) 
5% (w/v) skimmed milk or 
BSA 
Dissolve in 1x TBST 
Buffer I (Cell 
Fractionation) 
0.32M Sucrose, 10mM Tris-
HCl pH 8.0, 3mM Calcium 
Chloride, 2mM Magnesium 
actetate, 0.1mM EDTA, 0.5% 
NP-40 (v/v), 1mM DTT 
Sterile Filter. Add protease 
and phosphatase inhibitors 
as needed. (Mathew et al. 
2013)                                     
Buffer II (Cell 
Fractionation) 
2M Sucrose, 10mM Tris-HCl 
ph 8.0, 5mM Magnesium 
Acetate, 0.1mM EDTA, 1mM 
DTT 
Sterile Filter. Add protease 
and phosphatase inhibitors 
as needed. (Mathew et al. 
2013)                                      
Coomassie Safe Stain 
60-80mg Coomassie brilliant 
blue G250, 3ml 
Concentrated HCl 
 
E3 Embryo Medium 
(Zebrafish) 
5mM NaCl, 0.17mM KCl, 
0.33mM CaCl2, 0.33mM 
MgSO4, 0.0001% methylene 
blue. 
 
ECL Solution I 
100 mM Tris-HCl pH8.5, 
25mM Luminol, 396µM p-
Coumaric Acid 
 
ECL Solution II 
100 mM Tris-HCl pH8.5, 











Loading Buffer (2x) 
20% Glycerol (v/v), 100mM 
Tris-HCl pH 6.8, 4% SDS 
(w/v), 0.2% Bromophenol 
Blue (w/v), 2% β-2-
mercaptoetanol (v/v) 
Concentration can be 









Running Buffer (10 x) 
250 mM Tris, 1.92 M Glycine (Laemmli, 1970) 
Laemmli SDS-PAGE 
Stacking Buffer 
0.5 M Tris-HCl pH 6.8, 0.4% 
SDS (w/v) 
(Laemmli, 1970) 
10x Loading Dye (DNA) 
0.25% Bromophenol Blue 
(w/v), 0.25% Xylene cyanol 
FF (v/v), 30% glycerol (v/v) 
 
Mild Lysis Buffer (IP) 
50 mM Tris-HCl pH 7.4, 150 
mM NaCl, 1 mM EDTA, 1% 
Triton X-100 (v/v) 
 
Mild Stripping Buffer 
(1L) 
15g Glycine, 1g SDS, 1 ml 
Tween 20 
Adjust the pH to 2.2 
Mounting Medium 
10 ng/ml DAPI, 2.5% DABCO 
(w/v) 




PBS, 0.2% (v/v) tween-20, 
1% BSA (w/v) 0.01% DMSO 
(v/v) 
 
10 x Phosphate 
Buffered Saline (10x 
PBS) 
1.37 M NaCl, 0.027 M KCl, 
0.1 M Na2HPO4, 0.018M 
KH2HPO4 
Adjust pH to 7.4 with HCl 
PBST PBS, 0.2% (v/v) tween-20 
 
Propidium iodide stain 
20µg/ml Propidium Iodide, 
200µg/ml RNAse A 
Made in PBS pH7.4 and 





Assay Buffer (RIPA 
Buffer) 
50mM Tris- HCl pH 7.5, 150 
mM NaCl, 1 mM EGTA, 1 
mM EDTA, 1% Triton X-100 
(v/v), 0.5% Sodium 
Deoxycholate (w/v), 0.1% 
SDS (w/v) 
Add protease and 
phosphatase inhibitors as 
required (James et al. 
2000).                                                   
SDS Running Buffer 
200 mM Glycine, 25mM Tris, 
0.01% SDS 
 
1x TAE buffer 
40mM Tris-Acetate, 1mM 
EDTA 
 
Tris Buffered Saline 
(TBS) (1x) 
50 mM Tris-HCl pH 7.4, 150 
mM NaCl 
 
Tris Buffered Saline 
Tween (TBST) (1x) 
50 mM Tris-HCl pH 7.4, 150 




25 mM Tris, 192 mM 
Glycine, 20 % Methanol 
(v/v), 0.02% SDS (w/v) 
Towbin et al. 1979 
2x YT 
1% yeast extract (w/v, 1.6% 
















Appendix B: Methods Tables and 
Figures 
B.1 PLASMID TABLE 
B.2 OLIGONUCLEOTIDE TABLE 
 
 










Encodes full length 
mouse αβDGflag 
with the T788A 
mutation 
Ampicillin This study 
pcDNA3.1 (+) 
αβDGflagT788D 
Encodes full length 
mouse αβDGflag 
with the T788D 
mutation 
Ampicillin This study 
Oligonucleotide Sequence (5’-3’) Function 
αβDGflagT788A F CCCCTTCTTAATAAAGGCGGCCTGG
TCCTCAAG 
Site directed mutagenesis of T788 




Site directed mutagenesis of T788 




Site directed mutagenesis of T788 




Site directed mutagenesis of T788 






TAGAAGGCACAGTCGAGG BGH reverse primer used to 
sequence the plasmid pcDNA3.1 
(+) containing the αβDGflagT788A 
and αβDGflagT788D sequences 






T7 promoter forward primer used 
to sequence the plasmid 









B.3 PROTEASE AND PHOSPHATASE INHIBITORS 
 
 





Enzyme Target Final Concentration 
Sodium 
Orthovanadate 
Tyrosine phosphatases and alkaline 
phosphatases 
1 mM 
PMSF Serine proteases 1 mM 
TPCK Serine proteases 10 µM 
Leupeptin Serine and cysteine proteases 10 µM 
Pepstatin Aspartic acid proteases 1 µM 
Aprotinin Serine proteases 10 µg/ml 
Benzamidine Serine proteases 10 µg/ml 
NaF Serine, threonine and acidic phosphatases 10 mM 
Roche Complete 
Protease inhibitor mix 
Serine and cysteine proteases 1X 
 
Resolving Gel (10 ml for 2 gels) 
Stacking gel (5ml for 
2 gels) 
Concentration 7.5 % 10 % 12.5% 5% 
Acrylamide 2.5 3.35 4.15 0.8 
Gel stock 3.75 3.75 3.75 0.625 
Water 3.65 2.85 2.0 3.525 
TEMED 5 µl 5 µl 5 µl 15 µl 
10% APS 100 µl 100 µl 100 µl           50µl 
FigureB.1: DNA Sequence alignment of αβDGflag T788A and αβDGflagT788. Following Site-directed 
mutagenesis of (A) αβDGflag T788A and (D) αβDGflagT788 plasmids were sent for DNA sequencing at Source 
Bioscience for verification. Bovine growth hormone (BGH) and T7 stock primers were used. The subsequent DNA 
























Thi Man and G. 
Morris (Gift) 
Pereboev et al. 
2001 
βDG 1709 










In house (Ilsley 
et al. 2001) 
βDG JAF1 
βDG, carboxy 





D. Mornet (Gift) 












α- tubulin, Carboxy 
terminus 















































Cyclin B1, amino 
terminus 








































Mouse IgG1 1:3000 1:1000 







Rabbit IgG 1:3500 1:1500 
Sigma      
(F7425) 
γ- tubulin 






Sigma      
(T5326) 



























Ki67   
(MM1) 





Lamins A and C, 
recombinant fragment 














Santa Cruz     
(sc-20682) 
Nucleolin 
C23        
(MS-3) 
Nucleolin, full length 
residues 1-706 


































Mouse IgG Goat 1: 10000 N/A 







Sheep/Goat IgG Mouse 1:10000 N/A 






Rabbit IgG Goat 1: 15000 N/A 






Rat IgG Goat 1:10000 N/A 




































Rat IgG Goat N/A 1:100 




Sheep IgG Rabbit N/A 1:100 










Appendix C: Supplementary Figures 
 
Figure C.1 Thymidine synchronisation of LNCaP cells optimisation. LNCaP cells were seeded at a density 
of 5 x 105 per 100mm dish and grown for 48 hours. Cells were treated with 2mM thymidine or PBS 
control. Over 18 to 32 hours of thymidine treatment cells were collected and ethanol fixed every two 
hours. Control 1 and control 2 were collected at the first and last time points, 18 and 32 hours 
respectively. Samples were then stained with propidium iodide and analysed on the CyAn ADP and DNA 
histograms produced. The percentage of the population of cells in G1, S and G2/M phases of the cell 
cycle were calculated via manual gating using flow jo software (A). Histogram overlay of C2 (black) and 









Figure C.2. Cell cycle progression of LNCaP cells released from a double thymidine block. LNCaP cells 
were grown for 48 hours and then treated with 2mM Thymidine for 32 hours. Cells were released by 
addition of fresh media for 9 hours and then blocked for a further 22 hours with 2mM Thymidine. Cells 
were released into the cell cycle via the addition of fresh media and collected every two hours over 14 
hours. Control 1 and control 2 were PBS control treatments at 0 hr and 14 hours respectively.  The 
collected cells were harvested for lysate collection or ethanol fixed, stained with propidium iodide and 
analysed for cell cycle distribution via flow cytometry. Representative DNA histograms from one 




















Figure C.3.  Replicate immunoblots of βDG and pY892 βDG in total cell lysates from thymidine 
synchronised LNCaP cells. Independent repeats (A, B,C) of immunoblot of total cell lysates collected 
from double thymidine block synchronised LNCaP cells at each time point and immunoblotted for βDG 








Figure C.4.  Replicate immunoblots of βDG and pY892 βDG in non- nuclear and nuclear fractions of 
thymidine synchronised LNCaP cells.  Immunoblot of non-nuclear (left) and nuclear (right) lysates 
collected from double thymidine block synchronised LNCaP cells at each time point and immunoblotted 
for (A) βDG or (B) pY892 βDG. GAPDH and Lamin A/C were included as purity markers of the 
fractionation and loading controls of the non-nuclear and nuclear fractions respectively. Arrows indicate 









Figure C.5. βDG detection after FACS and trypsin cleavage of βDG. A) The amino acid sequence of βDG  
was analysed using the ExPASy Peptide cutter program (http://web.expasy.org/peptide_cutter/) to 
analyse for trypsin cleavage sites. Identified predicted cleavage sites in the extracellular domain of βDG 
are highlighted in purple. The transmembrane domain of βDG is highlighted in green and the NLS in red. 
B) LNCaP cells were detattched from the culture vessel via manual scrapping, trypsin incubation or 
incubation with two different enzyme free dissociation buffers. Total cell lysates from each treatment 
were immunoblotted for βDG  and pY892 βDG. 
 
Table C.1 Optimisation of Nocodazole treatment for arrest of LNCaP cells at mitosis. LNCaP cells were 
grown for 48 hours and then treated with either DMSO, 50ng/ml, 100ng/ml, 500ng/ml Nocodazole for 
12, 18, 24 and 30 hours. Cells were fixed with ethanol, stained with propidium iodide and the cell cycle 





AALTOMAA, S., LIPPONEN, P., ALA-OPAS, M., ESKELINEN, M., KOSMA, V.M. 1999. α-catenin 
expression has prognostic value in local and locally advanced prostate cancer. British Journal of 
Cancer. 80, 477-482. 
ADAMS, J.C. AND BRANCACCIO, A. 2015. The evolution of the dystroglycan complex, a major 
mediator of muscle integrity. Biology Open. 4, 1163-1179. 
AGUILAR, A., WAGSTAFF, K.M., SUAREZ-SANCHEZ, R., ZINKER, S., JANS, D.A., CISNEROS, B. 
2015. Nuclear localization of the dystrophin-associated protein α-dystrobrevin through 
importin α2/β1 is critical for interaction with the nuclear lamina/ maintenance of nuclear 
integrity. FASEB. 29, 1842- 1858. 
AKHAVAN, A., GRIFFITH, O.L., SOROCEANU, L., LEONOUDAKIS, D., LUCIANI-TORRES, M.G., 
DAEMEN, A., GRAY, J.W., MUSCHLER, J.L. 2012. Loss of cell-surface laminin anchoring 
promotes tumor growth and is associated with poor clinical outcomes. Cancer Res. 72, 2578-
2588. 
 
ALBER, F., DOKUDOVSKAYA, S., VEENHOFF, L.M., ZHANG, W., KIPPER, J., DEVOS, D., SUPRAPTO, 
A., KARNI-SCHMIDT, O., WILLIAMS, R., CHAIT, B.T., SALI, A., ROUT, M.P. 2007. The molecular 
architecture of the nuclear pore complex. Nature. 450, 695-701. 
ALTSCHUL, S.F., GISH, W., MILLER, W., MYERS, E.W., LIPMAN, D.J. 1990. Basic local alignment 
search tool. J.Mol. Biol. 215, 403-410.ANASTASI, G., CUTRONEO, G., GAETA, R., DI MAURO, D., 
ARCO, A., CONSOLO, A., SANTORO, G., TRIMARCHI, F., FAVALORO, A. 2009. Dystrophin-
glycoprotein complex and vinculin-talin-integrin system in human adult cardiac muscle. Int. J. 
Mol. Med. 23, 149-159. 
ANDERSON, C., WINDER, S.J., BORYCKI, A.G. 2007. Dystroglycan protein distribution conincides 
with basement membranes and muscle differentiation during mouse embryogenesis. 
Developmental Dynamics, 236, 2627-2635. 
ANDERSEN, J.S., WILKINSON, C.J., MAYOR, T., MORTENSEN, P., NIGG, E.A., MANN, M. 2003. 
Proteomic characterization of the human centrosome by protein correlation profiling. Nature. 
426, 570-574. 
ANGELONI, D. 2007. Molecular analysis of deletions in human chromosome 3p21 and the role 
of resident cancer genes in disease. Brief Funct. Genomic Proteomic. 6, 19-39 
 
ARQUINT, C., GABRYJONCZYK, A.M., NIGG, E.A. 2014. Centrosomes as signalling centres. Phil. 
Trans. R. Soc. B. 369: 20130464. 
AZIMZADEH, J. AND BORNENS, M. 2007. Structure and duplication of the centrosome. J. Cell 
Sci. 120, 2139-2142. 
AZIMZADEH, J. AND MARSHALL, W.F. 2010. Building the centriole. Curr. Biol. 20, R816-R825. 
BAE, Y.H., MUI, K.L., HSU, B.Y., LIU, S.L., CRETU, A., RAZINIA, Z., XU, T., PURE, E., ASSOIAN, R.K. 
2014.  
A FAK-Cas-Rac-Lamellipodin Signaling Module Transduces Extracellular Matrix Stiffness into 
Mechanosensitive Cell Cycling. Sci. Signal. 7, ra57. 
226 
 
BAKER, A.M., BIRD, D., LANG, G., COZ, T.R., ERLER, J.T. 2013. Lysyl oxidase enzymatic function 
increases stiffness to drive colorectal cancer progression through FAK. Oncogene, 32, 1863-
1888. 
BALK, S.P. AND KNUDSEN, K.E. 2008. AR, the cell cycle, and prostate cancer. Nuclear Receptor 
Signalling. 6, DOI: 10.1621/nrs.06001. 
BAO, X., KOBAYASHI, M., HATAKEYAMA, S., ANGATA, K., GULLBERG, D., NAKAYAMA, J., 
FUKUDA, M. N. & FUKUDA, M. 2009. Tumor suppressor function of laminin-binding alpha-
dystroglycan requires a distinct beta3-N-acetylglucosaminyltransferase. Proc Natl Acad Sci U S 
A, 106, 12109-14. 
BAR, S., BARNEA, E., LEVY, Z., NEUMAN, S., YAFFE, D., NUDEL, U. 1990. A novel product of the 
Duchenne muscular dystrophy gene which greatly differs from the known isoforms in its 
structure and tissue distribution. Biochem. J. 272, 557-560. 
BARR, A.R., KILMARTIN, J.V., GERGELY, F. 2010. CDK5RAP2 functions in centrosome spindle 
pole attachment and DNA damage response. J. Cell. Biol. 189, 23-39. 
BARRESI, R. AND CAMPBELL, K.P. 2006. Dystroglycan: from biosynthesis to pathogenesis of 
human disease. J. Cell Sci. 119, 199-207. 
BATCHELOR, C.L., HIGGINSON, J.R., CHEN, Y.J., VANNI, C., EVA, A., WINDER, S.J. 2007. 
Recruitment of Dbl by ezrin and dystroglycan drives membrane proximal Cdc42 activation and 
filopodia formation. Cell Cycle. 6, 353-363. 
BEATTIE, J., MCINTOSH, L., VAN DER WALLE, C.F. 2010. Cross-talk between the insulin-
like growth factor (IGF) axis and membrane integrins to regulate cell physiology. J. Cell. Physiol. 
224, 605-611. 
BEATY. B.T. AND CONDEELIS, J. 2014. Digging a little deeper: The stages of invadopodium 
formation and maturation. Eur. J. Cell. Biol. 93, 438-444. 
BEATY, B.T., SHARMA, V.P., BRAVO-CORDERO, J.J., SIMPSON, M.A., EDDY, R.J., KOLESKE, A.J., 
CONDEELIS, J. 2013. β1 integrin regulates Arg to promote invadopodial maturation 
and matrix degradation. Mol. Biol. Cell. 24, 1661-1675. 
BEAUDOUIN, J., GERLICH, D., DAIGLE, N., EILS, R., ELLENBERG, J. 2002. Nuclear envelope 
breakdown proceeds by microtubule-induced tearing of the lamina. Cell. 108, 83-96. 
BERK, J.M., TIFFT, K.E., WILSON, K.L. 2013. The nuclear envelope LEM-domain protein emerin. 
Nucleus. 4, 298-314. 
BHAT, H.F., ADAMS, M.E., KHANDAY, F.A. 2013. Syntrohin proteins as Santa Claus: Role(s) in 
cell signal transduction. Cell Mol. Life Sci. 70, 2533-54. 
BIES, R.D., FREIDMAN, D., ROBERTS, R., PERRYMAN, M.B., CASKEY, C.T. 1992. Expression and 
localisation of dystrophin in human cardiac Purkinje fibres. Circulation. 86, 147-153. 
BIONE, S., MAESTRINI, E., RIVELLA, S., MANCINI, M., REGIS, S., ROMEO, G., TONIOLO, D. 1994. 
Identification of a novel X-linked gene responsible for Emery-Dreifuss muscular dystrophy. Nat. 
Genet. 8, 39-41. 
BODOOR, K., SHAIKH, S., SALINA, D., RAHARJO, W.H., BASTOS, R., LOHKA, M., BURKE, B. 1999. 
Sequential recruitment of NPC proteins to the nuclear periphery at the end of mitosis. J. Cell 
Sci. 112, 2253-2264. 
227 
 
BONNE, G., BARLETTA, M.R., VARNOUS, S., BECANE, H.M., HAMMOUDA, E.H., MERLINI, L., 
MUNTONI, F., GREENBERG, C.R., GARY, F., URTIZBEREA, J.A., DUBOC, D., FARDEAU, M., 
TONIOLO, D., SCHWARTZ, K. 1999. Mutations in the gene encoding lamin A/C cause autosomal 
dominant Emery-Dreifuss muscular dystrophy. Nat Genet. 21, 285-288. 
BONUCCELLI, G., SOTGIA, F., SCHUBERT, W., PARK, D.S., FRANK, P.G., WOODMAN, S.E., 
INSABATO, L., CAMMER, M., MINETTI, C., LISANTI, M.P. 2003. Proteasome inhibitor (mg-132) 
treatment 
of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-
associated proteins. The American journal of pathology. 163, 1663-1675. 
 
BOOTSMA, D., BUDKE, L., VOS, O. 1964. Studies on synchronous division of tissue culture cells 
initiated by excess thymidine. Exptl. Cell Res. 33, 301-309. 
BORDEAUX, J., WELSH, A.W., AGARWAL, S., KILLIAM, E., BAQUERO, M.T., HANNA, J.A., 
ANAGNOSTOU, V.K., & RIMM, D.L. 2010. Antibody validation. Biotechniques, 43, 197-209. 
BORREGO-PINTO, J., JEGOU, T., OSORIO, D.S., AURADE, F., GORJANACZ, M., KOCH, B., MATTAJ, 
I.W., GOMES, E.R. 2012. Samp1 is a component of TAN lines and is required for nuclear 
movement. J. Cell Sci. 125, 1099-1105. 
BOSTOCK, C.J., PRESCOTT, D.M., KIRKPATRICK, J.B. 1971. An evaluation of the double 
thymidine block for synchronising mammalian cells and the G1-S border. Exp. Cell Res. 68, 163-
168. 
BOVERI, T., 1914. Zur Frage der Entstehung Maligner Tumoren. Jena: Fischer Verlag. 1929 
English translation by M Boveri reprinted as 'The Origin of Malignant Tumors' Baltimore: 
Williams and Wilkins Co. 
BOWE, M.A., DEYST, K.A., LESZYK, D., FALLON, J.R. 1994. Identification and purification of 
an agrin receptor from Torpedo postsynaptic membranes: a heteromeric complex related to 
the dystroglycans. Neuron. 12, 1173-1180. 
BOWE, M.A., MENDIS, D.B., FALLON, J.R. 2000. The small leucine-rich repeat proteoglycan 
biglycan binds to alpha-dystroglycan and is upregulated in dystrophic muscle. J. Cell Biol. 148, 
801-810. 
BOZIC, D., SCIANDRA, F., LAMBA, D., & BRANCACCIO, A. 2004. The structure of the N-terminal 
region of murine skeletal muscle α-dystroglycan discloses a modular architecture. Journal of 
Biological Chemistry, 279, 44812-44816. 
BOZZI, M., BIANCHI, M., SCIANDRA, F., PACI, M., GIARDINA, B., BRANCACCIO, A., CICERO, D.O. 
2003. Structural characterization by NMR of the natively unfolded extracellular domain of 
beta-dystroglycan: toward the identification of the binding epitope for alpha-dystroglycan. 
Biochemistry. 42. 13717-31724. 
BOZZI, M., INZITARI, R., SBARDELL, D., MONACO, S., PAVONI, E., GIOIA, M., MARINI, S., 
MORLACCHI, S., SCIANDRA, F., CASTAGNOLA, M., GIARDINA, B., BRANCACCIO, A., COLETTA, M. 
2009. Enzymatic processing of β-dystroglycan recombinant ectodomain by MMP-9: 
Identification of the main cleavage site. IUBMB Life. 61, 1143-1152. 
BOZZI, M., MORLACCHI, S., BIGOTTI, M. G., SCIANDRA, F. & BRANCACCIO, A. 2009. Functional 
diversity of dystroglycan. Matrix Biol, 28, 179-87. 
BRANCACCIO, A., SCHULTHESS, T., GESEMANN, M., ENGEL, J. 1995. Electron microscopic 
evidence for a mucin-like region in chick muscle alpha-dystroglycan. FEBS Lett. 368, 139-142. 
228 
 
BRANCACCIO, A., SCHULTHESS, T., GESEMANN, M., ENGEL, J. 1997. The N-terminal region of 
alpha-dystroglycan is an autonomous globular domain. Eur. J. Biochem. 246, 166-172. 
BRENNAN, P.A., JING, J., ETHUNANDAN, M., GORECKI, D. 2004. Dystroglycan complex in 
cancer. Eur. J. Surg. Oncol. 30, 589-592. 
BROOKS, P.C., STROMBLAD, S., SANDERS, L.C., SCHALSCHA, T.L., AIMES, R.T., STETLER-
STEVENSON, W.G., QUIGLEY, J.P., CHERESH, D.A. 1996. Localization of matrix 
metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v 
beta 3. Cell. 85. 683-693. 
BROWN, S.C., TORELLI, S., BROCKINGTON, M., YUVA, Y., JIMENEZ, C., FENG, L., ANDERSON, L., 
USG, I., KROGER, S., BUSHBY, K., VOIT, T., SEWRY, C., MUNTONI, F. 2004. Abnormalities in 
alpha-dystroglycan expression in MDC1C and LGMD2I muscular dystrophies. Am. J. Pathol. 
164, 727-737. 
BUCH, C., LINDBERG, R., FIGUEROA, R., GUDISE, S., ONISCHENKO, E., HALBERG, E. 2009. An 
integral protein of the inner nuclear membrane localises to the mitotic spindle in mammalian 
cells. J. Cell Sci. 122, 2100-2107. 
BUCK, S.B., BRADFORD, J., GEE, K.R., AGNEW, B.J., CLARKE, S.T., SALIC, A. 2008. Detection of S-
phase cell cycle progression using 5-ethynyl-2’-deoxyuridine incorporation with click 
chemistry, an alternative to using 5-bromo-2’-deoxyuridine antibodies. Biotechniques. 44, 927-
929. 
BUDIRAHARDJA, Y. AND GONCZY. P. 2009. Coupling the cell cycle to development. 
Development. 136, 2861-2872. 
BURAKOV, A.V., NADEZHDINA, E.S., SLEPCHENKO, B., RODIONOV, V. 2003. Centrosome 
positioning in interphase cells. J. Cell Biol. 162, 963-969. 
BURAKOV, A.V., NADEZHDINA, E.S. 2013. Association of the nucleus and centrosome: magnet 
or Velcro? Cell Biol. Int. 37, 95-104. 
CAI, C., HSIEH, C. L., OMWANCHA, J., ZHENG, Z., CHEN, S. Y., BAERT, J. L. & SHEMSHEDINI, L. 
2007. ETV1 is a novel androgen receptor-regulated gene that mediates prostate cancer cell 
invasion. Mol Endocrinol, 21, 1835-46. 
CAI, H., BABIC, I., WEI, X., HUANG, J., WITTE, O. 2011. Invasive prostate carcinoma driven by c-
Src and androgen receptor synergy. Cancer Res. 71, 862-872. 
CAI, M., HUANG, Y., GHIRLANDO, R., WILSON, K.L., CRAIGIE, R., CLORE, G.M. 2001. Solution 
structure of the constant region of nuclear envelope protein LAP2 reveals 2 LEM-domain 
structures: one binds BAF and the other binds DNA. EMBO J. 20, 4399-4407. 
CALDON, C. E., SUTHERLAND, R.L., MUSGROVE, E.A. 2010. Cell cycle proteins in epithelial 
differentiation: implications for breast cancer. Cell Cycle. 9, 1918- 1928. 
CAMPBELL, K.P. 1995. Three muscular dystrophies: loss of cytoskeleton-extracellular matrix 
linkage. Cell. 5, 675-679. 
CAO, W., HENRY, M.D., BORROW, P., YAMADA, H., ELDER, J.H., RAVKOV, E.V., NICHOL, S.T., 
COMPANS, R.W., CAMPBELL, K.P., OLDSTONE, M.B. 1998. Identification of alpha-
dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus. 
Science. 282, 2079-2081. 
229 
 
CASSWELL, P.T., SPENCE, H.J., PARSONS, M., WHITE, D.P., CLARK, K., CHENG, K.W., MILLS, G.B., 
HUMPHRIES, M.J., MESSENT, A.J., ANDERSON, K.L.M MCCAFFREY, M.W., OZANNE, B.W., 
NORMAN, J.C. 2007. Rab25 associates with alpha5beta1 integrin to promote invasive 
migration in 3D microenvironments. Dev. Cell. 13, 496-510. 
CAUTAIN, B., HILL, R., DE PEDRO, N., LINK, W. 2015. Components and regulation of nuclear 
transport processes. FEBS J. 282, 445-462. 
CAVALCANTI-ADAM, E.A., MICOULET, A., BLUMMEL, J., AURENHEIMER, J., KESSLER, H., SPATZ, 
J.P. 2006. Lateral spacing of integrin ligands influences cell spreading and focal adhesion 
assembly. Eur. J. Cell Biol. 85, 219-224. 
CHAMBARD, J.C., LEFLOCH, R., POUYSSEGUR, J., LENORMAND, P. 2007. ERK implication in cell 
cycle regulation. Biochim. Biophys. Acta. 1773, 1299-1310. 
CHANG, W., ANTOKU, S., OSTLUND, C., WORMAN, H.J., GUNDERSEN, G.G. 2015. Linker of 
nucleoskeleton and cytoskeleton (LINC) complex- mediated actin-dependent nuclear 
positioning orients centrosomes in migrating myoblasts. Nucleus. 6, 77-88. 
CHANG, W., FOLKER, E.S., WORMAN, H.J., GUNDERSEN, G.G. 2013. Emerin organises actin flow 
for nuclear movement and centrosome orientation in migrating fibroblasts. Mol. Biol. Cell. 24, 
3869-3880. 
CHAUMET, A., WRIGHT, G.D., SEET, S.H., THAM, K.M., GOUNKO, N.V., BARD, F. 2015. Nuclear 
envelope-associated endosomes deliver surface proteins to the nucleus. Nat. Comm. 6: 8218. 
CHEN, R., SARNECKI, C, BLENIS, J. 1992. Nuclear Localization and Regulation of Erk and rsk-
Encoded Protein Kinases. Mol. Cell. Biol. 12, 915-927.  
CHEN, YJ, SPENCE, H. J., CAMERON, J. M., JESS, T., ILSLEY, J. L., WINDER, S. J. 2003. Direct 
interaction of beta-dystroglycan with F-actin. Biochem. J. 375, 329-337. 
CHEN, M.K., AND HUNG, M.C. 2015. Proteolytic cleavage, trafficking, and functions of nuclear 
receptor tyrosine kinase. FEBS J. 282, 3693-3721. 
CHEN, Z.J., WANG, W.P., CHEN, Y.C., WANG, J.Y., LIN, W.H., TAI, L.A., LIOU, G.G., YANG, C.S., 
CHI, Y.H. 2014. Dysregulated interaction between lamin A and SUN1 induce abnormalities in 
the nuclear envelope and endoplasmic reticulum in progeric laminopathies. J. Cell Sci.125, 
1729-1704. 
CHENG, K.W., LAHAD, J.P., KUO, W.L., LAPUK, A., YAMADA, K., AUERSPERG, N., LIU, J., SMITH-
MCCUNE, K., LU, K.H., FISHMAN, D., GRAY, J.W., MILLS, G.B. 2004. The RAB25 small GTPase 
determines aggressiveness of ovarian and breast cancers. Nat. Med. 10, 1251-1256. 
CHUAN, Y., PANG, S., CEDAZO-MINGUEZ, A., NORSTEDT, G., POUSETTE, A., FLORES-MORALES, 
A. 2006. Androgen induction of prostate cancer invasion is mediated by ezrin. J. Biol. Chem. 
281, 29938-29948. 
CHUNG, H., MULTHAUPT, H.A., OH, E.S., COUCHMAN, J.R. 2016. Minireview: Syndecans and 
their crucial roles during tissue regeneration. FEBS Lett.  
CHIBA, A., MATSUMURA, K., YAMADA, H., INAZU, T., SHIMIZU, T., KUSUNOKI, S., KANAZAWA, 
I., KOBATA, A., ENDO, T. 1997. Structures of sialylated O-linked oligosaccharides of bovine 
peripheral nerve alpha-dystroglycan. The role of a novel O-mannosyl-type oligosaccharide in 
the binding of alpha-dystroglycan with laminin. J. Biol. Chem. 272, 2156-2162 
230 
 
CIFUENTES, E., CROXEN, R., MENON, M., BARRACK, E.R., REDDY, G.P. 2003. Synchronised 
prostate cancer cells for studying androgen regulated events in cell cycle progression from G1 
into S phase. J. Cell Physiol. 195, 337-345. 
COHEN, M.W., JACOBSON, C., YURCHENCO, P.D., MORRIS, G.E., CARBONETTO, S. 1997. 
Laminin-induced clustering of dystroglycan on embryonic muscle cells: comparison with agrin-
induced clustering. J. Cell Biol. 136, 1047-1058. 
COHEN, M. W., MOODY-CORBETT, F. & GODFREY, E. W. 1995. Former neuritic pathways 
containing endogenous neural agrin have high synaptogenic activity. Dev Biol, 167, 458-68. 
COLLINS, B., GORELICK, G., SCHNEIDER, A. 2001. Dystroglycan is present in rat thyroid and rat 
thyroid cells and responds to Thyrotropin. Endocrinology. 142, 3152- 3162. 
COMBS, A.C. AND ERVASTI, J.M. 2005. Enhanced laminin binding by α-dystroglycan after 
enzymatic deglycosylation. Biochem. J. 390, 303-309. 
CONSTANTIN, B. 2014. Dystrophin complex functions as a scaffold for signalling proteins. 
Biochim. Biophys. Acta. 1838, 635-642. 
CORRADO, K., MILLS, P.L., CHAMBERLAIN, J.S. 1994. Deletion analysis of the dystrophin-actin 
binding domain. FEBS Letters. 344, 255-260. 
CÔTÉ, P.D., MOUKHLES, H., LINDENBAUM, M., CARBONETTO, S. 1999. Chimaeric mice deficient 
in dystroglycans develop muscular dystrophy and have disrupted myoneural synapses. Nat. 
Genet. 23, 338-342. 
COUMOU, J., NARASIMHAN, S., TRENTELMAN, J.J., WAGEMAKERS, A., KOETSVELD, J., ERSOZ, 
J.I., OEI, A., FIKRIG, E., HOVIUS, J.W. 2016. Ixodes scapualris dystroglycan-like proteins 
promotes Borrelia burgdorferi migration from the gut. J. Mol. Med. 94, 361-370. 
CRISP, M., LIU, Q., ROUX, K., RATTNER, J.B., SHANAHAN, C., BURKE, B., STAHL, P.D., HODZIC, D. 
2006. Coupling of the nucleus and cytoplasm role of the LINC complex. J. Cell Biol. 172, 41-53. 
CROSBIE, R.H., LEBAKKEN, C.S., HOLT, K.H., VENZKE, D.P., STRAUB, V., LEE, J.C., GRADY, R.M., 
CHAMBERLAIN, J.S., SANES, J.R., CAMPBELL, K.P. 1999. Membrane targeting and stabilisation 
of sarcospan is mediated by the sarcoglycan subcomplex. J. Cell Biol. 145, 153-165. 
CROSS, S. S., LIPPITT, J., MITCHELL, A., HOLLINGSBURY, F., BALASUBRAMANIAN, S. P., REED, M. 
W., EATON, C., CATTO, J. W., HAMDY, F. & WINDER, S. J. 2008. Expression of beta-dystroglycan 
is reduced or absent in many human carcinomas. Histopathology, 53, 561-6. 
CUKIER, I.H., LI, Y., LEE, J.M. 2007. Cyclin B1/Cdk1 binds and phosphorylates Filamin A and 
regulates its ability to cross-link actin. FEBS Letters. 581, 1661-1672. 
CUNNINGHAM, D. AND YOU, Z. 2015. In vitro and in vivo model systems used in prostate 
cancer research. J. Biol. Methods. 2, doi:10.14440/jbm.2015.63. 
D’ASSORO, A.B., LINGLE, W.L., SALISBURY, J.L. 2002. Centrosome amplification and the 
development of cancer. Oncogene.21, 6146-6153. 
DABAUVALLE, M.C., MULLER, E., EWALD, A., KRESS, W., KROHNE, G., MULLER, C.R. 1999. 
Distribution of emerin during the cell cycle. EJCB. 78, 749-756. 
DE BERNABE, D.B., VAN BOKHOVEN, H., VAN BEUSEKOM, E., VAN DEN AKKER, W., KANT, S., 
DOBYNS, W.B., CORMAND, B., CURRIER, S., HAMEL, B., TALIM, B., TOPALOGLU, H., BRUNNER, 
231 
 
H.G. 2003. A homozygous nonsense mutation in the fukutin gene causes a Walker-Warburg 
syndrome phenotype. J. Med. Genet. 40, 845-848. 
DE BRABANDER, M.J., VAN DE VEIRE, R.M., AERTS, F.E., BORGERS, M., JANSSEN, P.A. 1976. The 
effects of methyl (5-(2-thienylcarbonyl)-1H-benzimidazol-2-yl) carbamate, (R 17934; NSC 
238159), a new synthetic antitumoral drug interfering with microtubules, on mammalian cells 
cultured in vitro. Cancer Res. 36, 905-916. 
DENG, W.M., SCHNEIDER, M.,FROCK, R., CASTILLEJO-LOPEZ, C., GAMAN, E.A., BAUMGARTNER, 
A., RUOHOLA-BAKER, H. 2003. Dystroglycan is required for polarizing the epithelial cells and 
the oocyte in Drosophila. Development. 130, 173-184. 
DESGROSELLIER, J.S. AND CHERESH, D.A. 2010. Integrins in cancer: biological implications and 
therapeutic opportunities. Nat. Rev. Cancer. 10, 9-21. 
DESTAING, O., PLANUS, E., BOUVARD, D., ODDOU, C., BADOWSKI, C., BOSSY, V., RADUCANU, 
A., FOURCADE, B., ALBIQES-RIZO, C., BLOCK, M.R. 2010. β1A integrin is a master regulator of 
invadosome organisation and function. Mol. Biol. Cell. 21, 4108-4119. 
DEYST, K.A., BOWE, M.A., LESZYK, J.D., FALLON, J.R. 1995. The α-dystroglycan-β-dystroglycan 
complex membrane organisation and relationship to an agrin receptor. J. Bio. Chem. 270, 
25956-25959. 
DI STASIO, E., SCIANDRA, F., MARAS, B., DI TOMMASO, F., PETRUCCI, T.C., GIARDINA, B., 
BRANCACCIO, A. 1999. Structural and Functional Analysis of the N-Terminal Extracellular 
Region of β-Dystroglycan. Biochem. Biophys. Res. Comm. 266, 274-278. 
DORNER, D., GOTZMANN, J., FOISNER, R. 2007. Nucleoplasmic lamins and their interaction 
partners, LAP2α, Rb, and BAF in transcriptional regulation. FEBS J. 274, 1362-1373. 
DOXSEY, S.J., STEIN, P., EVANS, L., CALARCO, P.D., KIRSCHNER, M. 1994. Pericentrin, a highly 
conserved centrosome protein involved in microtubule organisation. Cell. 76, 639-650. 
DURBEEJ, M. AND CAMPBELL, K.P. 1999. Biochemical characterization of the epithelial 
dystroglycan complex. J. Biol. Chem. 274, 26609–26616. 
DURBEEJ, M., HENRY, M.D., CAMPBELL, K.P. 1998. Dystroglycan in development and disease. 
Curr. Opin. Cell Biol. 10, 594-601. 
DURBEEJ, M., HENRY, M.D., FERLETTA, M., CAMPBELL, K.P., EKBLOM, P. 1998. Distribution of 
Dystroglycan in normal adult mouse tissues. J. Histochem. Cytochem. 46, 449-457. 
DURBEEJ, M., LARSSON, E., IBRAGHIMOV-BESKROVNAYA, O., ROBERDS, S.L., CAMPBELL, K.P., 
EKBLOM, P. 1995. Non-muscle alpha-dystroglycan is involved in epithelial development. J. Cell. 
Biol. 130, 79–91. 
 
DURBEEJ, M., TALTS, J.F., HENRY, M.D., YURCHENCO, P.D., CAMPBELL, K.P., EKBLOM, P. 2001. 
Dystroglycan binding to laminin a1LG4 module influences epithelial morphogenesis of salivary 
gland and lung in vitro. Differentiation. 69, 121-134. 
 
DURONIO, R.J., XIONG, Y. 2013. Signaling pathways that control cell proliferation. Cold Spring 
Harb. Perspect. Biol. 5, a008904. 
EDMONDSON, R., JENKINS-BROGLIE, J., ADCOCK, A.F., YANG, L. 2014. Three-dimensional cell 
culture systems and their applications in drug discovery and cell-based biosensors. Assay and 
drug development technologies. 12, 207-218. 
232 
 
ELLENBERG, J., SIGGIA, E.D., MOREIRA, J.E., SMITH, C.L., PRESLEY, J.F., WORMAN, H.J., 
LIPPINCOTT-SCHWARTZ, J. 1997. Nuclear membrane dynamics and reassembly in living cells: 
targeting of an inner nuclear membrane protein in interphase and mitosis. J. Cell Biol. 138, 
1193-1206. 
ENSERINK, J.M. AND KOLODNER, R.D. 2010. An overview of Cdk1-controlled targets and 
processes. Cell Division. 5, 11 
ERIKSSON, M., BROWN, W.T., GORDON, L.B., GLYNN, M.W., SINGER, J., SCOTT, L., ERDOS, M.R., 
ROBBINS, C.M., MOSES, T.Y., BERGLUND, P., DUTRA, A., PAK, E., DURKIN, S., CSOKA, A.B., 
BOEHNKE, M., GLOVER, T.W., COLLINS, F.S. 2003. Recurrent de novo point mutations in lamin 
A cause Hutchinson-Gilford progeria syndrome. Nature. 423, 293-298. 
 
ERVASTI, J. M. & CAMPBELL, K. P. 1991. Membrane organization of the dystrophin-
glycoprotein complex. Cell, 66, 1121-31.  
 
ERVASTI, J.M. AND CAMPBELL, K.P. 1993. A role for the dystrophin-glycoprotein complex as a 
transmembrane linker between laminin and actin. J. Cell Biol. 122, 809-823. 
ERVASTI, J.M., OHLENDIECK, K., KAHL, S.D., GAVER, M.G., CAMPBELL, K.P. 1990. Deficiency of a 
glycoprotein component of the dystrophin complex in dystrophic muscle. Nature. 345, 315-
319. 
ESSER, K.A., MILLER, M. R., HUANG, Q., MEIER, M. M., BELTRAN-VALERO DE BERNABE, D., 
STIPP, C. S., CAMPBELL, K. P., LYNCH,C. F., SMITH, B. J., COHEN, M. B., HENRY, M. D. 2013. Loss 
of LARGE2 Disrupts Functional Glycosylation of α-Dystroglycan in Prostate Cancer. J Biol. Chem. 
288, 2132- 2142. 
 
EYERMANN, C., CZAPLINSKI, K., COLOGNATO, H. 2012. Dystroglycan promotes filopodial 
formation and process branching in differentiating oligodendroglia J. Neurochem. 120, 928-
947. 
FEHON, R.G., MCCLATCHEY, A.I., BRETSCHER, A. 2010. Organising the cell cortex: the role of 
ERM proteins. Nat. Rev. Mol. Cell Biol. 11, 276-287. 
FELDMAN, B.J. and FELDMAN, D. 2001. The development of androgen-independent prostate 
cancer. Nat. Rev. Cancer.  1, 34-45. 
 
FERLETTA, M., KIKKAWA, Y., YU, H., TALTS, J.F., DURBEEJ, M., SONNENBERG, A., TIMPL, R., 
CAMPBELL, K.P., EKBLOM, P., GENERSCH, E. 2003. Opposing roles of integrin α6Aβ1 and 
dystroglycan in laminin-mediated extracellular signal-regulated kinase activation. Mol. Biol. 
Cell. 14, 2088-2103. 
FIDZIANSKA, A., TONIOLO, D., HAUSMANOWA-PETRUSEWICZ, I. 1998. Ultrastructural 
abnormality of sarcolemmal nuclei in Emery-Dreifuss muscular dystrophy (EDMD). J. Neurol. 
Sci. 159, 88–93. 
FLOTHO, A., MELCHOIR, F. 2013. Sumoylation: A regulatory protein modification in health and 
disease. Ann. Rev. Biochem. 82, 357-385. 
FORNEROD, M., OHNO, M., YOSHIDA, M., MATTAJ, I.W. 1997. CRM1 is an export receptor for 
leucine-rich nuclear export signals. Cell. 90, 1051-1060. 




FOISNER, R., AND GERACE, L. 1993. Integral membrane proteins of the nuclear envelope 
interact with lamins and chromosomes, and DNA binding is modulated by mitotic 
phosphorylation. Cell. 73, 1267-1279. 
FONTES, M.R., TEH, T., TOTH, G., JOHN, A., PAVO, I., JANS, D.A., KOBE, B. 2003, Role of flanking 
sequences and phosphorylation in the recognition of the simian-virus-40 large T-antigen 
nuclear localization sequences by importin-alpha. Biochem. J. 375, 339-349.  
FORSBURG, S.L. 2004. Eukaryotic MCM proteins: Beyond replication initiation. Microbiol. Mol. 
Biol. Rev. 68, 109-131. 
FRISCH, S.M. AND FRANCIS, H. 1994. Disruption of epithelial cell-matrix interactions induces 
apoptosis. J. Cell Biol. 124, 619-626. 
FRISCH, S.M. AND SCREATON, R.A. 2001. Anoikis mechanisms. Curr. Op. Cell Biol. 13, 555-562. 
FROST, A.R., BOHM, S.V., SEWDUTH, R.N., JOSIFOVA, D., OGILIVE, C.M., IZATT, L., ROBERTS, 
R.G. 2010. Heterozygous deletion of a 2-Mb region including the dystroglycan gene in a patient 
with mild myopathy, facial hypotonia, oral-motor dyspraxia and white matter abnormalities. 
Eur J Hum Genet. 18, 852-855. 
FUENTES-MERA, L., RODRIGUEZ-MUNOZ, R., GONZALEZ-RAMIREZ, R., GARCIA-SIERRA, F., 
GONZALEZ, E., MORNET, D., CISNEROS, B. 2006. Characterization of a novel Dp71 dystrophin-
associated protein complex (DAPC) present in the nucleus of HeLa cells: members of the 
nuclear DAPC associate with the nuclear matrix. Exp. Cell Res. 312, 3023-3035. 
FULLER, S.D., GOWEN, B.E., REINSCH, S., SAWYER, A., BUENDIA, B., WEPF, R., KARSENTI, E. 
1995. The core of the mammalian centriole contains gamma-tubulin. Curr. Biol. 5, 1384-1393. 
FUNKHOUSER, C.M., SKNEPNEK, R., TAKESHI, S., GOLDMAN, A.E., GOLDMAN, R.D., OLVERA DE 
LA  
CRUZ, M. 2013. Mechanical model of blebbing in nuclear lamin meshworks. PNAS. 110, 3248- 
3253.  
GALVAGNI, F., NARDI, F., MAIDA, M., BARNARDI, G., VANNUCCINI, S., PETRAGLIA, F., 
SANTUCCI, A., ORLANDINI, M. 2016. CD93 and dystroglycan cooperation in human endothelial 
cell adhesion and migration adhesion and migration. Oncotarget. 7, 10090-10103. 
GANEM, N.J., GODINHO, S.A., PELLMAN, D. 2009. A mechanism linking extra centrosomes to 
chromosomal instability. Nature. 460, 278- 282. 
GAUTIER, T., ROBERT-NICOUD, M., GUILLY, M.N., HERNANDEZ-VERDUN, D. 1992. Relocation of 
nucleolar proteins around the chromosomes at mitosis. A study by confocal laser scanning 
microscopy. J. Cell Sci. 102, 729-737. 
GE, X., FRANK, C.L., CALDERON DE ANDA, F., TSAI, L.H. 2010. Hook3 interacts with PCM1 to 
regulate pericentriolar matrix assembly and the timing of neurogenesis. Neuron. 65, 191-203. 
GEE, S.H., BLACHER, R.W., DOUVILLE, P.J., PROVOST, P.R., YURCHENCO, P.D., CARBONETTO, S. 
1993. Laminin-binding protein 120 from brain is closely related to the dystrophin associated 
glycoprotein, dystroglycan, and binds with high affinity to the major heparin binding domain of 
laminin. J. Biol. Chem. 268, 14972-14980. 
GEIS, T., MARQUARD, K., RODL, T., REIHLE, C., SCHRMER, S., VON KALLE, T., BORNEMANN, A., 
HEHR, U., BLANKENBURG, M. 2013. Homozygous dystroglycan mutation associated with a 
234 
 
novel muscle-eye-brain disease-like phenotype with multicystic leucodystrophy. 
Neurogenetics. 14, 205-213. 
GEORGE, S.J., AND DWIVEDI, A. 2004. MMPs, cadherins, and cell proliferation. Trends 
Cardiovasc. Med. 14, 100-105. 
GIANCOTTI, F.G. 1997. Integrin signalling: specificity and control of cell survival and cell cycle 
progression. Curr. Op. Cell Biol. 9, 691-700. 
GILLE, H., KORTENJANN, M., THOMAE, O., MOOMAW, C., SLAUGHTER, C., COBB, M.H., SHAW, 
P.E. 1995. ERK phosphorylation potentiates Elk-1-mediated ternary complex formation and 
transactivation. EMBO. J. 14, 951-962.  
GODFREY, C., FOLEY, A.R., CLEMENT, E., MUNTONI, F. 2011. Dystroglycanopathies: coming into 
focus. Curr. Opin. Genet. Dev. 21, 278-285. 
GOMES, E.R., JANI, S., GUNDERSEN, G.G. 2005. Nuclear movement regulated by Cdc42, MRCK, 
myosin, and actin flow establishes MTOC polarization in migrating cells. Cell. 121, 451-63. 
GONZALEZ-RAMIREZ, R., MORALES-LAZARO, S. L., TAPIA-RAMIREZ, V., MORNET, D. & 
CISNEROS, B. 2008. Nuclear and nuclear envelope localization of dystrophin Dp71 and 
dystrophin-associated proteins (DAPs) in the C2C12 muscle cells: DAPs nuclear localization is 
modulated during myogenesis. J Cell Biochem, 105, 735-45.  
GONCZY, P. 2002. Nuclear envelope: torn apart at mitosis. Curr. Biol. 12, R242-244. 
GONCZY, P. 2012. Towards a molecular architecture of centriole assembly. Nat. Mol. Cell Biol. 
13, 425-435. 
GONCZY, P., PICHLER, S., KIRKHAM, M., HYMAN, A.A. 1999. Cytoplasmic dynein is required for 
distinct aspects of MTOC positioning, including centrosome separation in one cell stage 
Caenorhabditis elegans embryo.  Mol. Biol. Cell. 147, 135-150. 
GORECKI, D.C., DERRY, J.M.J., BARNARD, E.A. 1994. Dystroglycan: brain localisation and 
chromosome mapping in the mouse. Hum. Mol. Genet. 3, 1589-1597. 
GORECKI, D.C., MONACO, A.P., DERRY, J.M., WALKER, A.P., BARNARD, E.A., BARNARD, P.J. 
1992. Expression of four alternative dystrophin transcripts in brain regions regulated by 
different promoters. Hum. Mol. Genet. 1, 505-510. 
GORLICH, D., PANTE, N., KUTAY, U., AEBI, U., BISCHOFF, F.R. 1996. Identification of different 
roles for RanGDP and RanGTP in nuclear protein import. EMBO J. 15, 5584-5594. 
GOSS, V.L., HOCEVAR, B.A., THOMPSON, L.J., STRATTON, C.A., BURNS, D.J., FIELDS, A.P. 1994. 
Identification of nuclear beta II protein kinase C as a mitotic lamin kinase. J. Biol. Chem. 269, 
19074-19080. 
GOSTI-TESTU, F., MARTY, M.C., BERGES, J., MAUNORY, R., BORNENS, M. 1986. Identification of 
centrosomal proteins in a human lymphoblastic cell line. EMBO J. 5, 2545-2550. 
GOULD, C. M., DIELLA, F., VIA, A., PUNTERVOLL, P., GEMUND, C., CHABANIS-DAVIDSON, S., 
MICHAEL, S., SAYADI, A., BRYNE, J. C., CHICA, C., SEILER, M., DAVEY, N. E., HASLAM, N., 
WEATHERITT, R. J., BUDD, A., HUGHES, T., PAS, J., RYCHLEWSKI, L., TRAVE, G., AASLAND, R., 
HELMER-CITTERICH, M., LINDING, R. & GIBSON, T. J. 2010. ELM: the status of the 2010 
eukaryotic linear motif resource. Nucleic Acids Res, 38, D167-80. 
235 
 
GRUENBAUM, Y., MARGALIT, A., GOLDMAN, R.D., SHUMAKER, D.K., WILSON, K.L. 2005. The 
nuclear lamina comes of age. Nat. Rev. Mol. Cell Biol. 6, 21-31. 
GUPTA, V., KAWAHARA, G., GUNDRY, S.R., CHEN, A.T., LENCER, W.I., ZHOU, Y., ZON, L.I., 
KUNKEL, L.M., BEGGS, A.H. 2011. The zebrafish DAG1 mutant: a novel genetic model for 
dystroglycanopathies. Hum. Mol. Genet. 20, 1712-1725. 
GURUHARSHA, K.G., KANKEL, M.W., ARTAVANIS-TSAKONAS, S. 2012. The Notch signalling 
system: recent insights into the complexity of a conserved pathway. Nat. Rev. Genet. 13, 654-
666. 
HAKKINEN, K.M., HARUNAGA, J.S., DOYLE, A.D., YAMADA, K.M. 2011. Direct Comparisons of 
the Morphology, Migration, Cell Adhesions, and Actin Cytoskeleton of Fibroblasts in Four 
Different Three-Dimensional Extracellular Matrices. Tissue Engineering. 17, 713-724.  
HALE, C.M., SHRESTHA, A.L., KHATAU, S.B., STEWART-HUTCHINSON, P.J., HERNANDEZ, L., 
STEWART, C.L., HODZIC, D., WIRTZ, D. 2008. Dysfunctional connections between the nucleus 
and the actin and microtubule networks in laminopathic models. Biophysical J. 95, 5462-5475. 
HAMARATOGLU, F., WILLECKE, M., KANGO-SINGH, M., NOLO, R., HYUN, E., TAO, C., JAFAR-
NEJAD, H., HALDER, G. 2006. The tumour-suppressor genes NF2/ Merlin and Expanded act 
through Hippo signalling to regulate cell proliferation and apoptosis. Nat. Cell Biol. 8, 27-36. 
HANDWERGER, K.E., AND GALI, J.G. 2006. Subnuclear organelles: new insights into form and 
function. Trends Cell Biol. 16, 19-26. 
HAQUE, F., MAZZEO, D., PATEL, J.T., SMALLWOOD, D.T., ELLIS, J.A., SHANAHAN, C.M., 
SHACKLETON, S. 2010. Mammalian SUN protein interaction networks at the inner nuclear 
membrane and their role in laminopathy disease processes. J. Biol. Chem., 29, 3487-3498. 
HAQUE, F., LLOYD, D.J., SMALLWOOD, D.T., DENT, C.L., SHANAHAN, C.M., FRY, A.M., 
TREMBATH, R.C., SHACKLETON, S. 2006. SUN1 interacts with nuclear lamin A and cytoplasmic 
nesprins to provide a physical connection between the nuclear lamina and the cytoskeleton. 
Mol. Cell Biol. 26, 3738-3751. 
HARA, Y., BALCI-HAYTA, B., YOSHIDA-MORIGUCHI, T., KANAGAWA, M., BELTRAN-VALERO DE 
BERNABE, D., GUNDESLI, H., WILLER, T., SATZ, J.S., CRAWFORD, R.W., BURDEN, S.J., KUNZ, S., 
OLDSTONE, M.B., ACCARDI, A., TALIM, B., MUTONI, F., TOPALOGLU, H., DINCER, P., CAMPBELL, 
K.P. 2011. A dystroglycan mutation associated with limb-girdle muscular dystrophy. N Engl J 
Med. 364, 939-946. 
 
HARA, Y., KANAGAWA, M., KUNZ, S., YOSHIDA-MORIGUCHI, T., SATZ, J.S., KOBAYASHI, Y.M., 
ZHU, Z., BURDEN, S.J., OLDSTONE, M.B., CAMPBELL, K.P. 2011. Like-
acetylglucosaminyltransferase (LARGE)-dependent modification of dystroglycan at Thr-
317/319 is required for laminin binding and arena virus infection. Proc. Natl. Acad. Sci. USA. 
108, 17426-17431. 
HARAGUCHI, T., KOUJIN, T., HAYAKAWA, T., KANEDA, T., TSUTSUMI, C., IMAMOTO, N., 
AKAZAWA, C., SUKEGAWAJ., YONEDA, Y., HIRAOKA, Y. 2000. Live fluorescent imaging reveals 
early recruitment of emerin, LBR, RanBP2, and Nup153 to reforming, functional nuclear 
envelopes. J. Cell Sci. 113, 779-794. 
HARAGUCHI, T., KOUJIN, T., SEGURA-TOTTEN, M., LEE, K.K., MATSUOKA, Y., YONEDA, Y., 
WILSON, K.L., HIRAOKA, Y. 2001. BAF is required for emerin assembly into the reforming 
nuclear envelope. J. Cell Sci. 114, 4574-4585. 
236 
 
HELLIWELL, T.R., MAN, N., MORRIS, G.E. 1994. Expression of the 43 kD dystrophin-associated 
glycoprotein in human neuromuscular disease. Neuromusc. Disord. 4, 101-113. 
HEMMING, M.L., ELIAS, J.E., GYGI, S.P., SELKOE, D.J. 2008. Proteomic profiling of gamma-
secretase substrates and mapping of substrate requirements. PLoS Biol. 6, e257. 
HENRY, M. D. & CAMPBELL, K. P. 1998. A role for dystroglycan in basement membrane 
assembly. Cell, 95, 859-70.  
 
HENRY, M. D., COHEN, M. B. & CAMPBELL, K. P. 2001a. Reduced expression of dystroglycan in 
breast and prostate cancer. Hum Pathol, 32, 791-5. 
HENRY, M.D., SATZ, J.S., BRAKEBUSCH, C., COSTELL, M., GUSTAFSSON, E., FASSLER, R., 
CAMPBELL, K.P. 2001b. Distinct roles for dystroglycan, beta1 integrin and perlecan in cell 
surface laminin organization. J Cell Sci. 114, 1137-1144. 
HERNANDEZ-IBARRA, J.A., LAREDO-CISNEROS, M.S., MONDRAGO-GONZALEZ, R., 
SANTAMARIA-GUAYASAMIN, N., CISNEROS, B. 2015. Localization of α-Dystrobrevin in Cajal 
bodies and the nucleoli: A new role for α-dystrobrevin in the structure/stability of the 
Nucleolus. J. Cell Biochem. 116, 2755-2765. 
HERNANDEZ-VERDUN, D. 2011. Assembly and disassembly of the nucleolus during the cell 
cycle. Nucleus. 2, 189-194. 
HERRMANN, R., STRAUB, V., BLANK, M., KUTZICK, C., FRANKE, N., JACOBS, N.E., HANS-GERD, 
L., KRӦGER, S., VOIT, T. 2000. Dissociation of the Dystroglycan complex in caveolin-3-deficient 
limb girdle muscular dystrophy. Hum. Mol. Genet. 9, 2335- 2340. 
HERZOG, C., HAS, C., FRANZKE, C. W., ECHTERMEYER, F. G., SCHLOTZER-SCHREHARDT, U., 
KROGER, S., GUSTAFSSON, E., FASSLER, R. & BRUCKNER-TUDERMAN, L. 2004. Dystroglycan in 
skin and cutaneous cells: beta-subunit is shed from the cell surface. J Invest Dermatol, 122, 
1372-80. 
HETZER, M.W. 2010. The nuclear envelope. Cold Spring Harbor Perspectives in Biology. 2, 
a000539. 
HETZER, M., BILBAO-CORTES, D., WALTHER, T.C., GRUSS, O.J., MATTAJ, I.W. 2000. GTP 
hydrolysis by Ran is required for nuclear envelope assembly. Mol. Cell.5, 1013-1024. 
HIGGINSON, J. R., THOMPSON, O. & WINDER, S. J. 2008. Targeting of dystroglycan to the 
cleavage furrow and midbody in cytokinesis. Int J Biochem Cell Biol, 40, 892-900.  
HOHENESTER, E., TISI, D., TALTS, J.F., TIMPL, R. 1999. The crystal structure of a laminin G-like 
module reveals the molecular basis of alpha-dystroglycan binding to laminins, perlecan, and 
agrin. Mol. Cell. 4, 783-792. 
 
HOLT, K.H. AND CAMPBELL, K.P. 1998. Assembly of the sarcoglycan complex. Insights for 
muscular dystrophy. J. Biol. Chem. 273, 34667-34670. 
HOLT, K.H., CROSBIE, R.H., VENZKE, D.P., CAMPBELL, K.P. 2000. Biosynthesis of Dystroglycan: 
processing of a precursor propeptide. FEBS Letters. 468, 79-83. 
HOLT, L.J. 2012. Regulatory molecules: coupling protein stability to phospho regulation during 
cell division. FEBS Letters. 586, 2773-2777. 
237 
 
HORNBECK, P.V., ZHANG, B., MURRAY, B., KORNHAUSER, J. M., LATHAM, V., SKRZYPEK, E. 
2014. PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res, 43, D512-
20. URL : http://www.phosphosite.org/homeAction.action 
HOROSZEWICZ, J. S., LEONG, S. S., KAWINSKI, E., KARR, J. P., ROSENTHAL, H., CHU, T. M., 
MIRAND, E. A. & MURPHY, G. P. 1983. LNCaP model of human prostatic carcinoma. Cancer Res, 
43, 1809-18. 
HOSOKAWA, H., NINOMIYA, H., KITAMURA, Y., FUJIWARA, K., MASAKI, T. 2001. Vascular 
endothelial cells that express dystroglycan are involved in angiogenesis. J. Cell Sci. 115, 1487-
1496. 
HOYTE, K., JAYASINHA, V., XIA, B., MARTIN, P.T. 2004. Transgenic overexpression of 
dystroglycan does not inhibit muscular dystrophy in mdx mice. Am. J. Pathol. 164,711-718. 
HSU, T., TROJANOWSKA, M., WATSON, D.K. 2004 Ets proteins in biological control and cancer. J 
Cell Biochem 91,896–903 
HU, M. AND POLYAK, K. 2008. Microenvironmental regulation of cancer development. Curr. 
Opin. Genet. Dev. 18, 27-34. 
HUA, Q., KNUDSON, C.B., KNUDSON, W. 1993. Internalization of hyaluronan by chondrocytes 
occurs via receptor-mediated endocytosis. J. Cell. Sci. 365-375. 
HUANG, X., POY, F., ZHANG, R., JOACHIMIAK, A., SUDOL, M. & ECK, M.J. 2000. Structure of a 
WW domain containing fragment of dystrophin in complex with β-dystroglycan. Nature 
Structural Biology, 7, 634-638. 
HUANG, Q., MILLER, M.R., SCHAPPET, J., HENRY, M.D. 2015. The glycosyltransferase LARGE2 is 
repressed by Snail and ZEB1 in prostate cancer. Cancer Biol. Ther. 16, 125-136. 
HUMPHREY, E.L., LACEY, E., LE, L.T., FENG, L., SCIANDRA, F., MORRIS, C. R., HEWITT, J. E., HOLT, 
I., BRANCACCIO, A., BARRESI, R., SEWRY, C.A., BROWN, S. C., MORRIS, G.E. 2015. A new 
monoclonal antibody DAG-6F4 against human alpha-dystroglycan reveals reduced core protein 
in some, but not all, dystroglycanopathy patients. Neuromuscular Disorders, 25, 32-42. 
IWATA, Y., NAKAMURA, H., FUJIWARA, K., SHIGEKAWA, M. 1993. Altered membrane-
dystrophin association in the cardiomyopathic hamster heart muscle. Biochem. Biophys. Res. 
Commun. 190, 589-595. 
IBRAGHIMOV-BESKROVNAYA, O., ERVASTI, J. M., LEVEILLE, C. J., SLAUGHTER, C. A., SERNETT, S. 
W. & CAMPBELL, K. P. 1992. Primary structure of dystrophin-associated glycoproteins linking 
dystrophin to the extracellular matrix. Nature, 355, 696-702.  
 
IBRAGHIMOV-BESKROVNAYA, O., MILATOVICH, A., OZCELIK, T., YANG, B., KOEPNICK, K., 
FRANCKE, U. & CAMPBELL, K. P. 1993. Human dystroglycan: skeletal muscle cDNA, genomic 
structure, origin of tissue specific isoforms and chromosomal localization. Hum Mol Genet, 2, 
1651-7. 
ILSLEY, J. L., SUDOL, M. & WINDER, S. J. 2002. The WW domain: linking cell signalling to the 
membrane cytoskeleton. Cell Signal, 14, 183-189 
ILSLEY, J. L., SUDOL, M. & WINDER, S. J. 2001. The interaction of dystrophin with beta-
dystroglycan is regulated by tyrosine phosphorylation. Cell Signal, 13, 625-32 
238 
 
ISGRO, T.A., AND SCHULTEN, K. 2005. Binding dynamics of isolated nucleoporin repeat regions 
to importin-beta. Structure. 13, 1869-1879. 
ITO, N., RUEGG, U.T., KUDO, A., MIYAGOE-SUZUKI, Y., TAKEDA, S. 2013. Activation of calcium 
signalling through Trpv1 by nNOS and peroxynitrite as a key trigger of skeletal muscle 
hypertrophy. Nat. Med. 19. 101-106. 
JACOBSON, C., MONTANARO, F., LINDENBAUM, M., CARBONETTO, S., FERNS, M. 1998. alpha-
Dystroglycan functions in acetylcholine receptor aggregation but is not a coreceptor for agrin-
MuSK signaling. J. Neurosci. 18, 6340-6348. 
JAE, L.T., RAABEN, M., RIEMERSMA, M., VAN BEUSEKOM, E., BLOMEN, V.A., VELDS, A., 
KERKHOVEN, R.M., CARETTE, J.E., TOPALOGLU, H., MEINECKE, P., WESSELS, M.W., LEFEBER, 
D.J., WHELAN, S.P., VAN BOKHOVEN, H., BRUMMELKAMP, T.R. 2013. Deciphering the 
glycosylome of dytroglycaopathies using haploid screens for Lassa virus entry. Science. 340, 
479-483. 
JAMES, M., MAN, N.G., WISE, C.J., JONES, G.E., MORRIS, G.E. 1996. Utrophin-dystroglycan 
complex in membranes of adherent cultured cells. Cell Motil. Cytoskel. 33, 163-174. 
JAMES, M., NUTTALL, A., ILSLEY, J. L., OTTERSBACH, K., TINSLEY, J. M., SUDOL, M. & WINDER, S. 
J. 2000. Adhesion-dependent tyrosine phosphorylation of (beta)-dystroglycan regulates its 
interaction with utrophin. J Cell Sci, 113, 1717-1726 
JANS, D.A., AND HASSAN, G. 1998. Nuclear targeting by growth factors, cytokines, and 
their receptors: a role in signaling? Bioessays. 20, 400-411. 
JIMENEZ-MALLEBRERA, C., TORELLI, S., FENG, L., KIM, J., GODFREY, C., CLEMENT, E., MEIN, R., 
ABBS, S., BROWN, S.C., CAMPBELL, K.P., KROGER, S., TALIM, B., TOPALOGLU, H., QUINLIVAN, 
R., ROPER, H., CHILDS, A.M., KINALI, M., SEWRY, C.A., MUNTONI, F. 2009. A comparative 
study of alpha-dystroglycan glycosylation in dystroglycanopathies suggests that the 
hypoglycosylation of alpha-dystroglycan does not consistently correlate with clinical severity. 
Brain Pathol. 19. 596-611. 
JING, J., LIEN, C. F., SHARMA, S., RICE, J., BRENNAN, P. A. & GORECKI, D. C. 2004. Aberrant 
expression, processing and degradation of dystroglycan in squamous cell carcinomas. Eur J 
Cancer, 40, 2143-51. 
JORDAN, M.A., THROWER, D., WILSON, L. 1992. Effects of vinblastine, podophyllotoxin and 
nocodazole on mitotic spindles Implications for the role of microtubule dynamics in mitosis. J. 
Cell Sci. 102, 401-416. 
JUNG, D., YANG, B., MEYER, J., CHAMBERLAIN, J.S., CAMPBELL, K.P. 1995. Identification and 
characterisation of the dystrophin anchoring sire on beta-dystroglycan. J. Biol. Chem.270, 
27305-27310. 
KAHL, J., CAMPANELLI, J.T. 2003. A role for the juxtamembrane domain of beta-dystroglycan in 
agrin-induced acetylcholine receptor clustering. J. Neurosci. 23, 392-402. 
 
KAKU, N., MATSUDA, K., TSUJIMURA, A., KAWATA, M. 2008. Characterization of nuclear import 
of the domain-specific androgen receptor in association with the importin α/β and ran-
guanosine 5’-triphosphate systems. Endocrinology. 149, 3960-3969. 
KALDERON, D., ROBERTS, B.L., RICHARDSON, W.D., SMITH, A.E. 1984. Sequence requirements 
for nuclear location of simian virus 40 large-T antigen. Nature. 311, 33-38. 
239 
 
KANAGAWA, M., SAITO, F., KUNZ, S., YOSHIDA-MORIGUCHI, T., BARRESI, R., KOBAYASHI, Y.M., 
MUSCHLER, J., DUMANSKI, J.P., MICHELE, D.E., OLDSTONE, M.B., CAMPBELL, K.P. 2004. 
Molecular recognition by LARGE is essential for expression of functional dystroglycan. Cell. 
117, 953-964. 
KANG, R., WAN, J., ARSTIKAITIS, P., TAKAHASHI, H., HUANG, K., BAILEY, A .O., THOMPSON, J.X., 
ROTH, A.F., DRISDEL, R.C., MASTRO, R., GREEN, W.N., YATES, J.R., DAVIS, N.G., EL-HUSSEINI, A. 
2008. Neural palmitoyl-proteomics reveals dynamic synaptic palmitoylation. Nature. 456, 904-
909. 
KASAHARA, K., NAKAYAMA, Y., NAKAZATO, Y., IKEDA, K., KUGA, T., YAMAGUCHI, N. 2007. Src 
signalling regulates completion of abscission in cytokinesis through ERK/ MAPK activation at 
the midbody. J. Biol. Chem. 282, 5327-5339. 
KELLY, T., MUELLER, S.C., YEH, Y., CHEN, W.T. 1994. Invadopodia promote proteolysis of a wide 
range of extracellular matrix proteins. J. Cell Physiol. 158, 299-308. 
KENNEDY, B.K., BARBIE, D.A., CLASSON, M., DYSON, N., HARLOW, E. 2000. Nuclear 
organization of DNA replication in primary mammalian cells. Genes and Dev. 14, 2855-2868. 
KERYER, G., RIOS, R.M., LANDMARK, B, F., SKALHEGG, B., LOHMANN, S.M., BORNENS. M. 1993. 
A high-affinity binding protein for the regulatory subunit of cAMP-dependent protein kinase II 
in the centrosome of human cells. Exp. Cell Res.204, 230-240. 
KETTENBACH, A.N., SCHWEPPE, D.K., FAHERTY, B.K., PECHENICK, D., PLETNEV, A.A., GERBER, 
S.A. 2011. Quantitative Phosphoproteomics Identifies Substrates and Functional Modules of 
Aurora and Polo-Like Kinase Activities in Mitotic Cells. Sci. Signal. 4, rs5. doi: 
10.1126/scisignal.2001497. 
KIM, J,B. 2005. Three-dimensional tissue culture models in cancer biology. Semin. Cancer Biol. 
15, 365-377. 
KIM, W., BENNETT, E.J., HUTTLIN, E.L., GUO, A., LI, J., POSSEMATO, A., SOWA, M.E., RAD, R., 
RUSH, J., COMB, M.J., HARPER, J.W., GYGI, S.P. 2011. Systematic and quantitative assessment 
of the ubiquitin-modified proteome. Mol. Cell. 44, 325-340. 
KING, M.C., DRIVAS, T.G., BLOBEL, G. 2008. A network of nuclear envelope membrane proteins 
linking centromeres to microtubules. Cell. 134, 427-438. 
KINOSHITA, E., KINOSHITA-KIKUTA, E., TAKIYAMA, K., KOIKE, T. 2005. Phosphate-binding Tag, a 
New Tool to Visualise Phosphorylated Proteins. Molecular & Cellular Proteomics, 749-757.  
KITAMURA, R., SEKIMOTO, T., ITO, S., HARADA, S., YAMAGATA, H., MASAI, H., YONEDA, Y., 
YANAGI,  
K. 2006. Nuclear import of Epstein-Barr virus nuclear antigen 1 mediated by NPI-1 (Importin 
alpha5) is up- and down-regulated by phosphorylation of the nuclear localization signal for 
which Lys379 and Arg380 are essential. J. Virol. 80, 1979-1991.  
 
KNUDSEN, B. S., MIRANTI, C. K. 2006. The impact of cell adhesion changes on proliferation and 
survival during prostate cancer development and progression. J. Cell. Biochem. 99, 345-361. 
KOBAYASHI, K., NAKAHORI, Y., MIYAKE, M., MATSUMURA, K., KONDO-LIDA, E., NOMURA, Y., 
SEGAWA, M., YOSHIOKA, M., SAITO, K., OSAWA, M., HAMANO, K., SAKAIHARA, Y., NONAKA, I., 
NAKAGOME, Y., KANAZAWA, I., NAKAMURA, Y., TOKUNAGA, K., TODA, T. 1998. An 
240 
 
ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy. 
Nature. 394, 388-392. 
KOENIG, M., HOFFMAN, E.P., BERTELSON, C.J., MONACO, A.P., FEENER, C., KUNKEL, L.M. 1987. 
Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic 
organization of the DMD gene in normal and affected individuals. Cell. 50, 509–517. 
 
KOENIG, M.M BEGGS, A.G., MOYER, M., SCHERPF, S., HEINDRICH, K., BETTECKEN, T., MULLER, 
C.R., LINDLOF, M., KAARIAINEN, H. 1989. The molecular basis for Duchenne versus Becker 
muscular dystrophy: correlation of severity with type of deletion. Am. J. Hum. Genet. 45, 498–
506. 
 
KOLE, R., AND KRIEG, A.M. 2015. Exon skipping therapy for Duchenne muscular dystrophy. Adv 
Drug Deliv Rev. 87, 104-107. 
 
KORYAKINA, Y., KNUDSEN, K. E., GIOELI, D. 2015. Cell cycle dependent regulation of androgen 
receptor function. Endocr. Relat. Cancer. 22, 249-264. 
KRUDE, T., MUSAHL, C., LASKEY, R.A., KNIPPERS, R. 1996. Human replication proteins hCdc21, 
hCdc46 and P1Mcm3 bind chromatin uniformly before S-phase and are displaced locally during 
DNA replication. J. Cell Sci. 109. 309-318, 
KUNDA, P., AND BAUM, B. 2009. The actin cytoskeleton in spindle assembly and positioning. 
Trends Cell Biol. 19, 174-179. 
KUNZ, S., ROJEK, J.M., KANAGAWA, M., SPIROPOULOU, C.F., BARRESI, R., CAMPBELL, K.P., 
OLDSTONE, M.B. 2005. Posttranslational modification of alpha-dystroglycan, the cellular 
receptor for arenaviruses, by the glycosyltransferase LARGE is critical for virus binding. J. Virol. 
79, 14282-14296. 
 
KUTAY, U., BISCHOFF, F.R., KOSTKA, S., KRAFT, R., GORLICH, D. 1997. Export of importin alpha 
from the nucleus is mediated by a specific nuclear transport factor. Cell. 90, 1061-1071. 
 
LA COUR, T., KIEMER, L., MOLGAARD, A., GUPTA, R., SKRIVER, K., BRUNAK, S. 2004. Analysis 
and prediction of leucine-rich nuclear export signals. Protein Eng. Des. Sel. 17, 527-536. 
 
LAEMMLI, U.K. 1970. Cleavage of structural proteins during the assembly of the head of 
bacteriophage T4. Nature. 227, 680-685. 
 
LAI, Y., THOMAS, G.D., YUE, Y., YANG, H.T., LI, D., LONG, C., JUDGE, L., BOSTICK, B., 
CHAMBERLAIN, J.S. TERJUNG, R.L. 2009. Dystrophins carrying spectrin-like repeats 16 and 17 
anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of 
muscular dystrophy. J. Clin. Invest. 119, 624-635. 
LAM, M.H., HOUSE, C.M., TIGANIS, T., MITCHELHILL, K. I., SARCEVIC, B., CURES, A., RAMSAY, 
R., KEMP, B.E., MARTIN, T.J., GILLESPIE, M.T. 1999. Phosphorylation at the cyclin-dependent 
kinases site (Thr85) of parathyroid hormone-related protein negatively regulates its nuclear 
localization. J, Biol. Chem. 274, 18559-18566.  
 
LAMMERDING, J., HSAIO, J., SCHULZE, P.C., KOZLOV, S., STEWART, C.L., LEE, R.T. 2005. 
Abnormal nuclear shape and impaired mechanotransduction in emerin-deficient cells. J. Cell 




LANGE, A., MILLS, R.E., LANGE, C.J., STEWART, M., DEVINE, S.E., CORBETT, A.H. 2007. Classical 
nuclear localisation signals: definition, function, and interaction with importin alpha. J. Biol. 
Chem. 282, 5101-5105. 
LANGE, A., MCLANE, L.M., MILLS, R.E., DEVINE, S.E., CORBETT, A. H. 2010. Expanding the 
definition of the classical bipartite nuclear localisation signal. Traffic. 11, 311-323. 
LANGENBACH, K.J. AND RANDO, T.A. 2002. Inhibition of dystroglycan binding to laminin 
disrupts the PI3k/AKT pathway and survival signalling in muscle cells. Muscle Nerve. 26, 644-
653. 
LARA-CHACON, B., DE LEON, M. B., LEOCADIO, D., GOMEZ, P., FUENTES-MERA, L., MARTINEZ-
VIEYRA, I., ORTEGA, A., JANS, D. A. & CISNEROS, B. 2010. Characterization of an Importin 
alpha/beta-recognized nuclear localization signal in beta-dystroglycan. J Cell Biochem, 110, 
706-17. 
LAURENT, J., FROGIA, C., CAZALES, M., MONDESERT, O., DUCOMMUN, B., LOBJOIS, V. 2013. 
Multicellular tumor spheroid models to explore cell cycle checkpoints in 3D. BMC Cancer. 13 
LAWO, S., HASEGAN, M., GUPTA, G.D., PELLETIER, L. 2012. Subdiffraction imaging of 
centrosomes reveals higher-order organizational features of pericentriolar material. Nat. Cell 
Biol. 14, 1148-1158. 
LEE. K. A., HAMMERLE, L. P., ANDREWS, P.S., STOKES, M.P., MUSTELIN, T., SILVA, J.C., 
DOEDENS, J.R. (2011). Ubiquitin ligase substrate identification through quantitative proteomics 
at both the protein and peptide levels. J. Biol Chem., 286, 41530-41538. 
 
LEE, K.K., HARAGUCHI, T., LEE, R.S., KOUJIN, T., HIRAOKA, Y., WILSON, K.L. 2001. Distinct 
functional domains in emerin bind lamin A and DNA-bridging protein BAF. J. Cell Sci. 114, 4567-
4573. 
LEI, M. 2005. The MCM complex: Its role in DNA replication and implications for cancer 
therapy. Curr. Cancer Drug targets. 5, 365-380. 
LEI, K., ZHU, X., XU, R., XU, T., ZHUANG, Y., HAN, M. 2012. Inner nuclear envelope proteins 
SUN1 and SUN2 play a prominent role in the DNA damage response. Curr. Biol. 22, 1609-1615. 
LEOCADIO, D. 2014. Post-Translational Modifiation And Nuclear Targeting Of Beta-
Dystroglycan. PhD Thesis. The University of Sheffield. 
 
LEOCADIO, D., MITCHELL, A., WINDER, S.J. 2016. γ-secretase dependent nuclear targeting of 
Dystroglycan. J Cell. Biochem.117, 2149-2157. 
LEONOUDAKIS, D., HUANG, G., AKHAVAN, A., FATA, J.E., SINGH, M., GRAY, J.W., MUSCHLER, 
J.L. 2014. Endocytic trafficking of laminin is controlled by dystroglycan and is disrupted in 
cancers. J. Cell Sci. 127, 4894-4903. 
LEVENTAL, K.R., YU, H., KASS, L., LAKINS, J.N., EGEBALD, M., ERLER, J.T., FONG, S.F., CSISZAR, K., 
GIACCIA, S., WENWINGER, W., YAMAUCHI, M., GASSER, D.L., WEAVER, V.M. 2009. Matrix 
crosslinking forces tumour progression by enhancing integrin signalling. Cell. 139, 891-906. 
LIDOV, H.G., SELIG, S., KUNKEL, L.M. 1995. Dp140: a novel 140 kDa CNS transcript from the 
dystrophin locus. Hum. Mol. Genet. 4, 77-81. 
LIN, R.Z. AND CHANG, H.Y. 2008. Recent advances in three-dimensional multicellular spheroid 
culture for biomedical research. Biotechnol. J. 3, 1172-1184. 
242 
 
LIN, Y. Y., WHITE, R.J., TORELLI, S., CIRAK, S., MUNTONI, F., STEMPLE, D.L. 2011. Zebrafish 
fukutin family proteins link the unfolded protein response with dystroglycanopathies. Hum. 
Mol. Genet. 20, 1763-1775. 
LINDER, M.E., DESCHENES, R.J.2007. Palmitoylation: policing protein stability and traffic. Nat 
Rev Mol Cell Biol.8, 74-84. 
LINDSAY, M.E., HOLASKA, J.M., WELCH, K., PASCHAL, B.M., MACARA, I.G. 2001. Ran-binding 
protein 3 is a cofactor for Crm1-mediated nuclear protein export. J. Cell Biol. 153, 1391-1402. 
LIPSCOMB, L., PIGGOTT, R.W., EMMERSON, T., WINDER, S.J. 2016. Dasatinib as a treatment for 
Duchenne muscular dystrophy. Hum. Mol. Genet. 25, 266-274. 
LIU, X., DU, L., FENG, R. 2013. c-Src regulates cell cycle proteins expression through protein 
kinase B/glycogen synthase kinase 3 beta and extracellular signal-regulated kinases 1/2 
pathways in MCF-7 cells. Acta. Biochim. Biophys. 45, 586-592. 
LO, H.W., ALI-SEYED, M., WU, Y., BARTHOLOMEUSZ, G., HSU, S.C., HUNG, M.C. 2006. Nuclear-
cytoplasmic transport of EGFR involves receptor endocytosis, importin β1 and CRM1. J. Cell 
Biochem. 98, 1570-1583. 
LO, H.W., XIA, W., WEI, Y., ALI-SEYED, M., HUANG, S.F., HUNG, M.C. 2005. Novel prognostic 
value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res. 65, 338-348. 
LOESSNER, D., STOK, K.S., LUTOLF, M.P., HUTMACHER, D.W., CLEMENTS, J.A., RIZZI, S.C. 2010. 
Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial 
ovarian cancer cells. Biomaterials. 31, 8494-8506. 
LOMBARDI, M.L., JAALOUK, D.E., SHANAHAN, C.M., BURKE, B., ROUX, K.J., LAMMERDING, J. 
2011. The interaction between nesprins and sun proteins at the nuclear envelope is critical for 
force transmission between the nucleus and cytoskeleton. J Biol Chem. 286, 26743–26753 
LOSASSO, C., DI TOMMASO, F., SGAMBATO, A., ARDITO, R., CITTADINI, A., GIARDINA, B., 
PETRUCCI, T. C. & BRANCACCIO, A. 2000. Anomalous dystroglycan in carcinoma cell lines. FEBS 
Lett, 484, 194-8. 
LOUVET-VALLEE, S. 2000. ERM proteins: from cellular architecture to cell signalling. Biol. Cell 
92, 305-316. 
LOVISA, SL, LEBLEU, V.S., TAMPE, B., SUGIMOTO, H., VADNAGARA, K., CARSTENS, J.L., WU, 
C.C., HAGOS, Y., BURCKHARDT, B.C., PENTCHEVA-HOANG, T., NISCHAL, H., ALLISON, J.P., 
ZEISBERG, M., KALLURI, R. 2015. Epithelial-to-mesenchymal transition induces cell cycle arrest 
and parenchymal damage in renal fibrosis. Nat. Med. 21, 998-1009. 
LUCA, A.C., MERSCH, S., DEENEN, R.et al. 2013. Impact of the 3D microenvironment on 
phenotype, gene expression, and EGFR inhibition of colorectal cancer cell lines. PLoS One. 8, 
e59689. 
LUDERS, J. AND STEARNS, T. 2007. Microtubule-organising centres: a re-evaluation. Nat. Rev. 
Mol. Cell Biol. 8, 161-167. 
LUKE, Y. H., ZAIM, I., KARAKESISOGLOU, V.M., JAEGER, L., SELLIN, W., LU, M., SCHNEIDER, S., 
NEUMANN, A., BEIJER, A., MUNCK. M. 2008. Nesprin-2 Giant (NUANCE) maintains nuclear 
envelope architecture and composition in skin. J. Cell Sci. 121, 1887-1898. 
243 
 
LUMENG, C., PHELPS, S., CRAWFORD, G.E., WALDEN, P.D., BARALD, K., CHAMBERLAIN, J.S. 
1999. Interactions between beta-2-syntrophin and a family of microtubule-associated 
serine/threonine kinases. Nat. Neurosci.2, 611-617. 
LUXTON, G.W., GOMES, E.R., FOLKER, E. S., VINTINNER, E., GUNDERSEN, G.G. 2010. Linear 
arrays of nuclear envelope proteins harness retrograde actin flow for nuclear movement. 
Science. 329, 956-959. 
LUXTON, G.W., AND GUNDERSON, G.G. 2011. Orientation and function of the nuclear-
centrosomal axis during cell migration. Curr. Opin. Cell Biol. 23, 579-588. 
LUZHNA, L., KATHIRIA, P., KOVALCHUK, O. 2013. Micronuclei in genotoxicity assessment: from 
genetics to epigenetics and beyond. Front. Genet. 4, 131. 
MAISON, C., HORSTMANN, H., GEORGATOS, S.D. 1993. Regulated docking of nuclear 
membrane vesicles to vimentin filaments during mitosis. J. Cell Biol. 123, 133-144. 
MALONE, C.J., MISNER, L., LE BOT, N., TSAI, M.C., CAMPBELL, J.M., AHRINGER, J., WHITE, J.G. 
2003. The C. elegans Hook protein, ZYG-12, mediates the essential attachment between the 
centrosome and the nucleus. Cell. 115, 825-836. 
MALUMBRES, M., AND BARBACID, M. 2009. Cell Cycle, CDKs and cancer: a changing paradigm. 
Nat. Rev. Cancer. 9, 153-166. 
MANILAL, S., THI MAN, N., MORRIS, G.E. 1998. Colocalization of emerin and lamins in 
interphase nuclei and changes during mitosis. Biochem. And Biophys. Res. Comm. 249, 643-
647. 
MANSUR, N. R., MEYER-SIEGLER, J.C., WURZER, J.C. AND SIROVER, M.A. 1993. Cell cycle 
regulation of the glyceraldehyde-3-phosphate dehydrogenase/ uracil DNA glycosylase gene in 
normal human cells. Nucleic Acids Res. 21, 993-998. 
MARTIN, C., CHEN, S., MAYA-MENDOZA, A., LOVRIC, J., SIMS, P.F.G., JACKSON, D.A. 2009. 
Lamin B1 maintains the functional plasticity of the nucleoli. J. Cell Sci. 122, 1551-1562.  
MARTINEZ-VIEYRA, I. A., VASQUEZ-LIMETA, A., GONZALEZ-RAMIREZ, R., MORALES-LAZARO, S. 
L., MONDRAGON, M., MONDRAGON, R., ORTEGA, A., WINDER, S. J., CISNEROS, B. 2013. A role 
for β-Dystroglycan in the organisation and structure of the nucleus in myoblasts. Biochem. 
Biophys. Acta.1833 (3), 698-711. 
MARTINS, R.P., FINAN, J.D., GUILAK, F., LEE, D.A. 2012. Mechanical regulation of nuclear 
structure and function. Annu. Rev. Biomed. Eng. 14, 431-455. 
MASCKAUCHAN, T. N., SHAWBER, C.J., FUNAHASHI, Y., LI, C.M., KITAJEWSKI, J. 2005. 
Wnt/Beta-catenin signalling induces proliferation, survival and interleukin-8 in human 
endothelial cells. Angiogenesis. 8, 43-51. 
MATHEW, G. 2011. The nuclear function of dystroglycan in prostate cancer. PhD Thesis. The 
University of Sheffield. 
 
MATHEW, G., MITCHELL, A., DOWN, J.M., JACOBS, L. A., HAMDY, F.C., EATON, C., ROSARIO, 
D.J., CROSS, S.S., WINDER, S.J. 2013. Nuclear targeting of Dystroglycan promotes the 
expression of androgen regulated transcription factors in prostate cancer. Sci. Rep. 30, 2792 
244 
 
MATSUMURA, K., ZHONG, D., SAITO, F., ARAI, K., ADACHI, K., KAWAI, H., HIGUCHI, I., NISHINO, 
I, SHIMIZU, T. 2005. Proteolysis of beta-dystroglycan in muscular diseases. Neuromuscul. 
Disord. 15, 336-341. 
MEIER, J., AND GEORGATOS, S.D. 1994. Type B lamins remain associated with the integral 
nuclear envelope protein p58 during mitosis: implications for nuclear reassembly. EMBO J. 13, 
1888-1898. 
MEJAT, A. AND MISTELI, T. 2010. LINC complexes in health and disease. Nucleus. 1, 40-52. 
MERCURI, E. AND MUNTONI, F. 2013. Muscular Dystrophies. Lancet. 381, 845-860. 
MEYER, A.J., ALMENDRALA, D.K., GO, M. M., WALD KRAUSS, S. 2010. Structural protein 4.1R is 
integrally involved in nuclear envelope protein localization, centrosome-nucleus association 
and transcriptional signalling. J. Cell Sci. 124, 1433-1444. 
MEYER, T., BEGITT, A., LODIGE, I., VAN ROSSUM, M., VINKEMEIER, U. 2002. Constitutive and 
IFN gamma-induced nuclear import of STAT1 proceed through independent pathways. Embo. 
J. 21, 344354.  
MEYERZON, M., FRIDOLFSSON, H.N., LY, N., MCNALLY, F.J., STARR, D.A. 2009. UNC-83 is a 
nuclear -specific cargo adaptor for kinesin-1-mediated nuclear migration. Development. 136, 
2725-2733. 
MILLER, G., MOORE, C. J., TERRY, R., LA RIVIERE, T., MITCHELL, A., PIGGOTT, R., DEAR, T. N., 
WELLS, D. J., WINDER, S. J. 2012. Preventing phosphorylation of dystroglycan ameliorates the 
dystrophic phenotype in MDX mouse. Hum.Mol. Genet. 21, 4508-4520. 
MILLER, G., WANG, E.L., NASSAR, K.L., PETER, A.K., CROSBIE, R.H. 2007. Structural and 
functional analysis of the sarcoglycan-sarcospan subcomplex. Exp. Cell Res. 313, 639-651. 
MILLER, M.R., MA, D., SCHAPPET, J., BREHENY, P., MOTT, S.L., BANNICK, N., ASKELAND, E., 
BROWN, J., HENRY, M.D. 2015. Downregulation of dystroglycan glycosyltransferases LARGE2 
and ISPD associate with increased mortality in clear cell renal cell carcinoma. Molecular 
Cancer. 14, 141. 
MINN, I. L., ROLLS, M. M., HANNA-ROSE, W., MALONE, C.J. 2009. SUN-1 and ZYG-12, mediators 
of centrosome nucleus attachment, are a functional SUN/ KASH pair in Caenorhabditis elegans. 
Mol. Biol. Cell. 20, 4586-4595. 
MITCHELL, A., MATHEW, G., JIANG, T., HAMDY, F.C., CROSS, S.S., EATON, C.L., WINDER, S.J. 
2013, Dystroglycan function is a novel determinant of tumor growth and behaviour in prostate 
cancer. Prostate.73, 389-408. 
MIURA, P. AND JASMIN, B.J. 2006. Utrophin upregulation for treating Duchenne or Becker 
muscular dystrophy: how close are we? Trends Mol. Med.12, 122-129 
MOIR, R.D., SPANN, T. P., LOPEZ-SOLER, R.I., YOON, M., GOLDMAN, A.E., KHUON, S., 
GOLDMAN, R.D. 2000a. Review: The dynamics of the nuclear lamins during the cell cycle- 
relationship between structure and function. J. Struct. Biol. 129, 324-334. 
MOIR, R.D., YOON, M., KHUON, S., GOLDMAN, R.D. 2000b. Nuclear lamins A and B1: different 
pathways of assembly during nuclear envelope formation in living cells. J. Cell Biol. 151, 1155- 
1168. 
MOIR, R.D., SPANN, T., HERRMANN, H., GOLDMAN, R.D. 2000c. Disruption of nuclear lamin 
organisation blocks the elongation phase pf DNA replication. J. Cell Biol. 149, 1179-1192. 
245 
 
MOORE, C. J. & WINDER, S. J. 2010. Dystroglycan versatility in cell adhesion: a tale of multiple 
motifs. Cell Commun Signal, 8, 3. 
MOORE, C.J. & WINDER, S.J. 2012.The inside and out of dystroglycan post-translational 
modification. Neuromusc. Disord. 22, 959-965. 
MOORE, M. S. 1998. Ran and nuclear transport. J. Biol. Chem. 273, 22857-22860. 
MORAZ, M. L., PYTHOUD, C., TURK, R., ROTHENBERGER, S., PASGUATO, A., CAMPBELL, K.P., 
KUNZ, S.2013. Cell entry of Lassa virus induces tyrosine phosphorylation of dystroglycan. Cell 
Microbiol.15, 689-700. 
MORENO-LAYSECA, P., STREULI, C.H. 2014. Signalling pathways linking integrins with cell cycle 
progression. Matrix Biology. 34, 144-153. 
MORGAN, J.T., PFEIFFER, E.R., THIRKILL, T.L., KUMAR, P., PENG, G., FRIDOLFSSON, H.N., 
DOUGLAS, G.C., STARR, D.A., BARAKAT, A.I. 2011. Nesprin-3 regulates endothelial cell 
morphology, perinuclear cytoskeletal architecture, and flow-induced polarization. Mol. Biol. 
Cell. 22, 4324-4334. 
MORGIA, G., FALASAPERLA, M., MALAPONTE G., MADONIA, M., INDELICATO, G., TRAVALI,S., 
MAZZARINO, M. C. 2005. Matrix metalloproteinases as diagnostic (MMP-13) and prognostic 
(MMP-2, MMP-9) markers of prostate cancer. Urol. Res. 33, 44-50. 
MORITA, N., UEMURA, H., TSUMATANI, K., CHO, M., HIRAO, Y., OKAJIMA, E., KONISHI, N., 
HIASA, Y. 1999. E-cadherin and α-, β-, and γ-catenin expression in prostate cancers: correlation 
with tumour invasion. British Journal of Cancer. 79, 1879-1883. 
MORITZ, M., BRAUNFELD, M.B., SEDAT, J.W., ALBERTS, B., AGARD, D.A. 1995. Microtubule 
nucleation by gamma-tubulin-containing rings in the centrosome. Nature. 378, 638–640. 
MORO, L., VENTURINO, M., BOZZO, C., SILENGO, L., ALTRUDA, F., BEGUINOT, L., TARONE, G., 
DEFILIPPI, P. 1998. Integrins induce activation of EGF receptor: role in MAP kinase induction 
and adhesion-dependent cell survival. EMBO J. 17, 6622-6632. 
MORRIS, G.E., MAN, N., PEREBOEV, A., KENDRICK-JONES, J., WINDER, S.J. 1999. Disruption of 
the utrophin-actin interaction by monoclonal antibodies and prediction of an acti-binding 
surface of utrophin. Biochem. J. 337, 119-123. 
MOUDJOU, M., BORDES, N., PAINTRAND, M., BORNENS, M. 1996. γ-tubulin in mammalian 
cells: the centrosomal and cytosolic forms. J. Cell Sci. 109, 875-887. 
MUCHIR, A., BONNE, G., VAN DER KOOI, A.J., VAN MEEGEN, M., BAAS, F., BOLHUIS, P.A., DE 
VISSER, M., SCHWARTZ, K. 2000. Identification of mutations in the gene encoding lamins A/C in 
autosomal dominant limb girdle muscular dystrophy with atrioventricular conduction 
disturbances (LGMD1B). Hum. Mol. Genet. 9, 1453-1459. 
MULHOLLAND, D.J., CHENG, H., REID, K. RENNIE, P.S., NELSON, C.C. 2002. The androgen 
receptor can promote beta-catenin nuclear translocation independently of adenomatous 
polyposois coli. J. Biol. Chem. 17, 17933-17943. 
MUNTONI, F., TORELLI, S., FERLINI, A. 2003. Dystrophin mutations: one gene, several proteins, 
multiple phenotypes. Lancet Neurol. 2, 731-740. 
MURANEN, T., GRӦNHOLM, M., RENKEMA, G.H., CARPEN, O. 2005. Cell cycle-dependent 




MURPHY, L.O., MACKEIGAN, J.P., BLENIS, J. 2004. A network of immediate early gene products 
propagates subtle differences in mitogen-activated protein kinase signal amplitude and 
duration. Mol. Cell Biol. 24, 144-153. 
MURTHY, S., WU, M., BAI, V.U., HOU, Z., MENON, M., BARRACK, E.R., KIM, S.H., REDDY, G.P.R. 
2013. Role of androgen receptor in progression of LNCaP prostate cancer cells from G1 to S 
phase. PLOS ONE. e56692. 
MUSACCHIO, A. AND SLAMON, E.D. 2007. The spindle-assembly checkpoint in space and time. 
Nature Rev. Mol. Cell. Biol. 8, 379-393. 
MUSCHLER, J., LEVY, D., BOUDREAU, R., HENRY, M., CAMPBELL, K., BISSELL, M.J. 2002. A role 
for dystroglycan in epithelial polarization loss of function in breast tumor cells. Cancer Res. 62, 
7102-7109. 
 
MYERS, J.M., MARTINS, G.G., OSTROWSKI, J., STACHOWIAK, M.K. 2003. Nuclear trafficking of 
FGFR1: a role for the transmembrane domain. J. Cell Biochem. 88, 1273-1291. 
NADEZHDINA, E.S., FAIS, D., CHENTSOV, Y.S. 1979. On the association of centrioles with the 
interphase nucleus. Eur. J. Cell Biol. 19, 109- 115. 
NARDOZZI, J. D., LOTT, K. L., CINGOLANI, G. 2010. Phosphorylation meets nuclear import: a 
review. Cell Commun Signal, 8, 32. 
NAWROTZKI, R., LOH, N.Y., RUEGG, M.A., DAVIES, K.E., BLAKE, D.J. 1998. Characterization of 
alpha-dystrobrevin in muscle. J. Cell Sci. 111, 2595-2605. 
NEGI, S.S. AND OLSON, M.O. 2006. Effects of interphase and mitotic phosphorylation on the 
mobility and location of the nucleolar protein B23. J. Cell Sci. 119, 3676-3685. 
NELSON, C.M. AND CHEN, C.S. 2002. Cell-cell signalling by direct contact increases cell 
proliferation via a PI3K-dependent signal. FEBS Letters. 514, 238-242. 
NEWEY, S.E., HOWMAN, E.V., PONTING, C.P., BENSON, M.A., NAWROTZKI, R., LOH, N.Y., 
DAVIES, K.E., BLAKE, D.J. 2000. Alternative splicing of dystrobrevin regulates the stoichiometry 
of syntrophin binding to the dystrophin protein complex. Curr. Biol. 10, 1295-1298. 
NEWPORT, J., AND YAN, H. 1996. Organization of DNA into foci during replication. Curr. Op. 
Cell Biol. 8, 365-368. 
NIGG, E.A., STEARNS, T. 2011. The centrosome cycle: centriole biogenesis, duplication and 
inherent asymmetries. Nat. Cell Biol. 13, 1154-1160. 
NIKOLAKAKI, E., MEIER, J., SIMOS, G., GEORGATOS, S.D., GIANNAKOUROS, T. 1997. Mitotic 
phosphorylation of the lamin B receptor by a serine/arginine kinase and p34(cdc2). J. Biol. 
Chem. 272, 6208-6213. 
NIWA, T., SAITO, H., IMAJOH-OHMI, S., KAMINISHI, M., SETO, Y., MIKI, Y., NAKANISHI, A. 2009. 
BRCA2 interacts with the cytoskeletal linker protein plectin to form a complex controlling 
centrosome localization. Cancer Sci. 100, 2115- 2125. 
NOBES, C.D. AND HALL, A. 1995. Rho, rac, and cdc42 GTPases regulate the assembly of 
multimolecular focal complexes associated with actin stress fibres, lamellipodia, and filopodia. 
Cell. 81, 53-62. 
NURSE, P., THURIAX, P., NASMYTH, K. 1976. Genetic control of the cell division cycle in the 
fission yeast Schizosaccharomyces pombe. Mol. Gen. Genet. 146, 167-178. 
247 
 
NÜSSLEIN-VOLHARD, C. AND DAHM, R. 2002. Zebrafish: a practical approach. New York: 
Oxford University Press, 303. 
OAK, S.A., RUSSO, K., PETRUCCI, T.C., JARRET, H.W. 2002. Mouse α1-syntrophin binding to 
Grb2: Further evidence of a role for syntrophin in cell signalling. Biochemistry. 40, 11270-
11278. 
OAKLEY, B.R., OAKLEY, C.E., YOON, Y., JUNG, K. 1990. γ-tubulin is a component of the spindle 
pole body that is essential for microtubule function is Aspergillus nidulans. Cell. 61, 1289-1301. 
OBINO, D., FARINA, F., MALBEC, O., SAEZ, P.J., MAURIN, M., GAILLARD, J., DINGLI, F., LOEW, D., 
GAUTREAU, A., YUSEFF, M. A., BLANCHOIN, L., THERY, M., LENNON-DUMENIL, A.M. 2015. 
Actin nucleation at the centrosome controls lymphocyte polarity. Nat. Comm. 7:10969 doi: 
10.1038/ncomms10969.  
OLSEN, J.V., ONG, S., MANN, M. 2004. Trypsin cleaves exclusively C-terminal to arginine and 
lysine residues. Mol. & Cell Proteomics. 3, 608-614. 
OLSON, M.F. AND SAHAI, E. 2009. The actin cytoskeleton in cancer cell motility. Clin. Exp. 
Metastasis. 26. 273-287. 
OPPIZZI, M. L., AKHAVAN, A., SINGH, M., FATA, J. E. & MUSCHLER, J. L. 2008. Nuclear 
translocation of beta-dystroglycan reveals a distinctive trafficking pattern of autoproteolyzed 
mucins. Traffic, 9, 2063-72. 
OTTAVIANO, Y., AND GERACE, L. 1985. Phosphorylation of the nuclear lamins during mitosis 
and interphase. J. Biol. Chem. 260, 624-632. 
OXLEY, C.L., ANTHIS, N.J., LOWE, E.D., VAKONAKIS, I, CAMPBELL, I.D., WEGENER, K.L. 2008. An 
integrin phosphorylation switch: the effect of beta3 integrin tail phosphorylation of Dok1 and 
talin binding. J. Biol. Chem. 283, 5420-5426. 
PAINTRAND, M., MOUDJOU, M., DELACROIX, H., BORNENS, M. 1992. Centrosome organisation 
and centriole architecture: their sensitivity to divalent cations. J. Struct. Biol. 108, 107-128. 
PARBERRY-CLARK, C., BURY, J. P., CROSS, S. S. & WINDER, S. J. 2011. Loss of dystroglycan 
function in oesophageal cancer. Histopathology, 59, 180-7. 
PATEL, J.T., BOTTRILL, A., PROSSER., S.L., JAYARAMAN, S., STRAATMAN, K., FRY, A.M., 
SHACKELTON, S. 2014. Mitotic phosphorylation of SUN1 loosens its connection with the 
nuclear lamina while the LINC complex remains intact. Nucleus. 5, 462-73. 
PEARCE, M., BLAKE, D.J., TINSLEY, J.M., BYTH, B.C., CAMPBELL, L., MONACO, A.P., DAVIES, K.E. 
1993. The utrophin and dystrophin genes share similarities in genomic structure. Hum. Mol. 
Genet. 2, 1765–1772. 
 
PENG, H.B., ALI, A.A., DAGGETT, D.F., RAUVALA, H., HASSELL, J.R., SMALHEISER, N.R. 1998. The 
relationship between perlecan and dystroglycan and its implication in the formation of the 
neuromuscular junction. Cell Adhes. Commun. 5, 475-489. 
PEREBOEV, A.V., AHMED, N., MAN, N., MORRIS, G.E. 2001. Epitopes in the interacting regions 
of β-dystroglycan (PPxY motif) and dystrophin (WW domain). BBA, 1527, 54-60. 
PETROF, B.J. 1998. The molecular basis of activity-induced muscle injury in Duchenne muscular 
dystrophy. Mol. Cell. Biochem.179, 111-123. 
248 
 
PIEL, M., MEYER, P., KHODJAKOV, A., RIEDER, C.L., BORNENS, M. 2000. The respective 
contributions of the mother and daughter centrioles to centrosome activity and behaviour in 
vertebrate cells. J. Cell Biol. 149, 317-329. 
PINTO, L.C., FAVARO, W.J., CAGNON, V.H.A. 2010. Proliferative, structural and molecular 
features of the Mdx mouse prostate. Int. J. Exp. Path. 91, 408-419. 
PLANQUE, N. 2006. Nuclear trafficking of secreted factors and cell surface receptors: new 
pathways to regulate cell proliferation and differentiation and involvement in cancers. Cell 
Comm. and Sig.4 
POLLICE, A.A., MCCOY, J. P., SHACKNEY, S.E., SMITH, C.A., AGARWAL, J., BURHOLT, D.R., 
JANOCKO, L.E., HORNICEK, F.J., SINGH, S.G., HARTSOCK, R.J. 1992. Sequential 
paraformaldehyde and methanol fixation for simultaneous flow cytometric analysis of DNA, 
cell surface proteins, and intracellular proteins. Cytometry.13, 432-444. 
POZAROWSKI, P. AND DARZYNKIEWICZ, Z. 2004. Analysis of cell cycle by flow cytometry. 
Methods Mol. Biol. 281, 301-311. 
PROKOCIMER, M., DAVIDOVICH, M., NISSIM-RAFINIA, M., WIESEL-MOTIUK, N., BAR, D.Z., 
BARKAN, R., MESHORER, E., GRUENBAUM, Y. 2009. Nuclear lamins: key regulators of nuclear 
structure and activities. J. Cell Mol. Med. 13, 1059- 1085. 
PROVENZANO, P.P., ELICEIRI, K.W., CAMPBELL, J.M., INMAN, D.R., WHITE, J.G., KEELEY, P.J. 
2006. Collagen reorganisation at the tumour-stroma interface facilitates local invasion. BMC 
Med. 4, 38. 
PRUNUSKE, A.J. AND ULLMAN, K.S. 2006. The nuclear envelope: form and reformation. Curr. 
Opin. Cell Biol. 18, 108-116. 
PUCKETT, R.L., MOORE, S.A., WINDER, T.L., WILLER, T., ROMANSKY, S.G., COVAULT, K.K., 
CAMPBELL, W.P., ABDENUR, J.E. 2009. Further evidence of Fukutin mutations as a cause of 
childhood onset limb-girdle muscular dystrophy without mental retardation. Neuromuscul 
Disord. 19, 352-356. 
PUGACHEVA, E. N., ROEGIERS, F. & GOLEMIS, E. A. 2006. Interdependence of cell attachment 
and cell cycle signalling. Curr Opin Cell Biol, 18, 507-15. 
RABE, B., VLACHOU, A., PANTE, N., HELENIUS, A., KANN, M. 2003. Nuclear import of hepatitis 
B virus caspids and release of the viral genome. PNAS. 100, 9849-9854.  
RADU, A., NEUBAUER, V., AKAGI, T., HANAFUSA, H., GEORGESCU, M. 2003. PTEN induces cell 
cycle arrest by decreasing the level and nuclear localization of cyclin D1. Mol. Cell Biol. 23, 
6139- 6149. 
RAMASWAMY, S., NAKAMURA, N., VAZQUEZ, F., BATT, D.B., PERERA, S., ROBERTS, T.M., 
SELLERS, W.R. 1999.Biology Regulation of G1 progression by the PTEN tumor suppressor 
protein is linked to inhibition of the phosphatidylinositol 3-kinaseyAkt pathway. Proc. Natl. 
Acad. Sci. 96, 2110-2115. 
RAMBUKKANA, A., YAMADA, H., ZANAZZI, G., MATHUS, T., SALZER, J.L., YURCHENCO, P.D., 
CAMPBELL, K.P., FISCHETTI, V.A. 1998. Role of alpha-dystroglycan as a Schwann cell receptor 
for Mycobacterium leprae. Science. 282, 2076-2079. 
RASKA, I., SHAW, P.J., CMARKO, D. 2006. New insights into nucleolar architecture and activity. 
Int. Rev. Cytol. 255, 177-235.  
249 
 
RAVID, T. AND HOCHSTRASSER, M. 2008. Diversity of degradation signals in the ubiquitin-
proteasome system. Nat. Rev. Mol. Cell Biol. 9, 679-689. 
RAZAFSKY, D., HODZIC, D. 2009. Bringing KASH under the SUN: the many faces of nucleo-
cytoskeletal connections. J. Cell Biol. 186, 461-472. 
REILLY, J.F., AND MAHER, P.A. 2001. Importin beta-mediated nuclear import of fibroblast 
growth factor receptor: role in cell proliferation. J. Cell Biol. 152, 1307-1312. 
RENTSCHLER, S., LINN, H., DEININGER, K., BEDFORD, M.T., ESPANEL, X., SUDOL, M. 1999. The 
WW domain of dystrophin requires EF-hands region to interact with β-dystroglycan. Biological 
Chemistry. 380, 431-442. 
RIDLEY, A.J., SCHWARTZ, M.A., BURRIDGE, K., FIRTEL, R.A., GINSBERG, M.H., BORISY, G., 
PARSONS, J.T., HORWITZ, A.R. 2003. Cell migration: integrating signals from front to back. 
Science. 302, 1704-1709. 
RIEMERSMA, M., MANDEL, H., VAN BEUSEKOM, E., GAZZOLI, I., ROSCIOLI, T., ERAN, A., 
GERSHONI-BARUCH, R., GERSHONI, M., PIETROKOVSKI, S., VISSERS, L.E., LEFEBER, D.J., 
WILLEMSEM, M.A., WEVERS, R.A., VAN BOKHOVEN, H. 2015. Absence of α- and β-dystroglycan 
is associated with Walker-Warburg syndrome. Neurology. 28, 2177-2182. 
RIVIER, F., ROBERT, A., ROYUELA, M., HUGON, G., BONET-KERRACHE, A., MORNET, D. 1999. 
Dystrophin and utrophin complexed with different associated proteins in cardiac purkinje 
fibers. Histochem. J. 31, 425-432. 
RO, S. AND YANG, L.X. 2004, Centrosomes- Their role in Tumors and cancer therapy. 
Anticancer Res. 24, 3269-3273. 
ROBBINS, E., JENTZSCH, G., MICALI, A. 1968. The centriole cycle in synchronized HeLa cells. J. 
Cell Biol. 36, 329–39. 
ROBERDS, S.L., ERVASTI, J.M., ANDERSON, R.D., OHLENDIECK, K., KAHL, S.D., ZOLOTO, D., 
CAMPBELL, K.P. 1993. Disruption of the dystrophin-glycoprotein complex in the 
cardiomyopathic hamster. J. Biol. Chem. 268, 11496-11499. 
ROSNER, M., SCHIPANY, K., HENGSTSCHLAGER, M. 2013. Merging high-quality biochemical 
fractionation with a refined flow cytometry approach to monitor nucleocytoplasmic protein 
expression throughout the unperturbed mammalian cell cycle. Nature Protocols, 8, 602-626. 
RUSSO, K., DI STASIO, E., MACCHIA, G., ROSA, G., BRANCACCIO, A., PETRUCCI, T.C. 2000. 
Characterization of the beta-dystroglycan-growth-factor receptor 2 (Grb2) interaction. 
Biochem. Biophys. Res. Commun. 274, 93-98. 
SAITO, F., MOORE, S.A., BARRESI, R., HENRY, M.D., MESSING, A., ROSS-BARTA, S.E., COHN.R.D., 
WILLIAMSON, R.A., SLUKA, K.A., SHERMAN, D.L., BROPHY, P.J., SCHMELZER, J.D., LOW, P.A., 
WRABETZ, L., FELTRI, M.L., CAMPBELL, K.P. 2003. Unique Role of Dystroglycan in Peripheral 
Nerve Myelination, Nodal Structure, and Sodium Channel Stabilization. Neuron. 38, 747-758. 
SAKAKI, M., KOIKE, H., TAKAHASHI, N., SASAGAWA, N., TOMIOKA, S., ARAHATA, K., ISHIURA, S. 
2001. Interaction between emerin and the nuclear lamins. J. Biochem . 129, 321-327. 
SAKAUE-SAWANO, A., KUROKAWA, H., MORIMURA, T., HANYU, A., HAMA, H., OSAWA, H., 
KASHIWAGI, S., FUKAMI, K., MIYATA, T., MIYOSHI, H., IMAMURA, T., OGAWA, M., MASAI, H., 
MIYAWAKI, A. 2008. Visualizing spatiotemporal dynamics of multicellular cell-cycle 
progression. Cell. 132, 487-498. 
250 
 
SALINA, D., BODOOR, K., ECKLEY, D.M., SCHROER, T.A., RATTNER, J.B., BURKE, B. 2002. 
Cytoplasmic dynein as a facilitator of nuclear envelope breakdown. Cell. 108, 97-107. 
SALPINGIDOU, G., SMERTENKO, A., HAUSMANOWA-PETRUCEWICZ, I., HUSSEY, P.J., 
HUTCHISON, C.J. 2007. A novel role for the nuclear membrane protein emerin in association of 
the centrosome to the outer nuclear membrane. J. Cell Biol. 178, 897-904. 
SCALTRITI, M. AND BASELGA, J. 2006. The epidermal growth factor receptor pathway: A model 
for targeted therapy. Clin. Cancer Res. 12, 5268-5272 
SCHAFER, K. AND BRAUN, T. 1995. Monoclonal anti-FLAG antibodies react with a new isoform 
of rat MG2+ dependent protein phosphatase beta. Biochem. Biophys. Res Commun. 207, 708-
714. 
SCHAUSBERGER, E., EFERL, R., PARZEFALL W., CHABICOVSKY, M., BREIT, P., WAGNER, E. F., 
SCHULTE-HERMANN, R., GRASL-KRAUPP, B. 2003. Induction of DNA synthesis in primary 
mouse hepatocytes is associated with nuclear pro-transforming growth factor alpha and ERBB-
1 and is independent of C-Jun. Carcinogenesis. 24, 835-841. 
SCHRODER, J.E., TEGELER, M.R., GROβHANS, U., PORTEN, E., BLANK, M., LEE, J., ESAPA, C., 
BLAKE, D.J., KRӦGER, S. 2007. Dystroglycan regulates structure, proliferation and 
differentiation of neuroepithelial cells in the developing vertebrate CNS. Dev. Biol. 307, 62-78. 
SCHNEIDER, M., KHALIL, A.A., POULTON, J., CASTILLEJO-LOPEZ, C., EGGER-ADAM, D., WODARZ, 
A., DENG, W.M., BAUMGARTNER, S. 2006. Perlecan and Dystroglycan act at the basal side of 
the Drosophila follicular epithelium to maintain epithelial organization. Development. 133, 
3805-3815. 
 
SCIANDRA, F., SCHNEIDER, M., GIARDINA, B., BAUMGARTNER, S., PETRUCCI, T.C., 
BRANCACCIO, A. 2001. Identification of the β-dystroglycan binding epitope within the C-
terminal region of α-dystroglycan. Eur. J. Biochem. 268, 4590- 4597. 
SGAMBATO, A. AND BRANCACCIO, A. 2005. The dystroglycan complex: from biology to cancer. 
J. Cell Physiol. 205, 163-169. 
SGAMBATO, A., CAMERINI, A., AMOROSO, D., GENOVESE, G., DE LUCA, F., CECCHI, M., 
MIGALDI, M., RETTINO, A., VALSUANI, C., TARTARELLI, G., DONATI, S., SICLARI, O., ROSSI, G. & 
CITTADINI, A. 2007a. Expression of dystroglycan correlates with tumor grade and predicts 
survival in renal cell carcinoma. Cancer Biol Ther, 6, 1840-6.  
 
SGAMBATO, A., CAMERINI, A., FARAGLIA, B., PAVONI, E., MONTANARI, M., SPADA, D., 
LOSASSO, C., BRANCACCIO, A. & CITTADINI, A. 2004. Increased expression of dystroglycan 
inhibits the growth and tumourigenicity of human mammary epithelial cells. Cancer Biol Ther, 
3, 967-75.  
 
SGAMBATO, A., CAMERINI, A., GENOVESE, G., DE LUCA, F., VIACAVA, P., MIGALDI, M., 
BONINSEGNA, A., CECCHI, M., SEPICH, C. A., ROSSI, G., ARENA, V., CITTADINI, A. & AMOROSO, 
D. 2010. Loss of nuclear p27(kip1) and alpha-dystroglycan is a frequent event and is a strong 
predictor of poor outcome in renal cell carcinoma. Cancer Sci, 101, 2080-6. 
SGAMBATO, A., DE PAOLA, B., MIGALDI, M., DI SALVATORE, M., RETTINO, A., ROSSI, G., 
FARAGLIA, B., BONINSEGNA, A., MAIORANA, A. & CITTADINI, A. 2007b. Dystroglycan 
expression is reduced during prostate tumorigenesis and is regulated by androgens in prostate 




SGAMBATO, A., DI SALVATORE, M. A., DE PAOLA, B., RETTINO, A., FARAGLIA, B., BONINSEGNA, 
A., GRAZIANI, C., CAMERINI, A., PROIETTI, G. & CITTADINI, A. 2006. Analysis of dystroglycan 
regulation and functions in mouse mammary epithelial cells and implications for mammary 
tumorigenesis. J Cell Physiol, 207, 520-9.  
 
SGAMBATO, A., MIGALDI, M., MONTANARI, M., CAMERINI, A., BRANCACCIO, A., ROSSI, G., 
CANGIANO, R., LOSASSO, C., CAPELLI, G., TRENTINI, G. P. & CITTADINI, A. 2003. Dystroglycan 
expression is frequently reduced in human breast and colon cancers and is associated with 
tumor progression. Am J Pathol, 162, 849-60. 
SGAMBATO, A., TARQUINI, E., RESCI, F., DE PAOLA, B., FARAGLIA, B., CAMERINI, A., RETTINO, 
A., MIGALDI, M., CITTADINI, A., ZANNONI, G.F. 2006. Aberrant expression of alpha-
dystroglycan in cervical and vulvar cancer. Gynecol. Oncol. 103, 397-404. 
SHAH, S.P., ROTH, A., GOYA, R., OLOUMI, A., HA, G., ZHAO, Y., TURASHVILI, G., DING, J., TSE, K., 
HAFFARI, G., BASHASHATI, A., PRENTICE, L.M..APARICIO, A. ET AL. 2012. 
The clonal and mutational evolution spectrum of primary triple-negative breast cancers. 
Nature. 486, 395-399. 
SHANG, Z.J., ETHUNANDAN, M., GORECKI, D.C., BRENNAN, P.A. 2008. Aberrant expression of 
beta-dystroglycan may be due to processing by matrix metalloproteinases-2 and -9 in 
oral squamous cell carcinoma. Oral Oncol. 44, 1139-1146. 
SHAY, J.W., PORTER, K.R., PRESCOTT, D.M. 1974. The surface morphology and fine structure of 
CHO (Chinese Hamster Ovary) cells following enucleation. PNAS. 71, 3059-3063. 
SHCHERBATA, H.R., YATSENKO, A.S., PATTERSON, L., SOOD, V.D., NUDEL, U., YAFFE, D., BAKER, 
D., RUOHOLA-BAKER, H. 2007. Dissecting muscle and neuronal disorders in a drosophila model 
of muscular dystrophy. EMBO J. 26, 481-493. 
SHEN, T. AND GUAN, J. 2001. Differential regulation of cell migration and cell cycle progression 
by FAK complexes with Src, PI3K, Grb7 and Grb2 in focal contacts. FEBS Letters. 499, 176-181. 
SHEN, J. G., XU, C. Y., LI, X., DONG, M. J., JIANG, Z, N., WANG, J., WANG, L. B. 2012. 
Dystroglycan is associated with tumour progression and patient survival in gastric cancer. 
Pathol. Oncol. Res. 18, 79-84. 
SHERR, C.J. 1996. Cancer cell cycle. Science. 274, 1672-1677. 
 
SHERR, C.J. AND ROBERTS, J.M. 1999. CDK-inhibitors: positive and negative regulators of G1- 
Phase progression. Genes Dev. 13, 1501-1512. 
 
SHIMI, T., BUTIN-ISRAELI, V., ADAM, S.A., HAMANAKA, R.B., GOLDMAN, A.E., LUCAS, C.A., 
SHUMAKER., D.A., KOSAK, S.T., CHANDEL., N.S., GOLDMAN, R.D. 2011. The role of nuclear 
lamin B1 in cell proliferation and senescence. Genes & Development. 25, 2579-2593. 
SHIMI, T., KITTISOPIKUL, M., TRAN, J., GOLDMAN, A.E., ADAM, S.A., ZHENG, Y., JAGAMAN, K., 
GOLDMAN, R.D. 2015. Structural organization of nuclear lamins A, C, B1, and B2 revealed by 
superresolution microscopy. Mol. Biol. Cell. 26, 4075-4086. 
SHIMOJO, H., KOBAYASHI, M., KAMIGAITO, T., SHIMOJO, Y., FUKUDA, M. & NAKAYAMA, J. 
2011. Reduced glycosylation of alpha-dystroglycan on carcinoma cells contributes to formation 
of highly infiltrative histological patterns in prostate cancer. Prostate, 71, 1151-1157. 
252 
 
SINGH, J., ITAHANA, Y., KNIGHT-KRAJEWSKI, S., KANAGAWA, M., CAMPBELL, K. P., BISSELL, M. 
J. & MUSCHLER, J. 2004. Proteolytic enzymes and altered glycosylation modulate dystroglycan 
function in carcinoma cells. Cancer Res, 64, 6152- 6159. 
SOLINET, S., MAHMUD, K., STEWMAN, S.F., EL KADHI, K.B., DECELLE, B., TALJE, L., MA, A., 
KWOK, B.H., CARRENO, S. 2013. The actin-binding ERM protein moesin binds to and stabilises 
microtubules at the cell cortex. J. Cell Biol. 202, 251-260. 
SONGYANG, Z., BLECHNER, S., HOAGLAND, N., HOEKSTRA, M.F., PIWNICA-WORMS, H., 
CANTLEY, L.C. 1994. Use of an oriented peptide library to determine the optimal substrates of 
protein kinases. Curr. Biol. 4, 973-982. 
SOROKIN, S. 1962. Centrioles and the formation of rudimentary cilia by fibroblasts and smooth 
muscle cells. J. Cell Sci. 3, 207- 230. 
SOTGIA, F., LEE, J.K., DAS, K., BEDFORD, M., PETRUCCI, T.C., MACIOCE, P., SARGIACOMO, M., 
BRICARELLI, F.D., MINETTI, C., SUDOL, M., LISANTI, M.P. 2000. Caveolin-3 directly interacts 
with the C-terminal tail of beta-dystroglycan. Identification of a central WW-like domain within 
caveolin family members. J. Biol. Chem. 275, 38048-38058. 
SOTGIA, F., BONUCCELLI, G., BEDFORD, M., BRANCACCIO, A., MAYER, U., WILSON, M. T., 
CAMPOS-GONZALEZ, R., BROOKS, J. W., SUDOL, M. & LISANTI, M. P. 2003. Localization of 
phospho-beta-dystroglycan (pY892) to an intracellular vesicular compartment in cultured cells 
and skeletal muscle fibres in vivo. Biochemistry, 42, 7110-23.  
 
SOTGIA, F., LEE, H., BEDFORD, M. T., PETRUCCI, T., SUDOL, M. & LISANTI, M. P. 2001. Tyrosine 
phosphorylation of beta-dystroglycan at its WW domain binding motif, PPxY, recruits SH2 
domain containing proteins. Biochemistry, 40, 14585-92. 
SPANN, T.P., MOIR, R.D., GOLDMAN, A.E., STICK. R. AND GOLDMAN, R.D. 1997. Disruption of 
nuclear lamina organisation alters the distribution of replication factors and inhibits DNA 
synthesis. J. Cell Biol. 136, 1201-1212. 
SPENCE, H.J., CHEN, Y.J., BATCHELOR, C.L., HIGGINSON, J.R., SUILA, H., CARPEN, O., WINDER, 
S.J. 2004. Ezrin-dependent regulation of the actin cytoskeleton by beta-dystroglycan. Hum. 
Mol. Genet. 13, 1657-1668. 
SPENCE, H. J., DHILLON, A. S., JAMES, M. & WINDER, S. J. 2004. Dystroglycan, a scaffold for the 
ERK-MAP kinase cascade. EMBO Rep, 5, 484-9. 
STALNAKER, S.H., HASHMI, S., LIM, J.M., AOKI, K., PORTERFIELD, M., GUTIERREZ-SANCHEZ, G., 
WHEELER, J., ERVASTI, J.M., BERGMANN, C., TIEMEYER, M., WELLS, L. 2010. Site mapping and 
characterization of O-glycan structures on alpha-dystroglycan isolated from rabbit skeletal 
muscle. J. Biol Chem. 285: 24882-24891. 
STEWART-HUTCHINSON, P.J., HALE, C.M., WIRTZ, D., HODZIC, D. 2008. Structural requirements 
for the assembly of LINC complexes and their function in cellular mechanical stiffness. Exp. 
Cell. Res. 314, 1892-1905. 
STOKER, M., O’NEILL, C., BERRYMAN, S., WAXMAN, V. 1968. Anchorage and growth regulation 
in normal and virus-transformed cells. Int. J. Cancer. 3, 683-693. 
STUURMAN, N., HEINS, S., AEBI, U. 1998. Nuclear lamins: their structure, assembly, and 




SUAREZ-SANCHEZ, R., AGUILAR, A., WAGSTAFF, K.M., VELEZ, G., AZUARA-MEDINA, P.M., 
GOMEZ, P., VASQUEZ-LIMETA, A., HERNANDEZ-HERNANDEZ, O., LIEU, K.G., JANS, D.A., 
CISNEROS, B. 2014. Nucleocytoplasmic shuttling of the Duchenne muscular dystrophy gene 
product dystrophin Dp71 is dependent on the importin α/β and CRM1 nuclear transporters 
and microtubule motor dynein. Biochim. Biophys. Acta. 1843, 985-1001. 
SUEL, K.E., GU, H., COOK, Y.M. 2008. Modular organization and combinatorial energetics of 
proline-tyrosine nuclear localization signals. PLoS Biol. 6, e137. 
SUZUKI, A., YOSHIDA, M., YAMAMOTO, H., OZAWA, E. 1992. Glycoprotein-binding site of 
dystrophin is confined to the cysteine-rich domain and the first half of the carboxy-terminal 
domain. FEBS Letters. 308, 154-160. 
SUZUKI, A., YOSHIDA, M., OZAWA, E. 1995. Mammalian alpha1- and beta1- syntrophin bind to 
the alternative splice-prone region of the dystrophin COOh terminus. J. Cell Biol. 128, 373-381. 
SZETO, S.G., WILLIAMS, E.C., RUDNER, A.D., LEE, J.M. 2015. Phosphorylation of filamin A by 
Cdk1 regulates filamin A localization and daughter cell separation. Exp. Cell Res. 330, 248-266. 
TADAYONI, R., RENDON, A., SORIA-JASSO, CISNEROS, B. 2012. Dystrophin Dp71: The smallest 
but multifunctional product of the Duchenne Muscular Dystrophy gene. Mol. Neurobiol. 45, 
43-60. 
TAKAYAMA, S., ISHII, S., IKEDA, T., MASAMURA, S., DOI, M., KITAJIMA, M. 2005. The 
relationship between bone metastasis from human breast cancer and integrin alpha (v) beta 3 
expression. Anticancer Res.25, 79-83. 
TALTS, J.F., ANDAC, Z., GOHRING, W., BRANCACCIO, A., TIMPL, R. 1999. Binding of the G 
domains of laminin alpha1 and alpha2 chains and perlecan to heparin, sulfatides, alpha-
dystroglycan and several extracellular matrix proteins. EMBO J. 18, 863-870. 
TANIGUCHI-IKEDA, M., MORIOKA, I, IIJIMA, K., TODA, T. 2016. Mechanistic aspects of the 
formation of α-dystroglycan and therapeutic research for the treatment of α-
dystroglycanopathy: A review. Mol. Aspects. Med. 16, 30043-30047 
TANG, X., FALLS, D.L., LI, X., LANE, T., LUSKIN, M.B. 2007. Antigen-retrieval procedure for 
bromodeoxyuridine immunolabeling with concurrent labelling of nuclear DNA and antigens 
damaged by HCl pretreatment. J. Neurosci. 27, 5837-5844. 
TEIXIDO-TRAVESA, N., ROIG, J., LUDERS, J. 2012. The where, when and how of microtubule 
nucleation- one ring to rule them all. J. Cell Sci. 125, 4445-4456. 
TERRIN, A., MONTERISI, S., STANGHERLIN, A., ZOCCARATO, A., KOSCINSKI, A., SURDO, N.C., 
MONGILLO, M., SAWA, A., JORDANIDES, N.E., MOUNTFORD, C., ZACCOLO, M. 2012. PKA and 
PDE4D3 anchoring to AKAP9 provides distinct regulation of cAMP signals at the centrosome. J. 
Cell Biol. 198, 607-621.  
TETSU, O. AND MCCORMICK, F. 1999. Beta-catenin regulates expression of cyclin D1 in colon 
carcinoma cells. Nature. 398, 422-426.  
THALMANN, G. N., ANEZINIS, P, E., CHANG, S., ZHAU, H. E., KIM, E., HOPWOOD, V. L., PATHAK, 
S., VON ESCHENBACH, A. C., CHUNG, L. W. K. 1994. Androgen-independent Cancer Progression 




THI MAN, N., HELLIWELL, T.R., SIMMONS, C., WINDER, S.J., KENDRICK-JONES, J., DAVIES, K.E., 
MORRIS, G.E. 1995. Full-length and short forms of utrophin, the dystrophin-related protein. 
FEBS Letters. 358, 262–266. 
 
THOMAS, D.B. AND LINGWOOD, C.A. 1975. A model of cell cycle control: effects of thymidine 
on synchronous cell cultures. Cell. 5, 37-42. 
THOMSON, A. A., CUNHA, G. R., MARKER, P. C. 2008. Prostate development and pathogenesis. 
Differentiation. 76, 559-564. 
THOMPSON, L.J., BOLLEN, M., FIELDS, A.P. 1997. Identification of protein phosphatase 1 as a 
mitotic lamin phosphatase. J. Biol. Chem. 272, 29639-29697. 
THOMPSON, O., MOORE, C. J., HUSSAIN, S. A., KLEINO, I., PECKHAM, M., HOHENESTER, E., 
AYSCOUGH, K. R., SAKSELA, K. & WINDER, S. J. 2010. Modulation of cell spreading and cell-
substrate adhesion dynamics by dystroglycan. J Cell Sci, 123, 118-27. 
THOMPSON, O., KLEINO, I., CRIMALDI, L., GIMONA, M., SAKSELA, K., WINDER, S.J. 2008. 
Dystroglycan, Tks5 and Src mediated assembly of podosomes in myoblasts. PLoS One. 3, e3638 
 
TISI, D., TALTS, J.F., TIMPL, R., HOHENESTER, E. 2000. Structure of the C-terminal laminin G-like 
domain pair of the laminin alpha2 chain harbouring binding sites for alpha-dystroglycan and 
heparin. EMBO J, 19, 1432-1440. 
TOMLINS, S. A., RHODES, D. R., PERNER, S., DHANASEKARAN, S. M., MEHRA, R., SUN, X. W., 
VARAMBALLY, S., CAO, X., TCHINDA, J., KUEFER, R., LEE, C., MONTIE, J. E., SHAH, R. B., PIENTA, 
K. J., RUBIN, M. A. & CHINNAIYAN, A. M. 2005. Recurrent fusion of TMPRSS2 and ETS 
transcription factor genes in prostate cancer. Science, 310, 644-8. 
 
TORELLI, S., FERLINI, A., OBICI, L., SEWRY, C., MUNTONI, F. 1999. Expression, regulation and 
localisation of dystrophin isoforms in human foetal skeletal and cardiac muscle. Neuromusc. 
Disord. 9, 541-551. 
TORII, S., YAMAMOTO, T., TSUCHIYA, Y., NISHIDA, E. 2006. ERK MAP kinase in G1 cell cycle 
progression and cancer. Cancer Sci. 97, 697-702. 
TOWBIN, H., STAEHELIN, T., GORDON, J. 1979. Electrophoretic transfer of proteins from 
polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. 
Acad. Sci. USA. 76, 4350-4354. 
TRAN, T.D., LIM, J.M., LIU, M., STALNAKER.S.H., WELLS, L., TEN HAGEN, K.G., LIVE, D. 2012. 
Glycosylation of α-Dystroglycan: O- mannosylation influences the subsequent addition of 
GalNAc by UDP-GalNAc polypeptide N-acetylgalactosaminyltransferases. J. Bio. Chem. 287, 
20967-20974. 
TSAI, R.Y.L., AND PEDERSON, T. 2014. Connecting the nucleolus to the cell cycle and human 
disease. FASEB J. 28, 3290-3296. 
TSOU, M.F., AND STEARNS, T. 2006. Mechanism limiting centrosome duplication to once per 
cell cycle. Nature. 442, 947-951. 
VAN DIJK, M., GORANSSON, S.A., STROMBLAD, S. 2013. Cell to extracellular matrix interactions 
and their reciprocal nature in cancer. Exp. Cell. Res. 319, 1663-1670. 
255 
 
VAN STEENBRUGGE, G.J., VAN UFFELEN, C.J.C., BOLT, J., SCHRODER, F.H. 1991. The human 
prostatic cancer cell line LNCaP and its derived sublines: an in vitro model for the study of 
androgen sensitivity. J. Steroid Biochem. Molec. Biol. 40, 207-214. 
VASQUEZ-LIMETA, A., WAGSTAFF, K.M., ORTEGA, A., CROUCH, D.H., JANS, D.A., CISNEROS, B. 
2014. Nuclear import of β-dystroglycan is facilitated by Ezrin-mediated cytoskeleton 
reorganization. PLOS one, 9, e90629.  
VILLARREAL-SILVA, M., CENTENO-CRUZ, F., SUAREZ-SANCHEZ, R., GARRIDO, E. & CISNEROS, B. 
2011. Knockdown of dystrophin dp71 impairs PC12 cells cycle: localization in the spindle and 
cytokinesis structures implies a role for dp71 in cell division. PLoS One, 6, e23504.  
 
VILLARREAL-SILVA, M., SUAREZ-SANCHEZ, R., RODRIGUEZ-MUNOZ, R., MORNET, D. & 
CISNEROS, B. 2010. Dystrophin Dp71 is critical for stability of the DAPs in the nucleus of PC12 
cells. Neurochem Res, 35, 366-73. 
WALKER, J.L., AND ASSOIAN, R.K. 2005. Integrin-dependent signal transduction 
regulating cyclin D1 expression and G1 phase cell cycle progression. Cancer Metastasis Rev. 24, 
383-393. 
WALKER, J.L., FOURNIER, A.K., ASSOIAN, R.K. 2005. Regulation of growth factor signalling and 
cell cycle progression by cell adhesion and adhesion-dependent changes in cellular tension. 
Cytokine & Growth Factor Reviews. 16, 395-405. 
WALTER, J., SUN, L., NEWPORT, J. 1998. Regulated chromosomal DNA replication in the 
absence of a nucleus. Mol. Cell. 1, 519-529. 
WANG, Y.N. and HUNG, M.C. 2012. Nuclear functions and subcellular trafficking mechanisms 
of the epidermal growth factor receptor family.  Cell and Bioscience. 2:13.  
WANG, Y.N., LEE, H.H., LEE, H.J., DU, Y., YAMAGUCHI, H., HUNG, M.C. 2012. Membrane-bound 
trafficking regulates nuclear transport of integral epidermal growth factor receptor (EGFR) and 
ErbB-2. J. Biol. Chem. 287, 16869-16879. 
WANG, Y.N., WANG, H., YAMAGUCHI, H., LEE, H.J., LEE, H.H., HUNG, M.C. 2010a. COPI-
mediated retrograde trafficking from the golgi to the ER regulates EGFR nuclear transport. 
Biochem. Biophys. Res. Commun. 399, 498-504. 
WANG, Y.N., YAMAGUCHI, H., HUO, L., DU, Y., LEE, H.J., LEE, H.H., WANG, H., HSU, J.M., HUNG, 
M.C. 2010b. The translocon sec61β localised in the inner nuclear membrane transports 
membrane-embedded EGF receptor to the nucleus. J. Biol. Chem. 285. 38720-38729. 
WEILING, H., XIAOWEN, Y., CHUNMEI, L., JIANPING, X. 2013. Function and evolution of 
ubiquitous bacterial signalling adapted phosphopeptide recognition domain FHA. Cell Signal. 
25, 660- 665. 
WEIR, M. L., OPPIZZI, M. L., HENRY, M. D., ONISHI, A., CAMPBELL, K. P., BISSELL, M. J. & 
MUSCHLER, J. L. 2006. Dystroglycan loss disrupts polarity and beta-casein induction in 
mammary epithelial cells by perturbing laminin anchoring. J Cell Sci, 119, 4047-58. 
WEISE, C., AND ZHENG, Y.A. 2000. A new function for the γ-tubulin ring complex as a 
microtubule minus end cap. Nat. Cell Biol. 2, 358-364. 
WEN, W., MEINKOTH, J.L., TSIEN, R.Y., TAYLOR, S.S. 1995. Identification of a signal for rapid 
export of proteins from the nucleus. Cell. 82, 463-473. 
256 
 
WILHELMSEN, K., LITJENS, S.H.M., KUIKMAN, I., TSHIMBALANGA, N., JANSSEN, H., VAN DEN 
BOUT, I., RAYMOND, K., SONNENBERG, A. 2005. Nesprin-3, a novel outer nuclear membrane 
protein, associates with the cytoskeletal linker protein plectin. J. Cell Biol. 171, 799-810. 
WILKIE, G.S., KORFALI, N., SWANSON, S.K., MALIK, P., SRSEN, V., BATRAKOU, D.G., DE LAS 
HERAS, J., ZULEGER, N., KERR, A.R.W., FLORENS, L., SCHIRMER, E.C. 2011. Several novel nuclear 
envelope transmembrane proteins identified in skeletal muscle have cytoskeletal associations. 
Mol. And Cell. Proteomics. 10, 1-16 
WILLIAMS, C.C., ALLISON, J.G., VIDAL, G.A., BURROW, M.E., BECKMAN, B.S., MARRERO, L., 
JONES, F.E. 2004. The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by 
functioning as a STAT5A nuclear chaperone. J. Cell Biol. 167, 469-478. 
WILLIAMSON, R.A., HENRY, M.D., DANIELS, K.J., HRSTKA, R.F., LEE, J.C., SUNADA, Y., 
IBRAGHIMOV-BESKROVNAYA, O., CAMPBELL, K.P. 1997. Dystroglycan is essential for early 
embryonic development: distribution of Reichert’s membrane in Dag1-null mice. Hum. Mol. 
Genet. 6, 831-841. 
WILSON, M.D., SOPONARO, M., LEIDL, M.A.., SVEJSTRUP, J.Q. (2012) MultiDsk: A Ubiquitin-
Specific Affinity Resin. PLOS One, 7 (10), e6398. 
 
WINDER, S.J. 2001. The complexities of Dystroglycan. Trends Biochem Sci. 26, 118-124. 
 
WINDER, S.J., AND KENDRICK-JONES, J. 1995. Calcium/calmodulin-dependent regulation of 
the NH2-terminal F-actin binding domain of utrophin. FEBS Letters. 357, 125–128. 
 
WOLFE, M.S. 2010. Structure, mechanism and inhibition of gamma-secretase and presenilin-
like proteases. Biol. Chem. 391, 839-847. 
WORMAN, H.J. 2012. Nuclear lamins and laminopathies. J. Pathol. 226, 316-325. 
WORMAN, H.J., OSTLUND, C., WANG, Y. 2010. Diseases of the nuclear envelope. Cold Spring 
Harb. Perspect. Biol. 2, a000760. 
WORMAN, H.J., YUAN, J., BLOBEL, G., GEORGATOS, S.D. 1988. A lamin B receptor in the 
nuclear envelope. Proc. Natl. Acad. Sci. USA. 85, 8531-8534. 
WU, J., MISRA, G., RUSSELL, R.J., LADD, A.J., LELE, T.P., DICKINSON, R.B. 2011, Effects of dynein 
on microtubule mechanics and centrosome positioning. Mol. Biol. Cell. 22, 4834-4841. 
XU, J., RODRIGUEZ, D., PETITCLERC, E., KIM, J.J., HANGAI, M., MOON, Y.S., DAVIS, G.E., 
BROOKS, P.C. 2001. Proteolytic exposure of a cryptic site within collagen type IV is required for 
angiogenesis amd tumor growth in vivo. J. Cell Biol. 154, 1069-1079. 
XU, L.N., XU, B.N., CAI, J., YANG, J.B., LIN, N. 2013. Tumor-associated fibroblast-conditioned 
medium promotes tumor cell proliferation and angiogenesis. Genetics and Molecular 
Research. 12, 5863- 5871. 
YAMADA, H., SAITO, F., FUKUTA-OHI, H., ZHONG, D., HASE, A., ARAI, K., OKUYAMA, A., 
MAEKAWA, R., SHIMIZU, T., MATSUMURA, K. 2001. Processing of b-dystroglycan by matrix 
metalloproteinase disrupts the link between the extracellular matrix and cell membrane via 
the Dystroglycan complex. Hum. Mol. Genet. 10, 1563-1569. 
 
YAMADA, H., SHIMIZU, T., TANAKA, T., CAMPBELL, K.P., MATSUMURA, K. 1994. Dystroglycan is 




YAMAKITA, Y., TOTSUKAWA, G., YAMASHIRO, S., FRY, D., ZHANG, X., HANKS, S.K., 
MATSUMURA, F. 1999. Dissociation of FAK/p130(CAS)/c-Src complex during mitosis: role of 
mitosis specific serine phosphorylation of FAK. J. Cell Biol. 144, 315-324.  
YANG, B., JUNG, D., MOTTO, D., MEYER, J., KORETZKY, G., CAMPBELL, K.P. 1995. SH3 domain 
mediated interaction of dystroglycan and Grb2. J. Biol. Chem. 270, 11711-11714. 
 
YANG, L., GUAN, T., GERACE, L. 1997. Integral membrane proteins of the nuclear envelope are 
dispersed throughout the endoplasmic reticulum during mitosis. J. Cell Biol. 137, 1199-1210.  
YATSENKO, A.S., KUCHERENKO, M.M., PANTOJA, M., FISCHER, K.A., MADEOY, J., DENG, W.M., 
SCHNEIDER, M., BAUMGARTNER, S., AKEY, J., SHCHERBATA, H.R., RUOHOLA-BAKER, H. 2009. 
The conserved WW-domain binding sites in Dystroglycan C-terminus are essential but partially 
redundant for Dystroglycan function. BMC Dev Biol .9, 18. 
 
YE, Q., AND WORMAN, H. J. 1994. Primary structure analysis and lamin B and DNA binding of 
human LBR, an integral protein of the nuclear envelope inner membrane. J. Biol. Chem. 269, 
11306-11311. 
YONEMURA, S., HIRAO, M., DOI, Y., TAKAHASHI, N., KONDO, T., TSUKITA. S., TSUKITA, S. 1998. 
Ezrin/ Radixin/ Moesin (ERM) proteins bind to a positively charged amino acid cluster in the 
juxta-membrane cytoplasmic domain of CD44, CD43, and ICAM-2. J. Cell Biol. 140, 885-895. 
YONEMURA, S., NAGAFUCHI, A., SATO, N., TSUKITA, S. 1993. Concentration of an integral 
membrane protein, CD43 (Leukosialin, sialophorin), in the cleavage furrow through the 
interaction of its cytoplasmic domain with actin-based cytoskeletons. J. Cell Biol. 120, 437-449. 
YONGMIN, X., YANWEN, Z., HARRY, W.J. 2009. Dystrophin glycoprotein complex-associated 
Gbetagamma subunits activate phosphatidylinositol-3-kinase/Akt signaling in skeletal muscle 
in a laminin-dependent manner. J Cell Physiol. 219, 402-414.  
YOSHIDA, M. AND OZAWA, E. 1990. Glycoprotein complex anchoring dystrophin to 
sarcolemma. J. Biochem. 108, 748-752. 
YOSHIDA, M., HAMA, H., ISHIKAWA-SAKURAI, M., IMAMURA, M., MIZUNO, Y, ARAISHI, K., 
WAKABAYASHI-TAKAI, E., NOGUCHI, S., SASAOKA, T., OZAWA, E. 2000. Biochemical evidence 
for association of dystrobrevin with the sarcoglycan-sarcospan complex as a basis for 
understanding sarcoglycanopathy. Hum. Mol. Genet. 9, 1033-1040. 
YOSHIDA, M., SUZUKI, A., YAMAMOTO, H., NOGUCHI, S., MIZUNO, Y., OZAWA, E. 1994. 
Dissociation of the complex of dystrophin and its associated proteins into several unique 
groups by n-octyl-D-glucoside. Eur. J. Biochem. 222, 1055-1061. 
YOSHIDA-MORIGUCHI, T., YU, L., STALNAKER, S.H., DAVIS, S., KUNZ, S., MADSON, M., 
OLDSTONE, M.B., SCHACHTER, H., WELLS, L., CAMPBELL, K.P. 2010. O-mannosyl 
phosphorylation of alpha-dystroglycan is required for laminin binding. Science. 327, 88-92.  
YOSHIDA-MORIGUCHI, T., AND CAMPBELL, K.P. 2015. Matriglycan: a novel polysaccharide that 
links dystroglycan to the basement membrane. Glycobiology. 7, 702-713. 
YUAN, X., LI, T., WANG, H., ZHANG, T., BARUA, M., BORGESI, R.A., BUBLEY, G.J., LU, M.L., BALK, 
S.P. 2006. Androgen receptor remains critical for cell cycle progression in androgen-
independent CWR22 prostate cancer cells. AJP. 169, 682-696. 
YUAN, X., WU, H., XU, H., XIONG, H., CHU, Q., YU, S., WU, G.S., WU, K. 2015. Notch signaling: 
an emerging therapeutic target for cancer treatment. Cancer Lett. 369, 20-27. 
258 
 
ZHANG, Q., BETHMANN, C., WORTH, N.F., DAVIES, J.D., WASNER, C., FEUER, A., RAGNAUTH, 
C.D., YI, Q., MELLAD, J.A., WARREN, D.T., WHEELER, M.A., ELLIS, J.A., SKEPPER, J.N., VORGERD, 
M., SCHLOTTER-WEIGEL, B., WEISSBERG, P.L., ROBERTS, R.G., WEHNERT, M., SHANAHAN, C.M. 
2007. Nesprin-1 and -2 are involved in the pathogenesis of Emery-Dreifuss muscular dystrophy 
and are critical for nuclear envelope integrity. Hum. Mol. Genet. 16, 2816-2833. 
ZHANG, Q., RAGNAUTH, C., GREENER, M.J., SHANAHAN, C.M., ROBERTS, R.G. 2002. The 
nesprins are giant actin-binding proteins, orthologous to Drosophila melanogaster muscle 
protein MSP-300. Genomics. 80, 473-481. 
ZHANG, W. AND LIU, H. T. 2002, MAPK signal pathways in the regulation of cell proliferation in 
mammalian cells. Cell Research. 12, 9-18. 
ZHANG, X., LEI, K., YUAN, X., WU, X., ZHUANG, Y., XU, T., XU, R., HAN, M. 2009. SUN1/2 and 
Syne/Nesprin-1/2 complexes connect centrosome to the nucleus during neurogenesis and 
neuronal migration in mice. Neuron. 64, 173-187. 
ZHONG, D., SAITO, F., SAITO, Y., NAKAMURA, A., SHIMIZU, T. & MATSUMURA, K. 2006. 
Characterization of the protease activity that cleaves the extracellular domain of beta-
dystroglycan. Biochem Biophys Res Commun, 345, 867-71. 
ZHOU, K., ROLLS, M.M., HALL, D.H., MALONE, C.J., HANNA-ROSE, W. 2009. A ZYG-12 dynein 
interaction at the nuclear envelope defines cytoskeletal architecture in the C. elegans gonad. J. 
Cell Biol. 186, 229-241. 
ZIELINSKA, D.F., GNAD, F., WISNIEWSKI, J.R., MANN, M. 2010. Precision mapping of an in vivo 
N-glycoproteome reveals rigid topological and sequence constraints. Cell. 141, 897-907. 
ZIEVE, G.W., TURNBULL, D., MULLINS, J.M., MCINTOSH, J.R. 1980. Production of large numbers 
of mitotic mammalian cells by use of the reversible microtubule inhibitor nocodazole: 
nocodazole accumulated mitotic cells. Exp. Cell Res. 126, 397-405. 
ZUTTER, M.M., SANTORO, S.A., STAATZ, W.D., TSUNG, Y.L. 1995. Re-expression of 
the alpha 2 beta 1 integrin abrogates the malignant phenotype of breast carcinoma cells. Proc 
Natl Acad Sci U S A., 92, 7411-7415. 
 
 
 
